

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and
APOTEX, INC.,
Petitioners

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner

Case IPR2021-00881¹
Patent No. 9,254,338 B2

EXPERT DECLARATION OF RICHARD MANNING, PH.D.

CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

¹ IPR2022-00258 and IPR2022-00298 have been joined with this proceeding.

Summary of Contents

1. Introduction	1
2. Regeneron Pharmaceuticals, Inc.	8
3. U.S. Patent No. 9,254,338	10
4. Relevant Economic Principles	14
5. Medical Conditions at Issue	17
6. Overview of Treatment Options for Relevant Angiogenic Eye Disorders	24
7. Medicare Part B Reimbursement Policy	43
8. Commercial Success	52
9. Dosing Regimen is an Important Driver of Demand for Eylea	97
10. Eylea’s Commercial Success Cannot be Explained by Factors Not Related to the Claimed Methods of Treatment	122

Table of Contents

1.	Introduction	1
1.1.	Qualifications.....	1
1.2.	Scope of work.....	3
1.3.	Framework for commercial success	4
2.	Regeneron Pharmaceuticals, Inc.	8
3.	U.S. Patent No. 9,254,338.....	10
4.	Relevant Economic Principles	14
5.	Medical Conditions at Issue	17
6.	Overview of Treatment Options for Relevant Angiogenic Eye Disorders	24
6.1.	Laser-based treatment options available prior to anti-VEGF therapies.....	24
6.2.	Anti-VEGF treatment options	26
6.2.1.	Macugen	27
6.2.2.	Avastin.....	28
6.2.3.	Lucentis	29
6.2.4.	Eylea	31
6.2.5.	Beovu.....	34
6.2.6.	FDA approvals for anti-VEGF treatments	38
6.2.7.	FDA-approved dosing schedules for anti-VEGF treatment options	39
7.	Medicare Part B Reimbursement Policy	43
8.	Commercial Success	52
8.1.	U.S. Eylea sales and revenue.....	52
8.1.1.	Gross sales	53
8.1.2.	Net sales	54
8.2.	U.S. Eylea profits.....	56
8.3.	Eylea’s share of anti-VEGF sales.....	60
8.3.1.	Data sources	61
	Medicare Part B services and procedures	61

CONFIDENTIAL MATERIAL– SUBJECT TO PROTECTIVE ORDER

Vestrum Health	64
Regeneron ATU surveys	66
8.3.2. Eylea’s historic patient share as an indicator of commercial success	69
8.3.3. Eylea’s displacement of other anti-VEGF treatments as an indicator of commercial success.....	80
8.3.4. Eylea status as physicians’ most used treatment.....	86
8.4. Price has not hindered Eylea’s commercial success	89
9. Dosing Regimen is an Important Driver of Demand for Eylea	97
9.1. Eylea’s patented dosing regimen addressed an unmet need for longer dosing intervals	99
9.2. Eylea’s patented dosing regimen is a key differentiating factor ..	103
9.2.1. Regeneron has promoted the patented dosing schedule and credits it as a key factor causing commercial success	104
9.2.2. Regeneron ATU surveys show that dosing interval has been an important driver of Eylea prescribing.....	109
9.2.3. Members of the ASRS identified Eylea as allowing the longest treatment interval	114
9.2.4. Regeneron public statements demonstrate the importance of the patented dosing schedule to Eylea’s commercial success	117
9.3. Eylea is more effective at treating patients with worse visual acuity, which imparts a downward bias to its observed treatment interval	118
10. Eylea’s Commercial Success Cannot be Explained by Factors Not Related to the Claimed Methods of Treatment	122
10.1. Regeneron’s marketing efforts have been limited and have included promotion of the patented dosing regimen	122
10.2. Regeneron has had limited discounting and rebate programs.....	126
10.3. Regeneron’s sampling program is unlikely to have driven Eylea’s commercial success	129

Table of Attachments

Section A Expert Materials

Attachment A-1 Curriculum Vitae of Richard Manning, Ph.D.

Section B Dosing Directions

Attachment B-1 Dosing Directions on FDA Labels

Section C Sales Shares

Attachment C-1 Sales Share Summary - All Indications

Attachment C-2 Sales Share Summary - Wet AMD

Attachment C-3 Sales Share Summary - DME

Attachment C-4 Sales Share Summary - DR without DME

Attachment C-5 Sales Share Summary - RVO

Attachment C-6 Eylea's Sales Share Across Different Data Sources - All
Indications

Attachment C-7 Eylea's Sales Share Across Different Data Sources - Wet AMD

Attachment C-8 Eylea's Sales Share Across Different Data Sources - DME

Attachment C-9 Eylea's Sales Share Across Different Data Sources - DR
without DME

Attachment C-10 Eylea's Sales Share Across Different Data Sources - RVO

Attachment C-11 Percentage Point Change in Total Sales Share Since Eylea
Launch – ATU Data

Attachment C-12 Percentage Point Change in Total Sales Share Since Eylea
Launch – Medicare Part B Data

CONFIDENTIAL MATERIAL– SUBJECT TO PROTECTIVE ORDER

Section D

Financials

- Attachment D-1 Eylea Profit and Loss Data (Actuals, 2011–2021)
- Attachment D-2 Eylea Volume and Revenue Performance (2011–2021)
- Attachment D-3 Eylea Promotional and Marketing Expenses As Share of Net Sales (2011–2021)
- Attachment D-4 Eylea Samples As Share of Total Unit Sales (2011–2020)
- Attachment D-5 Summary of Payment Allowance Limits for Medicare Part B Drugs (2012–2021)
- Attachment D-6 Payment Limit per Injection for Anti-VEGF Treatment Options (2012–2021)
- Attachment D-7 U.S. Eylea Net Sales (2011–2021)
- Attachment D-8 Payment Limit per Injection for Different Treatments (2012–2021)

Section E

Other Analyses

- Attachment E-1 Most Prescribed Treatment Options (2012–2019)
- Attachment E-2 Volume of Medicare Patients by Brand – Medicare Part B

Section X

Data

- Attachment X-1 Vestrum Sales Share Data by Indication
- Attachment X-2 ATU Sales Share Data by Indication
- Attachment X-3 Medicare Part B Sales Shares Data (2012–2019)
- Attachment X-4 Payment Allowance Limits for Medicare Part B Drugs (2012–2021)

I, Richard Manning, Ph.D., do hereby declare:

1. Introduction

1.1. Qualifications

- (1) I am a Managing Director at Intensity, LLC. I provide data-driven insights to help clients address complex economic questions. Among other things, I have experience conducting economic analyses in matters involving breach of contract, fraud, pricing, economic valuation, intellectual property, antitrust, patent infringement, business strategy, and public policy.
- (2) I earned my B.A. in Economics from Brigham Young University. I received my Ph.D. in Economics from the University of Chicago. After obtaining my Ph.D., I was an economics professor at Brigham Young University and a visiting professor in the Graduate School of Business at the University of Chicago. As an academic, my teaching and research focused on price theory, the economic analysis of law, industrial organization, and the economics of government regulation.
- (3) My career includes 14 years as an executive at multinational pharmaceutical companies. I was Executive Director at Merck & Co., Inc. and Senior Director at Pfizer, Inc. I led economic analysis and strategy development to shape practices related to emerging business concerns. Examples of my work include:

- Leading and undertaking economic analysis and strategy relative to challenges affecting pricing, reimbursement, and intellectual property protection in global markets.
 - Collaborating with outside academic economists to analyze critical issues including healthcare benefit design, healthcare system reform proposals, marketing and advertising, intellectual property protection, FDA regulatory reform, including biosimilars approval processes and safety, and new product R&D.
- (4) Previously, I also was a Director in the Advisory Strategy Group at PricewaterhouseCoopers where my responsibilities included working on strategic partnerships, merger and acquisitions activity, economic valuation of early-stage companies, and other economic analyses for biopharmaceutical, medical device, financial, and healthcare clients.
- (5) Prior to joining Intensity, I was a Partner at Bates White, an economics consulting firm offering analysis and expert testimony services to law firms, Fortune 500 companies, and government agencies.
- (6) My areas of expertise include:
- Economic Valuation and Damages
 - Breach of Contract, Fraud, and other Commercial Litigation
 - Intellectual Property

- Securities Litigation
 - Tax, Antitrust and Competition
 - Public Policy
- (7) I have testified before U.S. District Court, the Delaware Court of Chancery, and the International Chamber of Commerce; served as consulting expert; and prepared reports on various matters in the biopharmaceutical and healthcare industries.

1.2. Scope of work

- (8) Intensity has been retained by Arnold & Porter Kaye Scholer LLP on behalf of Regeneron Pharmaceuticals, Inc. (Regeneron). Intensity is being compensated at my standard hourly rate for my work in this matter. Intensity is being compensated for time spent by others on my team at rates lower than my hourly rate. The compensation of Intensity does not depend on the substance of my testimony or the outcome of this matter.
- (9) I was asked to evaluate and, if called upon, to testify concerning commercial success as an objective indicia of non-obviousness in *Inter Partes* review No. IPR2021-00881 regarding U.S. Patent No. 9,254,338 (the '338 Patent).
- (10) In forming the opinions expressed in this declaration, I relied upon my education, experience, and knowledge of the subjects discussed. Additionally,

I relied on the declarations of Dr. David M. Brown and Dr. Diana Do. I also have considered documents and other materials, which are cited herein.

(11) In connection with my work in this matter, I have been informed by interviews with the following individuals:

- a. Regeneron Director, Customer Insights, interviewed on November 30th, 2021.
- b. Regeneron Associate Director, Field Force Effectiveness and Ophthalmology, and Regeneron Associate Director, Sample Operations and Accountability, interviewed on December 15th, 2021.
- c. Regeneron Executive Director, Commercial Finance & Business Planning and Regeneron Senior Director, FP&A, interviewed on December 16th, 2021.
- d. Regeneron Senior Director, Market Access Strategy, interviewed on February 9th, 2022.

1.3. Framework for commercial success

(12) I understand that evidence of commercial success is one of the objective indicia that a patent owner may rely upon to support an argument of non-

obviousness of a claimed invention.² I understand that the Federal Circuit has stated that “[c]ommercial success is relevant because the law presumes an idea would successfully have been brought to market sooner, in response to market forces, had the idea been obvious to persons skilled in the art.”³ I understand that, for commercial success to constitute evidence of non-obviousness of a patent, there must be a nexus between the claimed technology and evidence of commercial success, and that the evidence must demonstrate that the commercial success is due at least in part to the claimed features of the invention and not to factors unrelated to the claimed invention.⁴ I further

² *Demaco Corp. v. F. Von-Langsdorff Licensing Ltd.*, 851 F.2d 1387, at PDF 3 (Fed. Cir. 1988).

³ *Merck v. Teva*, 395 F.3d 1364, 1376 (Fed. Cir. 2005).

⁴ United States Patent and Trademark Office, Manual of Patent Examining Procedure, Eighth Edition, Revision: 7/2010, 716.03 I., at 700-298. (“An applicant who is asserting commercial success to support its contention of nonobviousness bears the burden of proof of establishing a nexus between the claimed invention and evidence of commercial success.”) (“The term “nexus” designates a factually and legally sufficient connection between the evidence

understand that Federal Circuit case law holds that “if the commercial success is due to an unclaimed feature or device, the commercial success is irrelevant.”⁵

- (13) It is my understanding that the courts commonly accept indicators including significant sales levels, significant sales growth, substitution towards the

of commercial success and the claimed invention so that the evidence is of probative value in the determination of nonobviousness.”) (“In considering evidence of commercial success, care should be taken to determine that the commercial success alleged is directly derived from the invention claimed, in a marketplace where the consumer is free to choose on the basis of objective principles, and that such success is not the result of heavy promotion or advertising, shift in advertising, consumption by purchasers normally tied to applicant or assignee, or other business events extraneous to the merits of the claimed invention, etc.”)

Demaco Corp. v. F. Von-Langsdorff Licensing Ltd., 851 F.2d 1387, at PDF 3 (Fed. Cir. 1988).

⁵ *Ormco Corporation, et al. v. Align Technology, Inc.*, 463 F.3d 1299, 1312 (Fed. Cir. 2006).

novel product or method and away from alternative products or methods, price premiums, or the absence of substantial discounting, and other economic indicators as evidence of commercial success of a novel product.⁶ In the context of pharmaceutical products (and by extension biologic products), sales can be measured in terms of revenues, prescriptions, or daily doses, and sales growth can be measured in terms of sales or share of sales within a product category.⁷

⁶ Ex. 2201 (Guha, Rahul, Jian Li, and Andrea L. Scott (2009), “The Economics of Commercial Success in Pharmaceutical Patent Litigation,” *Landslide* 1(5)).

⁷ Ex. 2201 (Guha (2009)).

2. Regeneron Pharmaceuticals, Inc.

- (14) Regeneron Pharmaceuticals, Inc. (Regeneron) is a biotechnology company that discovers and develops biotherapeutics for people with serious illnesses.⁸ Regeneron was incorporated in the state of New York in 1988 and has its corporate headquarters in Tarrytown, New York.⁹ Regeneron was publicly listed on NASDAQ in 1991.¹⁰
- (15) The company's approved therapeutic products and its therapeutic candidates in development target eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and other rare diseases.¹¹ Regeneron's portfolio includes "over 30 investigational medicines."¹²

⁸ Ex. 2246 (Regeneron Website, About, <https://www.regeneron.com/about> (accessed 11/3/2021)).

⁹ Ex. 2254 (Regeneron, Form 10-K, 2020, at 37).

¹⁰ Ex. 2254 (Regeneron, Form 10-K, 2020, at 37).

¹¹ Ex. 2254 (Regeneron, Form 10-K, 2020, at 3).

¹² Ex. 2253 (Regeneron Website, Research Areas, <https://www.regeneron.com/science/research-areas> (accessed 11/3/2021)).

- (16) In 2011, the FDA approved Regeneron’s EYLEA (aflibercept) injection for the treatment of wet age-related macular degeneration (wet AMD).¹³ EYLEA is a prescription medicine approved for the treatment of patients with a variety of angiogenic eye diseases and is the subject of this proceeding.¹⁴

¹³ Ex. 2251 (Regeneron Website, History, <https://www.regeneron.com/about/history> (accessed 12/15/2021)).

Ex. 2185 (Drugs@FDA, Eylea Label, 11/2011, at 1, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf).

¹⁴ Ex. 2254 (Regeneron, Form 10-K, 2020, at 3).

3. U.S. Patent No. 9,254,338

(17) U.S. Patent No. 9,254,338, entitled “Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders,” was issued on February 9, 2016.¹⁵ The ’338 Patent lists George D. Yancopoulos as its inventor and Regeneron Pharmaceuticals, Inc. as its assignee.¹⁶ The ’338 Patent claims a priority date of January 13, 2011, and the application resulting in the ’338 Patent was filed on July 12, 2013.¹⁷

(18) The abstract of the ’338 Patent reads as follows:¹⁸

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age-related

¹⁵ Ex. 1001 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders, U.S. Patent No. 9,254,338 (filed 7/12/2013, issued 2/9/2016)).

¹⁶ Ex. 1001 (U.S. Patent No. 9,254,338).

¹⁷ Ex. 1001 (U.S. Patent No. 9,254,338).

¹⁸ Ex. 1001 (U.S. Patent No. 9,254,338).

macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

- (19) The '338 Patent has 26 claims.¹⁹ Of these 26 claims, 22 are currently under review in this proceeding: claims 1, 3-11, 13, 14, 16-24, and 26.²⁰ Generally, I understand that the '338 Patent teaches the use of a VEGF antagonist made from specific amino acid sequences or a specific nucleic acid sequence to treat angiogenic eye disorders according to a dosing regimen that includes three phases: a single initial dose; one or more secondary doses administered 2 to 4 weeks after the preceding dose; and one or more tertiary doses administered at least 8 weeks after the preceding dose.²¹

¹⁹ Ex. 1001 (U.S. Patent No. 9,254,338).

²⁰ Decision Granting Institution of *Inter Partes* Review, 11/10/2021, at 2.

²¹ Ex. 1001 (U.S. Patent No. 9,254,338).

Ex. 2050 (Expert Declaration of David M. Brown, M.D. (“Brown Declaration”), 2/10/2022. at ¶94). (“The dosing regimen of Claim 1 requires treatment of an angiogenic eye disorder by administration of an initial dose of the claimed VEGF antagonist followed by one or more “secondary” doses

- (20) I understand that Eylea is administered according to the claimed dosing regimen.²² For example, the FDA approved label for Eylea for wet AMD recommends a monthly injection for the first three to five months, depending on the indication, followed by an on-going 8-week or longer maintenance dosing schedule.²³ I will refer to these initial monthly doses (i.e., the single

administered two to four weeks after the preceding dose, and then one or more “tertiary” doses that are administered at least eight weeks following the preceding dose.

Ex. 2051 (Declaration of Diana V. Do, M.D. (“Do Declaration”), 2/10/2022, at ¶35). (“The dosing regimen of Claim 1 requires treatment of an angiogenic eye disorder by administration of an initial dose of the claimed VEGF antagonist followed by one or more “secondary” doses administered two to four weeks after the preceding dose, and then one or more “tertiary” doses that are administered at least eight weeks following the preceding dose.”)

²² Ex. 2051 (Do Declaration, 2/10/2022, at ¶¶ 135–139).

²³ Ex. 2189 (Drugs@FDA, Eylea Label, 3/2021, at 3, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125387s069lbl.pdf). (“The recommended dose for EYLEA is 2 mg (0.05 mL) administered by

initial dose and the one or more secondary doses administered 2 to 4 weeks after the preceding dose) as the “loading doses” or loading period, and tertiary doses as the “maintenance doses” or maintenance phase.

intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).”)

4. Relevant Economic Principles

- (21) The economic theory of demand dictates that consumers choose to buy goods and services to achieve satisfaction, or to meet various wants and needs.²⁴ Demand theory also dictates that consumers only buy things when the good purchased provides them greater value than the cost they incur to acquire the good.²⁵ The cost incurred includes more than the money paid.²⁶
- (22) As a consumer evaluates a purchase, he or she considers other things that are “bundled” with the purchase, and, importantly, a consumer considers the

²⁴ Ex. 2219 (Mankiw, Nicholas Gregory (2009), *Principles of Microeconomics*, 5th ed., Mason, OH: South-Western Cengage Learning, at 6). (“You will also encounter individuals who decide how much time to spend working and what goods and services to buy with the resulting income to achieve the highest possible level of satisfaction.”)

²⁵ Ex. 2219 (Mankiw (2009), at 5). (“Because people face trade-offs, making decisions requires comparing the costs and benefits of alternative courses of actions.”)

²⁶ Ex. 2219 (Mankiw (2009), at 5). (“In many cases, however, the cost of an action is not as obvious as it might appear.”)

alternative consumption opportunities that are given up in exchange for the purchased good.²⁷ Within the consumption bundle, the consumer may find things both good and bad that contribute to the “price” paid in exchange for the thing he or she wants to buy. When a consumption bundle includes bad things, demand for the bundle is diminished.²⁸

- (23) In this matter, the medical treatments provide significant benefits and value to patients by preventing vision loss and restoring some lost vision caused by the relevant medical conditions. However, as discussed subsequently in my declaration, the most commonly used treatments for these conditions (including Eylea) involve ongoing treatments, which impose certain “bads” on patients. See Section 9. In particular, these treatments are administered by injection into patients’ eyes, compounding the negative impact of ongoing

²⁷ Ex. 2219 (Mankiw (2009), at 5–6). (“The **opportunity cost** of an item is what you give up to get that item. When making any decision, decision makers should be aware of the opportunity costs that accompany each possible action.”)

²⁸ Ex. 2245 (Pindyck, Robert and Daniel Rubinfeld (2013), *Microeconomics*, Upper Saddle River, NJ: Prentice Hall, at 76-77). (“However, some things are **bads**: *Less of them is preferred to more.*”)

treatment.²⁹ Hence, economic theory indicates, all else the same, that a treatment that requires fewer or less frequent doses and/or evaluations will be in greater demand by consumers than is a treatment that requires more evaluations, and/or more frequent dosing.

²⁹ Ex. 2221 (Mayo Clinic Website, Wet Macular Degeneration, <https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113> (accessed 11/11/2021)).

5. Medical Conditions at Issue

- (24) The '338 Patent teaches “methods for treating angiogenic eye disorders.”³⁰ I understand that angiogenic eye disorders result from the growth of abnormal blood vessels in the eyes³¹ when a naturally-produced protein, vascular endothelial growth factor (VEGF), is produced in excess amounts. The creation of these abnormal blood vessels in eyes can damage the eye and impair vision.³²
- (25) The '338 Patent specifically identifies the patented methods as being useful for the treatment of specific angiogenic eye disorders, including age-related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.³³ Of these, Eylea has obtained FDA approval for use

³⁰ Ex. 1001 (U.S. Patent No. 9,254,338).

³¹ Ex. 2179 (Dreyfuss, Juliana L., Ricardo J. Giordano, and Caio V. Regatieri (2015), “Ocular Angiogenesis,” *Journal of Ophthalmology* 2015:892043).

The formation of new blood vessels is labeled angiogenesis.

³² Ex. 2050 (Brown Declaration, 2/10/2022, at ¶ 26).

³³ Ex. 1001 (U.S. Patent No. 9,254,338).

treating four angiogenic eye disorders: wet AMD, diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion (RVO).³⁴

- (26) Detailed descriptions of each of the angiogenic eye disorders at issue in this matter can be found from sites including the American Society of Retina Specialists (ASRS).³⁵ Across the diseases at issue, the majority of anti-VEGF

³⁴ Ex. 2185 (Eylea Label, 11/2011, at 1).

Ex. 2187 (Drugs@FDA, Eylea Label, 10/2014, at 4, available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125387s043lbl.pdf).

Ex. 2188 (Drugs@FDA, Eylea Label, 5/2019, at 4, available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf).

³⁵ Ex. 2149 (American Society of Retina Specialists Website, Age-Related Macular Degeneration, <https://www.asrs.org/patients/retinal-diseases/2/agerelated-macular-degeneration> (accessed 12/30/2021)).

Ex. 2152 (American Society of Retina Specialists Website, Diabetic Retinopathy, <https://www.asrs.org/patients/retinal-diseases/3/diabetic-retinopathy> (accessed 12/30/2021)).

injections regardless of type are used on patients with wet AMD and DME.

See Table 1. Indeed, 83.5% of all anti-VEGF injections are used on patients with either wet AMD or DME. See Table 1.

Ex. 2182 (Elyasi, Niki and Houman David Hemmati (2021), “Diabetic Macular Edema: Diagnosis and Management,” *EyeNet Magazine*, May 2021: 35-37).

Ex. 2151 (American Society of Retina Specialists Website, Central Retinal Vein Occlusion, <https://www.asrs.org/patients/retinal-diseases/22/central-retinal-vein-occlusion> (accessed 12/30/2021)).

Ex. 2150 (American Society of Retina Specialists Website, Branch Retinal Vein Occlusion, <https://www.asrs.org/patients/retinal-diseases/24/branch-retinal-vein-occlusion> (accessed 12/30/2021)).

Table 1: U.S. Anti-VEGF Injections by Relevant Disease in 2021³⁶

Disease	Total Injections	Percent of Total Injections
Wet AMD		
DME		
DR without DME		
RVO		

(27) Generally speaking, these diseases tend to afflict individuals who are age 50 or older. For example, wet AMD is most common in people aged 55 or older.³⁷

³⁶ Ex. 2273 (Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022, at tab “Eylea – Quarterly by Indication”).

³⁷ Ex. 2222 (Mayo Clinic Website, Wet Macular Degeneration Symptoms and Causes, <https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/symptoms-causes/syc-20351107> (accessed 11/11/2021)).

Additional sources discussing the age at which wet AMD appears:

Similarly, the average age at patients’ diagnosis of DME is “just over 50 years old.”³⁸

Ex. 2164 (Bright Focus Foundation Website, Age-Related Macular Degeneration: Facts & Figures, <https://www.brightfocus.org/macular/article/age-related-macular-facts-figures> (accessed 11/5/2021)). (“Macular degeneration is a leading cause of vision loss in Americans 60 years of age and older.”)

Ex. 2264 (Verywell Health Website, Macular Degeneration: Timeline of Vision Loss Progression, 3/21/2021, <https://www.verywellhealth.com/macular-degeneration-timeline-5069947>). (“Age-related macular degeneration usually begins at age 55 or older.”)

Ex. 2183 (Eye Care Surgery Center Website, Macular Degeneration, <https://www.eyecaresurgerycenterbr.com/diabetes-retina/macular-degeneration/> (accessed 11/18/2021)). (“It [wet AMD] rarely occurs before the age of 50.”)

³⁸ Ex. 2262 (Sivaprasad, Sobha (2021), “Sustained-Release Steroid Options For DME Therapy,” *Retina Today* (0921): 34–36, at 34).

- (28) These angiogenic eye disorders are treated by ophthalmologists, either retinal specialists or comprehensive ophthalmologists.³⁹ As of 2016, there were over 17,000 ophthalmologists in the U.S., with 3,329 identified as retina providers.⁴⁰ Of these 3,329 retina providers, 1,034 were identified as

³⁹ Ex. 2141 (American Academy of Ophthalmology Website, Anti-VEGF Treatments, <https://www.aao.org/eye-health/drugs/anti-vegf-treatments> (accessed 11/8/2021)).

Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 3).

Regeneron’s ATU surveys are conducted for retinal specialists and general ophthalmologists that administer the anti-VEGF treatments through intravitreal injection.

Conversation with Regeneron Director, Customer Insights.

⁴⁰ Ex. 2203 (Healio, “Access to Retina Providers Shows No Geographic Bias in U.S.,” 3/12/2019, at 1, available at: <https://www.healio.com/news/ophthalmology/20190312/access-to-retina-providers-shows-no-geographic-bias-in-us>).

Ex. 2148 (American Society of Retina Specialists Website, About Us. <https://www.asrs.org/about> (accessed 12/6/2021)).

comprehensive providers or hybrid providers (physicians that diagnose and treat a broad array of eye diseases); the remaining 2,295 were identified as retina specialists (ophthalmologists with additional intensive training through a fellowship that focused on the retina).⁴¹

⁴¹ Ex. 2203 (Healio, “Access to Retina Providers Shows No Geographic Bias in U.S.,” 3/12/2019, at 1).

Ex. 2148 (American Society of Retina Specialists Website, About Us. <https://www.asrs.org/about> (accessed 12/6/2021)).

Ex. 2143 (American Academy of Ophthalmology, “Ophthalmology Subspecialists,” 6/6/2016, <https://www.aao.org/eye-health/tips-prevention/ophthalmology-subspecialists>).

6. Overview of Treatment Options for Relevant Angiogenic Eye Disorders

(29) Various options have been or are currently used by physicians for treatment of angiogenic eye disorders, with different treatment options available for each disorder. Eylea and other anti-VEGF therapies are now the most common treatment for angiogenic eye diseases.⁴² See Attachment C-1. A more in-depth discussion of these treatments can be found in the Brown Declaration.⁴³

6.1. Laser-based treatment options available prior to anti-VEGF therapies

(30) In addition to other medicines no longer in common use, early treatments for wet AMD included the use of lasers applied to the retina. Laser photocoagulation, also known as laser ablation, was an early treatment option

⁴² Ex. 2271 (Yorston, David (2014), “Anti-VEGF Drugs in the Prevention of Blindness,” *Community Eye Health Journal* 27(87): 44-47, at 47). (“In summary, anti-VEGF drugs are probably the most significant advance in ophthalmology in the last decade. They have enabled us to treat what were previously untreatable conditions.”)

⁴³ Ex. 2050 (Brown Declaration, 2/10/2022, at ¶¶ 26–69).

for wet AMD and DR, dating back to the 1970s.⁴⁴ This treatment involved the use of a laser to create microscopic burns in target tissue to stop new blood vessels from growing in the eye.⁴⁵ In 2000, the FDA granted approval to treat wet AMD using photodynamic therapy. In photodynamic therapy, or PDT, the drug Visudyne is injected into the patient's arm and a laser is used to activate the injected drug in the patient's eye.⁴⁶ Generally, I understand that

⁴⁴ Ex. 2255 (Retinal Physician, “Revisiting an Early Treatment for Wet AMD: Is There a Role for Thermal Laser in the Era of Anti-VEGF Therapy?” 9/1/2011, <https://www.retinalphysician.com/issues/2011/september-2011/revisiting-an-early-treatment-for-wet-amd>).

⁴⁵ Ex. 2228 (Medline Plus Website, Laser Photocoagulation – Eye, <https://medlineplus.gov/ency/article/007664.htm> (accessed 12/2/2021)).

Ex. 2050 (Brown Declaration, 2/10/2022, at ¶¶ 27–28).

⁴⁶ Ex. 2267 (Drugs@FDA, Visudyne Label, 4/2016, at 3, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021119s027lbl.pdf).

Ex. 2158 (Bausch and Lomb Website, Visudyne, <https://www.bauschretinarx.com/visudyne/ecp/about/> (accessed 12/2/2021)).

these laser-based treatments were able to slow or prevent further vision loss for some patients, but they did not help patients recover vision.⁴⁷

6.2. Anti-VEGF treatment options

- (31) Since the mid-2000s, anti-VEGF products have become the primary treatment for angiogenic eye disorders.⁴⁸ Anti-VEGF treatments are administered by

Ex. 2159 (Bausch and Lomb Website, Help Your Patients Obtain Access to Visudyne, <https://www.bauschretinarx.com/visudyne/ecp/ordering/> (accessed 1/12/2022)).

Ex. 2204 (Hopkins Medicine Website, Photodynamic Therapy for Age-Related Macular Degeneration, <https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/photodynamic-therapy-for-agerelated-macular-degeneration> (accessed 12/2/2021)).

⁴⁷ Ex. 2050 (Brown Declaration, 2/10/2022, at ¶ 28).

⁴⁸ Ex. 2271 (Yorston (2014), at 46). (“In summary, anti-VEGF drugs are probably the most significant advance in ophthalmology in the last decade. They have enabled us to treat what were previously untreatable conditions.”)

injection into patients’ eyes.⁴⁹ These treatments have included the following products.

6.2.1. Macugen

(32) In December 2004, the FDA approved Macugen (the brand name for pegaptanib) for the treatment of wet AMD.⁵⁰ Macugen is an anti-VEGF aptamer (a single strand DNA or RNA molecule that binds to specific targets) developed by Eyetech Pharmaceuticals and Pfizer.⁵¹ I understand that

⁴⁹ Ex. 2221 (Mayo Clinic Website, Wet Macular Degeneration (accessed 11/11/2021)).

⁵⁰ Ex. 2191 (FDA, “Macugen Drug Approval Package Page,” 3/23/2005, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-756_Macugen.cfm).

Ex. 2217 (Drugs@FDA, Macugen Label, 12/2004, at 4, 8, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021756lbl.pdf).

⁵¹ Ex. 2217 (Macugen Label, 12/2004, at 4, 5, 11).

Ex. 2157 (BasePair Biotechnologies Website, What is an Aptamer? – Aptamers and SELEX, <https://www.basepairbio.com/what-is-an-aptamer/> (accessed 12/30/2021)).

Macugen was more effective at slowing continued vision loss than prior treatments, but that it did not stop or restore vision loss.⁵²

6.2.2. Avastin

(33) Avastin is the brand name for the antibody bevacizumab, which was developed by Genentech (a member of the Roche group) and initially approved by the FDA in February 2004 as a treatment for metastatic colorectal cancer.⁵³ Beginning in 2005, however, Avastin began to be used as an off-label treatment for wet AMD, diabetic eye disease, and other problems of the

⁵² Ex. 2050 (Brown Declaration, 2/10/2022, at ¶ 30).

⁵³ Ex. 2261 (ScienceDaily, “FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer,” 2/27/2004, <https://www.sciencedaily.com/releases/2004/02/040227071334.htm>).

Ex. 2156 (Drugs@FDA, Avastin Label, c. 2004, at 2, 7, 27, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125085lbl.pdf).

retina.⁵⁴ I understand that in some patients Avastin use results in restoration of some of the vision losses from angiogenic eye disorders.⁵⁵

6.2.3. Lucentis

(34) Lucentis is the brand name for ranibizumab, an antibody fragment designed to block VEGF inside the eye.⁵⁶ Lucentis was developed by Genentech and

⁵⁴ Thomas Albini, Dep Tr., 1/20/2022, at 29:17–18.

Ex. 2145 (American Academy of Ophthalmology, “What is Avastin”, 4/3/2021, <https://www.aao.org/eye-health/drugs/avastin>).

Avastin is not approved by the FDA for the treatment of wet AMD or any angiogenic eye disorders. See:

Ex. 2142 (American Academy of Ophthalmology, “Bevacizumab,” 11/2/2021, <https://eyewiki.aao.org/Bevacizumab>.)

⁵⁵ Ex. 2050 (Brown Declaration, 2/10/2022, at ¶ 40).

⁵⁶ Ex. 2147 (American Academy of Ophthalmology, “What is Lucentis”, 4/26/2021, <https://www.aao.org/eye-health/drugs/lucentis>).

Ex. 2212 (Drugs@FDA, Lucentis Label, c. 2006, at 4, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf).

received FDA approval for treatment of wet AMD in June 2006.⁵⁷ Lucentis has since been approved to treat patients with macular edema following RVO (June 2010), DME (August 2012), and DR (April 2017).⁵⁸ I understand that

⁵⁷ Ex. 2199 (Genentech Press Release, “FDA Approves Lucentis for the Treatment of Wet Age-Related Macular Degeneration,” 6/30/2006, <https://www.roche.com/dam/jcr:4ca7683d-1513-4e46-bd43-23faa0232507/en/irp060703.pdf>).

Ex. 2212 (Lucentis Label, c. 2006, at 1).

⁵⁸ Ex. 2198 (GEN, “FDA Green-Lights Genentech’s Lucentis for Macular Edema following Retinal Vein Occlusion,” 6/23/2010, <https://www.genengnews.com/news/fda-green-lights-genentechs-lucentis-for-macular-edema-following-retinal-vein-occlusion/>).

Ex. 2257 (Roche Press Release, “FDA Approves Lucentis for Treatment of Diabetic Macular Edema,” 8/13/2012, <https://www.roche.com/investors/updates/inv-update-2012-08-13.htm>).

Ex. 2258 (Roche Press Release, “FDA Approves Roche’s Lucentis for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age

Lucentis administration can allow patients to regain some of the vision losses from angiogenic eye disorders.⁵⁹

6.2.4. Eylea

(35) Eylea is the brand name of the biologic aflibercept, an anti-VEGF fusion protein developed by Regeneron Pharmaceuticals.⁶⁰ Eylea was approved for

Adults in the United States, 4/18/2017,

<https://www.roche.com/media/releases/med-cor-2017-04-18b.htm>).

Ex. 2213 (Drugs@FDA, Lucentis Label, 6/2010, at 5, available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125156s053lbl.pdf).

Ex. 2214 (Drugs@FDA, Lucentis Label, 8/2012, at 6, available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf).

⁵⁹ Ex. 2050 (Brown Declaration, 2/10/2022, at ¶ 40).

⁶⁰ Ex. 2146 (American Academy of Ophthalmology, “What is Eylea”, 4/23/2021, <https://www.aao.org/eye-health/drugs/what-is-eylea>).

Ex. 2185 (Eylea Label, 11/2011, at 9, 15).

the treatment of wet AMD in November of 2011.⁶¹ Eylea has also been approved for treatment of DME (July 2014), RVO (initially in September 2012 for CRVO, expanded in October 2014), and general DR (May 2019).⁶²

A fusion protein is an engineered molecule that incorporates the genes of two proteins and has an enhanced ability to treat disease. See:

Ex. 2153 (Amgen Website, Fusion Protein, <https://www.amgen.com/stories/2018/08/the-shape-of-drugs-to-come/fusion-protein> (accessed 1/7/2022)).

⁶¹ Ex. 2185 (Eylea Label, 11/2011, at 1).

⁶² Ex. 2247 (Regeneron Press Release, “Eylea Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME),” 7/29/2014, <https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-treatment>).

Ex. 2252 (Regeneron Press Release, “Regeneron Announces FDA Approval of Eylea Injection for Macular Edema Following Central Retinal Vein Occlusion,” 9/21/2012, <https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylear-aflibercept-injection>).

Most recently in 2019, Eylea was approved to treat patients with any stage of DR.⁶³ As with Lucentis and Avastin, I understand that Eylea administration can assist patients to regain some of the vision losses from angiogenic eye disorders.⁶⁴

Ex. 2248 (Regeneron Press Release, “Eylea Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO),” 10/6/2014, <https://investor.regeneron.com/news-releases/news-release-details/eylear-aflibercept-injection-receives-fda-approval-macular-edema>).

Ex. 2249 (Regeneron Press Release, “FDA Approves Eylea Injection for Diabetic Retinopathy”, 5/13/2019, <https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-diabetic-retinopathy>).

Ex. 2187 (Eylea Label, 10/2014, at 4).

⁶³ Ex. 2188 (Eylea Label, 5/2019, at 4).

⁶⁴ Ex. 1001 (U.S. Patent No. 9,254,338, Example 4).

6.2.5. Beovu

- (36) Beovu is the brand name for the biologic brolucizumab, an antibody fragment and VEGF inhibitor introduced by Novartis.⁶⁵ The FDA approved Beovu in vial form in October 2019 to treat patients with wet AMD.⁶⁶ At the time, it was the only anti-VEGF product to offer possible vision maintenance for wet

⁶⁵ Ex. 2161 (Drugs@FDA, Beovu Label, 10/2019, at 7, 14, 18, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf).

⁶⁶ Ex. 2231 (Novartis Press Release, “Novartis Receives FDA Approval for Beovu, Offering Wet AMD Patients Vision Gains and Greater Fluid Reductions vs Aflibercept,” 10/8/2019, <https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept>).

Ex. 2161 (Beovu Label, 10/2019, at 7, 18).

AMD patients using a three-month dosing interval following a loading phase of three injections administered monthly.⁶⁷

- (37) Although Beovu had initial success, safety concerns arose regarding vision loss associated with the product. In February 2020, the American Society of Retina Specialists issued a note to members informing them of cases of retinal vasculitis in Beovu patients.⁶⁸ Four months later, Novartis revised Beovu’s label to include the newly established risk. The FDA approved the new label

⁶⁷ Ex. 2231 (Novartis Press Release, “Novartis Receives FDA Approval for Beovu, Offering Wet AMD Patients Vision Gains and Greater Fluid Reductions vs Aflibercept,” 10/8/2019).

Ex. 2161 (Beovu Label, 10/2019, at 7).

⁶⁸ Ex. 2193 (FiercePharma, “Novartis’ Hot New Eye Drug Beovu Tied to Potential Vision Loss: Experts,” 2/24/2020, <https://www.fiercepharma.com/pharma/retinal-society-flags-serious-side-effect-for-novartis-beovu>).

Retinal vasculitis is the inflammation of retinal blood vessels. See:

Ex. 2144 (American Academy of Ophthalmology Website, Retinal Vasculitis, https://eyewiki.aao.org/Retinal_Vasculitis (accessed 1/13/2022)).

in June 2020.⁶⁹ Beovu’s revised label added expanded “warnings and precautions” to include retinal vasculitis and RVO,⁷⁰ both of which can result in permanent vision loss.⁷¹ Further, these new side effects do not apply to other

⁶⁹ Ex. 2232 (Novartis Press Release, “US FDA Approves Updated Novartis Beovu Label, to Include Additional Safety Information,” 6/11/2020, <https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information>).

⁷⁰ See changes to the warnings and precautions between the two labels:

Ex. 2162 (Drugs@FDA, Beovu Label, 6/2020, at 3, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761125s004lbl.pdf).

Ex. 2161 (Beovu Label, 10/2019, at 7).

⁷¹ Ex. 2180 (Miller & Zois, LLC, “Novartis Looking to Repurpose its Dangerous Beovu Drug,” 11/28/2020, <https://www.drugrecalllawyerblog.com/novartis-repurpose-beovu.html>).

available anti-VEGF treatments.⁷² Ophthalmologists may have hastened their disuse of Beovu because Covid-19 related shutdowns made it difficult for physicians to undertake recommended post-administration monitoring of patients following Beovu injections, and as a result, Beovu utilization has fallen substantially.⁷³ According to data from Vestrum, Beovu's sales share peaked at ~2.5% in 2020-Q1, two quarters after its launch in 2019-Q3. See Attachment X-1. The sales share began declining in 2020-Q2 and Q3, which

⁷² Unlike the Beovu label, the warnings and precautions on the labels for Eylea and Lucentis do not list retinal vasculitis nor retinal vascular occlusion. See: Ex. 2189 (Eylea Label, 3/2021, at 3).

Ex. 2216 (Drugs@FDA, Lucentis Label, 3/2018 at 4, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf).

Ex. 2193 (FiercePharma, "Novartis' Hot New Eye Drug Beovu Tied to Potential Vision Loss: Experts," 2/24/2020).

⁷³ Ex. 2192 (FiercePharma, "Beovu, Novartis," 10/25/2021, <https://www.fiercepharma.com/special-report/beovu-novartis-top-10-drug-launch-disasters>).

corresponds with the timing of the new warnings on the label. Beovu's sales share in 2021-Q3 was ~0.7%. See Attachment X-1.

6.2.6. FDA approvals for anti-VEGF treatments

(38) Table 2 contains the FDA approval dates, if applicable, for the 5 anti-VEGF treatment options (Macugen, Avastin, Lucentis, Eylea, and Beovu).

Table 2: FDA Approval Dates⁷⁴

Treatment	Wet AMD	RVO	DME	DR
Macugen	Dec. 2004	n/a	n/a	n/a
Avastin	Off-label	Off-label	Off-label	Off-label
Lucentis	Jun. 2006	Jun. 2010	Aug. 2012	Apr. 2017
Eylea	Nov. 2011	Sep. 2012	Jul. 2014	May 2019
Beovu	Oct. 2019	n/a	n/a	n/a

⁷⁴ For Macugen See Section 6.2.1

For Avastin See Section 6.2.2

For Lucentis See Section 6.2.3

For Eylea See Section 6.2.4

6.2.7. FDA-approved dosing schedules for anti-VEGF treatment options

- (39) Three of the anti-VEGF treatment options used for diseases of the retina (Eylea, Lucentis, and Beovu) have a recommended dosing schedule on their FDA approved labels.⁷⁵ Avastin is used off-label for the treatment of retinal disease and as such does not have an FDA approved label for these uses.⁷⁶ The FDA approved label for each of the three products recommends monthly loading injections for the first three to five months, depending on the indication, followed by an on-going maintenance dosing schedule.⁷⁷

For Beovu See Section 6.2.5

⁷⁵ Ex. 2189 (Eylea Label, 3/2021, at 3).

Ex. 2216 (Lucentis Label, 3/2018, at 4).

Ex. 2162 (Beovu Label, 6/2020, at 3).

⁷⁶ Recall that treatment of retinal diseases with Avastin is “off-label”. See Section 6.2.2.

⁷⁷ For example, Eylea’s directions for wet AMD state: “The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4

- (40) Following the loading period, each of the three FDA approved treatments has a different recommended dosing interval depending upon the indication. Table 3 below summarizes the recommended dosing intervals. See Attachment B-1.

weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).”

Ex. 2189 (Eylea Label, 3/2021, at 3).

Ex. 2216 (Lucentis Label, 3/2018, at 4).

Ex. 2162 (Beovu Label, 6/2020, at 13).

Table 3: Recommended and Maximum Dosing in Maintenance Phase⁷⁸

Condition⁷⁹	Eylea	Lucentis	Beovu⁸⁰
Wet AMD (Recommended)	8 weeks	4 weeks	8 to 12 weeks
Wet AMD (Maximum)	12 weeks	12 weeks	8 to 12 weeks
DME	8 weeks	4 weeks	n/a
DR	8 weeks	4 weeks	n/a
RVO	4 weeks	4 weeks	n/a

(41) For wet AMD, DME, and DR, Eylea’s recommended dosing interval of 8 weeks is longer than Lucentis’ recommended dosing interval of 4 weeks. For the treatment of wet AMD only, the FDA labels for Eylea and Lucentis also

⁷⁸ Avastin omitted as there is no approved label for the relevant conditions.

⁷⁹ Eylea and Lucentis labels contain different recommended dosing intervals and maximum dosing intervals for the maintenance phase when treating wet AMD. Recommended and maximum dosing intervals do not differ for the three other disorders.

⁸⁰ Beovu is not indicated for treatment of DME, DR, or RVO.

disclose alternative dosing schedules with longer time between injections.

However, these alternatives come with precautions that the alternative intervals are not as effective as the recommended dosing interval.⁸¹ See Attachment B-1.

- (42) Although Eylea’s recommended dosing for RVO calls for maintenance doses every 4 weeks, I understand that for some RVO patients, physicians will use maintenance doses with 8 week or longer intervals.⁸² Because the patented dosing regimen is used for some RVO patients and may have contributed to commercial success, I include RVO treatments in the analyses presented later in my declaration.

⁸¹ Ex. 2189 (Eylea Label, 3/2021, at 3). (“Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.”)

Ex. 2216 (Lucentis Label, 3/2018, at 4). (“Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.”)

⁸² Ex. 2051 (Do Declaration, 2/10/2022, at ¶ 138).

7. Medicare Part B Reimbursement Policy

(43) Because angiogenic eye diseases are more likely to affect older patients (see Section 5), a large portion of anti-VEGF treatments are paid for through Medicare Part B which provides outpatient medical coverage.⁸³ Medicare eligibility generally begins at age 65.⁸⁴ The anti-VEGF treatments are reimbursed as Medicare Part B physician-administered drugs.⁸⁵ Physician-

⁸³ Ex. 2223 (Medicare Interactive Website, Medicare Part B Covered Services, <https://www.medicareinteractive.org/get-answers/medicare-covered-services/medicare-coverage-overview/summary-of-part-b-covered-services> (accessed 11/22/2021)).

Ex. 2218 (Regeneron, “Eylea (aflibercept) Injection: Components of Reimbursement,” c. 2015, at 3–6).

⁸⁴ Ex. 2227 (Medicare Website, When Does Medicare Coverage Start?, <https://www.medicare.gov/basics/get-started-with-medicare/sign-up/when-does-medicare-coverage-start> (accessed 12/15/2021)).

⁸⁵ Ex. 2223 (Medicare Interactive Website, Medicare Part B Covered Services (accessed 11/22/2021)). (“Select prescription drugs, including

administered drugs are typically purchased by physicians and then “sold” to patients upon administration.⁸⁶ This process creates two parts to Medicare Part B reimbursement – drug costs and physician fees.⁸⁷

immunosuppressant drugs, some anti-cancer drugs, some anti-emetic drugs, some dialysis drugs, and drugs that are typically administered by a physician.”)

All anti-VEGF treatments are included in the Centers for Medicare & Medicaid Services Medicare Part B Drug Average Sales Price files.

Ex. 2172 (Centers for Medicare & Medicare Services Website, 2021 ASP Drug Pricing Files, <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files> (accessed 11/22/2021)).

⁸⁶ Ex. 2165 (USC-Brookings, “Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward,” 2/10/2021, at PDF 1, available at: <https://www.brookings.edu/blog/usc-brookings-schaeffer-on-health-policy/2021/02/10/medicare-payment-for-physician-administered-part-b-drugs/>).

⁸⁷ Ex. 2165 (USC-Brookings, “Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward,” 2/10/2021, at PDF 1). (“Medicare bases payment for physician-administered medicines on

- (44) Starting in 2005, physician-administered drugs were reimbursed at a drug's Average Sales Price (ASP) plus 6%.⁸⁸ “By law, a drug's ASP is defined as the volume-weighted average manufacturer sales price net of all rebates, discounts, and other price concessions to U.S. purchasers.”⁸⁹ This 106% of ASP is referred to as the “payment limit.”⁹⁰

the prices charged for products grouped together into a single billing code, plus 6 percent of the ‘average sales price’ (ASP) for that billing code. (Medicare also separately pays physicians for the cost of administration based its physician fee schedule rather than the cost of the medicine).”)

⁸⁸ Ex. 2155 (U.S. Department of Health and Human Services (ASPE), “Medicare Part B Reimbursement of Prescription Drugs,” 6/2014, at 2, available at: https://aspe.hhs.gov/sites/default/files/private/pdf/106966/ib_mprpd.pdf).

⁸⁹ Ex. 2155 (U.S. Department of Health and Human Services (ASPE), “Medicare Part B Reimbursement of Prescription Drugs,” 6/2014, at 2).

⁹⁰ Centers for Medicare & Medicaid Services Website, 2021 ASP Drug Pricing Files, <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asg-drug-pricing-files> (accessed 11/22/2021). (“ ... the payment limit determined using the current ASP+6% methodology.”)

- (45) In addition to drug cost reimbursement, physicians are also reimbursed for their services under the Physician Fee Schedule.⁹¹ The fees are calculated based on a variety of factors including amount of time, technical skill, equipment, and professional liability involved in the provision of the service.⁹²

Beginning in 2013, a federal sequestration order resulted in a Part B drug reimbursement falling from 106% to 104.3% of ASP.

Ex. 2268 (Weidner, Susan, et al. (2021), “Observations Regarding the Average Sales Price Reimbursement Methodology,” *Evidence-Based Oncology* 27(4): 156–160, at PDF 1).

⁹¹ Ex. 2174 (Centers for Medicare & Medicaid Services Website, Physician Fee Schedule, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched> (accessed 11/22/2021)).

Ex. 2154 (American Speech-Language-Hearing Association Website, Calculating Medicare Fee Schedule Rates, <https://www.asha.org/practice/reimbursement/medicare/calculating-medicare-fee-schedule-rates/> (accessed 11/22/2021)).

⁹² Ex. 2154 (American Speech-Language-Hearing Association Website, Calculating Medicare Fee Schedule Rates, (accessed 11/22/2021)).

CONFIDENTIAL MATERIAL– SUBJECT TO PROTECTIVE ORDER

As an example, CMS’s National Coverage Policy for Eylea instructs that physicians submit two claims in order to bill for their services.⁹³ The first claim is a billing code with the description “Injection, aflibercept, 1mg” (despite the fact that a single injection of Eylea is a 2mg dose), and the second claim is a billing code for “Intravitreal injection of a pharmacologic agent” (i.e., the physician fee).⁹⁴

- (46) Medicare Part B does not cover the full amount of the payments owed to physicians. Instead, Medicare covers 80% of the payments, and Medicare beneficiaries (patients) are responsible for a copayment equal to the remaining

⁹³ Ex. 2175 (CMS.gov Medicare Coverage Database, “Billing and Coding: Aflibercept (Eylea),” 4/22/2021, at 2, available at: <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=53387&ver=28&keyword=&keywordType=starts&areaId=all&docType=6,3,5,1,F,P&contractOption=all&hcpcsOption=code&hcpcsStartCode=J0178&hcpcsEndCode=J0178&sortBy=title&bc=1>).

⁹⁴ Ex. 2175 (CMS.gov Medicare Coverage Database, “Billing and Coding: Aflibercept (Eylea),” 4/22/2021, at 2).

20% of the cost of both the drug and the physician’s service.⁹⁵ While there are exceptions to this 80/20 split, according to Medicare.gov, macular degeneration tests and treatment require the 20% copayment.⁹⁶ That said, beneficiaries can offset the cost of copayments through participation in a

⁹⁵ Ex. 2165 (USC-Brookings, “Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward,” 2/10/2021, at PDF 2). (“For the minority of patients without supplemental coverage, physicians might take into consideration the 20 percent coinsurance that patients pay.”)

⁹⁶ Ex. 2225 (Medicare.gov Website, Macular Degeneration Tests & Treatment, <https://www.medicare.gov/coverage/macular-degeneration-tests-treatment> (accessed 11/22/2021)).

Medicare Supplement policy.⁹⁷ In 2018, approximately 83% of traditional Medicare beneficiaries had some type of supplementary coverage.⁹⁸

- (47) According to CMS, most Medicare beneficiaries enrolled in Medicare Advantage plans (approximately 42% of the total Medicare population)

⁹⁷ Ex. 2165 (USC-Brookings, “Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward,” 2/10/2021, at PDF 2). (“ For the minority of patients without supplemental coverage, physicians might take into consideration the 20 percent coinsurance that patients pay.”)

Ex. 2154 (American Speech-Language-Hearing Association Website, Calculating Medicare Fee Schedule Rates, (accessed 11/22/2021)). (“Medicare will accept 80% of the allowable amount of the Medicare Physician Fee Schedule (MPFS) and the patient will pay a 20% co-insurance at the time services are rendered or ask you to bill their Medicare supplemental policy.”)

⁹⁸ Ex. 2209 (Kaiser Family Foundation, “A Snapshot of Sources of Coverage Among Medicare Beneficiaries in 2018,” 3/23/2021, at PDF 2, available at: <https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries-in-2018/>).

receive coverage for Part B drugs as part of their overall plan.⁹⁹ These plans limit exposure to out-of-pocket costs for these products.¹⁰⁰ Coverage for prescription drugs varies across Medicare Advantage plans and providers and across private insurance providers. Eylea is covered by most plans, including Medicare, Medicare Advantage, most commercial payers, and most state

⁹⁹ Ex. 2226 (Medicare.gov Website, Medicare Advantage Plans, <https://www.medicare.gov/sign-up-change-plans/types-of-medicare-health-plans/medicare-advantage-plans> (accessed 12/31/2021)).

Ex. 2210 (Kaiser Family Foundation, “Medicare Advantage in 2021: Enrollment Update and Key Trends,” 6/21/2021, <https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2021-enrollment-update-and-key-trends/>).

¹⁰⁰ Ex. 2226 (Medicare.gov Website, Medicare Advantage Plans (accessed 12/31/2021)).

Medicaid plans.¹⁰¹ Further, most commercial payers provide the same benefits for Eylea and Lucentis.¹⁰²

¹⁰¹ Ex. 2218 (Regeneron, “Eylea (aflibercept) Injection Components of Reimbursement,” c. 2015, at 5, 6).

¹⁰² Ex. 2218 (Regeneron, “Eylea (aflibercept) Injection Components of Reimbursement,” c. 2015, at 5, 6).

8. Commercial Success

(48) Eylea has achieved commercial success as a treatment for angiogenic eye disorders. This commercial success is demonstrated by its sales since launch, by its performance relative to other available treatments, and by the nexus of these sales to the method of treatment covered by the '338 Patent's claims. Eylea's historical commercial performance is discussed below.

8.1. U.S. Eylea sales and revenue

(49) Regeneron has provided gross sales and net sales of Eylea in the United States over the period from 2011 to 2021.¹⁰³ In calculating net sales, Regeneron deducts returns, rebates, and discounts from gross sales.¹⁰⁴ These deductions are similar to the deductions used by other pharmaceutical companies to

¹⁰³ Ex. 2285 (Regeneron, Eylea Gross & Net Sales P&L YTD, c.2021, at tab "Gross & Net Sales P&L YTD").

¹⁰⁴ Ex. 2285 (Regeneron, Eylea Gross & Net Sales P&L YTD, c.2021, at tab "Gross & Net Sales P&L YTD").

Ex. 2263 (Regeneron, Eylea Sales Summary, c.2020).

calculate net sales.¹⁰⁵ Eylea has achieved commercial success as measured by gross sales and net sales.

8.1.1. Gross sales

- (50) Regeneron generated [REDACTED] and [REDACTED] in U.S. gross sales of Eylea in 2012 and 2021, respectively. See Attachment D-2. From 2012 to 2021, the compound annual growth rate was [REDACTED], and the absolute growth rate was [REDACTED]. See Attachment D-2. Cumulative U.S. gross sales of Eylea from its launch in 2011 through 2021 were [REDACTED].
- (51) Eylea’s successful growth of net and gross sales has been driven by its increasing use by physicians. In terms of unit sales, Eylea has been sold in both vials and prefilled syringes (introduced in 2019), each containing one dose (2mg) and constituting one unit. See Attachment D-1. In 2012, Regeneron sold [REDACTED] units of Eylea in the U.S., and in 2021, Regeneron sold [REDACTED] units in the U.S. See Attachment D-2. This demonstrates a

¹⁰⁵ See for example:

Ex. 2256 (Roche, “Finance Report”, 2020, at 63).

Ex. 2230 (Novartis, “Annual Report”, 2020, at 65).

Ex. 2160 (Bausch Health Companies, Form 10-K, 2020, at 77).

compound annual growth rate of [REDACTED], and an absolute growth rate of [REDACTED] over the period.¹⁰⁶ See Attachment D-2. Cumulative U.S. unit sales of Eylea from its launch in 2011 through 2021 were [REDACTED] units.¹⁰⁷

8.1.2. Net sales

(52) In 2012, the first full calendar year following Eylea’s launch, Regeneron generated \$837.94 million in total net sales. See Attachment D-2. Since 2012, Eylea has realized positive year over year growth in net sales in every year, with all but one year (2020) experiencing double digit percentage sales growth. See Attachment D-2. In 2021, Eylea achieved \$5.8 billion in U.S. net sales. See Attachment D-2. Consistent with this level of success domestically, one online source reported that Eylea ranked 6th in global drug sales.¹⁰⁸

¹⁰⁶ Differences in calculated growth rates for unit sales and gross sales are due to rounding of gross sales values. See Attachment D-2.

¹⁰⁷ Since Regeneron launched its Eylea PFS version in 2019, nearly all unit sales have converted to PFS. See Attachment D-1.


¹⁰⁸ Ex. 2194 (FiercePharma, “The Top 20 Drugs by Worldwide sales in 2020,” 5/3/2021, <https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales>).

Despite the fact that Regeneron has not increased the price of Eylea since its launch in 2011,¹⁰⁹ Eylea’s U.S. net sales grew at a compound annual rate of 24.0% and an absolute rate of 591.3% from 2012 to 2021. See Attachment D-2. Total cumulative U.S. net sales of Eylea from its launch in 2011 through 2021 were \$33.2 billion. Chart 1 below illustrates the growth in U.S. net sales of Eylea. See Attachment D-7.

¹⁰⁹ See Attachment D-6.

Ex. 2229 (Regeneron, WAC Pricing File, 5/2021, at tab “Analysis”).

Chart 1: Eylea U.S. Net Sales (2011–2021)



8.2. U.S. Eylea profits

(53) Regeneron has earned substantial profit from its sales of Eylea. Regeneron evaluates Eylea’s financial performance by calculating gross profits and operating profits, common performance metrics for companies in the biopharmaceutical industry.¹¹⁰ Eylea’s gross profits are calculated by subtracting costs of goods sold (COGS) such as product manufacturing costs (referred to in the commercial P&L for Eylea as “Drug”), royalties (including

¹¹⁰ Conversation with Regeneron Executive Director, Commercial Finance & Business Planning and Senior Director, FP&A.

royalties to Genentech and [REDACTED]), and spoilage costs from net product sales.¹¹¹ Table 4 below illustrates the P&L line items for Eylea. See Attachment D-1.

¹¹¹ Ex. 2200 (Regeneron, “U.S. Eylea Historical Brand P&L,” 5/2021, at 2).

A complete P&L for Eylea can be found in Attachment D-1.

Table 4: U.S. Eylea P&L Example (*values in millions*)

Metric	2020	2021
Gross sales [a]	████████	████████
Gross sales deductions [b] ¹¹²	████████	████████
Net sales [c = a + b]	\$4,947.2	\$5,792.3
Total cost of goods sold [d]	████████	████████
Drug	████████	████████
Royalty	████████	████████
Spoilage & reserves	████████	████████
Total other operating costs [e]	████████	████████
External expenses	████████	████████
People expenses	████████	████████
Pharma fee	████████	████████
Gross profit [f = c - d]	████████	████████
Operating profit [g = c - e]	████████	████████

¹¹² Gross sales deductions refer to line items deducted from gross sales to obtain net sales. Deductions for Eylea include reserves, Medicare rebates, co-pay

- (54) Gross profits from Eylea sales in the U.S. have grown from [REDACTED] in 2011, or [REDACTED] of 2011 net sales, to [REDACTED] in 2021, or [REDACTED] of 2021 net sales. See Attachment D-1. From 2011 through 2021, Regeneron earned [REDACTED] in gross profits from sales of Eylea in the U.S., or [REDACTED] of total net sales over the same period. See Attachment D-1.
- (55) Regeneron calculates operating profits by subtracting additional expenses, including marketing expenditures (referred to as “External Expenses”), labor costs (referred to as “People Expenses”), and the branded prescription drug fee under the Affordable Care Act (referred to as “Pharma Fee”) from gross profits.¹¹³ Operating profits from sales of Eylea in the U.S. have grown from [REDACTED] in 2011, or [REDACTED] of 2011 net sales, to [REDACTED] in 2021, or [REDACTED] of net sales. See Attachment D-1. From 2011 through 2021, Regeneron earned

assistance, chargebacks, rebates, discounts, and specialty pharmacy, distributor, and credit card fees. See Attachment D-1.

¹¹³ Ex. 2200 (Regeneron, “U.S. Eylea Historical Brand P&L,” 5/2021, at 3).

Conversation with Regeneron Executive Director, Commercial Finance & Business Planning and Senior Director, FP&A.

██████████ in operating profits from sales of Eylea in the U.S, or ██████████ of total net sales over the same period. See Attachment D-1.

8.3. Eylea's share of anti-VEGF sales

- (56) In addition to sales since launch, a product's performance relative to other available products provides evidence of commercial performance that may demonstrate commercial success. The performance of other products provides context necessary for evaluating whether a patented product was commercially successful. Moreover, if a patented product captures sales previously made by other products, the patented product demonstrates that it offers, at least for some consumers, a value proposition superior to that offered by the previously available products. After establishing a nexus to the patented features, these captured sales can demonstrate demand for the patented features and that the patented feature directly contributed to the commercial success of the product
- (57) Because of the price disparities of the treatments being compared in this matter (see Section 8.4), relative performance is evaluated using "share of sales" measures, either share of unit sales or share of treated patients. Such measures isolate treatment uptake from price disparities. For simplicity, I refer to both measures as "sales shares" or "share of sales."

8.3.1. Data sources

(58) For analysis of relative sales performance among potential treatments for the relevant angiogenic eye disorders, I rely on three data sources: Medicare Part B physician treatment data provided by the Centers for Medicare & Medicaid Services (CMS), Vestrum data, and Regeneron’s Awareness, Trial, and Usage (ATU) surveys. Each of these data sources is described below. I consider all three data sources as each has its respective merits. However, all of the data sources show strong sales growth and overall sales share for Eylea since launch.

Medicare Part B services and procedures

(59) CMS reports annual usage of physician services paid under Medicare Part B over the period from 2012 to 2019 (the latest year available).¹¹⁴ Medicare Part

¹¹⁴ Data first became available in 2012. See:

Ex. 2220 (Manning, Richard, et al. (2015), “Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?” *International Journal of the Economics of Business* 22(2): 231–243, at 234). (“Recently, the Centers for Medicare and Medicaid Services made available to the public for

B data provide information on services and procedures provided to Medicare Part B beneficiaries by physicians and other healthcare professionals, aggregated by provider and service.¹¹⁵ The data contain information including

the first time detailed data regarding the Medicare Part B program. The data cover all of 2012...”)

The latest available data is 2019. See: Ex. 2168 (Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, (accessed 11/19/2021)).

Medicare has four components. Part A provides coverage for inpatient/hospital care; Part B provides coverage for physician care, Part C (also referred to as Medicare Advantage) provides Parts A and B services via a private health plan; and Part D provides prescription drug coverage. See:

Ex. 2224 (Medicare Interactive Website, The Parts of Medicare (A, B, C, D), <https://www.medicareinteractive.org/get-answers/medicare-basics/medicare-coverage-overview/original-medicare> (accessed 11/30/2021)).

¹¹⁵ Ex. 2168 (Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, (accessed 11/19/2021)).

services provided, drugs administered, and the amounts paid by Medicare Part B for those services and drugs.¹¹⁶ For example, for all relevant conditions, the file for 2019 contains more than 10.1 million records of data for more than 1 million healthcare providers.¹¹⁷ The Medicare Part B data have various attributes that affect the analysis and provide insight into the share of relevant sales captured by Eylea.

- As indicated, Medicare Part B data are not limited to treatments for angiogenic eye disorders, but contain all services and procedures paid for under Medicare Part B. Because treatments like Avastin are used in settings other than angiogenic eye disorders (i.e., in treating cancer), calculating total treatments (and from these, shares of sales) using each relevant drug or biologic would not reflect the portion of people with relevant angiogenic eye disorders who received these treatments. In order

¹¹⁶ Ex. 2220 (Manning (2015), at 234).

¹¹⁷ See 2019 data file at:

Ex. 2168 (Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, (accessed 11/19/2021)).

to analyze sales shares of anti-VEGF treatments for the relevant indications paid for by Medicare Part B, I restrict the sample to include payments for treatments administered only by ophthalmologists.¹¹⁸

- The Medicare Part B dataset lacks information about underlying patient conditions being treated, so shares of sales by product can only be calculated in aggregate across all indications (rather than separately for, e.g., wet AMD and DR) treated by ophthalmologists.
- As indicated above, these data are reported annually and are available for the years 2012 through 2019. See Attachment X-3. Notably, these data include three of the four anti-VEGF treatment options (Eylea, Lucentis, and Avastin) and several of the other treatment options (e.g., Visudyne, and Macugen). See Attachment X-3. As discussed below, the other available data sources used in the sales share analysis focus on the anti-VEGF treatment options of Eylea, Avastin, Lucentis, and Beovu.

Vestrum Health

(60) Vestrum Health is a company that gathers and analyzes data from electronic health records and packages them for sale to retina practices and

¹¹⁸ This is consistent with the analytical approach used in: Ex. 2220 (Manning (2015), at 235). (“Specifically, we limited the data to ophthalmologists...”)

pharmaceutical companies, including Regeneron.¹¹⁹ Regeneron uses data from Vestrum in the course of its business to assess the commercial performance of its products.¹²⁰ Specifically, Regeneron began using Vestrum data in 2019 to supplement its use of ATU survey responses in comparing sales of Eylea, Avastin, Lucentis, and Beovu.¹²¹ The Vestrum data provided cover a period beginning in 2016.

- The Vestrum data are presented in quarterly reports on the sales shares of the four most commonly used anti-VEGF treatment options (i.e., Eylea, Lucentis, Avastin, and Beovu). See Attachment X-1. Vestrum data are available from 2016-Q1 to 2021-Q4. In addition, the Vestrum data include indication-level sales shares. In other words, the sales shares of Eylea,

¹¹⁹ Ex. 2265 (Vestrum Health Website, Homepage, <https://www.vestrumhealth.com/index.php> (accessed 1/3/2022)).

Ex. 2266 (Vestrum Health Website, Pharmaceutical Companies, <https://www.vestrumhealth.com/pharma.php> (accessed 1/3/2022)).

¹²⁰ Conversation with Regeneron Director, Customer Insights.

For example: Ex. 2272 (Regeneron, “Eylea Q2 2021 Performance,” 8/2/2021).

¹²¹ Conversation with Regeneron Director, Customer Insights.

Lucentis, Avastin, and Beovu are calculated separately for patients with wet AMD, with DR, with DME, and with RVO. See Attachment X-1.

Regeneron ATU surveys

- (61) The third source of data on sales shares is Regeneron’s ATU surveys. These are quarterly surveys of approximately 200 eye care practitioners in the U.S., or approximately 6% of the over 3,000 ophthalmologists and retinal specialists that treat the relevant diseases.¹²² See Section 5. Samples of this size are consistent with common practice in market research.¹²³ Moreover, the

¹²² Ex. 2176 (Regeneron, “Q4 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 1/29/2021, at 136).

Conversation with Regeneron Director, Customer Insights.

¹²³ Ex. 2195 (FocusVision, “Survey Sample Size: How Much Do I Need?” 4/11/2019, <https://www.focusvision.com/blog/survey-sample-size-how-much-do-i-need/>).

Under standard calculation approaches, sample sizes of 200 for a population of 3,000 physicians yields a 6.7% margin of error.

Ex. 2171 (CloudResearch Website, Determining Sample Size: How Many Survey Participants Do You Need?

presentations summarizing survey responses regularly contain results from statistical testing for differences between anti-VEGF treatments.¹²⁴

- Regeneron’s “Eylea brand team” began the ATU survey in 2011 to assess “the current state of the market on several critical metrics (awareness, opinions[,] and behavior).”¹²⁵ Regeneron has published the results and key takeaways in quarterly, internal reports. The surveys provide information

<https://www.cloudresearch.com/resources/guides/statistical-significance/determine-sample-size/> (accessed 1/25/2022)).

Ex. 2166 (Calculator.net Website, Sample Size Calculator, <https://www.calculator.net/sample-size-calculator.html?type=2&cl2=95&ss2=200&pc2=50&ps2=3000&x=68&y=18#findci> (accessed 1/25/2022)).

¹²⁴ For example: Ex. 2176 (Regeneron, “Q4 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME,” 1/29/2021, at 11-18).

¹²⁵ Ex. 2197 (Regeneron, “Physician ATU – Benchmark Wave,” 9/15/2011, at 2).

on relative product performance, drivers of physician treatment choice, and physician dosing practices, among other information.¹²⁶

- One of the key topics covered in the ATU surveys is the shares of the four most commonly used anti-VEGF treatment options (i.e., Eylea, Lucentis, Avastin, and Beovu). See Attachment X-2. Additionally, indication level data are available. See Attachment X-2.

(62) As discussed above, data from these three sources are used to calculate unit share (Vestrum) or patient share measures (Medicare Part B; ATU surveys). Patient shares for the Medicare Part B data are calculated by aggregating the number of unique Medicare beneficiaries that received each treatment. See Attachment X-3. Patient shares for the ATU data are reported within the produced documents as the share of treated eyes. For Vestrum data, generally Regeneron's presentations refer to the projections as a measure of the share of injections.¹²⁷

¹²⁶ For example: Ex. 2176 (Regeneron, "Q4 2020 Performance Update Wet AMD, DME, MEfRVO & DR w/out DME," 1/29/2021).

Conversation with Regeneron Director, Customer Insights.

¹²⁷ Ex. 2272 (Regeneron, "Eylea Q2 2021 Performance," 8/2/2021).

- (63) In my analyses of Eylea’s share of sales, I consider all three data sources. When discussing Eylea’s share of sales, I do not distinguish between Eylea’s share including non-anti-VEGF treatments (Medicare Part B) and its share excluding them (Vestrum and ATU). This is a reasonable simplification as the anti-VEGF treatments account for the vast majority of treatments (e.g., 95.4% as of 2019). See Attachment C-1. Further, this simplification does not impact any important conclusions of the analysis.

8.3.2. Eylea’s historic patient share as an indicator of commercial success

- (64) Eylea was approved for sale in the U.S. by the FDA on November 18, 2011 for the treatment of wet AMD.¹²⁸ The product was quickly adopted by physicians, and according to ATU data by the first quarter of 2012, it achieved

Although one presentation described Vestrum as measuring treated eyes, the August 2021 presentation characterized it as measuring injection shares.


Ex. 2275 (Regeneron, “Vestrum Anti-VEGF Market Share Adjustment Overview,” 5/10/2019, at 3).

¹²⁸ Ex. 2181 (Drugs.com Website, Eylea FDA Approval History, <https://www.drugs.com/history/eylea.html> (accessed 11/16/2021)).

Ex. 2185 (Eylea Label, 11/2011, at 1).

an [REDACTED] sales share among patients with wet AMD who were treated using the major anti-VEGF treatments (Eylea, Avastin, or Lucentis). See Attachment X-2. By the end of 2012, Eylea's sales share was between [REDACTED] and [REDACTED] (depending on the data source used). See Attachment C-1. By the end of 2021, Eylea's overall sales share (across all relevant indications) was between [REDACTED] and [REDACTED], making it the largest selling product in the product category. See Attachment C-1. Chart 2 illustrates the rapid rise in Eylea's patient share since its launch. See Attachment C-6. As discussed in greater detail below, Eylea achieved a sales share similar to Avastin's despite the latter's substantially lower price. See Section 8.4.

**Chart 2: Eylea's Sales Share Across Different Data Sources –
All Indications¹²⁹**



(65) This trend of success holds true across each indication for which Eylea is approved. In general, when Eylea has been approved for a new indication, it

¹²⁹ In this chart and all other charts related to sales shares, data for 2021 reflect the most current data produced by Regeneron. For ATU, data through 2021-Q2 has been produced. For Vestrum, data through 2021-Q4 has been produced. See Attachment X-1 and X-2.

Medicare Part B: A linear regression of Eylea Patient Share on Year results in a slope of ~3.8%*** (p-value of ~0.0006).

has quickly gained sales, achieving a share of sales of about [REDACTED] or more in the first year and rising to achieve the highest or second highest share of sales in the relevant category by 2021.¹³⁰ See Attachments C-2, C-3, C-4, and C-5.


- (66) As shown in Chart 3, for wet AMD, Eylea achieved a sales share of [REDACTED] in 2012, its first full year following launch. Its share has gradually increased each year and by the end of 2021, Eylea's share was 44.0% in the ATU survey and [REDACTED] in the Vestrum data. According to ATU and Vestrum data, Eylea is currently the most widely used product for wet AMD, with off-label Avastin being second with an ATU sales share of 39.0% and a Vestrum sales share of [REDACTED]. See Attachment C-2.

ATU: A linear regression of Eylea Patient Share on Year results in a slope of ~3.3%*** (p-value of ~0.0005).

Vestrum: A linear regression of Eylea Patient Share on Year results in a slope of ~1.5% (p-value of ~0.14).

- ¹³⁰ For DR without DME, the Vestrum data shows Avastin with a large sales share and Eylea capturing an [REDACTED] sales share in its first year. These numbers are incongruent with the ATU survey as well as Vestrum's total sales share statistics in Attachment C-1. See Attachment C-4.

Chart 3: Eylea's Sales Share Across Data Sources – Wet AMD¹³¹



(67) Eylea was approved to treat DME in July 2014.¹³² As shown in Chart 4, for DME, Eylea achieved a sales share of [REDACTED] in 2014. The sales share increased sharply again in 2015 to [REDACTED]. By the end of 2021, Eylea's sales


¹³¹ ATU: A linear regression of Eylea Patient Share on Year results in a slope of ~3.3%*** (p-value of ~0.0004).

Vestrum: A linear regression of Eylea Patient Share on Year results in a slope of ~2.1%** (p-value of ~0.02).

¹³² Ex. 2247 (Regeneron Press Release, “Eylea Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME),” 7/29/2014).

share in the DME indication was somewhere between 44.0% (ATU) and [REDACTED] (Vestrum). According to both Vestrum and ATU data, Eylea has the highest share among all anti-VEGF products for the treatment of DME. See Attachment C-3.

Chart 4: Eylea's Sales Share Across Data Sources – DME¹³³



(68) Measures of sales share for patients with DR without DME vary more greatly across data sources than measures for other indications.¹³⁴ However, both

¹³³ ATU: A linear regression of Eylea Patient Share on Year results in a slope of ~4.5%*** (p-value of ~0.01).

Vestrum: A linear regression of Eylea Patient Share on Year results in a slope of ~1.3% (p-value of ~0.11).

¹³⁴ The differences in sales share for DR patients likely is due to the different data sources and methodologies used by Regeneron to calculate those measures. For

ATU and Vestrum data show an upward trend in sales share for Eylea since obtaining FDA approval in 2019 for treating DR without DME.¹³⁵ As shown in Chart 5, Eylea’s sales share for DR without DME patients has grown since it was first tracked.¹³⁶ According to ATU data, Eylea achieved a sales share of 29.0% in 2017, which rose to 37.0% by the end of 2021, an increase of 8.0

example, one possible explanation for the difference between the Vestrum and ATU data is that the Vestrum data may capture use of Avastin in conjunction with laser treatments, whereas the ATU data does not. Regardless, the different measures both demonstrate growth in sales share for Eylea.

Conversations with Director, Customer Insights.

¹³⁵ The FDA approved Eylea to treat DR without DME on May 13th, 2019. See Section 6.2.4.

¹³⁶ The FDA approved Eylea to treat DR without DME on May 13th, 2019. See Section 6.2.4.

Moreover, Eylea sales to treat DR without DME represent approximately 1.1% of its total sales.

Ex. 2276 (Regeneron, “Eylea Q2 2020 Performance (Vestrum Projection Data),” 8/4/2020, at 27).

percentage points. See Attachment C-4. At the end of 2021, Eylea was the second largest anti-VEGF therapy behind Avastin in DR without DME, which had a sales share of 40.0%. The Vestrum data shows a similar increase in utilization, with Eylea’s sales share increasing [REDACTED] percentage points from [REDACTED] in 2016 to [REDACTED] in 2021. According to Vestrum, by the end of 2021, Eylea was second to Avastin, which had a sales share of [REDACTED]. See Attachment C-4.¹³⁷

¹³⁷ Sales for DR without DME have been limited, with Eylea 2020 sales for DR without DME accounting for 1.1% of total Eylea sales.

Ex. 2276 (Regeneron, “Eylea Q2 2020 Performance (Vestrum Projection Data),” 8/4/2020, at 27).

Chart 5: Eylea's Sales Share Across Data Sources – DR without DME¹³⁸



(69) As shown in Chart 6, for RVO, Eylea achieved a sales share of [REDACTED] in 2013, its first full year with an indication for RVO.¹³⁹ Starting in 2014, the ATU survey began tracking Eylea's sales share for CRVO and BRVO patients separately. In both cases, Eylea achieved a sales share of approximately 40%


¹³⁸ ATU: A linear regression of Eylea Patient Share on Year results in a slope of ~3.4% (p-value of ~0.17).

Vestrum: A linear regression of Eylea Patient Share on Year results in a slope of ~2.9%** (p-value of ~0.02).

¹³⁹ Eylea was indicated for RVO in September 2012. See Attachment B-1.

in 2015, which has grown slowly through 2021. Eylea's sales share by the end of 2021 was somewhere between 46.0% (ATU, CRVO) and [REDACTED] (Vestrum, All RVO). According to ATU and Vestrum data, Eylea currently has the highest sales share among anti-VEGF products used for RVO patients with Avastin in second. See Attachment C-5.

Chart 6: Eylea's Sales Share Across Data Sources – RVO¹⁴⁰



8.3.3. Eylea's displacement of other anti-VEGF treatments as an indicator of commercial success

(70) Eylea's increased utilization has come at the expense of two available and established anti-VEGF treatments, Avastin and Lucentis, which had been in wide use for several years before Eylea's introduction.

¹⁴⁰ ATU CRVO: A linear regression of Eylea Patient Share on Year results in a slope of ~2.5%** (p-value of ~0.02).

- (71) Economics recognizes a first mover advantage, which is that established products have an advantage that later entrants must overcome. This advantage arises because the familiarity that consumers (and physicians in this case) have with incumbent products leads to a certain degree of inertia in consumer demand or product utilization.¹⁴¹ In order to displace incumbent products, purchasers must be persuaded that a later entrant has benefits to them that are not provided by an incumbent product. Those benefits can include a lower price, beneficial features, or other attributes that consumers find attractive.

ATU BRVO: A linear regression of Eylea Patient Share on Year results in a slope of ~1.5% (p-value of ~0.18).

Vestrum RVO: A linear regression of Eylea Patient Share on Year results in a slope of ~3.1%*** (p-value of ~0.002).

- ¹⁴¹ Ex. 2211 (Ling, Davina C., et al. (2002), “Deregulating Direct-To-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-The-Counter Product Sales,” *Journal of Law and Economics*, XLV:691–723, at 698).

New entrants must typically spend resources in marketing to overcome the advantages of incumbency enjoyed by pre-existing products.¹⁴²

- (72) According to ATU data, prior to Eylea's launch, Avastin and Lucentis accounted for 63.0% and 37.0% of anti-VEGF sales. See Attachment C-1. Similarly, Medicare Part B data for 2012 (the first year available) show that Avastin and Lucentis were used on 39.4% and 35.5% of patients given ophthalmic treatment options. See Attachment C-1.
- (73) Although Eylea's growth has coincided with overall anti-VEGF sales growth, evidence demonstrates that at least a portion of Eylea's growth has come from patients that otherwise would have received Avastin or Lucentis. For example, Medicare Part B data shows that Eylea was used for an increasing number of patients each year from 2012 through 2019, whereas Avastin (2015, 2019) and Lucentis (2014–2017) both have seen multiple years with declining

¹⁴² Ex. 2211 Ling (2002). (“In the current context, it is worth emphasizing that Zantac was able to overcome Tagamet's first-mover advantage in the Rx market in part by employing aggressive marketing efforts that conveyed information on Zantac's claimed advantages—more convenient daily dosing, fewer side effects, and fewer adverse interactions with other drugs than Tagamet.”)


patients during that period, showing that Eylea’s growth came at least in part from patients that otherwise would have used one of those two products in those years.¹⁴³ See Attachment E-2. Further, Eylea’s patient share for second line of therapy is ■■■■, ■■■■, and ■■■■ for wet AMD, DME, and DR, respectively.¹⁴⁴

- (74) The sales shares of both Avastin and Lucentis peaked around 2011 and have since declined steadily. See Attachment C-1. Chart 7 below illustrates Avastin’s and Lucentis’s sales share passing to Eylea since Eylea’s launch in late 2011. Since Eylea’s launch, the decline in sales shares for Avastin and Lucentis has been approximately equal, with Avastin losing 23.9 percentage points and Lucentis losing 21.6 percentage points. See Attachment C-11.

¹⁴³ Moreover, even in years during which all three anti-VEGF treatments were used on more patients, had Eylea not been available it is likely that Avastin and Lucentis would have been used for at least some of the patients who historically were treated with Eylea.

¹⁴⁴ Ex. 2278 (Regeneron, “Wave 1 2021 Performance Update Wet AMD, DME, MEfRVO, and DR w/out DME,” 9/2021, at 78, 81, 90).

**Chart 7: Percentage Point Change in Sales Share
Since Eylea Launch – All Indications, ATU Data¹⁴⁵**



(75) Medicare Part B data show a similar trend with Lucentis losing 14.0 percentage points since 2012 and Avastin losing 8.8 percentage points. See

¹⁴⁵ Avastin: A linear regression of Percentage Point Change on Year results in a slope of $\sim -1.6\text{p.p.}^{***}$ (p-value of ~ 0.002).


Lucentis: A linear regression of Percentage Point Change on Year results in a slope of $\sim -2.1\text{p.p.}^{***}$ (p-value of ~ 0.00002).

Eylea: A linear regression of Percentage Point Change on Year results in a slope of $\sim 3.3\text{p.p.}^{***}$ (p-value of ~ 0.0005).

Attachment C-1. Chart 8 below shows the cumulative percentage point change in sales shares since Eylea launched. See Attachment C-12.¹⁴⁶

¹⁴⁶ Charts 7 and 8 focus on Eylea's displacement of Avastin and Lucentis. The limited data available also indicate that Eylea has displaced Beovu's sales share as Beovu's share fell as safety concerns for the product emerged. As discussed in Section 6.2.5, according to Vestrum data Beovu's sales share peaked in 2020-Q1 and declined quickly thereafter. From 2020-Q1 to 2020-Q2 Beovu's sales share in wet AMD declined by 2.6 pp. See Attachment X-1. Meanwhile, Eylea's sales share in wet AMD grew 2.8 pp. See Attachment X-1. Further, from 2020-Q1 to 2021-Q2 Eylea's sales share in wet AMD grew 4.6 pp while Beovu's declined 3.0 pp. See Attachment X-1. During this same time period, Avastin's wet AMD sales share was stagnant, and Lucentis' wet AMD sales share declined, indicating that Beovu's lost wet AMD sales share has been gained by Eylea.

Chart 8: Percentage Point Change in Sales Share
Since Eylea Launch – All Indications, Medicare Part B Data¹⁴⁷



8.3.4. Eylea status as physicians' most used treatment

(76) In addition to the analysis of sales shares, the therapy choices of individual practitioners further illustrate Eylea's commercial success as it has displaced

¹⁴⁷ Since Medicare Part B data begin in 2012, not 2011, the shares of Avastin and Lucentis are estimated. I use the 2011 ATU data share and adjust the numbers downward for each treatment in order to account for the fact that Medicare Part B data includes several minor treatment options (e.g., Visudyne).

Avastin and Lucentis in therapeutic use. Physicians do not necessarily prescribe one treatment to all their patients. Instead, practitioners utilize a variety of the treatment options depending upon the circumstances of the patient.¹⁴⁸ That said, Medicare Part B prescription data show that practitioners tend to use one treatment more often than others. In 2012, Avastin and Lucentis were the two most common treatment options, with Avastin being used most commonly by 46.4% of practitioners and Lucentis by 33.4% of practitioners. See Attachment E-1. Since 2012, Eylea has become the most commonly used treatment option for a larger share of practitioners than any

Avastin: A linear regression of Percentage Point Change on Year results in a slope of ~ -2.2 p.p.** (p-value of ~ 0.02).

Lucentis: A linear regression of Percentage Point Change on Year results in a slope of ~ -2.2 p.p.*** (p-value of ~ 0.0009).

Eylea: A linear regression of Percentage Point Change on Year results in a slope of ~ 4.9 p.p.*** (p-value of ~ 0.0004).

¹⁴⁸ Ex. 2220 (Manning (2015), at 241). (“Rather, it is consistent with the notion that physicians typically exercise medical judgment or are responsive to other factors on a patient-by-patient basis.”)

other treatment option, with 45.0% of practitioners using Eylea more than the other treatment options. Meanwhile, the percent of practitioners using Avastin and Lucentis as their most common treatment has fallen significantly, particularly for Lucentis. See Attachment E-1. Table 5 below illustrates that Eylea has become the most common treatment for practitioners and has gained share while all other available products, Lucentis and Avastin in particular, have lost share. See Attachment E-1.

**Table 5: Anti-VEGF Ophthalmic Treatment Options
Medicare Part B Prescription Data¹⁴⁹**

Treatment	2012	2019	Gain/Loss (Percentage Points)
Eylea	12.18%	44.97%	+32.79 pp
Avastin	46.35%	38.82%	-7.53% pp
Lucentis	33.43%	11.96%	-21.47% pp

¹⁴⁹ Table 5 presents only anti-VEGF treatment options. A more complete presentation of treatment options (including Macugen, corticosteroids, etc.) is presented in Attachment E-1.

8.4. Price has not hindered Eylea’s commercial success

(77) Economic theory clearly dictates that a product’s price affects its quantity demanded. Hence, Eylea’s price should be considered in an analysis of commercial success. All else the same, a product with a lower price should have greater consumer utilization than do products with higher prices. The available data show that price disparities between Eylea and other treatment options have not hindered its commercial success, so clearly, in this situation, “all else is not the same.” The extended dosing interval of Eylea has allowed it to succeed in the face of other products with lower prices.

(78) Generally, among available anti-VEGF products, list prices have remained stable over time:

- Eylea’s list price of \$1,850 has not changed since Eylea’s launch.¹⁵⁰
- Lucentis’s list prices, which also have stayed constant since Lucentis’s launch, depend upon the dosage. The 0.5mg dose of Lucentis, used for treating wet AMD and RVO, has had a list price of \$1,950, while the 0.3mg dose, used for treating DME and DR, has had a list price of \$1,170.¹⁵¹

¹⁵⁰ Ex. 2229 (Regeneron, WAC Pricing File, 5/2021, at tab “Analysis”).

¹⁵¹ Ex. 2229 (Regeneron, WAC Pricing File, 5/2021, at tab “Analysis”).

- Avastin’s list price per injection for the treatment of angiogenic eye disorders (i.e., per 1.25 mg dose) has changed over time, but was \$9.96 as of May 2021.¹⁵²
 - Beovu’s list price is \$1,850 and has not changed since launch.¹⁵³
- (79) List price histories indicate that Eylea's price disparity with Avastin has not hindered its commercial success, and that Eylea’s list price has been comparable to those of other FDA-approved anti-VEGF treatments. However, list prices do not fully reflect the prices experienced by physicians, patients, and payors.
- (80) To further compare prices across the treatments, I use payment limits for Medicare Part B prescription drug reimbursement. As explained in Section 7,

Lucentis’ price varies based on condition because the recommended dosage for Lucentis differs across conditions. See Attachment D-6. For wet AMD and RVO, the recommended dose of Lucentis is 0.5 mg (0.05 mL), whereas for DME and DR the recommended dose of Lucentis is 0.3mg (0.05 mL). See Attachment B-1.

¹⁵² Ex. 2229 (Regeneron, WAC Pricing File, 5/2021, at tab “Analysis”).

¹⁵³ Ex. 2229 (Regeneron, WAC Pricing File, 5/2021, at tab “Analysis”).

CONFIDENTIAL MATERIAL– SUBJECT TO PROTECTIVE ORDER

Medicare reimbursement for Medicare Part B drugs is set at 106% of the drug's ASP and is referred to as the payment limit.¹⁵⁴ The payment limit is an appropriate measure to evaluate because it reflects manufacturer rebates and discounts, and it incorporates the reimbursement for physician administration. See Section 7. CMS has published the payment limits for Part B covered drugs on its website annually since 2005.¹⁵⁵

¹⁵⁴ Actual reimbursements are closer to 104.3% of ASP due to a federal sequestration order; however, CMS publishes the payments limit data using a 6% mark up. See Section 7.

¹⁵⁵ Ex. 2173 (Centers for Medicare & Medicare Services Website, Medicare Part B Drug Average Sales Price, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice> (accessed 12/8/2021)).

Ex. 2172 (Centers for Medicare & Medicare Services Website, 2021 ASP Drug Pricing Files (accessed 11/22/2021)). (“The files below contain the payment amounts that will be used to pay for Part B covered drugs for the fourth quarter of 2021. The October 2021 ASP payment limits have been updated ... Where applicable, the payment amounts in the quarterly ASP files are 106 percent of

- (81) In my analysis, Medicare Part B payment limit data from 2012 to 2021 were aggregated into a single dataset. See Attachment X-6. This dataset was used to obtain annual payment limits per HCPCS code (and HCPCS code dosage amount) for various therapies used to treat the relevant angiogenic eye disorders.¹⁵⁶ See Attachment D-5.
- (82) However, the HCPCS code dosages for the various therapies do not necessarily reflect the volume used in a single treatment using those therapies. For example, Eylea’s HCPCS code dosage is 1mg, but the recommended dose


the Average Sales Price (ASP) calculated from data submitted by drug manufacturers. The quarter to quarter price changes are generally the result of updated data from the manufacturers of these drugs.”)

- ¹⁵⁶ HCPCS stands for Healthcare Common Procedure Coding System. HCPCS codes are used for billing Medicare & Medicaid patients. The HCPCS codes represent procedures, supplies, products, and services which may be provided to Medicare beneficiaries and to individuals enrolled in private health insurance programs. See:

Ex. 2202 (HCPCS Codes Website, HCPCS Codes, <https://hcpcs.codes/> (accessed 1/6/2022)).

per injection is 2mg. See Attachments B-1 and D-6. Therefore, to calculate the payment limit per injection for anti-VEGF products, the annual payment limits reported in CMS data are multiplied by a conversion factor to calculate annual payment limits per treatment for the relevant therapies. For example, Eylea's annual payment limits are multiplied by 2 because the recommended dosage per injection is double the HCPCS dosage. See Attachment D-6. Chart 9 below displays the annual payment limits of the four anti-VEGF treatments over time. See Attachment D-8.

**Chart 9: Medicare Part B Payment Limit per Injection
for Each Anti-VEGF Treatment, 2012 to 2021**



(83) Avastin’s payment limit per injection has historically been substantially lower than Eylea’s. Medicare part B payment limits for Eylea and Avastin from 2012 to 2021 were approximately \$1,929 and \$9.00 per injection, respectively. See Attachment D-6.

- (84) While the list price of Lucentis for wet AMD and RVO is larger than that of Eylea (\$1,950 versus \$1,850),¹⁵⁷ Lucentis' payment limit demonstrates that it has been subject to more substantial discounting over time than has Eylea. See Attachment D-6. This has resulted in the historic payment limit of Eylea being greater than the historic payment limit of Lucentis. Over the period from 2012 to 2021, the average of annual payment limits for Eylea and Lucentis were \$1929 and \$1,857, respectively. See Attachment D-6. Lucentis' annual payment limit has fallen approximately 20% since 2012, whereas Eylea's annual payment limit has declined only 6%.¹⁵⁸ See Attachment D-6. Over the same period, Lucentis' annual payment limit was \$1,114 for DME and DR. See Attachment D-6.
- (85) Moreover, physician surveys indicate that the price disparity between Eylea and its competitors has been a disincentive to prescribing Eylea.¹⁵⁹ Therefore, the fact that Eylea has achieved its position as a leader in its indicated

¹⁵⁷ Ex. 2229 (Regeneron, WAC Pricing File, 5/2021, at tab "Analysis").

¹⁵⁸ $\$1,592 / \$1,992 - 1 = \sim -20\%$; $\$1,836 / \$1,961 - 1 = \sim -6\%$

¹⁵⁹ Ex. 2278 (Regeneron, "Wave 1 2021 Performance Update: Wet AMD, DME, MEfRVO & DR w/out DME," 9/2021, at 97–106).

therapeutic areas despite these price disparities is a strong indication of the product's commercial success. Although higher-priced products could in principle incentivize physicians to prescribe those products rather than lower-priced alternatives because the higher-priced products would lead to the receipt of larger Medicare reimbursements, physician surveys and analyses of sales patterns demonstrate that this does not appear to be the case for Eylea.¹⁶⁰

¹⁶⁰ Ex. 2278 (Regeneron, “Wave 1 2021 Performance Update: Wet AMD, DME, MEfRVO & DR w/out DME,” 9/2021, at 97–106).

Ex. 2220 (Manning (2015), at 241). (“This is inconsistent with the hypothesis that the major factor driving product choice between these two products is a simple financial motivation on the part of the physician or the manufacturer. Rather, it is consistent with the notion that physicians typically exercise medical judgment or are responsive to other factors on a patient-by-patient basis.”)

9. Dosing Regimen is an Important Driver of Demand for Eylea

(86) The eye diseases treated by Eylea and the other products discussed here impose a very large cost on patients. Loss of vision is one of the most serious health insults an individual can experience, imposing substantial physical, social, and economic burdens on individuals.¹⁶¹ Adults with vision impairment often have lower rates of workforce participation and higher rates

¹⁶¹ Ex. 2167 (Centers for Disease Control and Prevention, “Vision Loss: A Public Health Problem,” 6/12/2020, https://www.cdc.gov/visionhealth/basic_information/vision_loss.htm).

(“People with vision loss are more likely to report depression, diabetes, hearing impairment, stroke, falls, cognitive decline, and premature death. Decreased ability to see often leads to the inability to drive, read, keep accounts, and travel in unfamiliar places, thus substantially compromising quality of life. The cost of vision loss, including direct costs and lost productivity, is estimated to exceed \$35 billion.”)

of depression and anxiety.¹⁶² In older adults, vision impairment can contribute to social isolation, difficulty walking, and a higher risk of falls and fractures.¹⁶³ Hence, a treatment that meaningfully diminishes the likelihood of vision loss or that extends the time until vision deteriorates is something on which most consumers would place a very high value. As discussed previously, it turns out that the treatments that allow this good outcome (delayed or diminished vision loss) are unavoidably bundled with a “bad” characteristic—having an injection into the eye.

- (87) Again, as discussed in Section 4, economic theory predicts that, all else the same, patients would be more likely to choose a treatment that provides a given therapeutic response with fewer, or less frequent injections. This is further supported by evidence that alleviation of treatment burden through extended dosing was an unmet need, that the patented dosing regimen has been a key differentiator for Eylea as compared to other treatment options,

¹⁶² Ex. 2269 (World Health Organization, “Blindness and Vision Impairment Fact Sheet,” 10/14/2021, at 3, available at: <https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment>).

¹⁶³ Ex. 2269 (World Health Organization, “Blindness and Vision Impairment Fact Sheet,” 10/14/2021, at 3).

and that a large share of physicians state they use Eylea according to the patented dosing regimen.

9.1. Eylea’s patented dosing regimen addressed an unmet need for longer dosing intervals

(88) Frequent dosing of therapies to treat the relevant angiogenic eye disorders places a significant treatment burden on patients and physicians. For example, following the approval of Beovu to treat wet AMD in Canada, a Yahoo finance article citing Doug Earle, president and CEO of Fighting Blindness Canada, noted the difficulty patients have keeping up with frequent appointments, especially for those living in remote or isolated communities or requiring mobility assistance.¹⁶⁴ The article acknowledges the potential for

¹⁶⁴ Ex. 2270 (Yahoo Finance, “Beovu Now Publicly Reimbursed in Ontario and New Brunswick for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration,” 12/17/2021, <https://finance.yahoo.com/news/beovu-brolucizumab-injection-now-publicly-120000109.html>).

wet AMD to have a “devastating impact on patients and their vision if patients don’t adhere to the regular treatment that is required[.]”¹⁶⁵

- (89) Frequent dosing, and the risk of significant harm to vision if doses are missed, represents a significant treatment burden for patients with the relevant angiogenic eye disorders. Physicians identified the need to alleviate this treatment burden as an unmet need in treating these disorders prior to the launch of Eylea. For example, a 2009 survey conducted by the ASRS asked participants to identify the (then-) current unmet need in the treatment of wet AMD.¹⁶⁶ 62.73% of survey respondents cited both improvement in visual outcomes and reduction in the frequency of injections (while maintaining visual acuity) as unmet needs, while 33.56% cited reduction of injection

¹⁶⁵ Ex. 2270 (Yahoo Finance, “Beovu Now Publicly Reimbursed in Ontario and New Brunswick for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration,” 12/17/2021).

¹⁶⁶ Ex. 2259 (American Society of Retina Specialists, “Preferences and Trends Membership Survey,” 2009, at 92).

frequency (while maintaining visual acuity) as the only unmet need.¹⁶⁷ In other words, 96.29% of participants identified reducing injection frequency as one of the key unmet needs in the treatment of wet AMD in 2009.¹⁶⁸

(90) A Regeneron marketing strategy presentation from September 2011 identified

[REDACTED]

[REDACTED]

[REDACTED]¹⁶⁹ The

presentation further identified [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED].¹⁷⁰

¹⁶⁷ Ex. 2259 (American Society of Retina Specialists, “Preferences and Trends Membership Survey,” 2009, at 92).

¹⁶⁸ $33.56\% + 62.73\% = 96.29\%$.

¹⁶⁹ Ex. 2277 (Regeneron, “Marketing Planning Process,” 9/2011, at 9).

¹⁷⁰ Ex. 2277 (Regeneron, “Marketing Planning Process,” 9/2011, at 10).

(91) ATU surveys conducted in 2012 and 2013 also show that [REDACTED]
[REDACTED]. The 2012-Q4, 2013-Q2, and 2013-Q3 ATU surveys asked participants [REDACTED]
[REDACTED]
[REDACTED]?¹⁷¹ In 2012-Q4, practitioners responded that [REDACTED]
[REDACTED].¹⁷² Further, practitioners stated that [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED].¹⁷³ Taken together, [REDACTED]
[REDACTED]
[REDACTED].¹⁷⁴

¹⁷¹ Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 25).

Ex. 2163 (Regeneron, “Physician ATU: Wave 4,” 8/6/2013, at 24).

Ex. 2140 (Regeneron, “Physician ATU: Wave 5,” 11/2013, at 25).

¹⁷² Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 25).

¹⁷³ Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 25).

¹⁷⁴ [REDACTED]

- (92) These survey responses demonstrate that less frequent dosing was an unmet need prior to the launch of Eylea and its patented dosing regimen and that longer dosing intervals remain an important consideration for physicians when selecting treatments for their patients. The ongoing need for increased dosing intervals means that the patented dosing regimen would be a relevant consideration for physicians and patients selecting treatment options when Eylea was first introduced and has remained so in the years since its introduction.¹⁷⁵

9.2. Eylea’s patented dosing regimen is a key differentiating factor

- (93) As compared to other anti-VEGF treatments available for the relevant diseases, Eylea’s patented dosing regimen is a key differentiating factor. I

¹⁷⁵ Ex. 2050 (Brown Declaration, 2/10/2022, at ¶¶ 160–173).

Dr. Brown has provided descriptions of various efforts to extend the dosing regimens for treatments available prior to Eylea’s launch, including Lucentis and Macugen, as well as more recent attempts including Conbercept. Since Eylea’s launch, attempts to develop new treatments have sought to extend the dosing interval relative to Eylea’s patented dosing schedule (rather than seeking to extend the dosing interval relative to the 4-week interval recommended for Lucentis).

understand that when seeking initial FDA approval for wet AMD, clinical testing of Eylea sought to show “non-inferiority” as compared to Lucentis (i.e., that Eylea and Lucentis had similar efficacy) using an extended dosing according to the ’338 Patent.¹⁷⁶ Evidence that the patented dosing regimen is a key differentiating factor for Eylea is discussed below.

9.2.1. Regeneron has promoted the patented dosing schedule and credits it as a key factor causing commercial success

(94) Regeneron’s marketing efforts for Eylea have included efforts to market the treatment’s patented dosing schedule. This can be seen from Regeneron’s marketing plans and promotional materials.

- A September 2011 internal marketing strategy presentation discussed Regeneron’s strategy for positioning the Eylea brand. The presentation stated “ [REDACTED] [REDACTED] [REDACTED] ”¹⁷⁷

¹⁷⁶ Ex. 2050 (Brown Declaration, 2/10/2022, at ¶¶ 75–78).

¹⁷⁷ Ex. 2277 (Regeneron, “Marketing Planning Process,” 9/2011, at 15).

- An online ad for Eylea emphasizes its “Dosing Flexibility” for wet AMD patients.¹⁷⁸ The ad highlights Eylea’s ability to be dosed at 8 weeks or longer following the initial loading doses as well as Eylea’s ability to be dosed at 12 weeks after 1 years of effective therapy.¹⁷⁹
- A Regeneron presentation meant for an external facing audience showcased the results of Eylea’s clinical studies, VIEW1 and VIEW2.¹⁸⁰ Regeneron stated that 2 mg of Eylea dosed at every 8 weeks is clinically equivalent to the industry standard at the time, Lucentis’s 0.5 mg dose every 4 weeks.¹⁸¹ In addition, Regeneron notes that monthly injections pose challenges for patients as each office visit can be quite lengthy.

¹⁷⁸ Ex. 2190 (Eylea Website, Wet AMD: Dosing Flexibility, <https://hcp.eylea.us/about/wet-amd-dosing/> (accessed 1/5/2022)).

¹⁷⁹ Ex. 2190 (Eylea Website, Wet AMD: Dosing Flexibility (accessed 1/5/2022)).

¹⁸⁰ Ex. 2139 (Regeneron, “For the Treatment of Wet Age-Related Macular Degeneration,” c. 2012).

¹⁸¹ Ex. 2139 (Regeneron, “For the Treatment of Wet Age-Related Macular Degeneration,” c. 2012, at 31.

Regeneron states that there is time lost from travel and from work for patients and their adult caregivers.¹⁸²

- A 2013 advertisement for Eylea uses the phrase “Time Between Treatments” as a slogan for Eylea.¹⁸³ This phrase is followed by important prescribing information that mentions Eylea is dosed once every 8 weeks.¹⁸⁴ In addition, the page’s background consists of an April and June calendar that are separated and in between them is a vial of Eylea.¹⁸⁵
- A similar 2013 advertisement for Eylea shows October and December calendars separated by the image of an elderly lady and a child sharing a story. This image speaks to Eylea’s ability to provide patients with a better quality of life as it can be dosed every two months instead of monthly, resulting in less time in the clinic.¹⁸⁶

¹⁸² Ex. 2139 (Regeneron, “For the Treatment of Wet Age-Related Macular Degeneration,” c. 2012, at 13).

¹⁸³ Ex. 2136 (Regeneron, Eylea Marketing Material, c. 2013).

¹⁸⁴ Ex. 2136 (Regeneron, Eylea Marketing Material, c. 2013).

¹⁸⁵ Ex. 2136 (Regeneron, Eylea Marketing Material, c. 2013).

¹⁸⁶ Ex. 2137 (Regeneron, Eylea Marketing Material, 11/2013, at 29).

Screenshot: Eylea Ad¹⁸⁷



- Regeneron marketing materials from 2013 characterized Eylea as “The Only VEGF Inhibitor Approved for Every 2-months Dosing Following 3 Initial Monthly Doses[.]”¹⁸⁸ This phrase was included as a page heading throughout the marketing materials, demonstrating the importance to

¹⁸⁷ Ex. 2137 (Regeneron, Eylea Marketing Material, 11/2013, at 29).

¹⁸⁸ Ex. 2137 (Eylea, Eylea Marketing Material, 11/2013 at 8–30).


Regeneron of conveying this statement about Eylea's unique dosing regimen.¹⁸⁹

Screenshot: Eylea Marketing Material¹⁹⁰

FOR THE TREATMENT OF WET AMD

EYLEA® (aflibercept) Injection: The Only VEGF Inhibitor Approved for Every 2-Months Dosing Following 3 Initial Monthly Doses^{1,2}

EYLEA Clinical Pharmacology and Formulation



Design

Binding

- Fusion protein of key domains from human VEGF receptors 1 (VEGFR1) and 2 (VEGFR2) with human IgGfC
 - Binds VEGF between its arms, reducing risk of aggregation³
- Aflibercept binds to VEGF-A and Placental Growth Factor (PIGF), as shown in preclinical studies
 - VEGF-A and PIGF are growth factors that can act as vascular permeability factors for endothelial cells
 - VEGF-A activates VEGFR1 and VEGFR2, which can result in neovascularization, the hallmark of wet AMD⁴
 - PIGF binds only to VEGFR1, which is also present on the surface of leucocytes
 - Aflibercept binds multiple isoforms of VEGF-A^{3,5} and PIGF to prevent their interaction with native VEGF receptors

Warnings and Precautions from the EYLEA Prescribing Information

- There is a potential risk of arterial thromboembolic events (ATEs) following use of intravitreal VEGF inhibitors, including EYLEA, defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of ATEs in the VIEW 1 and VIEW 2 wet AMD studies in patients treated with EYLEA was 1.8% during the first year. The incidence of ATEs in the COPERNICUS and GALILEO CRVO studies was 0% in patients treated

IP/ISI PI

IMPORTANT PRESCRIBING INFORMATION

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with neovascular (Wet) Age-related Macular Degeneration (AMD). The recommended dose for EYLEA is 2 mg administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.

EYLEA is indicated for the treatment of patients with Macular Edema following Central Retinal Vein Occlusion (CRVO). The recommended dose for EYLEA is 2 mg administered by intravitreal injection every 4 weeks (monthly).

IMPORTANT SAFETY INFORMATION

EYLEA® (aflibercept) Injection is contraindicated in patients with ocular

For additional Important Safety Information and full Prescribing Information, tap buttons above.



¹⁸⁹ Ex. 2137 (Eylea, Eylea Marketing Material, 11/2013 at 8–30).

¹⁹⁰ Ex. 2137 (Eylea, Eylea Marketing Material, 11/2013, at 8–30).

9.2.2. Regeneron ATU surveys show that dosing interval has been an important driver of Eylea prescribing

(95) After launching Eylea in late 2011, Regeneron began using ATU survey data to understand the opinions of physicians prescribing anti-VEGF products. Regeneron’s ATU surveys provide insight into the importance of Eylea’s recommended eight-week dosing schedule. These ATU surveys include results demonstrating that the treatment burden and dosing intervals were important to physicians and that practitioners viewed Eylea as a product that would improve treatment burden.

(96) Physician survey results illustrate that physicians [REDACTED]

▪ The 2012-Q4 ATU survey asked participants: “[REDACTED]

[REDACTED]”¹⁹¹ The [REDACTED] cited by physicians,

with [REDACTED] of participants [REDACTED]

[REDACTED] and [REDACTED] of participants [REDACTED]

[REDACTED]. Regeneron’s

¹⁹¹ Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 13).

own analysis of this data found “ [REDACTED]

[REDACTED]”¹⁹²

- The 2014-Q2 ATU DME Survey asked participants: “ [REDACTED]

” [REDACTED]

with [REDACTED] of respondents [REDACTED] and [REDACTED] of respondents [REDACTED].¹⁹³

Further, when physicians were asked [REDACTED], [REDACTED] of respondents [REDACTED] and only [REDACTED] of respondents [REDACTED].¹⁹⁴ This demonstrates the unique role [REDACTED] driving the prescribing behavior for Eylea in comparison to Lucentis.

- The 2012-Q4 ATU survey asked practitioners [REDACTED]

¹⁹² Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 13).

¹⁹³ Ex. 2205 (Regeneron, “DME Market Assessment,” 8/2014, at 46).

¹⁹⁴ Ex. 2205 (Regeneron, “DME Market Assessment,” 8/2014, at 46).

[REDACTED] 195

[REDACTED]

[REDACTED]. [REDACTED] of practitioners [REDACTED]

[REDACTED]; and [REDACTED] of practitioners [REDACTED]

[REDACTED] 196

- Regeneron’s internal presentation summarizing the 2011-Q3 ATU survey states: “[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]”¹⁹⁷ The survey presentation further states Eylea

¹⁹⁵ Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 34).

Ex. 2208 (Regeneron, “Eylea MD ATU – Wave 2 Final Questionnaire,” 12/19/2012, at 3).

¹⁹⁶ Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 34).

Another highly-rated attribute (with 86% of practitioners scoring 8, 9, or 10) was “better quality of life,” which likely is impacted by treatment burden (among other things).

¹⁹⁷ Ex. 2197 (Regeneron, “Physician ATU – Benchmark Wave,” 9/15/2011, at 2).

“ [REDACTED]

[REDACTED]”¹⁹⁸

- The 2012-Q4 ATU survey asked participants to [REDACTED]
[REDACTED]
[REDACTED]¹⁹⁹ [REDACTED]
[REDACTED]
[REDACTED].

- For physicians [REDACTED],
[REDACTED]
[REDACTED]
[REDACTED]²⁰⁰ In
other words, [REDACTED]
[REDACTED]

¹⁹⁸ Ex. 2197 (Regeneron, “Physician ATU – Benchmark Wave,” 9/15/2011, at 36).

¹⁹⁹ Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 23, 24).

²⁰⁰ Ex. 2138 (Regeneron, “Physician ATU: Wave 2,” 2/2013, at 23, 24).

[REDACTED]. This was the largest percentage point difference among the included options.²⁰¹

- Similarly, for physicians [REDACTED]
[REDACTED], [REDACTED] of respondents [REDACTED]
[REDACTED], whereas only [REDACTED]
who [REDACTED].²⁰² This was the
[REDACTED].²⁰³

(97) These results demonstrate that physicians are aware of the burdens that more frequent dosing puts on their patients and take dosing interval into account when selecting treatment options. Further, physicians provided these responses to surveys taken during the years immediately following Eylea's

²⁰¹ Ex. 2138 (Regeneron, "Physician ATU: Wave 2," 2/2013, at 23, 24).

²⁰² Ex. 2138 (Regeneron, "Physician ATU: Wave 2," 2/2013, at 23, 24).

²⁰³ Ex. 2138 (Regeneron, "Physician ATU: Wave 2," 2/2013, at 23, 24).

Cost/Reimbursement options were the largest percentage point difference, at 70% ("Cost / Reimbursement (NET)") and 65% ("Cost"). However, both of these differences favored Avastin (i.e., Cost was more a reason to switch to Avastin than to Eylea).

launch, meaning that dosing interval was identified as an important driver of physician choice over precisely the same time period that Eylea was experiencing rapid growth in share of sales. See Section 8.3. These responses, and their overlap with Eylea’s rapid sales growth, demonstrate that the patented dosing interval was an important driver of Eylea’s commercial success.

9.2.3. Members of the ASRS identified Eylea as allowing the longest treatment interval

(98) The ASRS conducts annual surveys of its members, referred to as the Preferences and Trends (PAT) survey. From 2014 – 2016, the PAT surveys included questions asking respondents, in their experience, which anti VEGF treatments allowed for the longest treatment intervals. The responses demonstrate that Eylea’s longer dosing interval is a differentiating factor relative to Avastin and Lucentis.

- The 2014 PAT survey asked “

”²⁰⁴

²⁰⁴ Ex. 2250 (American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2014, at 58).

- The 2015 and 2016 PAT surveys asked “ [REDACTED]

”²⁰⁵

(99) Table 6 below presents responses, both in the U.S. and internationally. For each of these years, Eylea is identified by a majority of respondents (both from the U.S. and internationally), with neither Avastin nor Lucentis exceeding 10%. See Table 6.


²⁰⁵ Ex. 2244 (American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2015, at 70).

Ex. 2243 (American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2016, at 58).

The 2015 survey omitted the word “agent” and the italicized the word “most” from the question.

Table 6: Share of Respondents Identifying

206



²⁰⁶ Ex. 2250 (American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2014, at 59).

Ex. 2244 (American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2015, at 70).

Ex. 2243 (American Society of Retina Specialists, “Preferences and Trends (PAT) Survey,” 2016, at 59)).

9.2.4. Regeneron public statements demonstrate the importance of the patented dosing schedule to Eylea’s commercial success

(100) Regeneron public statements near the time of Eylea’s launch further demonstrate the importance of the patented dosing schedule to Eylea’s commercial success. Such statements, contained in earnings call transcripts, show Regeneron’s view that commercial success of Eylea would (and did) depend on its ability to communicate the benefits of the patented dosing schedule.

- In the 2011-Q4 Regeneron earnings call, Regeneron’s CEO Leonard Schleifer stated, “We believe that Eylea with [its] less frequent dosing offers a much more attractive new treatment option that provides an important alternative to wet AMD patients and physicians.”²⁰⁷ Dr. Schleifer also stated the decreased monthly dosing has strongly resonated with the AMD community.²⁰⁸

²⁰⁷ Ex. 2133 (Regeneron, Earnings Call Transcript, 2/13/2012, at 3).

²⁰⁸ Ex. 2133 (Regeneron, Earnings Call Transcript, 2/13/2012, at 3). (“The benefit of less than monthly dosing with efficacy that is clinically equivalent to

- During Regeneron’s 2012-Q1 earnings call, one of Regeneron’s executives stated that some of Eylea’s highest use had come from people living in rural areas as their traveling burden for appointments makes the eight-week dosing more appealing.²⁰⁹
- During the 2012-Q2 Regeneron earnings call, one of Regeneron’s executives stated that Eylea’s convenience of less than monthly dosing (along with its efficacy) was contributing to Eylea’s strong wet AMD sales.²¹⁰

9.3. Eylea is more effective at treating patients with worse visual acuity, which imparts a downward bias to its observed treatment interval

(101) As discussed above, Eylea has recommended dosing practices with extended dosing relative to prior treatments. Indeed, Dr. Do has indicated that

monthly ranibizumab appears to have resonated strongly with the AMD community, as has our pricing.”)

²⁰⁹ Ex. 2134 (Regeneron, Earnings Call Transcript, 4/26/2012, at 9). (“I think some of our highest utilization, however, is in more rural areas where people have to travel far for their appointments and so the every eight week dosing is appealing in those types of settings.”)

²¹⁰ Ex. 2135 (Regeneron, Earnings Call Transcript, 7/25/2012, at 6).

physicians commonly seek to treat patients on an 8-week interval (or longer) during the maintenance phase of treatment for all angiogenic eye disorders.²¹¹

(102) With that said, clinical evidence has shown that Eylea (aflibercept) is more effective at improving vision among patients suffering from DME with worse initial visual acuity.²¹² As a result, physicians have an interest in treating patients with more serious disease with Eylea, and those patients on average may require more frequent dosing because of the severity of their condition.²¹³

²¹¹ Ex. 2051 (Do Declaration, 2/10/2022, at ¶ 138).

²¹² Ex. 2102 (Wells, John A., et al. (2015), “Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema,” *The New England Journal of Medicine* 372(13): 1193–1203, at 1193). (“At worse levels of initial visual acuity, aflibercept was more effective at improving vision.”)

²¹³ Ex. 2102 (Wells (2015) at 1195). (“The study drugs were injected into the study eyes at baseline and then every 4 weeks unless visual acuity was 20/20 or better with a central subfield thickness below the eligibility threshold and there was no improvement or worsening in response to the past two injections.”)

Thomas Albin, Dep Tr., 1/20/2022, at 37:7–40:16, 62:20–70:7, 72:3–9, 72:21–73:20.

(103) Data on physician switching behavior demonstrates this dynamic. For patients that are started on either Avastin or Lucentis, Eylea is likely to be the second treatment used if the physician decides to switch treatments. Regeneron documents show that [REDACTED] of patients with wet AMD are initially treated with Avastin.²¹⁴ Meanwhile, Eylea’s patient share for second line of therapy is [REDACTED], [REDACTED], and [REDACTED] for wet AMD, DME, and DR, respectively.²¹⁵

²¹⁴ The data shown is sourced through IQVIA. IQVIA provides a variety of data and analytics services to the life sciences industry. As part of their business IQVIA offers a variety of pharmaceutical and healthcare related data. See: Ex. 2206 (IQVIA, Form 10-K, 2020, at 5).

Ex. 2207 (IQVIA Website, Available IQVIA Data, <https://www.iqvia.com/insights/the-iqvia-institute/available-iqvia-data> (accessed 1/18/2022)).

Ex. 2274 (Regeneron, “Eylea Wet AMD Line of Therapy Insights,” 4/2020, at 3).

²¹⁵ Ex. 2278 (Regeneron, “Wave 1 2021 Performance Update Wet AMD, DME, MEfRVO, and DR w/out DME,” 9/2021, at 78, 81, 90).

(104) This means that even though Eylea is generally used with longer dosing intervals than Avastin or Lucentis for a given patient, for patients overall dosing intervals for Eylea would be even longer if all patients had equal severity of conditions.

The next highest share of second line therapy is [REDACTED] (Lucentis), [REDACTED] (Lucentis), and [REDACTED] (Avastin) for wet AMD, DME, and DR, respectively.

10. Eylea's Commercial Success Cannot be Explained by Factors Not Related to the Claimed Methods of Treatment

(105) Various other factors and attributes aside from dosing can contribute to a product's economic success, including other product attributes; the competitive environment facing the product; marketing efforts; pricing; and discount and rebate practices; etc. However, a review of the marketing efforts, pricing, and discount/rebate practices in this case demonstrates that Eylea's commercial success cannot be explained by these factors. The totality of evidence further supports the conclusion that the claimed dosing regimen has been an important factor contributing to Eylea's commercial success.

10.1. Regeneron's marketing efforts have been limited and have included promotion of the patented dosing regimen

(106) The economic purpose of marketing prescription medicines is intended to inform potential prescribers, and often potential patients, about innovations in healthcare treatment.²¹⁶ Economic theory indicates that biopharmaceutical companies engage in promotional activities because informing (and reminding) prescribers and patients about treatment options is effective at

²¹⁶ Ex. 2260 (Schweitzer, Stuart (2007), *Pharmaceutical Economics and Policy*, 2nd ed., New York: Oxford University Press, at 82).

increasing product utilization.²¹⁷ However, Eylea’s marketing efforts have been consistent with industry marketing levels. In other words, Eylea’s success is not attributable simply to excessive marketing.

(107) Because of the economic importance of informing prescribers and patients about new medicines, a meaningful share of pharmaceutical companies’ resources is typically dedicated to marketing. Gagnon and Lexchin (2008) reviews a number of sources estimating that U.S. pharmaceutical companies

²¹⁷ Ex. 2178 (Donohue, Julie, Ernst R. Berndt (2004), “Effect of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants,” *Journal of Public Policy & Marketing* 23(2): 115–127, at 116, 117). (“Another study of antiulcer medications finds that product marketing to physicians increases sales for the advertised product...”)

Ex. 2177 (Donohue, Julie et al. (2007), “A Decade of Direct-to-Consumer Advertising of Prescription Drugs,” *The New England Journal of Medicine* 35(7): 673–681, at 673). (“Evidence suggests that direct-to-consumer advertising of prescription drugs increases pharmaceutical sales...”)

spend between 22.5% and 33.0% of their sales revenue on marketing.²¹⁸ Their own estimate is that promotional expenditures as a percent of total U.S. sales is about 24.4%, including the cost of product sampling.²¹⁹ If product sampling costs are excluded, marketing expenditures are about 17.7% of total U.S. sales.²²⁰

(108) Based on these ratios, Regeneron spent relatively little on marketing for Eylea relative to the biopharmaceutical industry generally. Regeneron’s commercial P&L includes line items “External Expenses” and “People Expenses.”²²¹ I understand that the “External Expenses” line item includes Regeneron’s marketing expenditures for Eylea and the “People Expenses” line item refers to the labor expenses (e.g., salaries, benefits, and other employment costs) for

²¹⁸ Ex. 2196 (Gagnon, Marc-Andre and Joel Lexchin (2008), “The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States,” *PLoS Medicine* 5(1): 29–33, at 32).

²¹⁹ Ex. 2196 (Gagnon (2008), at 32).

²²⁰ $(\$57.5 \text{ billion} - \$15.9 \text{ billion}) / (\$235.4 \text{ billion}) = \sim 17.7\%$. See:

Ex. 2196 (Gagnon (2008), at 30, 32).

²²¹ Ex. 2200 (Regeneron, “U.S. Eylea Historical Brand P&L,” 5/2021, at 2).

Regeneron employees who spend part or all of their time working on the Eylea product.²²²

(109) Consistent with what would be expected, Regeneron made large initial investments in marketing Eylea in 2011. Regeneron launched Eylea in November 2011, incurring [REDACTED] in external expenses and [REDACTED] in people expenses during 2011. See Attachment D-3. Following these expenditures during Eylea's launch year, from 2012 through 2020, Regeneron's external expenses on Eylea never exceeded more than [REDACTED] of net sales and people expenses never exceeded more than [REDACTED] of net sales, both in 2012 (i.e., the first full year Eylea was available). See Attachment D-3. Since launch, Regeneron's total external expenditures have been [REDACTED], or [REDACTED] of net sales, while total people expenditures have been [REDACTED], or [REDACTED] of net sales. See Attachment D-3.

(110) These total expenditures are significantly smaller as a share of net sales than the industry average range of 22.5% to 33% for marketing expenditures²²³ Further, even if one compares the smallest Gagnon and Lexchin's estimate

²²² Conversation with Regeneron Executive Director, Commercial Finance & Business Planning and Senior Director, FP&A.

²²³ Ex. 2196 (Gagnon (2008), at 32).

against Eylea's highest spending year after its launch year, Eylea's marketing expenditures are still substantially below the percentage for the pharmaceutical industry as a whole. The Gagnon (2008) estimate (excluding samples) is equal to 17.7% of net sales, which is approximately [REDACTED] percentage points larger than Eylea's marketing spend of [REDACTED] of net sales in 2012.

(111) These values suggest Regeneron was able to spend less on advertising efforts than industry averages. In view of this relatively limited expenditure, it is highly unlikely that Regeneron's marketing efforts (rather than the patented dosing regimen) could have driven Eylea's commercial success. These comparisons further support a conclusion that the product's features (including its patented dosing regimen), rather than marketing efforts, were important factors driving commercial success.

10.2. Regeneron has had limited discounting and rebate programs

(112) In addition to the marketing efforts, Regeneron, like virtually any company selling innovative medicines, has implemented rebate and discounts as part of its commercialization of Eylea. Rebate, discount, and other price reduction activities are common in the pharmaceutical industry, and analyses of Regeneron's discounting practices demonstrate that they were unlikely to have been a key factor driving Eylea's commercial success.

(113) Over the period from 2011 to 2021, Regeneron's rebates and discounts for Eylea have ranged from [REDACTED] to [REDACTED] of gross sales. See Attachment D-1. In total from 2011 to 2021, Regeneron's rebates equaled [REDACTED] of gross sales. See Attachment D-1. Although direct comparisons of rebate and discount magnitudes (and the impact of rebates and discounts) between Eylea and other anti-VEGF options are limited by data availability, several pieces of evidence suggest that these rebate and discounts were unlikely to have driven Eylea's rapid sales growth and sustained commercial success, as can be seen from comparisons with Lucentis.

- The extensive discounting practices of Lucentis can be seen in its declining Medicare payment limit over time. See Attachment D-6. As shown in Section 8.4, the payment limit of Lucentis has decreased by approximately 20% since 2012. In comparison the payment limit of Eylea has decreased by only 6%. See Section 8.4.
- Additionally, I understand that the discounts and rebates offered for Lucentis make Lucentis the first choice among some large practices that treat enough patients with relevant conditions to qualify for the largest

discounts and rebates.²²⁴ I understand that both Regeneron and Genentech offer rebates to group purchasing organizations and off-invoice discounts, and that Regeneron estimates that historically the discounts and rebates offered for Lucentis have been approximately three times as large as those offered for Eylea.²²⁵ For example, I understand at present that the largest discounts or rebates Regeneron offers for Eylea are approximately [REDACTED], whereas Regeneron estimates that the largest rebates and discounts offered for Lucentis are approximately [REDACTED].²²⁶ I also understand that in recent years, Genentech has offered a third category of price reduction in the form of a loyalty program, whereas Regeneron does not offer such a program for Eylea.²²⁷

- Similarly, as compared to Avastin, the magnitude of Eylea’s rebates has little impact on the price disparity between Eylea and Avastin. For

²²⁴ Ex. 2275 (Regeneron, “Vestrum Anti-VEGF Market Share Adjustment Overview,” 5/10/2019, at 2).

²²⁵ Conversation with Regeneron Senior Director, Market Access Strategy.

²²⁶ Conversation with Regeneron Senior Director, Market Access Strategy.

²²⁷ Conversation with Regeneron Senior Director, Market Access Strategy.

example, the highest annual value of aggregate reductions (which would not all apply for any individual sale of Eylea), [REDACTED], would reduce Eylea's list price to [REDACTED].²²⁸ See Section 8.4. Such a reduction in price does not eliminate the disparity with Avastin, which is effectively priced under \$10 per injection. See Section 8.4. This demonstrates that Eylea's price discounts are unlikely to have driven commercial success for Eylea over Avastin.

10.3. Regeneron's sampling program is unlikely to have driven Eylea's commercial success

(114) Regeneron offers Eylea samples to physicians upon request, primarily to physicians at private or community practices.²²⁹ I understand that physicians generally use Eylea samples to provide treatment when insurance coverage is uncertain, for example when treating new patients with unclear coverage.²³⁰

²²⁸ [REDACTED].

²²⁹ Conversation with Regeneron Associate Director, Field Force Effectiveness, Ophthalmology and Associate Director, Sample Operations and Accountability.

²³⁰ Conversation with Regeneron Associate Director, Field Force Effectiveness, Ophthalmology and Associate Director, Sample Operations and Accountability

Samples allow physicians to treat a patient with Eylea while insurance or other coverage is being determined.²³¹

(115) Regeneron’s sampling program has been limited and is unlikely to have driven Eylea’s sales growth. Nor does sampling demonstrate that the patented dosing interval was not an important contributor to commercial success. As an initial matter, Regeneron achieved significant sales and sales growth prior to the introduction of a sampling program. Regeneron first offered product samples beginning in late 2013.²³² See Attachment D-5. These initial samples were offered after Eylea had already achieved a successful launch and captured a sales share of approximately [REDACTED] in its first two years available. See Section 8.3.2.

(116) Further, samples have never been a substantial portion of total unit sales of Eylea and hence are unlikely to have been a meaningful driver of commercial

²³¹ Conversation with Regeneron Associate Director, Field Force Effectiveness, Ophthalmology and Associate Director, Sample Operations and Accountability

²³² Ex. 2169 (Regeneron, “Eylea Sample Disbursement 2013 to 2021,” c. 2021, at tab “Knipper Eylea Distribution”).

The first samples were dated in September 2013 and shipped in October 2013.


success. Since launching its sample program, Regeneron has provided [REDACTED] samples, which represents [REDACTED] of total historical Eylea unit sales. See Attachment D-4. From 2014 through 2020 (i.e., the full years that Regeneron has run a sampling program), sample units have ranged from [REDACTED] to total unit sales (in 2014) to [REDACTED] of total unit sales (in 2019). See Attachment D-4. Regeneron has provided [REDACTED] samples from 2014 through 2020, or [REDACTED] of unit sales during the same period. See Attachment D-4.

(117) In conclusion, the delay in starting a sampling program after launching Eylea and the low quantity of samples offered by Regeneron render them unlikely to have caused commercial success and hence further demonstrate that product attributes, such as the patented dosing regimen, have been more important factors driving Eylea's commercial success.

CONFIDENTIAL MATERIAL– SUBJECT TO PROTECTIVE ORDER

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine, imprisonment, or both under Section 1001 of Title 18 of the United States Code.

Dated: Feb 11, 2022



Richard Manning, Ph.D.

Washington, D.C.

February 2022

Richard Manning, Ph.D.
Managing Director

Dr. Richard Manning is a Managing Director at Intensity, LLC. He provides data-driven insights to help clients solve complex economic problems. He has experience conducting economic analyses in matters involving breach of contract, fraud, pricing, economic valuation, intellectual property, antitrust, patent infringement, and public policy. His areas of expertise include:

- Economic Valuation and Damages
 - Breach of Contract, Fraud, and other Commercial Litigation
 - Intellectual Property
 - Securities Litigation
- Tax, Antitrust and Competition
- Public Policy

Dr. Manning has testified in U.S. District Court, the Delaware Court of Chancery, and the International Chamber of Commerce; served as consulting expert; and prepared reports on various matters in the biopharmaceutical and healthcare industries. His career includes 14 years as an executive at multinational pharmaceutical companies. He led economic analysis and strategy development to shape practices related to emerging business concerns.

Examples of Dr. Manning's work include:

- Economic analysis and strategy relative to challenges affecting pricing, reimbursement, and intellectual property protection in worldwide markets.
- Collaborating with outside academic economists to analyze critical issues including healthcare benefit design; healthcare system reform proposals; marketing and advertising; intellectual property protection; FDA regulatory reform, including biosimilars approval processes and safety; and new product R&D.
- Specializing in strategic partnerships, merger and acquisitions activity, economic valuation of early-stage companies, and other economic analyses for biopharmaceutical, medical device, financial, and healthcare clients.

Prior to joining Intensity, Dr. Manning was a Partner with Bates White, an economic consulting firm offering analysis and expert testimony services to law firms, Fortune 500 companies, and government agencies. Previously, Dr. Manning was Executive Director at Merck & Co., Inc., and

he was Senior Director at Pfizer, Inc. Also, Dr. Manning was a Director in the Advisory Strategy Group at PricewaterhouseCoopers.

Dr. Manning was an economics professor at Brigham Young University and a visiting professor in the Graduate School of Business at the University of Chicago. As an academic, his teaching and research focused on price theory, the economic analysis of law, industrial organization, and government regulation economics.

Dr. Manning received his Ph.D. in Economics from the University of Chicago. He earned his B.A. in Economics from Brigham Young University.

Education

PhD, Economics, University of Chicago, 1989.

MA, Economics, University of Chicago, 1984.

BA, Economics, Brigham Young University, magna cum laude, 1982.

Professional Experience

Intensity, LLC. Managing Director, 2021 to present.

Bates White Economic Consulting, Washington, DC. Partner, 2012–2021.

Merck & Co., Inc., Whitehouse Station, NJ. Executive Director, 2010–2011.

PricewaterhouseCoopers, LLP, New York, NY. Director, Advisory Strategy, 2008–2010.

Pfizer, Inc., New York, NY. Senior Director, 2003–2008.

Pfizer, Inc., New York, NY. Director, 2000–2003.

Pfizer, Inc., New York, NY. Assistant Director, 1999–2000.

Pfizer, Inc., New York, NY. Manager, 1997–1999.

Department of Economics, Brigham Young University Assistant Professor, 1990–1997.

Graduate School of Business, University of Chicago. Visiting Assistant Professor, 1995–1996.

Expert Testimony and Consulting Experience

Breach of Contract, Fraud, and other Commercial Litigation

1. *Perrigo v. United States of America*. United States District Court, Western District of Michigan, Case No. 1:17-cv-00737. Submitted expert report and testified in deposition and trial.
2. Served as expert witness in arbitration before the International Chamber of Commerce regarding damages due to an alleged breach of obligations to market a newly launched prescription medication. Submitted witness statement, rebuttal statement, and testified in hearing.
3. *Merix Pharmaceutical Corp. v. Clinical Supplies Management, Inc. (CSM)*, United States District Court, Northern District of Illinois, Case No. 1:11-cv-03318. Retained as testifying expert on behalf of CSM in connection with alleged fraud and breach of contract claims related to the performance of a clinical trial for an over-the-counter medication. Authored expert report and provided deposition testimony that assessed damages assertions made by plaintiff's experts. Judge Matthew F. Kennelly, of the US District Court for the Northern District of Illinois Eastern Division, granted summary judgment on a number of Merix's damages claims. A jury ultimately found in CSM's favor at trial.
4. *National Union Fire Insurance Company of Pittsburgh, Pennsylvania v. Tyco Integrated Security, LLC*. United States District Court, Southern District of Florida, Case No. 9:13-cv-80371. Authored an expert report and testified on behalf of Tyco regarding damages arising from a theft of prescription drugs from a pharmaceutical company warehouse. In April 2016, a Florida federal jury found in Tyco's favor, finding the security company not liable in the insurer's negligence suit.
5. *Elorac v. Sanofi-Aventis Canada*. United States District Court, Northern District of Illinois, Case No. 1:14-cv-01859. Authored an expert report and provided deposition testimony assessing damages in a breach of contract federal district court action on behalf of the plaintiff, asserting that the defendant failed to perform its duties to commercialize plaintiff's product under a licensing agreement.
6. *Fera Pharmaceuticals LLS v. Akorn Inc.* United States District Court, Southern District of New York, Case No. 1:12-cv-07694. Retained as the testifying expert on behalf of Fera. Authored expert report and provided deposition testimony evaluating damages, including diminished asset value, resulting from alleged breach of contract, fraudulent inducement, and misappropriation of trade secrets related to Fera's portfolio of prescription ophthalmic anti-infective ointment products. The matter settled on the eve of trial for an undisclosed amount.
7. Served as consulting expert to provide liability and damages analysis for a multinational pharmaceutical company in a qui tam case involving potential violations of state law in its marketing practices.
8. Retained as testifying and consulting expert to analyze the economics of a pharmacy services contract evaluation and award process for a leading institutional pharmacy in a dispute with a large state's Department of Public Safety and Correctional Services.
9. Retained as consulting expert by a class of state Medicaid claimants to evaluate the state's application of an econometric model for benefit determination decisions.

Intellectual Property

10. *Baxalta Incorporated and Baxalta GmbH v. Genentech, Inc. and Chugai Pharmaceutical Co., Ltd.* United States District Court, District of Delaware, Case No. 17-509-TBD. Submitted rebuttal expert report and testified in deposition. The matter concluded with a summary judgment for Genentech.
11. *Purdue Pharma v. Alvogen Pine Brook.* United States District Court, District of Delaware, Case No. 1:17-cv-00677. Retained as testifying expert to assess the commercial success of a prescription drug in a patent infringement litigation related to certain Abbreviated New Drug Applications (ANDAs) filed by defendant. Submitted expert reports and provided deposition testimony. The matter settled on the verge of trial.
12. *CoreSource v. Quality Healthcare Intermediary.* United States District Court, Northern District Court of Illinois, Case No. 1:13-cv-05182. Submitted declarations to US Patent Trial and Appeals Board on behalf of the petitioner in a patent infringement matter involving methods for optimizing healthcare services management. Patent owner respondent terminated its claims.
13. Retained as consulting expert on behalf of defendant in a breach of contract matter between biopharmaceutical companies before the International Chamber of Commerce. Plaintiff was seeking damages for alleged lost profits related to a joint marketing agreement. Provided support to testifying expert in preparing a rebuttal report regarding the impact of adoption and pricing of biosimilar products entering the marketplace in certain Asian countries.
14. Served as consultant to a university assessing damages against a consumer products company by an unauthorized filing of patents on property owned by the university. Submitted a declaration to a federal district court addressing recommended economic principles and methodologies for assessing the university's intellectual property market value.
15. Provided consulting support in an arbitration between large mobile telecommunications companies regarding royalties to be paid for standard-essential patents.
16. Served as consulting expert for a medical device manufacturer in an International Trade Commission (ITC) matter to evaluate potential harm to public interest in connection with alleged improper importation of surgical devices.

Securities Litigation

17. *Wells Fargo Bank et al. v. Merrimack Pharmaceuticals, Inc.* Court of Chancery of the State of Delaware. Retained as testifying expert on behalf of plaintiffs. The plaintiffs alleged that the company's asset sale was a sale of "substantially all" of the assets, which was a fundamental change, and Merrimack was required to repurchase the convertible notes. Submitted primary and rebuttal reports that valued Merrimack's pipeline of oncology drugs and opined that the sale of Merrimack's sole commercial product constituted a fundamental change of the company. Following the exchange of reports, the parties settled.
18. *Neogenix Oncology v. Peter Gordon et al.* United States District Court, Eastern District of New York, Case No. 2:14-cv-04427. Submitted a witness statement regarding the value of an early-stage biopharmaceutical company. The parties settled.

Antitrust and Competition

19. *Pharmaceutical Solutions, Inc. (VetSource) v. Nevada State Board of Pharmacy et al.* United States District Court, District of Nevada, Case No. 2:16-cv-171-RFB-VCF. Retained as the testifying expert on behalf of VetSource, which sued in federal court in response to a cease and desist action that alleged illegal kickbacks. Authored expert report evaluating the market for pet medications in Nevada and the VetSource business model to assess whether the company competes with other retail pharmacies in this market. The parties settled the federal lawsuit on undisclosed terms. VetSource continues to operate in the state under its previously existing business model, and the complaint from the Nevada Board of Pharmacy was rescinded.
20. Conducted detailed economic analysis on behalf of Eli Lilly in connection with its \$5.4 billion acquisition of Novartis Animal Health. Both firms were active in developing and marketing animal health products, including medications used to treat pets and livestock. Team assessed overlaps in several areas, and presented results of its analysis to the FTC. The FTC approved the merger after an eight-month investigation, with divestiture required in one product area, canine parasiticides.

Selected Policy and Business Consulting Experience

- Retained by a multinational pharmaceutical company to develop a tool based on economic theory to help the company optimize its participation in price-related contract negotiations with foreign purchasers of generic drug products and biosimilars. The tool provides the predicted win probability for a given bid and calculates expected profits based on observed market factors.
- Retained to provide consulting services to a start-up pharmaceutical manufacturing company pursuing opportunities in underserved product spaces in both public and private sector markets.
- Retained by a coalition of health insurance companies to assess the costs of compliance with proposed federal regulation regarding transparency and provision of information to customers.
- Analyzed the prospective impact of the “Cadillac tax” section of the Affordable Care Act on employer and employee choices regarding insurance options, healthcare spending, and federal revenue. Used the Congressional Budget Office health insurance simulation model and predicted that the tax would lead to a lower offer rate of health benefits by employers and an increase in overall healthcare spending, and that the tax would have disproportionate effects on minority populations.
- Retained as consulting expert for a multinational manufacturer of injectable blood plasma derivatives to evaluate the economics of manufacturing and distribution of plasma-based medications and the potential impact of regulatory restrictions on certain business practices.
- Retained as consulting expert for a global life sciences company to evaluate the economics of biosimilar entry in the United States and key international markets. The focus is on market penetration and pricing of medicines entering under a new regulatory framework for follow-on biologics.

- Retained by a leading healthcare company to prepare a report analyzing the economics of the market for blood plasma products in response to changing demand and cost conditions.
- Retained by a multinational life sciences company to analyze the market for oncology products with respect to the sustainability of current and projected future trends in pricing, utilization, and reimbursement.
- Retained by a multinational life sciences and healthcare company to analyze links between health status and economic well-being across countries and over time.
- Prepared a report for research-based pharmaceutical and biotechnology companies evaluating potential compliance costs resulting from Affordable Care Act price reporting requirements to government agencies.
- Performed an economic impact analysis of research and development activities for a leading non-profit stem cell foundation, working with scientists to evaluate programs and assess impact on future economic activity.

Selected Corporate Experience

- Led teams in the assessment of emerging strategic challenges facing a major biopharmaceutical company in both human and animal health businesses related to industry pricing, marketing and other business practices, managed care and government payor access restrictions, intellectual property protection, litigation threats, healthcare reform proposals, etc.
- Led teams working on mergers and acquisitions analysis for both human and animal health divisions of biopharmaceutical companies, undertaking commercial due diligence, evaluating target companies and market conditions, and providing economic analysis of divestiture options in response to regulatory concerns.
- Worked with leadership of disease management subsidiary of major biopharmaceutical company overseeing studies of health benefits design on issues including medication adherence, cost, and medical outcomes.
- Participated in an executive-level initiative on individualized medicine focused on identifying and evaluating future opportunities in the business of human genetics as it related to the development of gene-based diagnostics and therapeutics.
- Explored and evaluated various strategic business opportunities for a major medical center involved in research and development of gene-based diagnostics.
- Served as company spokesperson on major economic issues and as the company representative on key industry trade organization teams responsible for conducting research projects that addressed the value of innovation, pricing and reimbursement threats, intellectual property protection, international trade-related pricing challenges, etc.
- Developed and provided training on economics of drug discovery and development for research scientists at a global biopharmaceutical company.

Journal Articles

“Comment on ‘Market Exclusivity for Drugs with Multiple Orphan Approvals (1982–2017) and Associated Budget Impact in the US.’” *PharmacoEconomics* 38, 1373–1374 (2020).
<https://doi.org/10.1007/s40273-020-00975-7>

“The Clinical and Economic Impact of the Early Detection and Diagnosis of Cancer,” with Peter J. Deckers, Tricia Laursen, Stacey Worthy, and Shruti Kulkarni, *Health Law & Policy Brief* XIV, no. 2 (2020): 1–20.

“Prices and Related Controversies in the Biopharmaceutical Industry,” *International Journal of the Economics of Business* 25, no. 1 (2018): 157–66.

“Vaccination and GDP Growth Rates: Exploring the Links in a Conditional Convergence Framework,” with Neal A. Masia, Jonathan Smerling, Tendayi Kapfidze, and Mark Showalter, *World Development* 103 (2018): 88–99.

“Risk-based Decision Making and Ethical Considerations in Donor Compensation for Plasma-derived Medicinal Products,” with Mark Skinner, Ann Hedlund Hoppe, Henry Grabowski, Raffi Tachdjian, James Crone, and Stuart Youngner, *Transfusion* (2016): 1–6.

“An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors,” with Henry Grabowski, *International Journal of the Economics of Business* 23, no. 2 (2016): 149–66.

“Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?” with Christopher Stomberg, Benjamin Scher, Kathleen Twigg, and Andrew Huson, *International Journal of the Economics of Business* 22, no. 2 (2015): 231–44.

“Pharmaceutical Risk Sharing Agreements,” with Joseph Cook and John Vernon, *Pharmacoeconomics* 26, no. 7 (2008): 551–56.

“Special Issue on Economics of Pharmaceutical Industry,” co-editor with John Vernon, *Managerial and Decision Economics* 28, no. 4–5 (2007): 229–522.

“The Benefits of Switching Smoking Cessation Drugs to OTC,” with Teh-wei Hu, Hai-Yen Sung, Theodore E. Keeler, Martin Marciniak, and Alison Keith, *Health Economics* 11, no. 5 (2002): 389–402.

“Economic Impact of Product Liability in US Prescription Drug Markets,” *International Business Lawyer* 29, no. 3 (2001): 104–09.

“Have Changing Liability Rules Compensated Workers Twice for Occupational Hazards? Earnings Premiums and Cancer Risk,” with John R. Lott, Jr., *Journal of Legal Studies* 29 (2000): 99–130.

“The Length of Time Necessary to Break Even after Converting to Digital Mammography,” with Mark D. Hiatt and J. Jeffrey Carr, *Journal of Telemedicine and Telecare* 6, no. 4 (2000): 222–24.

“Products Liability and Prescription Drug Prices in Canada and the United States,” *Journal of Law and Economics* 40 (1997): 203–44.

“How Term Limits Enhance the Expression of Democratic Preferences,” with Einer Elhauge and John R. Lott, Jr., *Supreme Court Economic Review* 5 (1997): 59–80.

“Is the Insurance Aspect of Producer Liability Valued by Consumers? Liability Changes and Childhood Vaccine Consumption,” *Journal of Risk and Uncertainty* 12 (1996): 343–58.

“Logit Regressions with Continuous Dependent Variables Measured with Error,” *Applied Economics Letters* 3 (1996): 183–84.

“Changing Rules in Tort Law and the Market for Childhood Vaccines,” *Journal of Law and Economics* 37 (1994): 247–75.

Corporate Publications

Economic Realities in Health Care Policy, monograph series, Editor, Pfizer Inc., 1998–2005.

- “The Competitive Advantage of a Healthy Workforce,” Editor, with Alison Keith, 1998.
- “Pharmaceutical Prices: What’s Missing from the Public Discussion,” with Alison Keith, 2000.
- “Prescription Drug Advertising: Empowering Consumers through Information,” 2002.
- “Pharmaceutical Innovation: Lowering the Price of Good Health,” 2002.
- “Pharmaceutical Prices: What’s Missing from the Public Discussion, Updated,” with Neal Masia, 2002.
- “Pharmaceutical Marketing and Promotion: Creating Access to Innovation,” with Neal Masia, 2003.
- “Who Invents New Medicines?” Editor, with Neal Masia, 2005.

Other Publications

“Public Comment to Multilateral Pharmaceutical Merger Task Force” with Kira Stearns, Kyle Kost, and Richard Brady, June 2021, *available at* <https://www.regulations.gov/comment/FTC-2021-0025-0038>.

“Risks In Moving Too Quickly, Or Slowly, On COVID-19 Vaccine” Law360, December 2020, *available at* <https://www.law360.com/articles/1336937>.

“An Integrated Supply Chain: A White Paper on Addressing Essential Medicine Shortages” with Anthony Flammia, Kristina McKean, and Patricia Watson, August 2020, *available at* https://www.phlow-usa.com/wp-content/uploads/Phlow_SAPIR_Whitepaper_091020.pdf

“Economic Profitability of the Biopharmaceutical Industry: 2020 Update,” with Saurav Karki, Policy Brief, May 2020, *available at* <https://www.bateswhite.com/newsroom-insight-Economic-Profitability-Biopharmaceutical-Industry-2020-update.html>.

“Estimating the Burden of the Proposed Transparency in Coverage Rule,” with Arun Sharma and Zachary Mozenter, Bates White Economic Consulting White Paper, January 2020, *available at* https://www.bateswhite.com/media/publication/183_Estimating%20Burden%20of%20Proposed%20TCR.pdf.

“Policies to Reduce Prices of Prescription Medicines,” Policy Brief, September 2019, *available at* https://www.bateswhite.com/media/publication/181_Policy%20Brief%20on%20price%20control%20measures.2019.09.18.pdf.

“The International Pricing Index for Medicare Part B Drugs,” Policy Brief, February 2019, *available at*

https://www.bateswhite.com/media/publication/170_International%20Pricing%20Index%20for%20Medicare%20Part%20B%20Drugs.pdf.

“Continuous Manufacturing in Pharmaceuticals: Economic and Policy Issues,” with Richard Sciacca, October 2018, *available at* https://www.bateswhite.com/media/publication/171_Continuous%20Manufacturing.pdf.

“Economic Profitability of the Biopharmaceutical Industry,” with Saurav Karki, Policy Brief, September 2018, *available at* https://www.bateswhite.com/media/publication/167_Economic%20profitability%20of%20the%20drug%20industry.pdf.

“*Commentary on Biotech vs. Pharma Investments*,” Carlson School of Management, Medical Industry Leadership Institute *Exchange* 19, Summer 2018.

“Key Economic and Value Considerations in the US Market for Plasma Protein Therapies,” with Henry Grabowski, February 2018.

“Biosimilar Coding and Reimbursement under Medicare Part B,” with Christopher Stomberg and Ben Wolfert, November 2017.

“Poorly Executed Analyses of Drug Research and Development Is Useless.” *The Hill*. September 29, 2017, *available at* <http://thehill.com/opinion/healthcare/353072-poorly-executed-analyses-of-pharmaceutical-rd-is-useless?rnd=1506695357>.

“Penalizing Generic Drugs with the CPI Rebate Will Reduce Competition and Increase the Likelihood of Drug Shortages,” with Fred Selck, September 2017, *available at* <https://www.accessiblemeds.org/sites/default/files/2017-09/Bates-White-White-Paper-Report-CPI-Penalty-09-12-2017.pdf>.

“Drug Prices and Medical Innovation: A Response to Yu, Helms, and Bach,” with Henry Grabowski, *Health Affairs* Blog, June 2, 2017, *available at* <http://healthaffairs.org/blog/2017/06/02/drug-prices-and-medical-innovation-a-response-to-yu-helms-and-bach/>.

“Oncology Product Sales and Patent Expiration: A Policy Brief,” with Fred Selck, June 2017, *available at* <http://www.bateswhite.com/insight-173.html>.

“The Role of Value and Cost in Prescription Drug Pricing,” *Law360*, September 27, 2016.

“Tax Inversions: How Do Financial Metrics of Foreign Acquisitions Compare?” with Richard Sciacca and Alan Alford, Apr. 6, 2016.

“Tax Inversions: A Preliminary Review of Company Financial Data,” with Richard Sciacca and Alan Alford, Jan 12, 2016.

“Our Best Shot: Expanding Prevention through Vaccination in Older Adults,” with Fred Selck and Kathleen Chandler, July 29, 2015.

Recent Presentations and Panels

- “15th Meeting of the American College of Business Court Judges, “Pharmaceutical Regulation: Lessons and Enduring Impacts of Deregulatory Incentives Embraced During a Pandemic,” Panel discussion, George Mason University Antonin Scalia Law School Law and Economics Center, Savannah, GA, October 30, 2020.
- Global Plasma Summit 2020, “The Plasma Industry and Possible Effects of the COVID Pandemic,” Presenter, virtual conference, October 30, 2020

- Promoting Innovation in the Life Science Sector and Supporting Pro-Competitive Collaborations: The Role of Intellectual Property, “Academics’ and Economists’ Views on Collaboration and Competition,” Joint DOJ/USPTO Antitrust Webinar panelist, September 24, 2020
- Meeting of the Association of Blood Service of Ukraine and the Ukrainian Society of Immunology, Allergology and Immunorehabilitation, “Assessing Value for Plasma Protein Therapies,” Presentation, Kiev, Ukraine, September 19, 2019
- 8th Annual American Society of Health Economics meeting, “Setting Drug Prices in Medicare: Toward a Competitive Market?” Policy Roundtable moderator, Washington, DC, June 24, 2019.
- 2019 Plasma Protein Therapeutics Association, Plasma Forum, “Assessing Value for Plasma Protein Therapies,” Panel discussion, Reston, VA, June 18, 2019.
- Symposium on the Legal, Economic, and Regulatory Environment of the Pharmaceutical Industry, “Who Really Pays for Drugs and How Much? Marketing, Pricing, and Transparency,” Panel discussion, George Mason University Antonin Scalia Law School, Arlington, VA, April 15, 2019.
- 15th Annual Symposium of the Journal of Law, Economics, and Policy: Health Care Cost, Quality, and Transparency, “Why Do Drugs Cost so Much? What (If Anything) Should We Do About It?” Panel discussion, George Mason University Antonin Scalia Law School, Arlington, VA, November 16, 2018.
- Pneumococcal Vaccination Pharmacoeconomic Summit, “Childhood Vaccination and Economic Growth,” Presentation, Dubai UAE, February 24, 2018.
- George Mason University Center for the Protection of Intellectual Property Summer Institute, “The Challenges of Encouraging Long-Term Innovation,” Panel discussion, Beaver Creek, CO, July 12, 2017.
- International Health Economics Association, Boston 2017 Congress, “Global Spending Patterns for Oncology Medications,” Presentation, Boston, July 9, 2017.
- George Mason University Center for the Protection of Intellectual Property Fourth Annual Fall Conference, “Assessing the Economic Case for Patents,” Panel discussion, Arlington, VA, October 7, 2016.
- AcademyHealth Annual Research Meeting, “Building a Successful HSR Career Outside the Ivory Tower,” Panel discussion, Boston, MA, June 27, 2016.
- Sidley Austin’s Global Drug Pricing Conference, “Options for Responding to Price Scrutiny, including Value Based Contracting,” Washington, DC, April 20, 2016. Bates White Life Sciences Symposium, “Anti-Kickback Statute,” Panel moderator, Washington, DC, June 8, 2015.
- George Mason University Center for the Protection of Intellectual Property Roundtable, “Patented Innovation in the Pharmaceutical and Biotech Industries,” Hilton Head, SC, May 28–29, 2015.
- George Mason University Attorneys General Education Program, “Pharmaceutical Marketing: Economic and Legal Issues,” Arlington, VA, March 26, 2015.
- Bates White Life Sciences Symposium, “Oncology Case Study,” Washington, DC, June 13, 2014.
- Bates White Life Sciences Symposium, “Litigation Landscape since Last Year’s Supreme Court Decision in *FTC v. Actavis*,” Panelist, Washington, DC, June 12, 2014.

- Bates White Healthcare & Life Sciences Symposium, “Co-pay Coupons Case Study,” Washington, DC, June 10, 2013.
- Indian Institute of Management Bangalore Roundtable, “Ethical Issues in the Health Care Sector in India,” March 2013.
- ACI’s West Coast Edition Paragraph IV Disputes Conference, “Damages Analysis,” San Francisco, CA, December 5, 2012.
- McGuireWoods’ 4th Annual Medical Device and Life Sciences Conference, “Key Economic and Legal Issues in Prescription Drug Marketing,” Chicago, IL, November 8, 2012.
- George Mason University Attorneys General Education Program, “Marketing and Advertising of Prescription Drugs: An Economic Perspective,” Arlington, VA, May 3, 2012.
- Medical Industry Leadership Institute, Carlson School of Management, University of Minnesota, Panel discussion, May 2011.
- PhRMA Asia Pacific Meeting, Panel discussion chair, Singapore, January 2011.
- Incisive Media 7th Annual Healthcare M&A and Business Development Conference, Presentation, Atlanta, GA, September 2009.
- The Deal Healthcare Dealmaking Symposium, Presentation, New York, NY, March 2009.
- Drug Industry Association Annual Meeting, Presentation, 2008.

Professional Activities

- Advisory Board, Medical Industry Leadership Institute, Carlson School of Management, University of Minnesota
- Business Research Advisory Committee Member and Price Index Committee Chair, US Bureau of Labor Statistics
- Advisory Board, Rutgers Business School, Lerner Center for Pharmaceutical Management
- Founding Member and Advisory Board, Center for Value Based Insurance Design, University of Michigan
- Corporate Council Member, Brookings Institution
- Editorial Board, *Managerial and Decision Economics*
- Ad hoc referee for *International Journal of the Economics of Business*, *Journal of Political Economy*, *Journal of Law and Economics*, *Journal of Legal Studies*, *Journal of Industrial Economics*, *Health Affairs*, *Forum for Health Economics and Policy*, *The Social Science Journal*

PROFESSIONAL ASSOCIATIONS

- American Economic Association
- American Society of Health Economists
- Economic Club of New York

- International Society for Pharmacoeconomics and Outcomes Research
- National Association of Business Economists
- American Law and Economics Association

Attachment B-1

Dosing Directions on FDA Labels

Indication	Brand	Source	First Label for Each Brand and Indication	Most Recent Label
Wet AMD	Eylea	[A]	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). • Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy. Patients should be assessed regularly.
Wet AMD	Lucentis	[B]	• LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month. • Although less effective, treatment may be reduced to one injection every three months after the first four injections if monthly injections are not feasible. Compared to continued monthly dosing, dosing every 3 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average, over the following 9 months. Patients should be evaluated regularly.	• LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days). • Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. • Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.

Wet AMD	Beovu	[C]	• BEOVU is administered by intravitreal injection. The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks.	• BEOVU is administered by intravitreal injection. The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks.
RVO	Eylea	[D]	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection once every 4 weeks (monthly).	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection once every 4 weeks (approximately every 25 days, monthly).

RVO	Lucentis	[E]	• LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days). In the RVO clinical studies, patients received monthly injections of LUCENTIS for six months. In spite of being guided by optical coherence tomography and visual acuity re-treatment criteria, patients who were then not treated at Month 6 experienced on average, a loss of visual acuity at Month 7, whereas patients who were treated at Month 6 did not. Patients should be treated monthly.	• LUCENTIS 0.5 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
RVO	Beovu	[F]	n/a	n/a

DME	Eylea	[G]	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 5 injections followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).
DME	Lucentis	[H]	LUCENTIS 0.3 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).	• LUCENTIS 0.3 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

DME	Beovu	[I]	n/a	n/a
DR	Eylea	[J]	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).	• The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).

DR	Lucentis	[K]	• LUCENTIS 0.3 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).	• LUCENTIS 0.3 mg (0.05 mL) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
DR	Beovu	[L]	n/a	n/a

Notes and sources:

First Label:

[A] Ex. 2185 (Eylea label, 11/2011, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf).

[B] Ex. 2212 (Lucentis label, c. 2006, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf).

[C] Ex. 2161 (Beovu label, 10/2019, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf).

- [D] Ex. 2186 (Eylea label, 9/2012, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125387s004lbl.pdf).
- [E] Ex. 2213 (Lucentis label, 6/2010, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125156s053lbl.pdf).
- [F] Beovu is not approved for treatment outside of Wet AMD.
- [G] Ex. 2187 (Eylea label, 10/2014, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125387s043lbl.pdf).
- [H] Ex. 2214 (Lucentis label, 8/2012, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf).
- [I] Beovu is not approved for treatment outside of Wet AMD.
- [J] Ex. 2188 (Eylea label, 5/2019, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf).
- [K] Ex. 2215 (Lucentis label, 4/2017, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s114lbl.pdf).
- [L] Beovu is not approved for treatment outside of Wet AMD.

Most Recent Label:

- [A] Ex. 2189 (Eylea label, 3/2021, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125387s069lbl.pdf).
- [B] Ex. 2216 (Lucentis label, 3/2018, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125156s117lbl.pdf).
- [C] Ex. 2162 (Beovu label, 6/2020, at 1, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761125s004lbl.pdf).
- [D] Ex. 2189 (Eylea label, 3/2021, at 1).
- [E] Ex. 2216 (Lucentis label, 3/2018, at 1).
- [F] Beovu is not approved for treatment outside of Wet AMD.
- [G] Ex. 2189 (Eylea label, 3/2021, at 1).
- [H] Ex. 2216 (Lucentis label, 3/2018, at 1).
- [I] Beovu is not indicated for treatment outside of Wet AMD.
- [J] Ex. 2189 (Eylea label, 3/2021, at 1).
- [K] Ex. 2216 (Lucentis label, 3/2018, at 1).
- [L] Beovu is not approved for treatment outside of Wet AMD.

Attachment C-1

Sales Share Summary - All Indications

Data Source	Treatment Option	Source	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Change in Sales Share since 2012	Change in Sales Share since 2016
Medicare Part B Data	Eylea	[A]	n/a	16.18%	24.61%	26.84%	35.85%	40.45%	41.37%	40.68%	43.42%	n/a	n/a	27.24pp	2.96pp
	Avastin	[B]	n/a	39.40%	35.40%	37.35%	34.35%	33.24%	34.04%	33.01%	30.61%	n/a	n/a	-8.79pp	-2.63pp
	Lucentis	[C]	n/a	35.46%	33.24%	29.60%	23.76%	20.16%	18.88%	21.23%	21.41%	n/a	n/a	-14.05pp	1.25pp
	Triamcinolone	[D]	n/a	6.08%	4.56%	3.97%	3.61%	3.62%	3.12%	2.62%	2.37%	n/a	n/a	-3.72pp	-1.25pp
	Ozurdex	[E]	n/a	1.77%	1.56%	1.80%	2.17%	2.31%	2.37%	2.29%	2.05%	n/a	n/a	0.28pp	-0.26pp
	Visudyne	[F]	n/a	0.67%	0.44%	0.32%	0.23%	0.20%	0.19%	0.15%	0.12%	n/a	n/a	-0.55pp	-0.08pp
	Iluvien	[G]	n/a	n/a	n/a	n/a	n/a	0.03%	0.02%	0.02%	0.02%	n/a	n/a	n/a	-0.01pp
	Mvasi	[H]	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.01%	n/a	n/a	n/a	n/a
	Macugen	[I]	n/a	0.44%	0.18%	0.11%	0.04%	n/a	0.01%	0.01%	0.01%	n/a	n/a	-0.43pp	n/a
ATU Survey Data	Avastin	[J]	63.00%	48.48%	50.63%	45.00%	44.00%	43.00%	44.94%	42.00%	44.00%	40.42%	39.05%	-8.06pp	-3.95pp
	Eylea	[K]	0.00%	21.21%	21.46%	27.57%	35.00%	37.00%	37.45%	38.00%	39.00%	40.27%	41.89%	19.05pp	4.89pp
	Lucentis	[L]	37.00%	30.30%	27.91%	27.44%	21.00%	20.00%	17.60%	20.00%	15.00%	14.88%	15.40%	-15.42pp	-4.60pp
	Beovu	[M]	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.00%	5.00%	3.66%	n/a	n/a
Vestrum Data	Eylea	[N]													
	Avastin	[O]													
	Lucentis	[P]													
	Beovu	[Q]													

Notes and sources:

Change in Sales Share since 2012 is equal to 2021 minus 2012.

For Medicare Part B Data, Change in Sales Share since 2012 is equal to 2019 minus 2012 because 2021 data is not available

Change in Sales Share since 2016 is equal to 2021 minus 2016.

For Medicare Part B Data, Change in Sales Share since 2016 is equal to 2019 minus 2016 because 2021 data is not available

[A]-[] Attachment X-3, at [D] for corresponding brand_name and year

[J] Attachment X-2, at Avastin for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year except for 2011, which is Q3 and 2021, which is Q2

[K] Attachment X-2, at Eylea for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year except for 2011, which is Q3 and 2021, which is Q2

[L] Attachment X-2, at Lucentis for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year except for 2011, which is Q3 and 2021, which is Q2

[M] Attachment X-2, at Beovu for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year.

[N] Attachment X-1, at Eylea for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year.

[O] Attachment X-1, at Avastin for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year.

[P] Attachment X-1, at Lucentis for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year.

[Q] Attachment X-1, at Beovu for corresponding Quarter and where indication equals "All indications."

The values shown are for Q4 of each year.

Attachment C-2

Sales Share Summary - Wet AMD

Data Source	Treatment Option	Source	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Change in Sales Share since 2012	Change in Sales Share since 2016
ATU Survey Data	Avastin	[A]	63.00%	48.48%	48.48%	44.00%	45.00%	43.00%	46.00%	40.00%	45.00%	40.79%	39.00%	-9.48pp	-4.00pp
	Eylea	[B]	0.00%	21.21%	25.25%	30.00%	34.00%	35.00%	37.00%	41.00%	39.00%	40.47%	44.00%	22.79pp	9.00pp
	Lucentis	[C]	37.00%	30.30%	26.26%	26.00%	22.00%	22.00%	17.00%	19.00%	13.00%	13.96%	14.00%	-16.30pp	-8.00pp
	Beovu	[D]	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3.00%	4.77%	3.00%	n/a	n/a
Vestrum Data	Eylea	[E]													
	Avastin	[F]													
	Lucentis	[G]													
	Beovu	[H]													

Notes and sources:

Change in Sales Share since 2012 is equal to 2021 minus 2012.

Change in Sales Share since 2016 is equal to 2021 minus 2016.

[A] Attachment X-2, at Avastin for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year except for 2011, which is Q3 and 2021, which is Q2

[B] Attachment X-2, at Eylea for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year except for 2011, which is Q3 and 2021, which is Q2

[C] Attachment X-2, at Lucentis for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year except for 2011, which is Q3 and 2021, which is Q2

[D] Attachment X-2, at Beovu for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year except for 2011, which is Q3 and 2021, which is Q2

[E] Attachment X-1, at Eylea for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year.

[F] Attachment X-1, at Avastin for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year.

[G] Attachment X-1, at Lucentis for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year.

[H] Attachment X-1, at Beovu for corresponding Quarter and where indication equals "Wet AMD."

The values shown are for Q4 of each year.

Attachment C-3

Sales Share Summary - DME

Data Source	Treatment Option	Source	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Change in Sales Share since 2014	Change in Sales Share since 2016
ATU Survey Data	Avastin	[A]	n/a	64.00%	51.00%	41.00%	45.00%	43.00%	41.00%	37.00%	40.00%	38.00%	-13.00pp	-7.00pp
	Eylea	[B]	n/a	0.00%	19.00%	39.00%	38.00%	40.00%	41.00%	47.00%	43.00%	44.00%	25.00pp	6.00pp
	Lucentis	[C]	n/a	36.00%	30.00%	20.00%	17.00%	17.00%	18.00%	16.00%	15.00%	15.00%	-15.00pp	-2.00pp
	Beovu	[D]	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.00%	3.00%	n/a	n/a
Vestrum Data	Eylea	[E]												
	Avastin	[F]												
	Lucentis	[G]												
	Beovu	[H]												

Notes and sources:

Change in Sales Share since 2014 is equal to 2021 minus 2014.

Change in Sales Share since 2016 is equal to 2021 minus 2016.

[A] Attachment X-2, at Avastin for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year except 2021, which is Q2.

[B] Attachment X-2, at Eylea for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year except 2021, which is Q2.

[C] Attachment X-2, at Lucentis for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year except 2021, which is Q2.

[D] Attachment X-2, at Beovu for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year except 2021, which is Q2.

[E] Attachment X-1, at Eylea for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year.

[F] Attachment X-1, at Avastin for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year.

[G] Attachment X-1, at Lucentis for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year.

[H] Attachment X-1, at Beovu for corresponding Quarter and where indication equals "DME."

The values shown are for Q4 of each year.

Attachment C-4

Sales Share Summary - DR without DME

Data Source	Treatment Option	Source	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Change in Sales Share since 2016	Change in Sales Share since 2017
ATU Survey Data	Avastin	[A]	n/a	n/a	n/a	n/a	n/a	49.00%	54.00%	43.80%	39.24%	40.00%	n/a	-9.00pp
	Eylea	[B]	n/a	n/a	n/a	n/a	n/a	29.00%	20.00%	35.24%	37.91%	37.00%	n/a	8.00pp
	Lucentis	[C]	n/a	n/a	n/a	n/a	n/a	22.00%	26.00%	20.96%	16.52%	18.00%	n/a	-4.00pp
	Beovu	[D]	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	6.32%	5.00%	n/a	n/a
Vestrum Data	Eylea	[E]												
	Avastin	[F]												
	Lucentis	[G]												
	Beovu	[H]												

Notes and sources:

Change in Sales Share since 2016 is equal to 2021 minus 2016.

Change in Sales Share since 2017 is equal to 2021 minus 2017.

[A] Attachment X-2, at Avastin for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year except 2021, which is Q2.

[B] Attachment X-2, at Eylea for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year except 2021, which is Q2.

[C] Attachment X-2, at Lucentis for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year except 2021, which is Q2.

[D] Attachment X-2, at Beovu for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year except 2021, which is Q2.

[E] Attachment X-1, at Eylea for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year.

[F] Attachment X-1, at Avastin for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year.

[G] Attachment X-1, at Lucentis for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year.

[H] Attachment X-1, at Beovu for corresponding Quarter and where indication equals "DR."

The values shown are for Q4 of each year.

Attachment C-5

Sales Share Summary - RVO

Data Source	Treatment Option	RVO Type	Source	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Change in Sales Share since 2016	Change in Sales Share since 2017
ATU Survey Data	Avastin	CRVO	[A]	n/a	50.51%	52.00%	38.00%	39.00%	41.00%	41.00%	42.00%	42.36%	37.00%	-2.00pp	-4.00pp
	Eylea	CRVO	[B]	n/a	21.21%	24.00%	42.00%	42.00%	41.00%	44.00%	42.00%	39.33%	46.00%	4.00pp	5.00pp
	Lucentis	CRVO	[C]	n/a	28.28%	23.00%	20.00%	19.00%	18.00%	15.00%	16.00%	15.73%	15.00%	-4.00pp	-3.00pp
	Beovu	CRVO	[D]	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.57%	2.00%	n/a	n/a
ATU Survey Data	Avastin	BRVO	[E]	n/a	n/a	43.00%	38.00%	38.00%	38.00%	43.00%	45.00%	40.00%	36.00%	-2.00pp	-2.00pp
	Eylea	BRVO	[F]	n/a	n/a	25.00%	46.00%	43.00%	43.00%	40.00%	40.00%	41.58%	48.00%	5.00pp	5.00pp
	Lucentis	BRVO	[G]	n/a	n/a	32.00%	16.00%	19.00%	19.00%	17.00%	15.00%	15.89%	15.00%	-4.00pp	-4.00pp
	Beovu	BRVO	[H]	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.00%	2.00%	n/a	n/a
Vestrum Data	Eylea	All RVO	[I]												
	Avastin	All RVO	[J]												
	Lucentis	All RVO	[K]												
	Beovu	All RVO	[L]												

Notes and sources:

Change in Sales Share since 2016 is equal to 2021 minus 2016.

Change in Sales Share since 2017 is equal to 2021 minus 2017.

[A] Attachment X-2, at Avastin for corresponding Quarter and where indication equals "CRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[B] Attachment X-2, at Eylea for corresponding Quarter and where indication equals "CRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[C] Attachment X-2, at Lucentis for corresponding Quarter and where indication equals "CRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[D] Attachment X-2, at Beovu for corresponding Quarter and where indication equals "CRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[E] Attachment X-2, at Avastin for corresponding Quarter and where indication equals "BRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[F] Attachment X-2, at Eylea for corresponding Quarter and where indication equals "BRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[G] Attachment X-2, at Lucentis for corresponding Quarter and where indication equals "BRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[H] Attachment X-2, at Beovu for corresponding Quarter and where indication equals "BRVO."

The values shown are for Q4 of each year except 2021, which is Q2.

[I] Attachment X-1, at Eylea for corresponding Quarter and where indication equals "RVO."

The values shown are for Q4 of each year.

[J] Attachment X-1, at Avastin for corresponding Quarter and where indication equals "RVO."

The values shown are for Q4 of each year.

[K] Attachment X-1, at Lucentis for corresponding Quarter and where indication equals "RVO."


The values shown are for Q4 of each year.

[L] Attachment X-1, at Beovu for corresponding Quarter and where indication equals "RVO."

The values shown are for Q4 of each year.

Attachment C-6

Eylea's Sales Share Across Different Data Sources - All Indications




Notes and sources:

Attachment C-1, at [A], [K], [N].

Attachment C-7

Eylea's Sales Share Across Different Data Sources - Wet AMD




Notes and sources:

Attachment C-2, at [B], [E].

Attachment C-8

Eylea's Sales Share Across Different Data Sources - DME




Notes and sources:

Attachment C-3, at [B], [E].

Attachment C-9

Eylea's Sales Share Across Different Data Sources - DR without DME




Notes and sources:

Attachment C-4, at [B], [E].

Attachment C-10

Eylea's Sales Share Across Different Data Sources - RVO




Notes and sources:

Attachment C-5, at [B], [F], [I].

Attachment C-11

Percentage Point Change in Total Sales Share Since Eylea Launch – ATU Data




Notes and sources:

Attachment C-1, at ATU Survey Data.

Attachment C-12

Percentage Point Change in Total Sales Share Since Eylea Launch – Medicare Part B Data



Notes and sources:

Attachment C-1, at [A], [B], [C], [J], [K], [L].

For 2011, the values for Lucentis and Avastin are estimated using their ATU sales shares. The ATU data is adjusted based upon Avastin's and Lucentis's combined Medicare Part B sales share across total category in 2012. In 2012, Avastin and Lucentis held a combined sales share of approximately 91%. See Attachment C-1

Attachment D-1

Eylea Profit and Loss Data (Actuals, 2011–2021)

Metric	Source	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Total
46000 - Gross sales	[A]												
46010:46065 - Gross sale deduction	[B]												
46010 - EYLEA RESERVES	[C]												
46020 - EYLEA MED REBATES	[D]												
46030 - EYLEA CO-PAY ASSISTANCE	[E]												
46040 - EYLEA SP & DIST & CC FEES	[F]												
46050 - EYLEA CHARGEBACKS	[G]												
46055 - EYLEA GPO REBATES & ADMIN FEES	[H]												
46060 - EYLEA REBATES	[I]												
46065 - EYLEA DISCOUNTS	[J]												
Net sales	[K]	\$ 24.78	\$ 837.94	\$ 1,408.74	\$ 1,736.41	\$ 2,676.04	\$ 3,323.08	\$ 3,701.92	\$ 4,076.72	\$ 4,644.20	\$ 4,947.22	\$ 5,792.32	\$ 33,169.38
Total cost of goods sold	[L]												
Drug	[M]												
Royalty	[N]												
Spoilage & reserves	[O]												
Total other operating costs	[P]												
External expenses	[Q]												
People expenses	[R]												
Pharma fee	[S]												
Gross profit	[T]												
Operating profit	[U]												
Total units	[V]												
Vials (2 mg)	[W]												
Pre-filled syringes (2 mg)	[X]												
Net sales as percent of gross sales	[Y]												
Gross sale deduction as a percent of gross sales	[Z]												
Gross profit as percent of net sales	[AA]												
Operating profit as percent of net sales	[AB]												

Notes and sources:

All values in millions.

Since the two P&L data sources provided by Regeneron include gross and net sales, the two can be combined into a complete P&L for Eylea.

[A]–[K], [V]–[X] Ex. 2285 (Regeneron, Eylea Gross & Net Sales P&L YTD, c.2021, at tab "Gross & Net Sales P&L YTD.")

[L]–[O], [Q]–[S] Ex. 2170 (Regeneron, "US Eylea P&L LTD," c. 2021, at tab "Sheet1.")

[P] = [Q] + [R] + [S].

[T] = [K] - [L].

[U] = [K] - [L] - [P].

[Y] = [K] / [A].

[Z] = $-1 \times [B] / [A]$.

[AA] = [T] / [K].

[AB] = [U] / [K].

Attachment D-2

Eylea Volume and Revenue Performance (2011–2021)

Metric	Source	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Total
Gross sales	[A]												
Year over year growth	[B]												
CAGR since 2012	[C]												
Absolute growth since 2012	[D]												
Net sales	[E]	\$ 24.78	\$ 837.94	\$ 1,408.74	\$ 1,736.41	\$ 2,676.04	\$ 3,323.08	\$ 3,701.92	\$ 4,076.72	\$ 4,644.20	\$ 4,947.22	\$ 5,792.32	\$ 33,169.38
Year over year growth	[F]												
CAGR since 2012	[G]												
Absolute growth since 2012	[H]												
Gross profits	[I]												
Year over year growth	[J]												
CAGR since 2012	[K]												
Absolute growth since 2012	[L]												
Operating profits	[M]												
Year over year growth	[N]												
CAGR since 2012	[O]												
Absolute growth since 2012	[P]												
Total Units	[Q]												
Year over year growth	[R]												
CAGR since 2012	[S]												
Absolute growth since 2012	[T]												

Notes and sources:

Values in millions except percentages.

In the notes below, "[t]" represents a given year.

[A] Attachment D-1, at [A].

$$[B] = ([A][t] / [A][t-1]) - 1.$$

$$[C] = (([A][t] / [A][2012])^{1 / ([t] - 2012)}) - 1.$$

$$[D] = ([A][t] / [A][2012]) - 1.$$

[E] Attachment D-1, at [K].

$$[F] = ([E][t] / [E][t-1]) - 1.$$

$$[G] = (([E][t] / [E][2012])^{1 / ([t] - 2012)}) - 1.$$

$$[H] = ([E][t] / [E][2012]) - 1.$$

[] Attachment D-1, at [T].

$$[J] = ([I][t] / [] [t-1]) - 1.$$

$$[K] = (([] [t] / [I][2012])^{1 / ([t] - 2012)}) - 1.$$

$$[L] = ([I][t] / [] [2012]) - 1.$$

[M] Attachment D-1, at [U].

$$[N] = ([M][t] / [M][t-1]) - 1.$$

$$[O] = (([M][t] / [M][2012])^{1 / ([t] - 2012)}) - 1.$$

$$[P] = ([M][t] / [M][2012]) - 1.$$

[Q] Attachment D-1, at [V].

$$[R] = ([Q][t] / [Q][t-1]) - 1.$$

$$[S] = (([Q][t] / [Q][2012])^{1 / ([t] - 2012)}) - 1.$$

$$[T] = ([Q][t] / [Q][2012]) - 1.$$

Attachment D-3

Eylea Promotional and Marketing Expenses As Share of Net Sales (2011–2021)

Metric	Source	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Total
Net sales	[A]	\$ 24.78	\$ 837.94	\$ 1,408.74	\$ 1,736.41	\$ 2,676.04	\$ 3,323.08	\$ 3,701.92	\$ 4,076.72	\$ 4,644.20	\$ 4,947.22	\$ 5,792.32	\$33,169.38
Total external and people expenses	[B]												
External expenses	[C]												
People expenses	[D]												
Total external and people expenses as percent of net sales	[E]												
External expenses as percent of net sales	[F]												
People expenses as percent of net sales	[G]												

Notes and sources:

Values in millions except percentages.

[A] Attachment D-1, at [K].

[B] = [C] + [D].

[C] Attachment D-1, at [Q].

[D] Attachment D-1, at [R].

[E] = [B] / [A].

[F] = [C] / [A].

[G] = [D] / [A].

Attachment D-4

Eylea Samples As Share of Total Unit Sales (2011–2020)

Notes and sources:

[A] = Attachment D-1, at [V] × 1,000,000.

[B] = [C] + [D].

[C] Ex. 2169 (Regeneron, "Eylea Sample Disbursement 2013 to 2021," c. 2021, at tab "Knipper Eylea Distribution.")

Values include only those categorized as AOC Received, Order Shipped, Order Exported (Fulfillment), Order Delivered, and AOC Received Pending Review in the column titled "Order Header Status" (Column AN). These categories capture all shipped units less returns, cancellations, and units lost in transit.

Year was determined using the "Order Date" variable (Column D). Samples were determined using the "Shipped Quantity" variable (Column AL).

[D] Ex. 2169 (Regeneron, "Eylea Sample Disbursement 2013 to 2021," c. 2021, at tab "PSI Eylea Distribution.")

Values include only those categorized as AOC Discrepancy, AOC Incomplete, AOC Received, AOC Resolved, Delivered, and Shipped in the column titled "Order Status" (Column G).

These categories capture all shipped units less returns, cancellations, and units lost in transit.

Year was determined using the "Sample Request Signature Date" variable (Column B). Samples were determined using the "Container Quantity Shipped Per Lot & NDC" variable (Column AG).

[E] = [B] / [A].

Attachment D-5

Summary of Payment Allowance Limits for Medicare Part B Drugs (2012–2021)

Treatment	HCPCS Code	Short Description	HCPCS Code Dosage [B]	2012 [C]	2013 [D]	2014 [E]	2015 [F]	2016 [G]	2017 [H]	2018 [I]	2019 [J]	2020 [K]	2021 [L]
Eylea	n/a	Aflibercept injection	1 MG	\$ 980.50	\$ 980.50	\$ 980.50	\$ 980.50	\$ 980.46	\$ 974.59	\$ 967.33	\$ 952.47	\$ 928.24	\$ 917.94
Eylea (2013 to 2021)	J0178	Aflibercept injection	1 MG	n/a	\$ 980.50	\$ 980.50	\$ 980.50	\$ 980.46	\$ 974.59	\$ 967.33	\$ 952.47	\$ 928.24	\$ 917.94
Eylea (2012)	Q2046	Aflibercept injection	1 MG	\$ 980.50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Yutiq	J7314	Inj., yutiq, 0.01 mg	0.01 MG	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 491.13	\$ 513.16
Iluvien	J7313	Inj., iluvien, 0.01 mg	0.01 MG	n/a	n/a	n/a	n/a	\$ 490.95	\$ 490.80	\$ 490.33	\$ 490.87	\$ 490.87	\$ 490.95
Retisert	J7311	Inj., retisert, 0.01 mg	0.01 MG	\$ 19,345.00	\$ 19,345.00	\$ 19,641.05	\$ 20,138.08	\$ 20,126.60	\$ 20,114.35	\$ 20,130.50	\$ 341.62	\$ 340.62	\$ 339.00
Lucentis	J2778	Ranibizumab injection	0.1 mg	\$ 398.31	\$ 397.26	\$ 396.43	\$ 391.41	\$ 383.23	\$ 378.35	\$ 373.36	\$ 352.17	\$ 324.27	\$ 318.47
Beovu	J0179	Inj, brolucizumab-dbl, 1 mg	1 MG	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 311.99	\$ 312.01
Ozurdex	J7312	Dexamethasone intra implant	0.1 MG	\$ 195.76	\$ 195.91	\$ 201.31	\$ 201.03	\$ 200.90	\$ 200.74	\$ 200.17	\$ 200.03	\$ 199.76	\$ 199.69
Avastin	J9035	Bevacizumab injection	10 MG	\$ 62.32	\$ 64.62	\$ 66.65	\$ 69.60	\$ 72.31	\$ 75.18	\$ 79.25	\$ 81.18	\$ 76.36	\$ 70.41
Zirabev (Avastin Biosimilar)	Q5118	Inj., zirabev, 10 mg	10 MG	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 62.24	\$ 52.37
Mvasi (Avastin Biosimilar)	Q5107	Inj mvasi 10 mg	10 MG	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 69.77	\$ 60.94	\$ 44.56
Triamcinolone #1	J3304	Inj triamcinolone ace xr 1mg	1 MG	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 18.88	\$ 18.20	\$ 17.75
Visudyne	J3396	Verteporfin injection	0.1 MG	\$ 10.16	\$ 10.45	\$ 10.79	\$ 10.99	\$ 10.88	\$ 10.76	\$ 10.95	\$ 11.08	\$ 11.23	\$ 11.25
Triamcinolone #2	J3300	Triamcinolone a inj prs-free	1 MG	\$ 3.57	\$ 3.96	\$ 3.73	\$ 3.72	\$ 3.70	\$ 3.88	\$ 3.86	\$ 3.85	\$ 3.85	\$ 3.88
Triamcinolone #3	J3301	Triamcinolone acet inj nos	10 MG	\$ 1.67	\$ 1.74	\$ 1.77	\$ 1.75	\$ 1.77	\$ 1.88	\$ 1.74	\$ 1.57	\$ 1.33	\$ 1.20
Triamcinolone #4	Q9993	Inj., triamcinolone ext rel	1 MG	n/a	n/a	n/a	n/a	n/a	n/a	\$ 18.88	n/a	n/a	n/a
Macugen	J2503	Pegaptanib sodium injection	0.3 MG	\$ 1,029.95	\$ 1,026.70	\$ 1,034.02	\$ 1,031.85	\$ 1,054.70	\$ 729.47	\$ 713.86	\$ 722.05	\$ 722.99	n/a

Notes and sources:

[A] Attachment X-4, at Short Description for corresponding the HCPCS Code.

The most current description where pricing data exists is used. For example, Macugen's description is from 2020 while Eylea's is from 2021.

[B] Attachment X-4, at HCPCS Code Dosage for corresponding the HCPCS Code.

The most current dosage where pricing data exists is used. For example, Macugen's data is from 2020 while Avastin's is from 2021.

[C] Attachment X-4, at Payment Limit in 2012 for the corresponding HCPCS Code.

[D] Attachment X-4, at Payment Limit in 2013 for the corresponding HCPCS Code.

[E] Attachment X-4, at Payment Limit in 2014 for the corresponding HCPCS Code.

[F] Attachment X-4, at Payment Limit in 2015 for the corresponding HCPCS Code.

[G] Attachment X-4, at Payment Limit in 2016 for the corresponding HCPCS Code.

[H] Attachment X-4, at Payment Limit in 2017 for the corresponding HCPCS Code.

[I] Attachment X-4, at Payment Limit in 2018 for the corresponding HCPCS Code.

Retisert's payment limit decreases dramatically from 2018 to 2019 because the underlying dosage amount is reduced from 0.59 MG to 0.01MG.

[J] Attachment X-4, at Payment Limit in 2019 for the corresponding HCPCS Code.

[K] Attachment X-4, at Payment Limit in 2020 for the corresponding HCPCS Code.

[L] Attachment X-4, at Payment Limit in 2021 for the corresponding HCPCS Code.

Eylea is unique because its HCPCS code changed from 2012 to 2013. The data for both HCPCS codes are aggregated to get a complete time series of payment limits.

Attachment D-6

Payment Limit per Injection for Anti-VEGF Treatment Options (2012–2021)

Treatment	HCPCS Code Dosage [A]	Dosage per Injection [B]	Conversion Factor [C]	2012 [D]	2013 [E]	2014 [F]	2015 [G]	2016 [H]	2017 [I]	2018 [J]	2019 [K]	2020 [L]	2021 [M]	Average [N]
Eylea	1 MG	2 MG	2.00	\$ 1,961.00	\$ 1,961.00	\$ 1,961.00	\$ 1,961.00	\$ 1,960.91	\$ 1,949.17	\$ 1,934.65	\$ 1,904.95	\$ 1,856.48	\$ 1,835.89	\$ 1,928.61
Lucentis (Wet AMD and RVO)	0.1 mg	0.5 MG	5.00	\$ 1,991.55	\$ 1,986.29	\$ 1,982.14	\$ 1,957.03	\$ 1,916.14	\$ 1,891.77	\$ 1,866.82	\$ 1,760.87	\$ 1,621.36	\$ 1,592.36	\$ 1,856.63
Lucentis (DME and DR)	0.1 mg	0.3 MG	3.00	\$ 1,194.93	\$ 1,191.77	\$ 1,189.28	\$ 1,174.22	\$ 1,149.68	\$ 1,135.06	\$ 1,120.09	\$ 1,056.52	\$ 972.82	\$ 955.42	\$ 1,113.98
Beovu	1 MG	6 MG	6.00	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	\$ 1,871.96	\$ 1,872.06	\$ 1,872.01
Avastin	10 MG	1.25 MG	0.13	\$ 7.79	\$ 8.08	\$ 8.33	\$ 8.70	\$ 9.04	\$ 9.40	\$ 9.91	\$ 10.15	\$ 9.55	\$ 8.80	\$ 8.97

Notes and sources:

[A] Attachment D-5, at [B] for corresponding treatments

[B]:

Eylea: Attachment B-1, at [A], [D], [G], [J]

Note that the first and last label for all indications recommend the same dosage

Lucentis (Wet AMD and RVO): Attachment B-1, at [B], [E]

Note that the first and last label for all indications recommend the same dosage

Lucentis (DME and DR): Attachment B-1, at [H], [K]

Note that the first and last label for all indications recommend the same dosage

Beovu: Attachment B-1, at [C].

Note that the first and last label for all indications recommend the same dosage

Avastin is not indicated for use in retinal disease and therefore does not have a dosage identified on its label. However, the standard dose for retinal diseases appears to be 1.25 MG. For example

Ex. 2102 (Wells, John A., et al. (2015), "Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema," *The New England Journal of Medicine* 372(13): 1193–1203, at 1195).

"One eye of each participant was randomly assigned in a 1:1:1 ratio to be injected with aflibercept (at a dose of 2.0 mg), bevacizumab (1.25 mg), or ranibizumab (0.3 mg).

Ex. 2184 (EyeGuru.org Website, Intravitreal Injection Standard Dosing Table, <https://eyeguru.org/blog/intravitreal-injection-dosing/> (accessed 12/6/2021))


[C] = [B] / [A].

[D]–[M] Attachment D-5, at [C]–[L] × [C] for corresponding treatments

[N] Average of [D]–[M].

Attachment D-7


U.S. Eylea Net Sales (2011–2021)



Notes and sources:
Attachment D-1, at [K].

Attachment D-8

Payment Limit per Injection for Different Treatments (2012–2021)



Notes and sources:
Attachment D-6.

Attachment E-1**Most Prescribed Treatment Options (2012–2019)**

Treatment Option	2012	2013	2014	2015	2016	2017	2018	2019	Change from 2012 to 2019
	[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[J]
Eylea	12.18%	22.34%	23.43%	35.47%	41.44%	42.57%	41.69%	44.97%	32.79%
Avastin	46.35%	44.78%	49.95%	44.72%	42.46%	42.93%	42.07%	38.82%	-7.53%
Lucentis	33.43%	27.36%	22.50%	15.20%	11.64%	10.21%	12.19%	11.96%	-21.47%
Triamcinolone	6.82%	5.24%	3.92%	4.35%	4.05%	3.90%	3.81%	4.14%	-2.68%
Ozurdex	0.91%	0.69%	0.60%	0.90%	1.02%	0.93%	0.79%	0.57%	-0.34%
Macugen	0.35%	0.18%	0.10%	0.03%	n/a	0.00%	0.00%	0.03%	-0.33%
Visudyne	0.55%	0.18%	0.13%	0.06%	0.06%	0.06%	0.03%	0.03%	-0.52%
Iluvien	n/a	n/a	n/a	n/a	0.00%	0.00%	0.00%	0.00%	n/a
mvasi	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.00%	n/a
Beovu	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Notes and sources:

This table shows which treatment options are favored by physicians. It is calculated as the percent of physicians in the Medicare Part B data that prescribe a given treatment option the most.

For example, in 2016, 41.44% of physicians in the Medicare Part B data prescribed Eylea to more patients than any other treatment option.

[A]–[H] Ex. 2168 (Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service,

<https://data.cms.gov/provider-summary-by-type-of-service/medicare-physician-other-practitioners/medicare-physician-other-practitioners-by-provider-and-service> (accessed 11/19/2021).

Numbers do not sum to 100% because there are select instances where the top treatment option was a tie. In these instances both treatments are included.

[J] = [H] - [A].

Attachment E-2

Volume of Medicare Patients by Brand – Medicare Part B

Year	Total Volume					Year-Over-Year Change				
	Avastin	Lucentis	Eylea	Beovu	Anti-VEGF Category Total	Avastin	Lucentis	Eylea	Beovu	Anti-VEGF Category Total
	[A]	[B]	[C]	[D]	[E]	[F]	[G]	[H]	[I]	[J]
2012	158,929	143,020	65,267	n/a	367,216	n/a	n/a	n/a	n/a	n/a
2013	163,408	153,433	113,577	n/a	430,418	4,479	10,413	48,310	n/a	63,202
2014	193,444	153,315	139,000	n/a	485,759	30,036	(118)	25,423	n/a	55,341
2015	186,198	128,780	194,338	n/a	509,316	(7,246)	(24,535)	55,338	n/a	23,557
2016	186,651	113,202	227,156	n/a	527,009	453	(15,578)	32,818	n/a	17,693
2017	203,694	112,977	247,542	n/a	564,213	17,043	(225)	20,386	n/a	37,204
2018	210,797	135,556	259,766	n/a	606,119	7,103	22,579	12,224	n/a	41,906
2019	206,836	144,641	293,350	n/a	644,827	(3,961)	9,085	33,584	n/a	38,708

Notes and sources:

[A]–[D] Attachment X-3, at [C] for corresponding brand name and year.

[E] = [A] + [B] + [C] + [D].

[t] denotes a given year.

[F] = [A][t] - [A][t-1].

[G] = [B][t] - [B][t-1].


[H] = [C][t] - [C][t-1].


[I] = [D][t] - [D][t-1].

[J] = [E][t] - [E][t-1].

Attachment X-1

Vestrum Sales Share Data by Indication





CONFIDENTIAL MATERIAL – SUBJECT TO PROTECTIVE ORDER

Notes and sources:

Beovu is the brand name for brolucizumab.

Wet AMD:

Ex. 2273 (Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022, at tab "Projected by Indication (Test)" cells AQ9 to AU32).

DME:

Ex. 2273 (Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022, at tab "Projected by Indication (Test)" cells AQ45 to AU68).

DR:

Ex. 2273 (Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022, at tab "Projected by Indication (Test)" cells AQ80 to AU103).

RVO:

Ex. 2273 (Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022, at tab "Projected by Indication (Test)" cells AQ115 to AU138).

All indications:

Ex. 2273 (Vestrum, Anti-VEGF Category Sales Shares, c. 2/2022, at tab "final (nation projection)" cells AD6 to AH29).

ID = Indication_Quarter.

Attachment X-2

ATU Sales Share Data by Indication

Indication	Quarter	Avastin	Lucentis	Eylea	Beovu	ID
Wet AMD	2011-Q3	63.0%	37.0%	0.0%	n/a	Wet AMD_2011-Q3
Wet AMD	2012-Q1	56.6%	32.3%	11.1%	n/a	Wet AMD_2012-Q1
Wet AMD	2012-Q2	57.6%	28.3%	14.1%	n/a	Wet AMD_2012-Q2
Wet AMD	2012-Q3	52.5%	27.3%	20.2%	n/a	Wet AMD_2012-Q3
Wet AMD	2012-Q4	48.5%	30.3%	21.2%	n/a	Wet AMD_2012-Q4
Wet AMD	2013-Q1	46.0%	30.0%	24.0%	n/a	Wet AMD_2013-Q1
Wet AMD	2013-Q2	48.0%	28.6%	23.5%	n/a	Wet AMD_2013-Q2
Wet AMD	2013-Q3	46.5%	27.3%	26.3%	n/a	Wet AMD_2013-Q3
Wet AMD	2013-Q4	48.5%	26.3%	25.3%	n/a	Wet AMD_2013-Q4
Wet AMD	2014-Q1	49.5%	25.3%	25.3%	n/a	Wet AMD_2014-Q1
Wet AMD	2014-Q2	48.0%	26.0%	26.0%	n/a	Wet AMD_2014-Q2
Wet AMD	2014-Q3	47.0%	26.0%	27.0%	n/a	Wet AMD_2014-Q3
Wet AMD	2014-Q4	44.0%	26.0%	30.0%	n/a	Wet AMD_2014-Q4
Wet AMD	2015-Q1	46.0%	22.0%	32.0%	n/a	Wet AMD_2015-Q1
Wet AMD	2015-Q2	45.0%	24.0%	31.0%	n/a	Wet AMD_2015-Q2
Wet AMD	2015-Q3	43.0%	26.0%	32.0%	n/a	Wet AMD_2015-Q3
Wet AMD	2015-Q4	45.0%	22.0%	34.0%	n/a	Wet AMD_2015-Q4
Wet AMD	2016-Q1	47.0%	19.0%	35.0%	n/a	Wet AMD_2016-Q1
Wet AMD	2016-Q2	46.0%	19.0%	35.0%	n/a	Wet AMD_2016-Q2
Wet AMD	2016-Q3	45.0%	19.0%	34.0%	n/a	Wet AMD_2016-Q3
Wet AMD	2016-Q4	43.0%	22.0%	35.0%	n/a	Wet AMD_2016-Q4
Wet AMD	2017-Q1	46.0%	19.0%	35.0%	n/a	Wet AMD_2017-Q1
Wet AMD	2017-Q2	43.0%	18.0%	39.0%	n/a	Wet AMD_2017-Q2
Wet AMD	2017-Q3	44.0%	18.0%	38.0%	n/a	Wet AMD_2017-Q3
Wet AMD	2017-Q4	46.0%	17.0%	37.0%	n/a	Wet AMD_2017-Q4
Wet AMD	2018-Q1	43.0%	20.0%	37.0%	n/a	Wet AMD_2018-Q1
Wet AMD	2018-Q2	40.0%	19.0%	41.0%	n/a	Wet AMD_2018-Q2
Wet AMD	2018-Q3	43.0%	19.0%	38.0%	n/a	Wet AMD_2018-Q3
Wet AMD	2018-Q4	40.0%	19.0%	41.0%	n/a	Wet AMD_2018-Q4
Wet AMD	2019-Q1	41.0%	18.0%	41.0%	n/a	Wet AMD_2019-Q1
Wet AMD	2019-Q2	41.0%	19.0%	40.0%	n/a	Wet AMD_2019-Q2
Wet AMD	2019-Q3	40.0%	16.6%	43.5%	n/a	Wet AMD_2019-Q3
Wet AMD	2019-Q4	45.0%	13.0%	39.0%	3.0%	Wet AMD_2019-Q4
Wet AMD	2020-Q1	43.0%	13.0%	39.0%	5.0%	Wet AMD_2020-Q1
Wet AMD	2020-Q2	39.1%	14.8%	41.1%	4.9%	Wet AMD_2020-Q2
Wet AMD	2020-Q3	43.0%	14.0%	39.0%	4.0%	Wet AMD_2020-Q3
Wet AMD	2020-Q4	40.8%	14.0%	40.5%	4.8%	Wet AMD_2020-Q4
Wet AMD	2021-Q2	39.0%	14.0%	44.0%	3.0%	Wet AMD_2021-Q2
DME	2013-Q4	64.0%	36.0%	0.0%	n/a	DME_2013-Q4
DME	2014-Q2	57.0%	36.0%	7.0%	n/a	DME_2014-Q2
DME	2014-Q3	49.0%	32.0%	19.0%	n/a	DME_2014-Q3
DME	2014-Q4	51.0%	30.0%	19.0%	n/a	DME_2014-Q4
DME	2015-Q1	44.0%	23.0%	33.0%	n/a	DME_2015-Q1
DME	2015-Q2	42.0%	22.0%	36.0%	n/a	DME_2015-Q2
DME	2015-Q3	40.0%	21.0%	39.0%	n/a	DME_2015-Q3
DME	2015-Q4	41.0%	20.0%	39.0%	n/a	DME_2015-Q4
DME	2016-Q1	46.0%	15.0%	39.0%	n/a	DME_2016-Q1

Indication	Quarter	Avastin	Lucentis	Eylea	Beovu	ID
DME	2016-Q2	43.0%	16.0%	41.0%	n/a	DME_2016-Q2
DME	2016-Q3	43.0%	20.0%	38.0%	n/a	DME_2016-Q3
DME	2016-Q4	45.0%	17.0%	38.0%	n/a	DME_2016-Q4
DME	2017-Q1	43.0%	20.0%	37.0%	n/a	DME_2017-Q1
DME	2017-Q2	46.0%	14.0%	40.0%	n/a	DME_2017-Q2
DME	2017-Q3	42.0%	17.0%	41.0%	n/a	DME_2017-Q3
DME	2017-Q4	43.0%	17.0%	40.0%	n/a	DME_2017-Q4
DME	2018-Q1	43.0%	19.0%	38.0%	n/a	DME_2018-Q1
DME	2018-Q2	42.0%	18.0%	40.0%	n/a	DME_2018-Q2
DME	2018-Q3	41.0%	21.0%	38.0%	n/a	DME_2018-Q3
DME	2018-Q4	41.0%	18.0%	41.0%	n/a	DME_2018-Q4
DME	2019-Q1	36.0%	23.0%	41.0%	n/a	DME_2019-Q1
DME	2019-Q2	38.0%	22.0%	40.0%	n/a	DME_2019-Q2
DME	2019-Q3	35.3%	22.8%	41.9%	n/a	DME_2019-Q3
DME	2019-Q4	37.0%	16.0%	47.0%	n/a	DME_2019-Q4
DME	2020-Q1	41.0%	16.0%	41.0%	2.0%	DME_2020-Q1
DME	2020-Q2	40.3%	19.0%	39.0%	2.2%	DME_2020-Q2
DME	2020-Q3	40.0%	15.0%	42.0%	3.0%	DME_2020-Q3
DME	2020-Q4	40.0%	15.0%	43.0%	2.0%	DME_2020-Q4
DME	2021-Q2	38.0%	15.0%	44.0%	3.0%	DME_2021-Q2
CRVO	2012-Q3	77.0%	23.0%	0.0%	n/a	CRVO_2012-Q3
CRVO	2013-Q1	50.0%	29.0%	21.0%	n/a	CRVO_2013-Q1
CRVO	2013-Q2	55.0%	27.0%	18.0%	n/a	CRVO_2013-Q2
CRVO	2013-Q3	55.1%	27.6%	17.3%	n/a	CRVO_2013-Q3
CRVO	2013-Q4	50.5%	28.3%	21.2%	n/a	CRVO_2013-Q4
CRVO	2014-Q1	54.1%	25.5%	20.4%	n/a	CRVO_2014-Q1
CRVO	2014-Q2	48.0%	27.0%	24.0%	n/a	CRVO_2014-Q2
CRVO	2014-Q3	52.0%	26.0%	22.0%	n/a	CRVO_2014-Q3
CRVO	2014-Q4	52.0%	23.0%	24.0%	n/a	CRVO_2014-Q4
CRVO	2015-Q1	54.0%	18.0%	27.0%	n/a	CRVO_2015-Q1
CRVO	2015-Q2	46.0%	21.0%	33.0%	n/a	CRVO_2015-Q2
CRVO	2015-Q3	35.0%	26.0%	39.0%	n/a	CRVO_2015-Q3
CRVO	2015-Q4	38.0%	20.0%	42.0%	n/a	CRVO_2015-Q4
CRVO	2016-Q1	35.0%	21.0%	44.0%	n/a	CRVO_2016-Q1
CRVO	2016-Q2	33.0%	20.0%	47.0%	n/a	CRVO_2016-Q2
CRVO	2016-Q3	36.0%	16.0%	48.0%	n/a	CRVO_2016-Q3
CRVO	2016-Q4	39.0%	19.0%	42.0%	n/a	CRVO_2016-Q4
CRVO	2017-Q1	37.0%	16.0%	47.0%	n/a	CRVO_2017-Q1
CRVO	2017-Q2	40.0%	19.0%	41.0%	n/a	CRVO_2017-Q2
CRVO	2017-Q3	43.0%	20.0%	37.0%	n/a	CRVO_2017-Q3
CRVO	2017-Q4	41.0%	18.0%	41.0%	n/a	CRVO_2017-Q4
CRVO	2018-Q1	41.0%	16.0%	43.0%	n/a	CRVO_2018-Q1
CRVO	2018-Q2	41.0%	19.0%	40.0%	n/a	CRVO_2018-Q2
CRVO	2018-Q3	45.0%	13.0%	42.0%	n/a	CRVO_2018-Q3
CRVO	2018-Q4	41.0%	15.0%	44.0%	n/a	CRVO_2018-Q4
CRVO	2019-Q1	35.0%	14.0%	51.0%	n/a	CRVO_2019-Q1
CRVO	2019-Q2	42.9%	17.3%	39.8%	n/a	CRVO_2019-Q2
CRVO	2019-Q3	41.0%	16.0%	43.0%	n/a	CRVO_2019-Q3
CRVO	2019-Q4	42.0%	16.0%	42.0%	n/a	CRVO_2019-Q4
CRVO	2020-Q1	44.0%	15.0%	37.0%	4.0%	CRVO_2020-Q1
CRVO	2020-Q2	40.0%	22.3%	33.5%	3.6%	CRVO_2020-Q2

Indication	Quarter	Avastin	Lucentis	Eylea	Beovu	ID
CRVO	2020-Q3	40.6%	14.0%	41.0%	3.8%	CRVO_2020-Q3
CRVO	2020-Q4	42.4%	15.7%	39.3%	2.6%	CRVO_2020-Q4
CRVO	2021-Q2	37.0%	15.0%	46.0%	2.0%	CRVO_2021-Q2
BRVO	2014-Q2	54.0%	46.0%	0.0%	n/a	BRVO_2014-Q2
BRVO	2014-Q4	43.0%	32.0%	25.0%	n/a	BRVO_2014-Q4
BRVO	2015-Q1	49.0%	21.0%	30.0%	n/a	BRVO_2015-Q1
BRVO	2015-Q2	44.0%	23.0%	33.0%	n/a	BRVO_2015-Q2
BRVO	2015-Q3	36.0%	21.0%	43.0%	n/a	BRVO_2015-Q3
BRVO	2015-Q4	38.0%	16.0%	46.0%	n/a	BRVO_2015-Q4
BRVO	2016-Q1	35.0%	19.0%	46.0%	n/a	BRVO_2016-Q1
BRVO	2016-Q2	30.0%	23.0%	47.0%	n/a	BRVO_2016-Q2
BRVO	2016-Q3	34.0%	17.0%	49.0%	n/a	BRVO_2016-Q3
BRVO	2016-Q4	38.0%	19.0%	43.0%	n/a	BRVO_2016-Q4
BRVO	2017-Q1	43.0%	17.0%	40.0%	n/a	BRVO_2017-Q1
BRVO	2017-Q2	38.0%	20.0%	42.0%	n/a	BRVO_2017-Q2
BRVO	2017-Q3	44.0%	20.0%	36.0%	n/a	BRVO_2017-Q3
BRVO	2017-Q4	38.0%	19.0%	43.0%	n/a	BRVO_2017-Q4
BRVO	2018-Q1	48.0%	15.0%	37.0%	n/a	BRVO_2018-Q1
BRVO	2018-Q2	47.0%	18.0%	35.0%	n/a	BRVO_2018-Q2
BRVO	2018-Q3	49.0%	14.0%	37.0%	n/a	BRVO_2018-Q3
BRVO	2018-Q4	43.0%	17.0%	40.0%	n/a	BRVO_2018-Q4
BRVO	2019-Q1	35.0%	16.0%	49.0%	n/a	BRVO_2019-Q1
BRVO	2019-Q2	41.8%	15.1%	43.1%	n/a	BRVO_2019-Q2
BRVO	2019-Q3	40.0%	16.0%	44.0%	n/a	BRVO_2019-Q3
BRVO	2019-Q4	45.0%	15.0%	40.0%	n/a	BRVO_2019-Q4
BRVO	2020-Q1	44.0%	15.0%	38.0%	2.0%	BRVO_2020-Q1
BRVO	2020-Q2	38.0%	21.4%	37.0%	3.7%	BRVO_2020-Q2
BRVO	2020-Q3	43.0%	13.7%	39.9%	3.5%	BRVO_2020-Q3
BRVO	2020-Q4	40.0%	15.9%	41.6%	2.0%	BRVO_2020-Q4
BRVO	2021-Q2	36.0%	15.0%	48.0%	2.0%	BRVO_2021-Q2
DR	2017-Q4	49.0%	22.0%	29.0%	n/a	DR_2017-Q4
DR	2018-Q1	47.0%	26.0%	27.0%	n/a	DR_2018-Q1
DR	2018-Q2	48.0%	21.0%	32.0%	n/a	DR_2018-Q2
DR	2018-Q3	47.0%	28.0%	25.0%	n/a	DR_2018-Q3
DR	2018-Q4	54.0%	26.0%	20.0%	n/a	DR_2018-Q4
DR	2019-Q1	45.0%	28.0%	27.0%	n/a	DR_2019-Q1
DR	2019-Q2	47.8%	26.9%	25.3%	n/a	DR_2019-Q2
DR	2019-Q2	45.3%	23.7%	31.0%	n/a	DR_2019-Q2
DR	2019-Q3	43.7%	24.0%	32.4%	n/a	DR_2019-Q3
DR	2019-Q4	43.8%	21.0%	35.2%	n/a	DR_2019-Q4
DR	2020-Q1	37.8%	17.2%	40.7%	4.3%	DR_2020-Q1
DR	2020-Q2	37.3%	22.0%	36.6%	4.1%	DR_2020-Q2
DR	2020-Q3	41.9%	14.1%	34.8%	9.1%	DR_2020-Q3
DR	2020-Q4	39.2%	16.5%	37.9%	6.3%	DR_2020-Q4
DR	2021-Q2	40.0%	18.0%	37.0%	5.0%	DR_2021-Q2
All indications	2011-Q3	63.0%	37.0%	0.0%	n/a	All indications_2011-Q3
All indications	2012-Q1	56.6%	32.3%	11.1%	n/a	All indications_2012-Q1
All indications	2012-Q2	57.6%	28.3%	14.1%	n/a	All indications_2012-Q2
All indications	2012-Q3	52.5%	27.3%	20.2%	n/a	All indications_2012-Q3
All indications	2012-Q4	48.5%	30.3%	21.2%	n/a	All indications_2012-Q4
All indications	2013-Q1	48.0%	29.0%	23.0%	n/a	All indications_2013-Q1

Indication	Quarter	Avastin	Lucentis	Eylea	Beovu	ID
All indications	2013-Q2	48.6%	28.4%	23.0%	n/a	All indications_2013-Q2
All indications	2013-Q3	47.0%	27.3%	25.7%	n/a	All indications_2013-Q3
All indications	2013-Q4	50.6%	27.9%	21.5%	n/a	All indications_2013-Q4
All indications	2014-Q1	50.2%	25.5%	24.3%	n/a	All indications_2014-Q1
All indications	2014-Q2	50.1%	28.9%	20.9%	n/a	All indications_2014-Q2
All indications	2014-Q3	47.6%	27.3%	25.1%	n/a	All indications_2014-Q3
All indications	2014-Q4	45.0%	27.4%	27.6%	n/a	All indications_2014-Q4
All indications	2015-Q1	46.1%	22.1%	31.8%	n/a	All indications_2015-Q1
All indications	2015-Q2	42.8%	24.9%	32.3%	n/a	All indications_2015-Q2
All indications	2015-Q3	41.0%	24.0%	35.0%	n/a	All indications_2015-Q3
All indications	2015-Q4	44.0%	21.0%	35.0%	n/a	All indications_2015-Q4
All indications	2016-Q1	45.0%	18.0%	36.0%	n/a	All indications_2016-Q1
All indications	2016-Q2	44.0%	19.0%	37.0%	n/a	All indications_2016-Q2
All indications	2016-Q3	45.0%	19.0%	36.0%	n/a	All indications_2016-Q3
All indications	2016-Q4	43.0%	20.0%	37.0%	n/a	All indications_2016-Q4
All indications	2017-Q1	44.0%	19.0%	37.0%	n/a	All indications_2017-Q1
All indications	2017-Q2	44.0%	17.0%	39.0%	n/a	All indications_2017-Q2
All indications	2017-Q3	44.0%	18.0%	38.0%	n/a	All indications_2017-Q3
All indications	2017-Q4	44.9%	17.6%	37.5%	n/a	All indications_2017-Q4
All indications	2018-Q1	43.8%	19.6%	36.6%	n/a	All indications_2018-Q1
All indications	2018-Q2	42.0%	18.6%	39.4%	n/a	All indications_2018-Q2
All indications	2018-Q3	43.4%	19.8%	36.8%	n/a	All indications_2018-Q3
All indications	2018-Q4	42.0%	20.0%	38.0%	n/a	All indications_2018-Q4
All indications	2019-Q1	41.0%	20.0%	39.0%	n/a	All indications_2019-Q1
All indications	2019-Q2	42.0%	20.0%	38.0%	n/a	All indications_2019-Q2
All indications	2019-Q3	40.0%	19.1%	40.9%	n/a	All indications_2019-Q3
All indications	2019-Q4	44.0%	15.0%	39.0%	2.0%	All indications_2019-Q4
All indications	2020-Q1	41.8%	14.6%	39.4%	4.3%	All indications_2020-Q1
All indications	2020-Q2	38.9%	17.7%	39.2%	4.2%	All indications_2020-Q2
All indications	2020-Q3	42.1%	14.1%	38.7%	5.2%	All indications_2020-Q3
All indications	2020-Q4	40.4%	14.9%	40.3%	5.0%	All indications_2020-Q4
All indications	2021-Q2	39.1%	15.4%	41.9%	3.7%	All indications_2021-Q2

Notes and sources:

Beovu is the brand name for brolucizumab.

The following excel files contain the data underlying sales share charts in

Ex. 2278 (Regeneron, "Wave 1 2021 Performance Update Wet AMD, DME, MEfRVO, and DR w/out DME," 9/2021):

Ex. 2280 (Regeneron, ATU Sales Share Data: Wet AMD, c. 2021).

Ex. 2281 (Regeneron, ATU Sales Share Data: DME, c. 2021).

Ex. 2282 (Regeneron, ATU Sales Share Data: CRVO, c. 2021).

Ex. 2283 (Regeneron, ATU Sales Share Data: BRVO, c. 2021).

Ex. 2284 (Regeneron, ATU Sales Share Data: DR w/o DME, c. 2021).

Ex. 2279 (Regeneron, ATU Sales Share Data: All Indications, c. 2021).

ID = Indication_Quarter.

Attachment X-3

Medicare Part B Sales Shares Data (2012–2019)

brand_name	year	bene_unique_cnt	bene_unique_cnt_ yearshare	ID
[A]	[B]	[C]	[D]	[E]
Avastin	2012	158,929	39.40%	Avastin_2012
Avastin	2013	163,408	35.40%	Avastin_2013
Avastin	2014	193,444	37.35%	Avastin_2014
Avastin	2015	186,198	34.35%	Avastin_2015
Avastin	2016	186,651	33.24%	Avastin_2016
Avastin	2017	203,694	34.04%	Avastin_2017
Avastin	2018	210,797	33.01%	Avastin_2018
Avastin	2019	206,836	30.61%	Avastin_2019
Eylea	2012	65,267	16.18%	Eylea_2012
Eylea	2013	113,577	24.61%	Eylea_2013
Eylea	2014	139,000	26.84%	Eylea_2014
Eylea	2015	194,338	35.85%	Eylea_2015
Eylea	2016	227,156	40.45%	Eylea_2016
Eylea	2017	247,542	41.37%	Eylea_2017
Eylea	2018	259,766	40.68%	Eylea_2018
Eylea	2019	293,350	43.42%	Eylea_2019
luvien	2016	149	0.03%	luvien_2016
luvien	2017	139	0.02%	luvien_2017
luvien	2018	145	0.02%	luvien_2018
luvien	2019	140	0.02%	luvien_2019
Lucentis	2012	143,020	35.46%	Lucentis_2012
Lucentis	2013	153,433	33.24%	Lucentis_2013
Lucentis	2014	153,315	29.60%	Lucentis_2014
Lucentis	2015	128,780	23.76%	Lucentis_2015
Lucentis	2016	113,202	20.16%	Lucentis_2016
Lucentis	2017	112,977	18.88%	Lucentis_2017
Lucentis	2018	135,556	21.23%	Lucentis_2018
Lucentis	2019	144,641	21.41%	Lucentis_2019
Macugen	2012	1,778	0.44%	Macugen_2012
Macugen	2013	822	0.18%	Macugen_2013
Macugen	2014	579	0.11%	Macugen_2014
Macugen	2015	221	0.04%	Macugen_2015
Macugen	2017	61	0.01%	Macugen_2017
Macugen	2018	58	0.01%	Macugen_2018
Macugen	2019	50	0.01%	Macugen_2019
Ozurdex	2012	7,141	1.77%	Ozurdex_2012
Ozurdex	2013	7,216	1.56%	Ozurdex_2013
Ozurdex	2014	9,332	1.80%	Ozurdex_2014
Ozurdex	2015	11,749	2.17%	Ozurdex_2015
Ozurdex	2016	12,958	2.31%	Ozurdex_2016
Ozurdex	2017	14,208	2.37%	Ozurdex_2017
Ozurdex	2018	14,599	2.29%	Ozurdex_2018
Ozurdex	2019	13,831	2.05%	Ozurdex_2019
Triamcinolone	2012	24,540	6.08%	Triamcinolone_2012
Triamcinolone	2013	21,054	4.56%	Triamcinolone_2013
Triamcinolone	2014	20,568	3.97%	Triamcinolone_2014
Triamcinolone	2015	19,561	3.61%	Triamcinolone_2015
Triamcinolone	2016	20,328	3.62%	Triamcinolone_2016

brand_name	year	bene_unique_cnt	bene_unique_cnt_ yearshare	ID
[A]	[B]	[C]	[D]	[E]
Triamcinolone	2017	18,644	3.12%	Triamcinolone_2017
Triamcinolone	2018	16,731	2.62%	Triamcinolone_2018
Triamcinolone	2019	15,988	2.37%	Triamcinolone_2019
Visudyne	2012	2,700	0.67%	Visudyne_2012
Visudyne	2013	2,049	0.44%	Visudyne_2013
Visudyne	2014	1,633	0.32%	Visudyne_2014
Visudyne	2015	1,221	0.23%	Visudyne_2015
Visudyne	2016	1,098	0.20%	Visudyne_2016
Visudyne	2017	1,140	0.19%	Visudyne_2017
Visudyne	2018	962	0.15%	Visudyne_2018
Visudyne	2019	791	0.12%	Visudyne_2019
mvasi	2019	41	0.01%	mvasi_2019

Notes and sources:

[A]–[D] Ex. 2168 (Centers for Medicare & Medicaid Services Website, Medicare Physician & Other Practitioners - by Provider and Service, <https://data.cms.gov/provider-summary-by-type-of-service/medicare-physician-other-practitioners/medicare-physician-other-practitioners-by-provider-and-service> (accessed 11/19/2021).

[E] [A]_[B].

Attachment X-4
Payment Allowance Limits for Medicare Part B Drugs (2012–2021)

Year	HCPCS Code	Short Description	HCPCS Code Dosage	Payment Limit	ID
2021	90371	Hep b ig im	1 ML	\$ 130.31	2021_90371
2021	90375	Rabies ig im/sc	150 IU	\$ 267.30	2021_90375
2021	90376	Rabies ig heat treated	150 IU	\$ 287.38	2021_90376
2021	90377	Rabies ig ht&sol human im/sc	150 IU	\$ 272.34	2021_90377
2021	90586	Bcg vaccine intravesical	1 EACH	\$ 142.56	2021_90586
2021	90632	Hepa vaccine adult im	1 ML	\$ 64.08	2021_90632
2021	90662	liv no prsv increased ag im	0.5 ML	\$ 65.26	2021_90662
2021	90670	Pcv13 vaccine im	0.5 ML	\$ 241.38	2021_90670
2021	90672	Laiv4 vaccine intranasal	0.2 ML	\$ 26.88	2021_90672
2021	90674	Cciiv4 vac no prsv 0.5 ml im	0.5 ML	\$ 29.94	2021_90674
2021	90675	Rabies vaccine im	1 ML	\$ 327.53	2021_90675
2021	90677	Pcv20 vaccine im	0.5 ML	\$ 264.74	2021_90677
2021	90682	Riv4 vacc recombinant dna im	0.5 ML	\$ 65.26	2021_90682
2021	90685	liv4 vacc no prsv 0.25 ml im	0.25 mL	\$ 21.64	2021_90685
2021	90686	liv4 vacc no prsv 0.5 ml im	0.5 ml	\$ 20.53	2021_90686
2021	90687	liv4 vaccine splt 0.25 ml im	0.25 ML	\$ 9.95	2021_90687
2021	90688	liv4 vaccine splt 0.5 ml im	0.5 ML	\$ 19.91	2021_90688
2021	90694	Vacc AllV4 no prsv 0.5ML IM	0.5 ML	\$ 66.43	2021_90694
2021	90714	Td vacc no presv 7 yrs+ im	0.5 ML	\$ 26.22	2021_90714
2021	90715	Tdap vaccine 7 yrs/> im	0.5 ML	\$ 35.80	2021_90715
2021	90732	Ppsv23 vacc 2 yrs+ subq/im	0.5 ML	\$ 125.92	2021_90732
2021	90739	Hepb vacc 2 dose adult im	1 dose	\$ 144.21	2021_90739
2021	90740	Hepb vacc 3 dose immunsup im	40 MCG	\$ 140.76	2021_90740
2021	90744	Hepb vacc 3 dose ped/adol im	1 DOSE	\$ 28.22	2021_90744
2021	90746	Hepb vaccine 3 dose adult im	20 MCG	\$ 69.65	2021_90746
2021	90747	Hepb vacc 4 dose immunsup im	40 MCG	\$ 140.76	2021_90747
2021	90756	Cciiv4 vacc abx free im	0.5 ML	\$ 28.37	2021_90756
2021	A9575	Inj gadoterate meglumi 0.1ml	0.1 ML	\$ 0.16	2021_A9575
2021	A9576	Inj prohance multipack	1 ML	\$ 1.47	2021_A9576
2021	A9577	Inj multihance	1 ML	\$ 1.87	2021_A9577
2021	A9578	Inj multihance multipack	1 ML	\$ 1.80	2021_A9578
2021	A9579	Gad-base mr contrast nos,1ml	1 ML	\$ 1.56	2021_A9579
2021	A9581	Gadoxetate disodium inj	1 ML	\$ 14.73	2021_A9581
2021	A9585	Gadobutrol injection	0.1 ML	\$ 0.38	2021_A9585
2021	A9589	Insti hexaminolevulinate hcl	100 MG	\$ 1,202.70	2021_A9589
2021	A9606	Radium ra223 dichloride ther	1 microCurie	N/A	2021_A9606
2021	J0121	Inj., omadacycline, 1 mg	1 MG	\$ 3.30	2021_J0121
2021	J0122	Inj., eravacycline, 1 mg	1 MG	\$ 1.02	2021_J0122
2021	J0129	Abatacept injection	10 MG	\$ 45.27	2021_J0129
2021	J0132	Acetylcysteine injection	100 MG	\$ 0.83	2021_J0132
2021	J0133	Acyclovir injection	5 MG	\$ 0.04	2021_J0133
2021	J0153	Adenosine inj 1mg	1 MG	\$ 0.53	2021_J0153
2021	J0171	Adrenalin epinephrine inject	0.1 MG	\$ 0.74	2021_J0171
2021	J0178	Aflibercept injection	1 MG	\$ 917.94	2021_J0178
2021	J0179	Inj, brolucizumab-dbl, 1 mg	1 MG	\$ 312.01	2021_J0179
2021	J0180	Agalsidase beta injection	1 MG	\$ 198.14	2021_J0180
2021	J0185	Inj., aprepitant, 1 mg	1 MG	\$ 1.69	2021_J0185
2021	J0202	Injection, alemtuzumab	1 MG	\$ 2,086.32	2021_J0202
2021	J0221	Lumizyme injection	10 MG	\$ 180.35	2021_J0221
2021	J0222	Inj., patisiran, 0.1 mg	0.1 MG	\$ 97.75	2021_J0222
2021	J0223	Inj givosiran 0.5 mg	0.5 MG	\$ 106.76	2021_J0223
2021	J0248	Inj, remdesivir, 1 mg	1 MG	\$ 5.51	2021_J0248
2021	J0256	Alpha 1 proteinase inhibitor	10 MG	\$ 4.54	2021_J0256

2021	J0257	Glassia injection	10 MG	\$	4.95	2021_J0257
2021	J0278	Amikacin sulfate injection	100 MG	\$	1.06	2021_J0278
2021	J0280	Aminophyllin 250 mg inj	250 MG	\$	8.57	2021_J0280
2021	J0285	Amphotericin b	50 MG	\$	42.65	2021_J0285
2021	J0287	Amphotericin b lipid complex	10 MG	\$	9.50	2021_J0287
2021	J0289	Amphotericin b liposome inj	10 MG	\$	28.75	2021_J0289
2021	J0290	Ampicillin 500 mg inj	500 MG	\$	0.81	2021_J0290
2021	J0291	Inj., plazomicin, 5 mg	5 MG	\$	3.05	2021_J0291
2021	J0295	Ampicillin sulbactam 1.5 gm	1.5 GM	\$	2.21	2021_J0295
2021	J0348	Anidulafungin injection	1 MG	\$	0.57	2021_J0348
2021	J0360	Hydralazine hcl injection	20 MG	\$	5.20	2021_J0360
2021	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	6.01	2021_J0401
2021	J0456	Azithromycin	500 MG	\$	2.49	2021_J0456
2021	J0461	Atropine sulfate injection	0.01 MG	\$	0.08	2021_J0461
2021	J0475	Baclofen 10 mg injection	10 MG	\$	177.43	2021_J0475
2021	J0476	Baclofen intrathecal trial	50 MCG	\$	60.27	2021_J0476
2021	J0480	Basiliximab	20 MG	\$	4,013.08	2021_J0480
2021	J0485	Belatacept injection	1 MG	\$	3.80	2021_J0485
2021	J0490	Belimumab injection	10 MG	\$	47.57	2021_J0490
2021	J0500	Dicyclomine injection	20 MG	\$	32.99	2021_J0500
2021	J0515	Inj benztropine mesylate	1 MG	\$	19.51	2021_J0515
2021	J0517	Inj., benralizumab, 1 mg	1 MG	\$	170.80	2021_J0517
2021	J0558	Peng benzathine/procaine inj	100,000 UNITS	\$	11.79	2021_J0558
2021	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	14.95	2021_J0561
2021	J0565	Inj, bezlotoxumab, 10 mg	10 MG	\$	39.77	2021_J0565
2021	J0570	Buprenorphine implant 74.2mg	74.2 MG	\$	1,311.75	2021_J0570
2021	J0583	Bivalirudin	1 MG	\$	0.29	2021_J0583
2021	J0584	Injection, burosumab-twza 1m	1 MG	\$	369.11	2021_J0584
2021	J0585	Injection,onabotulinumtoxina	1 UNIT	\$	6.09	2021_J0585
2021	J0586	Abobotulinumtoxina	5 Unit	\$	8.41	2021_J0586
2021	J0587	Inj, rimabotulinumtoxinb	100 UNITS	\$	12.05	2021_J0587
2021	J0588	Incobotulinumtoxin a	1 UNIT	\$	5.05	2021_J0588
2021	J0592	Buprenorphine hydrochloride	0.1 MG	\$	4.37	2021_J0592
2021	J0594	Busulfan injection	1 MG	\$	1.71	2021_J0594
2021	J0595	Butorphanol tartrate 1 mg	1 MG	\$	2.94	2021_J0595
2021	J0596	Injection, ruconest	10 UNITS	\$	29.97	2021_J0596
2021	J0597	C-1 esterase, berinert	10 UNITS	\$	57.39	2021_J0597
2021	J0598	C-1 esterase, cinryze	10 UNITS	\$	58.93	2021_J0598
2021	J0600	Edetate calcium disodium inj	1000 MG	\$	5,708.59	2021_J0600
2021	J0610	Calcium gluconate injection	10 ML	\$	4.13	2021_J0610
2021	J0630	Calcitonin salmon injection	400 UNITS	\$	3,100.79	2021_J0630
2021	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.72	2021_J0636
2021	J0637	Caspofungin acetate	5 MG	\$	6.25	2021_J0637
2021	J0638	Canakinumab injection	1 MG	\$	115.61	2021_J0638
2021	J0640	Leucovorin calcium injection	50 MG	\$	3.66	2021_J0640
2021	J0641	Inj levoleucovorin nos 0.5mg	0.5 MG	\$	0.09	2021_J0641
2021	J0642	Injection, khapzory, 0.5 mg	0.5 MG	\$	1.86	2021_J0642
2021	J0670	Inj mepivacaine hcl/10 ml	10 ML	\$	2.76	2021_J0670
2021	J0690	Cefazolin sodium injection	500 MG	\$	0.75	2021_J0690
2021	J0691	Inj lefamulin 1 mg	1 MG	\$	0.72	2021_J0691
2021	J0692	Cefepime hcl for injection	500 MG	\$	1.85	2021_J0692
2021	J0694	Cefoxitin sodium injection	1 GM	\$	4.61	2021_J0694
2021	J0695	Inj ceftolozane tazobactam	75mg (50mg cft/25mg taz)	\$	6.64	2021_J0695
2021	J0696	Ceftriaxone sodium injection	250 MG	\$	0.50	2021_J0696
2021	J0697	Sterile cefuroxime injection	750 MG	\$	2.01	2021_J0697
2021	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	8.04	2021_J0702
2021	J0712	Ceftaroline fosamil inj	10 MG	\$	3.51	2021_J0712
2021	J0713	Inj ceftazidime per 500 mg	500 MG	\$	1.97	2021_J0713
2021	J0714	Ceftazidime and avibactam	.625 GM	\$	92.39	2021_J0714

2021	J0717	Certolizumab pegol inj 1mg	1 MG	\$	6.27	2021_J0717
2021	J0720	Chloramphenicol sodium injec	1 GM	\$	36.32	2021_J0720
2021	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	22.62	2021_J0725
2021	J0735	Clonidine hydrochloride	1 MG	\$	24.77	2021_J0735
2021	J0740	Cidofovir injection	375 MG	\$	563.76	2021_J0740
2021	J0741	Inj. cabote rilpivir 2mg 3mg	2MG/3MG	\$	20.56	2021_J0741
2021	J0742	Inj imip 4 cilas 4 releb 2mg	4 MG-4 MG-2 MG	\$	2.32	2021_J0742
2021	J0743	Cilastatin sodium injection	250 MG	\$	7.61	2021_J0743
2021	J0744	Ciprofloxacin iv	200 MG	\$	1.08	2021_J0744
2021	J0770	Colistimethate sodium inj	150 MG	\$	15.78	2021_J0770
2021	J0775	Collagenase, clost hist inj	0.01 MG	\$	56.66	2021_J0775
2021	J0780	Prochlorperazine injection	10 MG	\$	4.74	2021_J0780
2021	J0791	Inj crizanlizumab-tmca 5mg	5 MG	\$	123.29	2021_J0791
2021	J0800	Corticotropin injection	40 UNITS	\$	3,809.25	2021_J0800
2021	J0834	Inj., cosyntropin, 0.25 mg	0.25 MG	\$	35.63	2021_J0834
2021	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	2,743.36	2021_J0840
2021	J0841	Inj crotalidae im f(ab')2 eq	120 MG	\$	1,189.81	2021_J0841
2021	J0850	Cytomegalovirus imm iv /vial	PER VIAL	\$	1,538.70	2021_J0850
2021	J0875	Injection, dalbavancin	5 MG	\$	15.89	2021_J0875
2021	J0878	Daptomycin injection	1 MG	\$	0.06	2021_J0878
2021	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.15	2021_J0881
2021	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.15	2021_J0882
2021	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	8.15	2021_J0885
2021	J0887	Epoetin beta esrd use	1 MCG	\$	1.51	2021_J0887
2021	J0888	Epoetin beta non esrd	1 MCG	\$	1.51	2021_J0888
2021	J0894	Decitabine injection	1 MG	\$	3.43	2021_J0894
2021	J0895	Deferoxamine mesylate inj	500 MG	\$	7.66	2021_J0895
2021	J0896	Inj luspatercept-aamt 0.25mg	0.25 MG	\$	36.85	2021_J0896
2021	J0897	Denosumab injection	1 MG	\$	21.19	2021_J0897
2021	J1000	Depo-estradiol cypionate inj	5 MG	\$	23.98	2021_J1000
2021	J1020	Methylprednisolone 20 mg inj	20 MG	\$	3.17	2021_J1020
2021	J1030	Methylprednisolone 40 mg inj	40 MG	\$	5.63	2021_J1030
2021	J1040	Methylprednisolone 80 mg inj	80 MG	\$	10.68	2021_J1040
2021	J1050	Medroxyprogesterone acetate	1 MG	\$	0.57	2021_J1050
2021	J1071	Inj testosterone cypionate	1 MG	\$	0.03	2021_J1071
2021	J1100	Dexamethasone sodium phos	1 MG	\$	0.12	2021_J1100
2021	J1110	Inj dihydroergotamine mesylt	1 MG	\$	47.42	2021_J1110
2021	J1120	Acetazolamid sodium injectio	500 MG	\$	20.13	2021_J1120
2021	J1160	Digoxin injection	0.5 MG	\$	14.42	2021_J1160
2021	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	4,128.19	2021_J1162
2021	J1165	Phenytoin sodium injection	50 MG	\$	0.45	2021_J1165
2021	J1170	Hydromorphone injection	4 MG	\$	3.30	2021_J1170
2021	J1190	Dexrazoxane hcl injection	250 MG	\$	192.33	2021_J1190
2021	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.98	2021_J1200
2021	J1201	Inj. cetirizine hcl 0.5mg	0.5 MG	\$	15.38	2021_J1201
2021	J1205	Chlorothiazide sodium inj	500 MG	\$	56.14	2021_J1205
2021	J1212	Dimethyl sulfoxide 50% 50 ml	50 ML	\$	637.11	2021_J1212
2021	J1230	Methadone injection	10 MG	\$	17.80	2021_J1230
2021	J1240	Dimenhydrinate injection	50 MG	\$	7.39	2021_J1240
2021	J1245	Dipyridamole injection	10 MG	\$	3.65	2021_J1245
2021	J1250	Inj dobutamine hcl/250 mg	250 MG	\$	8.21	2021_J1250
2021	J1265	Dopamine injection	40 MG	\$	0.79	2021_J1265
2021	J1270	Injection, doxercalciferol	1 MCG	\$	0.41	2021_J1270
2021	J1290	Ecallantide injection	1 MG	\$	503.88	2021_J1290
2021	J1300	Ecuzimab injection	10 MG	\$	229.23	2021_J1300
2021	J1301	Injection, edaravone, 1 mg	1 MG	\$	20.51	2021_J1301
2021	J1303	Inj., ravulizumab-cwvz 10 mg	10 MG	\$	224.68	2021_J1303
2021	J1322	Elosulfase alfa, injection	1 MG	\$	250.33	2021_J1322
2021	J1325	Epoprostenol injection	0.5 MG	\$	16.21	2021_J1325

2021	J1335	Ertapenem injection	500 MG	\$	28.24	2021_J1335
2021	J1364	Erythro lactobionate /500 mg	500 MG	\$	77.75	2021_J1364
2021	J1380	Estradiol valerate 10 mg inj	10 MG	\$	11.27	2021_J1380
2021	J1410	Inj estrogen conjugate 25 mg	25 MG	\$	341.46	2021_J1410
2021	J1430	Ethanolamine oleate 100 mg	100 MG	\$	444.10	2021_J1430
2021	J1437	Inj. fe derisomaltose 10 mg	10 MG	\$	24.87	2021_J1437
2021	J1439	Inj ferric carboxymaltos 1mg	1 MG	\$	1.12	2021_J1439
2021	J1442	Inj filgrastim excl biosimil	1 MCG	\$	0.97	2021_J1442
2021	J1447	Inj tbo filgrastim 1 microg	1 MCG	\$	0.46	2021_J1447
2021	J1448	Injection, trilaciclib, 1mg	1 MG	\$	4.97	2021_J1448
2021	J1450	Fluconazole	200 MG	\$	5.57	2021_J1450
2021	J1453	Fosaprepitant injection	1 MG	\$	0.24	2021_J1453
2021	J1454	Inj fosnetupitant, palonoset	0.25 MG	\$	571.22	2021_J1454
2021	J1458	Galsulfase injection	1 MG	\$	411.92	2021_J1458
2021	J1459	Inj ivig privigen 500 mg	500 MG	\$	44.48	2021_J1459
2021	J1460	Gamma globulin 1 cc inj	1 CC	\$	44.13	2021_J1460
2021	J1554	Inj. asceniv	500 MG	\$	481.77	2021_J1554
2021	J1555	Inj cuvitru, 100 mg	100 MG	\$	14.50	2021_J1555
2021	J1556	Inj, imm glob bivigam, 500mg	500 MG	\$	70.49	2021_J1556
2021	J1557	Gammplex injection	500 MG	\$	48.53	2021_J1557
2021	J1558	Inj. xembify, 100 mg	100 MG	\$	13.61	2021_J1558
2021	J1559	Hizentra injection	100 MG	\$	11.58	2021_J1559
2021	J1560	Gamma globulin > 10 cc inj	10 CC	\$	441.31	2021_J1560
2021	J1561	Gamunex-c/gammaked	500 MG	\$	48.22	2021_J1561
2021	J1566	Immune globulin, powder	500 MG	\$	65.49	2021_J1566
2021	J1568	Octagam injection	500 MG	\$	41.63	2021_J1568
2021	J1569	Gammagard liquid injection	500 MG	\$	44.49	2021_J1569
2021	J1570	Ganciclovir sodium injection	500 MG	\$	49.40	2021_J1570
2021	J1571	Hepagam b im injection	0.5 ML	\$	70.94	2021_J1571
2021	J1572	Flebogamma injection	500 MG	\$	36.80	2021_J1572
2021	J1575	Hyqvia 100mg immunoglobulin	100 MG	\$	15.16	2021_J1575
2021	J1580	Garamycin gentamicin inj	80 MG	\$	1.68	2021_J1580
2021	J1602	Golimumab for iv use 1mg	1 MG	\$	16.82	2021_J1602
2021	J1610	Glucagon hydrochloride/1 mg	1 MG	\$	171.74	2021_J1610
2021	J1626	Granisetron hcl injection	100 MCG	\$	0.33	2021_J1626
2021	J1627	Inj. granisetron, xr, 0.1 mg	0.1 MG	\$	6.94	2021_J1627
2021	J1630	Haloperidol injection	5 MG	\$	1.46	2021_J1630
2021	J1631	Haloperidol decanoate inj	50 MG	\$	9.57	2021_J1631
2021	J1640	Hemin, 1 mg	1 MG	\$	26.64	2021_J1640
2021	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.02	2021_J1642
2021	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.25	2021_J1644
2021	J1645	Dalteparin sodium	2500 IU	\$	9.12	2021_J1645
2021	J1650	Inj enoxaparin sodium	10 MG	\$	0.76	2021_J1650
2021	J1652	Fondaparinux sodium	0.5 MG	\$	1.43	2021_J1652
2021	J1670	Tetanus immune globulin inj	250 UNITS	\$	441.70	2021_J1670
2021	J1720	Hydrocortisone sodium succ i	100 MG	\$	14.81	2021_J1720
2021	J1740	Ibandronate sodium injection	1 MG	\$	37.09	2021_J1740
2021	J1742	Ibutilide fumarate injection	1 MG	\$	205.06	2021_J1742
2021	J1743	Idursulfase injection	1 MG	\$	542.94	2021_J1743
2021	J1745	Infliximab not biosimil 10mg	10 MG	\$	39.53	2021_J1745
2021	J1746	Inj., ibalizumab-uiyk, 10 mg	10 MG	\$	66.39	2021_J1746
2021	J1750	Inj iron dextran	50 MG	\$	15.84	2021_J1750
2021	J1756	Iron sucrose injection	1 MG	\$	0.23	2021_J1756
2021	J1786	Imuglucerase injection	10 UNITS	\$	44.05	2021_J1786
2021	J1815	Insulin injection	5 UNITS	\$	0.95	2021_J1815
2021	J1817	Insulin for insulin pump use	50 UNITS	\$	11.14	2021_J1817
2021	J1823	Inj. inebilizumab-cdon, 1 mg	1 MG	\$	458.21	2021_J1823
2021	J1885	Ketorolac tromethamine inj	15 MG	\$	0.48	2021_J1885
2021	J1930	Lanreotide injection	1 MG	\$	67.64	2021_J1930

2021	J1931	Laronidase injection	0.1 MG	\$	34.75	2021_J1931
2021	J1940	Furosemide injection	20 MG	\$	0.48	2021_J1940
2021	J1943	Inj., aristada initio, 1 mg	1 MG	\$	3.05	2021_J1943
2021	J1944	Aripirazole lauroxil 1 mg	1 MG	\$	2.99	2021_J1944
2021	J1950	Leuprolide acetate /3.75 mg	3.75 MG	\$	1,406.37	2021_J1950
2021	J1951	Inj fensolvi 0.25 mg	0.25 MG	\$	126.28	2021_J1951
2021	J1953	Levetiracetam injection	10 MG	\$	0.09	2021_J1953
2021	J1955	Inj levocarnitine per 1 gm	1 GM	\$	21.06	2021_J1955
2021	J1956	Levofloxacin injection	250 MG	\$	0.91	2021_J1956
2021	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	30.36	2021_J1980
2021	J2001	Lidocaine injection	10 MG	\$	0.03	2021_J2001
2021	J2010	Lincomycin injection	300 MG	\$	10.33	2021_J2010
2021	J2020	Linezolid injection	200 MG	\$	6.62	2021_J2020
2021	J2060	Lorazepam injection	2 MG	\$	0.78	2021_J2060
2021	J2150	Mannitol injection	50 ML	\$	2.52	2021_J2150
2021	J2175	Meperidine hydrochl /100 mg	100 MG	\$	6.48	2021_J2175
2021	J2182	Injection, mepolizumab, 1mg	1 MG	\$	28.29	2021_J2182
2021	J2185	Meropenem	100 MG	\$	0.79	2021_J2185
2021	J2210	Methylegonovin maleate inj	0.2 MG	\$	19.62	2021_J2210
2021	J2248	Micafungin sodium injection	1 MG	\$	0.97	2021_J2248
2021	J2250	Inj midazolam hydrochloride	1 MG	\$	0.13	2021_J2250
2021	J2260	Inj milrinone lactate / 5 mg	5 MG	\$	1.89	2021_J2260
2021	J2270	Morphine sulfate injection	10 MG	\$	3.39	2021_J2270
2021	J2274	Inj morphine pf epid ithc	10 MG	\$	11.08	2021_J2274
2021	J2278	Ziconotide injection	1 MCG	\$	8.69	2021_J2278
2021	J2280	Inj. moxifloxacin 100 mg	100 MG	\$	9.22	2021_J2280
2021	J2300	Inj nalbuphine hydrochloride	10 MG	\$	2.85	2021_J2300
2021	J2310	Inj naloxone hydrochloride	1 MG	\$	10.93	2021_J2310
2021	J2315	Naltrexone, depot form	1 MG	\$	3.53	2021_J2315
2021	J2323	Natalizumab injection	1 MG	\$	23.24	2021_J2323
2021	J2350	Injection, ocrelizumab, 1 mg	1 MG	\$	58.29	2021_J2350
2021	J2353	Octreotide injection, depot	1 MG	\$	205.37	2021_J2353
2021	J2354	Octreotide inj, non-depot	25 MCG	\$	0.95	2021_J2354
2021	J2357	Omalizumab injection	5 MG	\$	37.67	2021_J2357
2021	J2358	Olanzapine long-acting inj	1 MG	\$	2.91	2021_J2358
2021	J2360	Orphenadrine injection	60 MG	\$	5.92	2021_J2360
2021	J2400	Chloroprocaine hcl injection	30 ML	\$	29.03	2021_J2400
2021	J2405	Ondansetron hcl injection	1 MG	\$	0.09	2021_J2405
2021	J2407	Injection, oritavancin	10 MG	\$	23.63	2021_J2407
2021	J2425	Palifermin injection	50 MCG	\$	23.93	2021_J2425
2021	J2426	Paliperidone palmitate inj	1 MG	\$	12.66	2021_J2426
2021	J2430	Pamidronate disodium /30 mg	30 MG	\$	9.16	2021_J2430
2021	J2469	Palonosetron hcl	25 MCG	\$	0.97	2021_J2469
2021	J2501	Paricalcitol	1 MCG	\$	0.65	2021_J2501
2021	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	2,221.63	2021_J2505
2021	J2507	Pegloticase injection	1 MG	\$	2,960.91	2021_J2507
2021	J2510	Penicillin g procaine inj	600000 UNITS	\$	32.09	2021_J2510
2021	J2515	Pentobarbital sodium inj	50 MG	\$	26.41	2021_J2515
2021	J2540	Penicillin g potassium inj	600000 UNITS	\$	0.92	2021_J2540
2021	J2543	Piperacillin/tazobactam	1.125 GM	\$	1.48	2021_J2543
2021	J2545	Pentamidine non-comp unit	300 MG	\$	123.72	2021_J2545
2021	J2550	Promethazine hcl injection	50 MG	\$	2.37	2021_J2550
2021	J2560	Phenobarbital sodium inj	120 MG	\$	40.22	2021_J2560
2021	J2562	Plerixafor injection	1 MG	\$	382.85	2021_J2562
2021	J2597	Inj desmopressin acetate	1 MCG	\$	9.40	2021_J2597
2021	J2675	Inj progesterone per 50 mg	50 MG	\$	1.41	2021_J2675
2021	J2680	Fluphenazine decanoate 25 mg	25 MG	\$	10.30	2021_J2680
2021	J2690	Procainamide hcl injection	1 GM	\$	90.16	2021_J2690
2021	J2700	Oxacillin sodium injecton	250 MG	\$	1.28	2021_J2700

2021	J2704	Inj. propofol, 10 mg	10 MG	\$	0.13	2021_J2704
2021	J2720	Inj protamine sulfate/10 mg	10 MG	\$	1.39	2021_J2720
2021	J2724	Protein c concentrate	10 UNITS	\$	15.13	2021_J2724
2021	J2760	Phentolaine mesylate inj	5 MG	\$	416.00	2021_J2760
2021	J2765	Metoclopramide hcl injection	10 MG	\$	1.13	2021_J2765
2021	J2770	Quinupristin/dalfopristin	500 MG	\$	444.67	2021_J2770
2021	J2778	Ranibizumab injection	0.1 mg	\$	318.47	2021_J2778
2021	J2783	Rasburicase	0.5 MG	\$	315.06	2021_J2783
2021	J2785	Regadenoson injection	0.1 MG	\$	59.70	2021_J2785
2021	J2786	Injection, reslizumab, 1mg	1 MG	\$	10.11	2021_J2786
2021	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	23.17	2021_J2788
2021	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	75.54	2021_J2790
2021	J2791	Rhophylac injection	100 IU	\$	4.70	2021_J2791
2021	J2792	Rho(d) immune globulin h, sd	100 IU	\$	31.42	2021_J2792
2021	J2794	Inj risperdal consta, 0.5 mg	0.5 MG	\$	11.04	2021_J2794
2021	J2795	Ropivacaine hcl injection	1 MG	\$	0.08	2021_J2795
2021	J2796	Romiplostim injection	10 MCG	\$	83.47	2021_J2796
2021	J2798	Inj., perseris, 0.5 mg	0.5 mg	\$	10.69	2021_J2798
2021	J2800	Methocarbamol injection	10 ML	\$	6.95	2021_J2800
2021	J2805	Sinacalide injection	5 MCG	\$	121.08	2021_J2805
2021	J2820	Sargramostim injection	50 MCG	\$	51.55	2021_J2820
2021	J2860	Injection, siltuximab	10 MG	\$	124.09	2021_J2860
2021	J2916	Na ferric gluconate complex	12.5 MG	\$	2.18	2021_J2916
2021	J2920	Methylprednisolone injection	40 MG	\$	4.11	2021_J2920
2021	J2930	Methylprednisolone injection	125 MG	\$	5.57	2021_J2930
2021	J2997	Alteplase recombinant	1 MG	\$	87.75	2021_J2997
2021	J3000	Streptomycin injection	1 GM	\$	34.55	2021_J3000
2021	J3010	Fentanyl citrate injection	0.1 MG	\$	0.63	2021_J3010
2021	J3032	Inj. eptinezumab-jjmr 1 mg	1 MG	\$	15.64	2021_J3032
2021	J3060	Inj, taliglucerase alfa 10 u	10 UNITS	\$	41.32	2021_J3060
2021	J3090	Inj tedizolid phosphate	1 MG	\$	1.60	2021_J3090
2021	J3095	Telavancin injection	10 MG	\$	6.16	2021_J3095
2021	J3101	Tenecteplase injection	1 MG	\$	134.74	2021_J3101
2021	J3105	Terbutaline sulfate inj	1 MG	\$	2.53	2021_J3105
2021	J3111	Inj. romosozumab-aqqg 1 mg	1 MG	\$	9.34	2021_J3111
2021	J3121	Inj testostero enanthate 1mg	1 MG	\$	0.05	2021_J3121
2021	J3145	Testosterone undecanoate 1mg	1 MG	\$	1.63	2021_J3145
2021	J3230	Chlorpromazine hcl injection	50 MG	\$	32.87	2021_J3230
2021	J3240	Thyrotropin injection	0.9 MG	\$	1,837.25	2021_J3240
2021	J3241	Inj. teprotumumab-trbw 10 mg	10 MG	\$	315.88	2021_J3241
2021	J3243	Tigecycline injection	1 MG	\$	1.12	2021_J3243
2021	J3245	Inj., tildrakizumab, 1 mg	1 MG	\$	134.08	2021_J3245
2021	J3250	Trimethobenzamide hcl inj	200 MG	\$	40.90	2021_J3250
2021	J3260	Tobramycin sulfate injection	80 MG	\$	3.84	2021_J3260
2021	J3262	Tocilizumab injection	1 MG	\$	5.55	2021_J3262
2021	J3285	Treprostinil injection	1 MG	\$	59.68	2021_J3285
2021	J3300	Triamcinolone a inj prs-free	1 MG	\$	3.88	2021_J3300
2021	J3301	Triamcinolone acet inj nos	10 MG	\$	1.20	2021_J3301
2021	J3304	Inj triamcinolone ace xr 1mg	1 MG	\$	17.75	2021_J3304
2021	J3315	Triptorelin pamoate	3.75 MG	\$	379.90	2021_J3315
2021	J3357	Ustekinumab sub cu inj, 1 mg	1 MG	\$	176.77	2021_J3357
2021	J3358	Ustekinumab, iv inject, 1 mg	1 MG	\$	11.68	2021_J3358
2021	J3360	Diazepam injection	5 MG	\$	5.79	2021_J3360
2021	J3370	Vancomycin hcl injection	500 MG	\$	2.84	2021_J3370
2021	J3380	Injection, vedolizumab	1 MG	\$	21.28	2021_J3380
2021	J3385	Velaglucerase alfa	100 UNITS	\$	359.29	2021_J3385
2021	J3396	Verteporfin injection	0.1 MG	\$	11.25	2021_J3396
2021	J3410	Hydroxyzine hcl injection	25 MG	\$	9.03	2021_J3410
2021	J3411	Thiamine hcl 100 mg	100 MG	\$	3.08	2021_J3411

2021	J3415	Pyridoxine hcl 100 mg	100 MG	\$	11.23	2021_J3415
2021	J3420	Vitamin b12 injection	1000 MCG	\$	2.12	2021_J3420
2021	J3430	Vitamin k phytonadione inj	1 MG	\$	3.56	2021_J3430
2021	J3465	Injection, voriconazole	10 MG	\$	1.75	2021_J3465
2021	J3471	Ovine, up to 999 usp units	1 UNIT	\$	0.47	2021_J3471
2021	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.36	2021_J3473
2021	J3475	Inj magnesium sulfate	500 MG	\$	0.75	2021_J3475
2021	J3480	Inj potassium chloride	2 MEQ	\$	0.14	2021_J3480
2021	J3485	Zidovudine	10 MG	\$	1.51	2021_J3485
2021	J3486	Ziprasidone mesylate	10 MG	\$	14.85	2021_J3486
2021	J3489	Zoledronic acid 1mg	1 MG	\$	8.25	2021_J3489
2021	J7030	Normal saline solution infus	1000 ML	\$	2.60	2021_J7030
2021	J7040	Normal saline solution infus	500 ML	\$	1.30	2021_J7040
2021	J7042	5% dextrose/normal saline	500 ML	\$	1.08	2021_J7042
2021	J7050	Normal saline solution infus	250 ML	\$	0.65	2021_J7050
2021	J7060	5% dextrose/water	500 ML	\$	1.74	2021_J7060
2021	J7070	D5w infusion	1000 CC	\$	3.48	2021_J7070
2021	J7120	Ringers lactate infusion	1000 CC	\$	2.51	2021_J7120
2021	J7170	Inj., emicizumab-kxwh 0.5 mg	0.5 MG	\$	48.88	2021_J7170
2021	J7175	Inj, factor x, (human), 1iu	1 IU	\$	8.20	2021_J7175
2021	J7177	Inj., fibryga, 1 mg	1 MG	\$	1.09	2021_J7177
2021	J7178	Inj human fibrinogen con nos	1 IU	\$	1.30	2021_J7178
2021	J7179	Vonvendi inj 1 iu vwf:co	1 IU	\$	1.85	2021_J7179
2021	J7180	Factor xiii anti-hem factor	1 IU	\$	9.14	2021_J7180
2021	J7181	Factor xiii recomb a-subunit	1 IU	\$	15.87	2021_J7181
2021	J7182	Factor viii recomb novoeight	1 IU	\$	1.51	2021_J7182
2021	J7183	Wilate injection	1 I.U. VWF:RCO	\$	1.16	2021_J7183
2021	J7185	Xyntha inj	1 IU	\$	1.33	2021_J7185
2021	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	1.14	2021_J7186
2021	J7187	Humate-p, inj	1 IU	\$	1.26	2021_J7187
2021	J7188	Factor viii recomb obizur	1 IU	\$	3.19	2021_J7188
2021	J7189	Factor viia recomb novoseven	1 MCG	\$	2.33	2021_J7189
2021	J7190	Factor viii	1 IU	\$	1.12	2021_J7190
2021	J7192	Factor viii recombinant nos	1 IU	\$	1.43	2021_J7192
2021	J7193	Factor ix non-recombinant	1 IU	\$	1.17	2021_J7193
2021	J7194	Factor ix complex	1 IU	\$	1.54	2021_J7194
2021	J7195	Factor ix recombinant nos	1 IU	\$	1.61	2021_J7195
2021	J7197	Antithrombin iii injection	1 IU	\$	3.20	2021_J7197
2021	J7198	Anti-inhibitor	1 IU	\$	2.21	2021_J7198
2021	J7200	Factor ix recombinan rixubis	1 IU	\$	1.54	2021_J7200
2021	J7201	Factor ix alprolix recomb	1 IU	\$	3.28	2021_J7201
2021	J7202	Factor ix idelvion inj	1 IU	\$	4.59	2021_J7202
2021	J7203	Factor ix recomb gly rebinyn	1 MG	\$	4.23	2021_J7203
2021	J7204	Inj recombin esperoct per iu	1 IU	\$	2.23	2021_J7204
2021	J7205	Factor viii fc fusion recomb	1 IU	\$	2.15	2021_J7205
2021	J7207	Factor viii pegylated recomb	1 IU	\$	1.92	2021_J7207
2021	J7208	Inj. jivi 1 iu	1 IU	\$	2.10	2021_J7208
2021	J7209	Factor viii nuwiq recomb 1iu	1 IU	\$	1.24	2021_J7209
2021	J7210	Inj, afstyla, 1 i.u.	1 IU	\$	1.36	2021_J7210
2021	J7211	Inj, kovaltry, 1 i.u.	1 IU	\$	1.24	2021_J7211
2021	J7212	Factor viia recomb sevenfact	1 MCG	\$	2.27	2021_J7212
2021	J7308	Aminolevulinic acid hcl top	354 MG	\$	392.48	2021_J7308
2021	J7311	Inj., retisert, 0.01 mg	0.01 MG	\$	339.00	2021_J7311
2021	J7312	Dexamethasone intra implant	0.1 MG	\$	199.69	2021_J7312
2021	J7313	Inj., iluvien, 0.01 mg	0.01 MG	\$	490.95	2021_J7313
2021	J7314	Inj., yutiq, 0.01 mg	0.01 MG	\$	513.16	2021_J7314
2021	J7321	Hyalgan or supartz inj dose	per dose	\$	77.24	2021_J7321
2021	J7323	Euflexxa inj per dose	per dose	\$	138.82	2021_J7323
2021	J7324	Orthovisc inj per dose	PER DOSE	\$	148.74	2021_J7324

2021	J7325	Synvisc or synvisc-one	1 MG	\$	11.24	2021_J7325
2021	J7327	Monovisc inj per dose	PER DOSE	\$	762.80	2021_J7327
2021	J7336	Capsaicin 8% patch	1 SQ CM	\$	3.23	2021_J7336
2021	J7340	Carbidopa levodopa ent 100ml	100 ML	\$	211.70	2021_J7340
2021	J7342	Ciprofloxacin otic susp 6 mg	6 MG	\$	29.98	2021_J7342
2021	J7345	Aminolevulinic acid, 10% gel	10 MG	\$	1.59	2021_J7345
2021	J7351	Inj bimatoprost itc imp1mcg	1 MCG	\$	205.63	2021_J7351
2021	J7402	Mometasone sinus sinuva	10 MCG	\$	10.56	2021_J7402
2021	J7500	Azathioprine oral 50mg	50 MG	\$	6.58	2021_J7500
2021	J7502	Cyclosporine oral 100 mg	100 MG	\$	2.42	2021_J7502
2021	J7503	Tacrol envarsus ex rel oral	0.25 MG	\$	1.47	2021_J7503
2021	J7504	Lymphocyte immune globulin	250 MG	\$	2,355.53	2021_J7504
2021	J7507	Tacrolimus imme rel oral 1mg	1 MG	\$	0.55	2021_J7507
2021	J7508	Tacrol astagraf ex rel oral	0.1 MG	\$	0.49	2021_J7508
2021	J7509	Methylprednisolone oral	4 MG	\$	0.26	2021_J7509
2021	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.23	2021_J7510
2021	J7511	Antithymocyte globuln rabbit	25 MG	\$	837.42	2021_J7511
2021	J7512	Prednisone ir or dr oral 1mg	1 MG	\$	0.02	2021_J7512
2021	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.82	2021_J7515
2021	J7516	Cyclosporin parenteral 250mg	250 MG	\$	62.15	2021_J7516
2021	J7517	Mycophenolate mofetil oral	250 MG	\$	0.32	2021_J7517
2021	J7518	Mycophenolic acid	180 MG	\$	1.56	2021_J7518
2021	J7520	Sirolimus, oral	1 MG	\$	4.50	2021_J7520
2021	J7525	Tacrolimus injection	5 MG	\$	219.33	2021_J7525
2021	J7527	Oral everolimus	0.25 MG	\$	5.92	2021_J7527
2021	J7605	Arformoterol non-comp unit	15 mcg	\$	10.72	2021_J7605
2021	J7606	Formoterol fumarate, inh	20 MCG	\$	11.42	2021_J7606
2021	J7608	Acetylcysteine non-comp unit	1 GM	\$	6.08	2021_J7608
2021	J7611	Albuterol non-comp con	1 MG	\$	0.25	2021_J7611
2021	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.29	2021_J7612
2021	J7613	Albuterol non-comp unit	1 MG	\$	0.05	2021_J7613
2021	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.06	2021_J7614
2021	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.12	2021_J7620
2021	J7626	Budesonide non-comp unit	0.5 MG	\$	1.05	2021_J7626
2021	J7631	Cromolyn sodium noncomp unit	10 MG	\$	2.62	2021_J7631
2021	J7639	Dornase alfa non-comp unit	1 MG	\$	47.80	2021_J7639
2021	J7644	Ipratropium bromide non-comp	1 MG	\$	0.20	2021_J7644
2021	J7674	Methacholine chloride, neb	1 MG	\$	0.81	2021_J7674
2021	J7677	Revefenacin inh non-com 1mcg	1 MCG	\$	0.19	2021_J7677
2021	J7682	Tobramycin non-comp unit	300 MG	\$	38.58	2021_J7682
2021	J7686	Treprostinil, non-comp unit	1.74 MG	\$	670.95	2021_J7686
2021	J8501	Oral aprepitant	5 MG	\$	4.57	2021_J8501
2021	J8520	Capecitabine, oral, 150 mg	150 MG	\$	0.59	2021_J8520
2021	J8521	Capecitabine, oral, 500 mg	500 MG	\$	0.92	2021_J8521
2021	J8530	Cyclophosphamide oral 25 mg	25 MG	\$	0.81	2021_J8530
2021	J8540	Oral dexamethasone	0.25 MG	\$	0.10	2021_J8540
2021	J8560	Etoposide oral 50 mg	50 MG	\$	75.63	2021_J8560
2021	J8610	Methotrexate oral 2.5 mg	2.5 MG	\$	0.42	2021_J8610
2021	J8655	Oral netupitant, palonosetro	0.5 MG	\$	315.59	2021_J8655
2021	J8670	Rolapitant, oral, 1mg	1 MG	\$	1.75	2021_J8670
2021	J8700	Temozolomide	5 MG	\$	0.36	2021_J8700
2021	J8705	Topotecan oral	0.25 mg	\$	103.75	2021_J8705
2021	J9000	Doxorubicin hcl injection	10 MG	\$	2.17	2021_J9000
2021	J9017	Arsenic trioxide injection	1 MG	\$	13.11	2021_J9017
2021	J9019	Erwinaze injection	1,000 IU	\$	427.27	2021_J9019
2021	J9022	Inj, atezolizumab,10 mg	10 MG	\$	79.75	2021_J9022
2021	J9023	Injection, avelumab, 10 mg	10 MG	\$	86.19	2021_J9023
2021	J9025	Azacitidine injection	1 MG	\$	0.93	2021_J9025
2021	J9027	Clofarabine injection	1 MG	\$	53.15	2021_J9027

2021	J9030	Bcg live intravesical 1mg	1 MG	\$	2.85	2021_J9030
2021	J9032	Injection, belinostat, 10mg	10 MG	\$	42.77	2021_J9032
2021	J9033	Inj., treanda 1 mg	1 MG	\$	22.01	2021_J9033
2021	J9034	Inj., bendeka 1 mg	1 MG	\$	19.65	2021_J9034
2021	J9035	Bevacizumab injection	10 MG	\$	70.41	2021_J9035
2021	J9036	Inj. belrapzo/bendamustine	1 MG	\$	21.47	2021_J9036
2021	J9037	Inj belantamab mafodont blmf	0.5 MG	\$	42.78	2021_J9037
2021	J9039	Injection, blinatumomab	1 MCG	\$	123.88	2021_J9039
2021	J9040	Bleomycin sulfate injection	15 UNITS	\$	25.24	2021_J9040
2021	J9041	Inj., velcade 0.1 mg	0.1 MG	\$	45.16	2021_J9041
2021	J9042	Brentuximab vedotin inj	1 MG	\$	189.34	2021_J9042
2021	J9043	Cabazitaxel injection	1 MG	\$	189.00	2021_J9043
2021	J9044	Inj. bortezomib, nos, 0.1 mg	0.1 MG	\$	18.31	2021_J9044
2021	J9045	Carboplatin injection	50 MG	\$	2.64	2021_J9045
2021	J9047	Injection, carfilzomib, 1 mg	1 MG	\$	41.10	2021_J9047
2021	J9050	Carmustine injection	100 MG	\$	1,234.46	2021_J9050
2021	J9055	Cetuximab injection	10 MG	\$	66.71	2021_J9055
2021	J9060	Cisplatin 10 mg injection	10 MG	\$	1.77	2021_J9060
2021	J9065	Inj cladribine per 1 mg	1 MG	\$	18.02	2021_J9065
2021	J9070	Cyclophosphamide 100 mg inj	100 MG	\$	29.15	2021_J9070
2021	J9100	Cytarabine hcl 100 mg inj	100 MG	\$	0.68	2021_J9100
2021	J9119	Inj., cemiplimab-rwlc, 1 mg	1 MG	\$	27.54	2021_J9119
2021	J9120	Dactinomycin injection	0.5 MG	\$	890.64	2021_J9120
2021	J9130	Dacarbazine 100 mg inj	100 MG	\$	3.71	2021_J9130
2021	J9144	Daratumumab, hyaluronidase	10 MG	\$	45.10	2021_J9144
2021	J9145	Injection, daratumumab 10 mg	10 MG	\$	57.55	2021_J9145
2021	J9150	Daunorubicin injection	10 MG	\$	40.36	2021_J9150
2021	J9153	Inj daunorubicin, cytarabine	1 MG/2.27 MG	\$	202.60	2021_J9153
2021	J9155	Degarelix injection	1 MG	\$	4.12	2021_J9155
2021	J9171	Docetaxel injection	1 MG	\$	0.48	2021_J9171
2021	J9173	Inj., durvalumab, 10 mg	10 MG	\$	76.86	2021_J9173
2021	J9176	Injection, elotuzumab, 1mg	1 MG	\$	6.77	2021_J9176
2021	J9177	Inj enfort vedo-ejfv 0.25mg	0.25 MG	\$	30.17	2021_J9177
2021	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.69	2021_J9178
2021	J9179	Eribulin mesylate injection	0.1 MG	\$	123.93	2021_J9179
2021	J9181	Etoposide injection	10 MG	\$	0.80	2021_J9181
2021	J9185	Fludarabine phosphate inj	50 MG	\$	69.34	2021_J9185
2021	J9190	Fluorouracil injection	500 MG	\$	1.70	2021_J9190
2021	J9198	Inj. infugem, 100 mg	100 MG	\$	34.00	2021_J9198
2021	J9200	Floxuridine injection	500 MG	\$	74.33	2021_J9200
2021	J9201	In gemcitabine hcl nos 200mg	200 MG	\$	3.82	2021_J9201
2021	J9202	Goserelin acetate implant	3.6 MG	\$	525.21	2021_J9202
2021	J9203	Gemtuzumab ozogamicin 0.1 mg	0.1 MG	\$	207.99	2021_J9203
2021	J9204	Inj mogamulizumab-kpkc, 1 mg	1 MG	\$	210.05	2021_J9204
2021	J9205	Inj irinotecan liposome 1 mg	1 MG	\$	57.20	2021_J9205
2021	J9206	Irinotecan injection	20 MG	\$	2.35	2021_J9206
2021	J9207	Ixabepilone injection	1 MG	\$	112.12	2021_J9207
2021	J9208	Ifosfamide injection	1 GM	\$	26.76	2021_J9208
2021	J9209	Mesna injection	200 MG	\$	2.11	2021_J9209
2021	J9210	Inj., emapalumab-lzsg, 1 mg	1 MG	\$	376.03	2021_J9210
2021	J9211	Idarubicin hcl injection	5 MG	\$	34.75	2021_J9211
2021	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	33.24	2021_J9214
2021	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	139.09	2021_J9217
2021	J9218	Leuprolide acetate injecton	1 MG	\$	18.32	2021_J9218
2021	J9223	Inj. lurbinectedin, 0.1 mg	0.1 MG	\$	174.03	2021_J9223
2021	J9225	Vantas implant	50 MG	\$	5,166.29	2021_J9225
2021	J9226	Supprelin la implant	50 MG	\$	43,467.03	2021_J9226
2021	J9227	Inj. isatuximab-irfc 10 mg	10 MG	\$	67.60	2021_J9227
2021	J9228	Ipilimumab injection	1 MG	\$	158.65	2021_J9228

2021	J9229	Inj inotuzumab ozogam 0.1 mg	0.1 MG	\$	2,371.62	2021_J9229
2021	J9245	Inj melpha hydroch nos 50 mg	50 MG	\$	208.41	2021_J9245
2021	J9247	Inj, melphalan flufenami 1mg	1 MG	\$	499.86	2021_J9247
2021	J9250	Methotrexate sodium inj	5 MG	\$	0.22	2021_J9250
2021	J9260	Methotrexate sodium inj	50 MG	\$	2.16	2021_J9260
2021	J9261	Nelarabine injection	50 MG	\$	155.90	2021_J9261
2021	J9262	Inj, omacetaxine mep, 0.01mg	0.01 MG	\$	3.30	2021_J9262
2021	J9263	Oxaliplatin	0.5 MG	\$	0.11	2021_J9263
2021	J9264	Paclitaxel protein bound	1 MG	\$	14.08	2021_J9264
2021	J9266	Pegaspargase injection	1 EA	\$	21,561.05	2021_J9266
2021	J9267	Paclitaxel injection	1 MG	\$	0.13	2021_J9267
2021	J9268	Pentostatin injection	10 MG	\$	1,880.67	2021_J9268
2021	J9269	Inj. tagraxofusp-erzs 10 mcg	10 MCG	\$	290.37	2021_J9269
2021	J9271	Inj pembrolizumab	1 MG	\$	52.75	2021_J9271
2021	J9280	Mitomycin injection	5 MG	\$	38.63	2021_J9280
2021	J9281	Mitomycin instillation	1 MG	\$	281.88	2021_J9281
2021	J9293	Mitoxantrone hydrochl / 5 mg	5 MG	\$	26.29	2021_J9293
2021	J9295	Injection, necitumumab, 1 mg	1 MG	\$	5.74	2021_J9295
2021	J9299	Injection, nivolumab	1 MG	\$	28.86	2021_J9299
2021	J9301	Obinutuzumab inj	10 MG	\$	64.54	2021_J9301
2021	J9302	Ofatumumab injection	10 MG	\$	63.96	2021_J9302
2021	J9303	Panitumumab injection	10 MG	\$	130.38	2021_J9303
2021	J9305	Inj. pemetrexed nos 10mg	10 MG	\$	74.93	2021_J9305
2021	J9306	Injection, pertuzumab, 1 mg	1 MG	\$	13.56	2021_J9306
2021	J9307	Pralatrexate injection	1 MG	\$	314.84	2021_J9307
2021	J9308	Injection, ramucirumab	5 MG	\$	62.69	2021_J9308
2021	J9309	Inj, polatuzumab vedotin 1mg	1 MG	\$	113.57	2021_J9309
2021	J9311	Inj rituximab, hyaluronidase	10 mg	\$	37.94	2021_J9311
2021	J9312	Inj., rituximab, 10 mg	10 MG	\$	86.94	2021_J9312
2021	J9313	Inj., lumoxiti, 0.01 mg	0.01 MG	\$	23.39	2021_J9313
2021	J9316	Pertuzu, trastuzu, 10 mg	10 MG	\$	72.15	2021_J9316
2021	J9317	Sacituzumab govitecan-hziy	2.5 MG	\$	30.35	2021_J9317
2021	J9319	Inj romidepsin lyophil 0.1mg	0.1 MG	\$	33.68	2021_J9319
2021	J9320	Streptozocin injection	1 GM	\$	348.51	2021_J9320
2021	J9325	Inj talimogene laherparepvec	1 million PFU	\$	57.26	2021_J9325
2021	J9328	Temozolomide injection	1 MG	\$	10.41	2021_J9328
2021	J9330	Temsirolimus injection	1 MG	\$	38.25	2021_J9330
2021	J9340	Thiotepa injection	15 MG	\$	305.84	2021_J9340
2021	J9349	Inj., tafasitamab-cxix	2 MG	\$	12.62	2021_J9349
2021	J9351	Topotecan injection	0.1 MG	\$	0.77	2021_J9351
2021	J9352	Injection trabectedin 0.1mg	0.1 MG	\$	325.03	2021_J9352
2021	J9353	Inj. margetuximab-cmkbb, 5 mg	5 MG	\$	43.87	2021_J9353
2021	J9354	Inj, ado-trastuzumab emt 1mg	1 MG	\$	34.18	2021_J9354
2021	J9355	Inj trastuzumab excl biosimi	10 MG	\$	89.81	2021_J9355
2021	J9356	Inj. herceptin hylecta, 10mg	10 MG	\$	71.85	2021_J9356
2021	J9357	Valrubicin injection	200 MG	\$	1,425.37	2021_J9357
2021	J9358	Inj fam-trastu deru-nxki 1mg	1 MG	\$	24.27	2021_J9358
2021	J9360	Vinblastine sulfate inj	1 MG	\$	3.35	2021_J9360
2021	J9370	Vincristine sulfate 1 mg inj	1 MG	\$	5.03	2021_J9370
2021	J9371	Inj, vincristine sul lip 1mg	1 MG	\$	3,370.23	2021_J9371
2021	J9390	Vinorelbine tartrate inj	10 MG	\$	10.01	2021_J9390
2021	J9395	Injection, fulvestrant	25 MG	\$	15.98	2021_J9395
2021	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.42	2021_J9400
2021	P9041	Albumin (human),5%, 50ml	50 ML	\$	10.49	2021_P9041
2021	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	52.45	2021_P9045
2021	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	20.98	2021_P9046
2021	P9047	Albumin (human), 25%, 50ml	50 ML	\$	52.45	2021_P9047
2021	Q0138	Ferumoxytol, non-esrd	1 MG	\$	1.00	2021_Q0138
2021	Q0139	Ferumoxytol, esrd use	1 MG	\$	1.00	2021_Q0139

2021	Q0162	Ondansetron oral	1 MG	\$	0.02	2021_Q0162
2021	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.33	2021_Q0164
2021	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	0.45	2021_Q0167
2021	Q2043	Sipuleucel-t auto cd54+	Per infusion (minimum 50 million cells)	\$	53,017.58	2021_Q2043
2021	Q2050	Doxorubicin inj 10mg	10 MG	\$	234.03	2021_Q2050
2021	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	55.29	2021_Q3027
2021	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	140.24	2021_Q4074
2021	Q4081	Epoetin alfa, 100 units esrd	100 UNITS	\$	0.82	2021_Q4081
2021	Q4101	Apligraf	1 SQ CM	\$	30.43	2021_Q4101
2021	Q4102	Oasis wound matrix	1 SQ CM	\$	11.05	2021_Q4102
2021	Q4106	Dermagraft	1 SQ CM	\$	32.03	2021_Q4106
2021	Q4110	Primatrix	1 SQ CM	\$	43.43	2021_Q4110
2021	Q4111	Gammagraft	1 SQ CM	\$	7.34	2021_Q4111
2021	Q4121	Theraskin	1 SQ CM	\$	43.84	2021_Q4121
2021	Q4133	Grafix stravax prime pl sqcm	1 SQ CM	\$	133.74	2021_Q4133
2021	Q4137	Amnioexcel biodexcel 1sq cm	1 SQ CM	\$	94.16	2021_Q4137
2021	Q4145	Epifix, inj, 1mg	1 MG	\$	17.96	2021_Q4145
2021	Q4151	Amnioband, guardian 1 sq cm	1 SQ CM	\$	124.42	2021_Q4151
2021	Q4160	Nushield 1 square cm	1 SQ CM	\$	96.26	2021_Q4160
2021	Q4163	Woundex, bioskin, per sq cm	1 SQ CM	\$	104.71	2021_Q4163
2021	Q4186	Epifix 1 sq cm	1 SQ CM	\$	155.49	2021_Q4186
2021	Q4187	Epicord 1 sq cm	1 SQ CM	\$	223.17	2021_Q4187
2021	Q4195	Puraply 1 sq cm	1 SQ CM	\$	110.33	2021_Q4195
2021	Q4196	Puraply am 1 sq cm	1 SQ CM	\$	108.29	2021_Q4196
2021	Q5101	Injection, zarxio	1 MCG	\$	0.32	2021_Q5101
2021	Q5103	Injection, inflectra	10 MG	\$	41.19	2021_Q5103
2021	Q5104	Injection, renflexis	10 MG	\$	38.79	2021_Q5104
2021	Q5105	Inj retacrit esrd on dialysi	100 UNITS	\$	0.87	2021_Q5105
2021	Q5106	Inj retacrit non-esrd use	1000 UNITS	\$	8.66	2021_Q5106
2021	Q5107	Inj mvsi 10 mg	10 MG	\$	44.56	2021_Q5107
2021	Q5108	Injection, fulphila	0.5 MG	\$	211.19	2021_Q5108
2021	Q5110	Nivestym	1 MCG	\$	0.33	2021_Q5110
2021	Q5111	Injection, udenyca 0.5 mg	0.5 MG	\$	222.38	2021_Q5111
2021	Q5112	Inj ontruzant 10 mg	10 MG	\$	66.55	2021_Q5112
2021	Q5113	Inj herzuma 10 mg	10 MG	\$	57.30	2021_Q5113
2021	Q5114	Inj ogivri 10 mg	10 MG	\$	59.91	2021_Q5114
2021	Q5115	Inj truxima 10 mg	10 MG	\$	60.58	2021_Q5115
2021	Q5116	Inj., trazimera, 10 mg	10 MG	\$	59.93	2021_Q5116
2021	Q5117	Inj., kanjinti, 10 mg	10 MG	\$	53.18	2021_Q5117
2021	Q5118	Inj., zirabev, 10 mg	10 MG	\$	52.37	2021_Q5118
2021	Q5119	Inj ruxience, 10 mg	10 MG	\$	58.80	2021_Q5119
2021	Q5120	Inj pegfilgrastim-bmez 0.5mg	0.5 MG	\$	245.43	2021_Q5120
2021	Q5121	Inj. avsola, 10 mg	10 MG	\$	47.12	2021_Q5121
2021	Q5122	Inj, nyvepria	0.5 MG	\$	284.69	2021_Q5122
2021	Q5123	Inj. riabni, 10 mg	10 MG	\$	72.23	2021_Q5123
2021	Q9950	Inj sulf hexa lipid microsph	1 ML	\$	18.77	2021_Q9950
2021	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	30.90	2021_Q9956
2021	Q9957	Inj perflutren lip micros,ml	1 ML	\$	46.36	2021_Q9957
2021	Q9958	Hocm <=149 mg/ml iodine, 1ml	1 ML	\$	0.07	2021_Q9958
2021	Q9961	Hocm 250-299mg/ml iodine,1ml	1 ML	\$	0.25	2021_Q9961
2021	Q9963	Hocm 350-399mg/ml iodine,1ml	1 ML	\$	0.19	2021_Q9963
2021	Q9965	Locm 100-199mg/ml iodine,1ml	1 ML	\$	0.84	2021_Q9965
2021	Q9966	Locm 200-299mg/ml iodine,1ml	1 ML	\$	0.34	2021_Q9966
2021	Q9967	Locm 300-399mg/ml iodine,1ml	1 ML	\$	0.12	2021_Q9967
2021	Q9991	Buprenorph xr 100 mg or less	Less than or equal to 100 MG	\$	1,796.80	2021_Q9991
2021	Q9992	Buprenorphine xr over 100 mg	Greater than 100 MG	\$	1,796.80	2021_Q9992
2020	90371	Hep b ig im	1 ML	\$	119.09	2020_90371
2020	90375	Rabies ig im/sc	150 IU	\$	273.04	2020_90375
2020	90376	Rabies ig heat treated	150 IU	\$	331.80	2020_90376

2020	90586	Bcg vaccine intravesical	1 EACH	\$	139.63	2020_90586
2020	90632	Hepa vaccine adult im	1 ML	\$	58.44	2020_90632
2020	90653	liv adjuvant vaccine im	0.5 ml	\$	59.53	2020_90653
2020	90662	liv no prsv increased ag im	0.5 ML	\$	60.98	2020_90662
2020	90670	Pcv13 vaccine im	0.5 ML	\$	230.14	2020_90670
2020	90672	Laiv4 vaccine intranasal	0.2 ML	\$	26.88	2020_90672
2020	90674	Cciiv4 vac no prsv 0.5 ml im	0.5 ML	\$	29.23	2020_90674
2020	90675	Rabies vaccine im	1 ML	\$	303.24	2020_90675
2020	90682	Riv4 vacc recombinant dna im	0.5 ML	\$	60.98	2020_90682
2020	90685	liv4 vacc no prsv 0.25 ml im	0.25 mL	\$	21.13	2020_90685
2020	90686	liv4 vacc no prsv 0.5 ml im	0.5 ml	\$	19.58	2020_90686
2020	90687	liv4 vaccine splrt 0.25 ml im	0.25 ML	\$	9.58	2020_90687
2020	90688	liv4 vaccine splrt 0.5 ml im	0.5 ML	\$	19.17	2020_90688
2020	90691	Typhoid vaccine im	0.5 ML	\$	75.16	2020_90691
2020	90694	Vacc AllV4 no prsv 0.5ML IM	0.5 ML	\$	61.00	2020_90694
2020	90714	Td vacc no presv 7 yrs+ im	0.5 ML	\$	25.27	2020_90714
2020	90715	Tdap vaccine 7 yrs/> im	0.5 ML	\$	34.28	2020_90715
2020	90732	Ppsv23 vacc 2 yrs+ subq/im	0.5 ML	\$	119.92	2020_90732
2020	90739	Hepb vacc 2 dose adult im	1 dose	\$	131.10	2020_90739
2020	90740	Hepb vacc 3 dose immunsup im	40 MCG	\$	140.76	2020_90740
2020	90744	Hepb vacc 3 dose ped/adol im	1 DOSE	\$	28.21	2020_90744
2020	90746	Hepb vaccine 3 dose adult im	20 MCG	\$	69.65	2020_90746
2020	90747	Hepb vacc 4 dose immunsup im	40 MCG	\$	140.76	2020_90747
2020	90756	Cciiv4 vacc abx free im	0.5 ML	\$	27.70	2020_90756
2020	A9575	Inj gadoterate meglumi 0.1ml	0.1 ML	\$	0.18	2020_A9575
2020	A9576	Inj prohance multipack	1 ML	\$	1.50	2020_A9576
2020	A9577	Inj multihance	1 ML	\$	1.81	2020_A9577
2020	A9578	Inj multihance multipack	1 ML	\$	1.75	2020_A9578
2020	A9579	Gad-base mr contrast nos,1ml	1 ML	\$	1.53	2020_A9579
2020	A9581	Gadoxetate disodium inj	1 ML	\$	14.76	2020_A9581
2020	A9585	Gadobutrol injection	0.1 ML	\$	0.36	2020_A9585
2020	A9589	Insti hexaminolevulinate hcl	100 MG	\$	1,173.51	2020_A9589
2020	A9606	Radium ra223 dichloride ther	1 microCurie	N/A		2020_A9606
2020	J0121	Inj., omadacycline, 1 mg	1 MG	\$	3.15	2020_J0121
2020	J0122	Inj., eravacycline, 1 mg	1 MG	\$	1.02	2020_J0122
2020	J0129	Abatacept injection	10 MG	\$	58.10	2020_J0129
2020	J0132	Acetylcysteine injection	100 MG	\$	1.06	2020_J0132
2020	J0133	Acyclovir injection	5 MG	\$	0.05	2020_J0133
2020	J0153	Adenosine inj 1mg	1 MG	\$	0.57	2020_J0153
2020	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.88	2020_J0171
2020	J0178	Aflibercept injection	1 MG	\$	928.24	2020_J0178
2020	J0179	Inj, brolucizumab-dbl, 1 mg	1 MG	\$	311.99	2020_J0179
2020	J0180	Agalsidase beta injection	1 MG	\$	188.99	2020_J0180
2020	J0185	Inj., aprepitant, 1 mg	1 MG	\$	1.73	2020_J0185
2020	J0202	Injection, alemtuzumab	1 MG	\$	1,984.32	2020_J0202
2020	J0207	Amifostine	500 MG	\$	1,135.69	2020_J0207
2020	J0221	Lumizyme injection	10 MG	\$	174.49	2020_J0221
2020	J0222	Inj., patisiran, 0.1 mg	0.1 MG	\$	97.84	2020_J0222
2020	J0223	Inj givosiran 0.5 mg	0.5 MG	\$	106.88	2020_J0223
2020	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.36	2020_J0256
2020	J0257	Glassia injection	10 MG	\$	4.83	2020_J0257
2020	J0278	Amikacin sulfate injection	100 MG	\$	1.30	2020_J0278
2020	J0280	Aminophyllin 250 mg inj	250 MG	\$	9.02	2020_J0280
2020	J0285	Amphotericin b	50 MG	\$	38.93	2020_J0285
2020	J0287	Amphotericin b lipid complex	10 MG	\$	9.36	2020_J0287
2020	J0289	Amphotericin b liposome inj	10 MG	\$	26.56	2020_J0289
2020	J0290	Ampicillin 500 mg inj	500 MG	\$	0.92	2020_J0290
2020	J0291	Inj., plazomicin, 5 mg	5 MG	\$	3.11	2020_J0291
2020	J0295	Ampicillin sulbactam 1.5 gm	1.5 GM	\$	2.64	2020_J0295

2020	J0348	Anidulafungin injection	1 MG	\$	0.51	2020_J0348
2020	J0360	Hydralazine hcl injection	20 MG	\$	3.38	2020_J0360
2020	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	5.70	2020_J0401
2020	J0456	Azithromycin	500 MG	\$	4.03	2020_J0456
2020	J0461	Atropine sulfate injection	0.01 MG	\$	0.09	2020_J0461
2020	J0475	Baclofen 10 mg injection	10 MG	\$	172.28	2020_J0475
2020	J0476	Baclofen intrathecal trial	50 MCG	\$	59.49	2020_J0476
2020	J0480	Basiliximab	20 MG	\$	4,005.19	2020_J0480
2020	J0485	Belatacept injection	1 MG	\$	3.78	2020_J0485
2020	J0490	Belimumab injection	10 MG	\$	46.18	2020_J0490
2020	J0500	Dicyclomine injection	20 MG	\$	33.57	2020_J0500
2020	J0515	Inj benzotropine mesylate	1 MG	\$	17.27	2020_J0515
2020	J0517	Inj., benralizumab, 1 mg	1 MG	\$	170.11	2020_J0517
2020	J0558	Peng benzathine/procaine inj	100,000 UNITS	\$	12.00	2020_J0558
2020	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	15.16	2020_J0561
2020	J0565	Inj. bezlotoxumab, 10 mg	10 MG	\$	39.65	2020_J0565
2020	J0570	Buprenorphine implant 74.2mg	74.2 MG	\$	1,207.16	2020_J0570
2020	J0583	Bivalirudin	1 MG	\$	0.48	2020_J0583
2020	J0584	Injection, burosumab-twza 1m	1 MG	\$	361.90	2020_J0584
2020	J0585	Injection,onabotulinumtoxin a	1 UNIT	\$	6.08	2020_J0585
2020	J0586	Abobotulinumtoxin a	5 Unit	\$	8.15	2020_J0586
2020	J0587	Inj, rimabotulinumtoxinb	100 UNITS	\$	11.93	2020_J0587
2020	J0588	Incobotulinumtoxin a	1 UNIT	\$	5.02	2020_J0588
2020	J0592	Buprenorphine hydrochloride	0.1 MG	\$	4.48	2020_J0592
2020	J0594	Busulfan injection	1 MG	\$	3.41	2020_J0594
2020	J0595	Butorphanol tartrate 1 mg	1 MG	\$	2.89	2020_J0595
2020	J0596	Injection, ruconest	10 UNITS	\$	29.11	2020_J0596
2020	J0597	C-1 esterase, berinert	10 UNITS	\$	54.13	2020_J0597
2020	J0598	C-1 esterase, cinryze	10 UNITS	\$	56.20	2020_J0598
2020	J0600	Edetate calcium disodium inj	1000 MG	\$	5,594.42	2020_J0600
2020	J0610	Calcium gluconate injection	10 ML	\$	3.98	2020_J0610
2020	J0630	Calcitonin salmon injection	400 UNITS	\$	2,839.22	2020_J0630
2020	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.75	2020_J0636
2020	J0637	Caspofungin acetate	5 MG	\$	6.87	2020_J0637
2020	J0638	Canakinumab injection	1 MG	\$	113.24	2020_J0638
2020	J0640	Leucovorin calcium injection	50 MG	\$	2.80	2020_J0640
2020	J0641	Inj levoleucovorin nos 0.5mg	0.5 MG	\$	0.28	2020_J0641
2020	J0642	Injection, khapzory, 0.5 mg	0.5 MG	\$	1.89	2020_J0642
2020	J0670	Inj mepivacaine hcl/10 ml	10 ML	\$	3.00	2020_J0670
2020	J0690	Cefazolin sodium injection	500 MG	\$	0.97	2020_J0690
2020	J0691	Inj lefamulin 1 mg	1 MG	\$	0.72	2020_J0691
2020	J0692	Cefepime hcl for injection	500 MG	\$	1.88	2020_J0692
2020	J0694	Cefoxitin sodium injection	1 GM	\$	7.36	2020_J0694
2020	J0695	Inj ceftolozane tazobactam	75mg (50mg cft/25mg taz)	\$	6.49	2020_J0695
2020	J0696	Ceftriaxone sodium injection	250 MG	\$	0.63	2020_J0696
2020	J0697	Sterile cefuroxime injection	750 MG	\$	1.94	2020_J0697
2020	J0698	Cefotaxime sodium injection	1 GM	\$	2.33	2020_J0698
2020	J0702	Betamethasone acet&sod phosph	3 MG & 3 MG	\$	6.55	2020_J0702
2020	J0712	Ceftaroline fosamil inj	10 MG	\$	3.32	2020_J0712
2020	J0713	Inj ceftazidime per 500 mg	500 MG	\$	1.95	2020_J0713
2020	J0714	Ceftazidime and avibactam	.625 GM	\$	92.00	2020_J0714
2020	J0717	Certolizumab pegol inj 1mg	1 MG	\$	8.16	2020_J0717
2020	J0720	Chloramphenicol sodium injec	1 GM	\$	32.68	2020_J0720
2020	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	21.67	2020_J0725
2020	J0735	Clonidine hydrochloride	1 MG	\$	23.26	2020_J0735
2020	J0740	Cidofovir injection	375 MG	\$	666.25	2020_J0740
2020	J0742	Inj imip 4 cilas 4 releb 2mg	4 MG-4 MG-2 MG	\$	2.26	2020_J0742
2020	J0743	Cilastatin sodium injection	250 MG	\$	6.33	2020_J0743
2020	J0744	Ciprofloxacin iv	200 MG	\$	1.00	2020_J0744

2020	J0770	Colistimethate sodium inj	150 MG	\$	15.62	2020_J0770
2020	J0775	Collagenase, clost hist inj	0.01 MG	\$	52.39	2020_J0775
2020	J0780	Prochlorperazine injection	10 MG	\$	5.10	2020_J0780
2020	J0791	Inj crizanlizumab-tmca 5mg	5 MG	\$	122.41	2020_J0791
2020	J0795	Corticotropin ovine triflural	1 MCG	\$	9.38	2020_J0795
2020	J0800	Corticotropin injection	40 UNITS	\$	4,013.24	2020_J0800
2020	J0834	Inj., cosyntropin, 0.25 mg	0.25 MG	\$	39.22	2020_J0834
2020	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	3,043.75	2020_J0840
2020	J0841	Inj crotalidae im f(ab')2 eq	120 MG	\$	1,264.21	2020_J0841
2020	J0850	Cytomegalovirus imm iv /vial	PER VIAL	\$	1,496.95	2020_J0850
2020	J0875	Injection, dalbavancin	5 MG	\$	15.39	2020_J0875
2020	J0878	Daptomycin injection	1 MG	\$	0.16	2020_J0878
2020	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.72	2020_J0881
2020	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.72	2020_J0882
2020	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	9.11	2020_J0885
2020	J0887	Epoetin beta esrd use	1 MCG	\$	1.54	2020_J0887
2020	J0888	Epoetin beta non esrd	1 MCG	\$	1.54	2020_J0888
2020	J0894	Decitabine injection	1 MG	\$	4.26	2020_J0894
2020	J0895	Deferoxamine mesylate inj	500 MG	\$	8.44	2020_J0895
2020	J0897	Denosumab injection	1 MG	\$	20.12	2020_J0897
2020	J1000	Depo-estradiol cypionate inj	5 MG	\$	24.06	2020_J1000
2020	J1020	Methylprednisolone 20 mg inj	20 MG	\$	3.46	2020_J1020
2020	J1030	Methylprednisolone 40 mg inj	40 MG	\$	5.88	2020_J1030
2020	J1040	Methylprednisolone 80 mg inj	80 MG	\$	11.19	2020_J1040
2020	J1050	Medroxyprogesterone acetate	1 MG	\$	0.56	2020_J1050
2020	J1071	Inj testosterone cypionate	1 MG	\$	0.03	2020_J1071
2020	J1100	Dexamethasone sodium phos	1 MG	\$	0.13	2020_J1100
2020	J1110	Inj dihydroergotamine mesylt	1 MG	\$	55.97	2020_J1110
2020	J1120	Acetazolamid sodium injectio	500 MG	\$	21.89	2020_J1120
2020	J1160	Digoxin injection	0.5 MG	\$	5.64	2020_J1160
2020	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	3,972.14	2020_J1162
2020	J1165	Phenytoin sodium injection	50 MG	\$	0.50	2020_J1165
2020	J1170	Hydromorphone injection	4 MG	\$	1.98	2020_J1170
2020	J1190	Dexrazoxane hcl injection	250 MG	\$	199.93	2020_J1190
2020	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.65	2020_J1200
2020	J1205	Chlorothiazide sodium inj	500 MG	\$	54.79	2020_J1205
2020	J1212	Dimethyl sulfoxide 50% 50 ml	50 ML	\$	635.67	2020_J1212
2020	J1230	Methadone injection	10 MG	\$	17.55	2020_J1230
2020	J1240	Dimenhydrinate injection	50 MG	\$	6.56	2020_J1240
2020	J1245	Dipyridamole injection	10 MG	\$	3.36	2020_J1245
2020	J1250	Inj dobutamine hcl/250 mg	250 MG	\$	5.69	2020_J1250
2020	J1265	Dopamine injection	40 MG	\$	0.56	2020_J1265
2020	J1270	Injection, doxercalciferol	1 MCG	\$	0.33	2020_J1270
2020	J1290	Ecallantide injection	1 MG	\$	494.69	2020_J1290
2020	J1300	Ecuzimab injection	10 MG	\$	230.48	2020_J1300
2020	J1301	Injection, edaravone, 1 mg	1 MG	\$	19.89	2020_J1301
2020	J1303	Inj., ravulizumab-cwvz 10 mg	10 MG	\$	226.28	2020_J1303
2020	J1322	Elosulfase alfa, injection	1 MG	\$	246.20	2020_J1322
2020	J1325	Epoprostenol injection	0.5 MG	\$	16.31	2020_J1325
2020	J1335	Ertapenem injection	500 MG	\$	32.80	2020_J1335
2020	J1364	Erythro lactobionate /500 mg	500 MG	\$	76.85	2020_J1364
2020	J1380	Estradiol valerate 10 mg inj	10 MG	\$	8.18	2020_J1380
2020	J1410	Inj estrogen conjugate 25 mg	25 MG	\$	325.62	2020_J1410
2020	J1430	Ethanolamine oleate 100 mg	100 MG	\$	444.10	2020_J1430
2020	J1439	Inj ferric carboxymaltos 1mg	1 MG	\$	1.11	2020_J1439
2020	J1442	Inj filgrastim excl biosimil	1 MCG	\$	0.93	2020_J1442
2020	J1447	Inj tbo filgrastim 1 microg	1 MCG	\$	0.47	2020_J1447
2020	J1450	Fluconazole	200 MG	\$	3.43	2020_J1450
2020	J1453	Fosaprepitant injection	1 MG	\$	0.79	2020_J1453

2020	J1454	Inj fosnetupitant, palonoset	0.25 MG	\$	695.77	2020_J1454
2020	J1458	Galsulfase injection	1 MG	\$	405.76	2020_J1458
2020	J1459	Inj ivig privigen 500 mg	500 MG	\$	41.50	2020_J1459
2020	J1460	Gamma globulin 1 cc inj	1 CC	\$	42.93	2020_J1460
2020	J1555	Inj cuvitru, 100 mg	100 MG	\$	14.02	2020_J1555
2020	J1556	Inj, imm glob bivigam, 500mg	500 MG	\$	70.49	2020_J1556
2020	J1557	Gammplex injection	500 MG	\$	53.66	2020_J1557
2020	J1558	Inj. xembify, 100 mg	100 MG	\$	14.22	2020_J1558
2020	J1559	Hizentra injection	100 MG	\$	10.86	2020_J1559
2020	J1560	Gamma globulin > 10 cc inj	10 CC	\$	429.26	2020_J1560
2020	J1561	Gamunex-c/gammaked	500 MG	\$	42.19	2020_J1561
2020	J1566	Immune globulin, powder	500 MG	\$	68.30	2020_J1566
2020	J1568	Octagam injection	500 MG	\$	41.23	2020_J1568
2020	J1569	Gammagard liquid injection	500 MG	\$	43.20	2020_J1569
2020	J1570	Ganciclovir sodium injection	500 MG	\$	12.84	2020_J1570
2020	J1571	Hepagam b im injection	0.5 ML	\$	63.40	2020_J1571
2020	J1572	Flebogamma injection	500 MG	\$	40.38	2020_J1572
2020	J1575	Hyqvia 100mg immunoglobulin	100 MG	\$	14.49	2020_J1575
2020	J1580	Garamycin gentamicin inj	80 MG	\$	1.79	2020_J1580
2020	J1602	Golimumab for iv use 1mg	1 MG	\$	19.00	2020_J1602
2020	J1610	Glucagon hydrochloride/1 mg	1 MG	\$	211.79	2020_J1610
2020	J1626	Granisetron hcl injection	100 MCG	\$	0.31	2020_J1626
2020	J1627	Inj, granisetron, xr, 0.1 mg	0.1 MG	\$	0.19	2020_J1627
2020	J1630	Haloperidol injection	5 MG	\$	0.91	2020_J1630
2020	J1631	Haloperidol decanoate inj	50 MG	\$	14.94	2020_J1631
2020	J1640	Hemin, 1 mg	1 MG	\$	24.44	2020_J1640
2020	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.01	2020_J1642
2020	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.29	2020_J1644
2020	J1645	Dalteparin sodium	2500 IU	\$	10.67	2020_J1645
2020	J1650	Inj enoxaparin sodium	10 MG	\$	0.69	2020_J1650
2020	J1652	Fondaparinux sodium	0.5 MG	\$	1.46	2020_J1652
2020	J1670	Tetanus immune globulin inj	250 UNITS	\$	476.57	2020_J1670
2020	J1720	Hydrocortisone sodium succ i	100 MG	\$	14.15	2020_J1720
2020	J1740	Ibandronate sodium injection	1 MG	\$	51.00	2020_J1740
2020	J1742	Ibutilide fumarate injection	1 MG	\$	316.20	2020_J1742
2020	J1743	Idursulfase injection	1 MG	\$	542.92	2020_J1743
2020	J1745	Infliximab not biosimil 10mg	10 MG	\$	47.62	2020_J1745
2020	J1746	Inj., ibalizumab-uiyk, 10 mg	10 MG	\$	63.62	2020_J1746
2020	J1750	Inj iron dextran	50 MG	\$	15.01	2020_J1750
2020	J1756	Iron sucrose injection	1 MG	\$	0.22	2020_J1756
2020	J1786	Imuglucerase injection	10 UNITS	\$	43.38	2020_J1786
2020	J1800	Propranolol injection	1 MG	\$	3.99	2020_J1800
2020	J1815	Insulin injection	5 UNITS	\$	0.87	2020_J1815
2020	J1817	Insulin for insulin pump use	50 UNITS	\$	10.23	2020_J1817
2020	J1885	Ketorolac tromethamine inj	15 MG	\$	0.67	2020_J1885
2020	J1930	Lanreotide injection	1 MG	\$	68.48	2020_J1930
2020	J1931	Laronidase injection	0.1 MG	\$	33.10	2020_J1931
2020	J1940	Furosemide injection	20 MG	\$	0.79	2020_J1940
2020	J1943	Inj., aristada initio, 1 mg	1 MG	\$	2.86	2020_J1943
2020	J1944	Aripirazole lauroxil 1 mg	1 MG	\$	2.85	2020_J1944
2020	J1950	Leuprolide acetate /3.75 mg	3.75 MG	\$	1,347.56	2020_J1950
2020	J1953	Levetiracetam injection	10 MG	\$	0.12	2020_J1953
2020	J1955	Inj levocarnitine per 1 gm	1 GM	\$	20.82	2020_J1955
2020	J1956	Levofloxacin injection	250 MG	\$	0.40	2020_J1956
2020	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	31.60	2020_J1980
2020	J2001	Lidocaine injection	10 MG	\$	0.02	2020_J2001
2020	J2010	Lincomycin injection	300 MG	\$	11.58	2020_J2010
2020	J2020	Linezolid injection	200 MG	\$	7.51	2020_J2020
2020	J2060	Lorazepam injection	2 MG	\$	0.75	2020_J2060

2020	J2150	Mannitol injection	50 ML	\$	2.07	2020_J2150
2020	J2175	Meperidine hydrochl /100 mg	100 MG	\$	8.35	2020_J2175
2020	J2182	Injection, mepolizumab, 1mg	1 MG	\$	28.70	2020_J2182
2020	J2185	Meropenem	100 MG	\$	0.86	2020_J2185
2020	J2210	Methylergonovin maleate inj	0.2 MG	\$	19.57	2020_J2210
2020	J2248	Micafungin sodium injection	1 MG	\$	1.18	2020_J2248
2020	J2250	Inj midazolam hydrochloride	1 MG	\$	0.13	2020_J2250
2020	J2260	Inj milrinone lactate / 5 mg	5 MG	\$	1.51	2020_J2260
2020	J2270	Morphine sulfate injection	10 MG	\$	1.87	2020_J2270
2020	J2274	Inj morphine pf epid ithc	10 MG	\$	10.40	2020_J2274
2020	J2278	Ziconotide injection	1 MCG	\$	8.17	2020_J2278
2020	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	9.36	2020_J2280
2020	J2300	Inj nalbuphine hydrochloride	10 MG	\$	3.07	2020_J2300
2020	J2310	Inj naloxone hydrochloride	1 MG	\$	11.03	2020_J2310
2020	J2315	Naltrexone, depot form	1 MG	\$	3.26	2020_J2315
2020	J2323	Natalizumab injection	1 MG	\$	21.63	2020_J2323
2020	J2350	Injection, ocrelizumab, 1 mg	1 MG	\$	57.38	2020_J2350
2020	J2353	Octreotide injection, depot	1 MG	\$	205.88	2020_J2353
2020	J2354	Octreotide inj, non-depot	25 MCG	\$	0.95	2020_J2354
2020	J2357	Omalizumab injection	5 MG	\$	37.70	2020_J2357
2020	J2358	Olanzapine long-acting inj	1 MG	\$	2.92	2020_J2358
2020	J2360	Orphenadrine injection	60 MG	\$	5.29	2020_J2360
2020	J2400	Chloroprocaine hcl injection	30 ML	\$	21.60	2020_J2400
2020	J2405	Ondansetron hcl injection	1 MG	\$	0.09	2020_J2405
2020	J2407	Injection, oritavancin	10 MG	\$	23.80	2020_J2407
2020	J2425	Palifermin injection	50 MCG	\$	22.81	2020_J2425
2020	J2426	Paliperidone palmitate inj	1 MG	\$	12.10	2020_J2426
2020	J2430	Pamidronate disodium /30 mg	30 MG	\$	11.52	2020_J2430
2020	J2469	Palonosetron hcl	25 MCG	\$	3.78	2020_J2469
2020	J2501	Paricalcitol	1 MCG	\$	0.61	2020_J2501
2020	J2503	Pegaptanib sodium injection	0.3 MG	\$	722.99	2020_J2503
2020	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	3,571.68	2020_J2505
2020	J2507	Pegloticase injection	1 MG	\$	2,801.08	2020_J2507
2020	J2510	Penicillin g procaine inj	600000 UNITS	\$	30.53	2020_J2510
2020	J2515	Pentobarbital sodium inj	50 MG	\$	33.93	2020_J2515
2020	J2540	Penicillin g potassium inj	600000 UNITS	\$	1.10	2020_J2540
2020	J2543	Piperacillin/tazobactam	1.125 GM	\$	1.65	2020_J2543
2020	J2545	Pentamidine non-comp unit	300 MG	\$	119.59	2020_J2545
2020	J2550	Promethazine hcl injection	50 MG	\$	2.31	2020_J2550
2020	J2560	Phenobarbital sodium inj	120 MG	\$	47.33	2020_J2560
2020	J2562	Plerixafor injection	1 MG	\$	365.29	2020_J2562
2020	J2597	Inj desmopressin acetate	1 MCG	\$	10.45	2020_J2597
2020	J2675	Inj progesterone per 50 mg	50 MG	\$	1.43	2020_J2675
2020	J2680	Fluphenazine decanoate 25 mg	25 MG	\$	10.64	2020_J2680
2020	J2690	Procainamide hcl injection	1 GM	\$	71.73	2020_J2690
2020	J2700	Oxacillin sodium injecton	250 MG	\$	1.30	2020_J2700
2020	J2704	Inj, propofol, 10 mg	10 MG	\$	0.11	2020_J2704
2020	J2720	Inj protamine sulfate/10 mg	10 MG	\$	1.08	2020_J2720
2020	J2724	Protein c concentrate	10 UNITS	\$	15.06	2020_J2724
2020	J2760	Phentolaine mesylate inj	5 MG	\$	359.14	2020_J2760
2020	J2765	Metoclopramide hcl injection	10 MG	\$	1.04	2020_J2765
2020	J2770	Quinupristin/dalfopristin	500 MG	\$	458.04	2020_J2770
2020	J2778	Ranibizumab injection	0.1 mg	\$	324.27	2020_J2778
2020	J2780	Ranitidine hydrochloride inj	25 MG	\$	3.31	2020_J2780
2020	J2783	Rasburicase	0.5 MG	\$	300.94	2020_J2783
2020	J2785	Regadenoson injection	0.1 MG	\$	59.19	2020_J2785
2020	J2786	Injection, reslizumab, 1mg	1 MG	\$	9.76	2020_J2786
2020	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	24.35	2020_J2788
2020	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	74.30	2020_J2790

2020	J2791	Rhophylac injection	100 IU	\$	4.73	2020_J2791
2020	J2792	Rho(d) immune globulin h, sd	100 IU	\$	36.37	2020_J2792
2020	J2794	Inj risperdal consta, 0.5 mg	0.5 MG	\$	10.53	2020_J2794
2020	J2795	Ropivacaine hcl injection	1 MG	\$	0.07	2020_J2795
2020	J2796	Romiplostim injection	10 MCG	\$	78.43	2020_J2796
2020	J2798	Inj., perseris, 0.5 mg	0.5 mg	\$	10.18	2020_J2798
2020	J2800	Methocarbamol injection	10 ML	\$	10.09	2020_J2800
2020	J2805	Sinacalide injection	5 MCG	\$	115.67	2020_J2805
2020	J2820	Sargramostim injection	50 MCG	\$	47.06	2020_J2820
2020	J2860	Injection, siltuximab	10 MG	\$	111.94	2020_J2860
2020	J2916	Na ferric gluconate complex	12.5 MG	\$	2.09	2020_J2916
2020	J2920	Methylprednisolone injection	40 MG	\$	4.17	2020_J2920
2020	J2930	Methylprednisolone injection	125 MG	\$	5.64	2020_J2930
2020	J2997	Alteplase recombinant	1 MG	\$	87.15	2020_J2997
2020	J3000	Streptomycin injection	1 GM	\$	33.32	2020_J3000
2020	J3010	Fentanyl citrate injection	0.1 MG	\$	0.78	2020_J3010
2020	J3060	Inj. taliglucerase alfa 10 u	10 UNITS	\$	40.86	2020_J3060
2020	J3090	Inj tedizolid phosphate	1 MG	\$	1.59	2020_J3090
2020	J3095	Telavancin injection	10 MG	\$	5.14	2020_J3095
2020	J3101	Tenecteplase injection	1 MG	\$	129.26	2020_J3101
2020	J3105	Terbutaline sulfate inj	1 MG	\$	3.01	2020_J3105
2020	J3111	Inj. romosozumab-aqqg 1 mg	1 MG	\$	9.01	2020_J3111
2020	J3121	Inj testostero enanthate 1mg	1 MG	\$	0.05	2020_J3121
2020	J3145	Testosterone undecanoate 1mg	1 MG	\$	1.54	2020_J3145
2020	J3230	Chlorpromazine hcl injection	50 MG	\$	34.62	2020_J3230
2020	J3240	Thyrotropin injection	0.9 MG	\$	1,740.23	2020_J3240
2020	J3241	Inj. teprotumumab-trbw 10 mg	10 MG	\$	315.88	2020_J3241
2020	J3243	Tigecycline injection	1 MG	\$	1.38	2020_J3243
2020	J3245	Inj., tildrakizumab, 1 mg	1 MG	\$	135.67	2020_J3245
2020	J3250	Trimethobenzamide hcl inj	200 MG	\$	36.81	2020_J3250
2020	J3260	Tobramycin sulfate injection	80 MG	\$	3.49	2020_J3260
2020	J3262	Tocilizumab injection	1 MG	\$	5.40	2020_J3262
2020	J3285	Treprostinil injection	1 MG	\$	62.81	2020_J3285
2020	J3300	Triamcinolone a inj prs-free	1 MG	\$	3.85	2020_J3300
2020	J3301	Triamcinolone acet inj nos	10 MG	\$	1.33	2020_J3301
2020	J3304	Inj triamcinolone ace xr 1mg	1 MG	\$	18.20	2020_J3304
2020	J3315	Triptorelin pamoate	3.75 MG	\$	385.61	2020_J3315
2020	J3357	Ustekinumab sub cu inj, 1 mg	1 MG	\$	184.36	2020_J3357
2020	J3358	Ustekinumab, iv inject, 1 mg	1 MG	\$	12.03	2020_J3358
2020	J3360	Diazepam injection	5 MG	\$	6.05	2020_J3360
2020	J3370	Vancomycin hcl injection	500 MG	\$	2.77	2020_J3370
2020	J3380	Injection, vedolizumab	1 MG	\$	20.30	2020_J3380
2020	J3385	Velaglucerase alfa	100 UNITS	\$	346.15	2020_J3385
2020	J3396	Verteporfin injection	0.1 MG	\$	11.23	2020_J3396
2020	J3410	Hydroxyzine hcl injection	25 MG	\$	7.83	2020_J3410
2020	J3411	Thiamine hcl 100 mg	100 MG	\$	2.53	2020_J3411
2020	J3415	Pyridoxine hcl 100 mg	100 MG	\$	7.82	2020_J3415
2020	J3420	Vitamin b12 injection	1000 MCG	\$	1.84	2020_J3420
2020	J3430	Vitamin k phytonadione inj	1 MG	\$	3.81	2020_J3430
2020	J3465	Injection, voriconazole	10 MG	\$	1.18	2020_J3465
2020	J3471	Ovine, up to 999 usp units	1 UNIT	\$	0.46	2020_J3471
2020	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.36	2020_J3473
2020	J3475	Inj magnesium sulfate	500 MG	\$	0.42	2020_J3475
2020	J3480	Inj potassium chloride	2 MEQ	\$	0.15	2020_J3480
2020	J3485	Zidovudine	10 MG	\$	1.51	2020_J3485
2020	J3486	Ziprasidone mesylate	10 MG	\$	23.87	2020_J3486
2020	J3489	Zoledronic acid 1mg	1 MG	\$	9.71	2020_J3489
2020	J7030	Normal saline solution infus	1000 ML	\$	2.54	2020_J7030
2020	J7040	Normal saline solution infus	500 ML	\$	1.27	2020_J7040

2020	J7042	5% dextrose/normal saline	500 ML	\$	1.08	2020_J7042
2020	J7050	Normal saline solution infus	250 ML	\$	0.63	2020_J7050
2020	J7060	5% dextrose/water	500 ML	\$	2.04	2020_J7060
2020	J7070	D5w infusion	1000 CC	\$	4.02	2020_J7070
2020	J7120	Ringers lactate infusion	1000 CC	\$	2.34	2020_J7120
2020	J7170	Inj., emicizumab-kxwh 0.5 mg	0.5 MG	\$	47.47	2020_J7170
2020	J7175	Inj., factor x, (human), 1iu	1 IU	\$	7.88	2020_J7175
2020	J7177	Inj., fibryga, 1 mg	1 MG	\$	1.07	2020_J7177
2020	J7178	Inj human fibrinogen con nos	1 IU	\$	1.24	2020_J7178
2020	J7179	Vonvendi inj 1 iu vwf:co	1 IU	\$	1.78	2020_J7179
2020	J7180	Factor xiii anti-hem factor	1 IU	\$	8.77	2020_J7180
2020	J7181	Factor xiii recomb a-subunit	1 IU	\$	15.53	2020_J7181
2020	J7182	Factor viii recomb novoeight	1 IU	\$	1.27	2020_J7182
2020	J7183	Wilate injection	1 I.U. VWF:RCO	\$	1.02	2020_J7183
2020	J7185	Xyntha inj	1 IU	\$	1.31	2020_J7185
2020	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	1.14	2020_J7186
2020	J7187	Humate-p, inj	1 IU	\$	1.21	2020_J7187
2020	J7188	Factor viii recomb obizur	1 IU	\$	3.19	2020_J7188
2020	J7189	Factor viia	1 MCG	\$	2.25	2020_J7189
2020	J7190	Factor viii	1 IU	\$	1.02	2020_J7190
2020	J7192	Factor viii recombinant nos	1 IU	\$	1.38	2020_J7192
2020	J7193	Factor ix non-recombinant	1 IU	\$	1.16	2020_J7193
2020	J7194	Factor ix complex	1 IU	\$	1.49	2020_J7194
2020	J7195	Factor ix recombinant nos	1 IU	\$	1.53	2020_J7195
2020	J7197	Antithrombin iii injection	1 IU	\$	3.50	2020_J7197
2020	J7198	Anti-inhibitor	1 IU	\$	2.05	2020_J7198
2020	J7200	Factor ix recombinan rixubis	1 IU	\$	1.46	2020_J7200
2020	J7201	Factor ix alprolix recomb	1 IU	\$	3.25	2020_J7201
2020	J7202	Factor ix idelvion inj	1 IU	\$	4.44	2020_J7202
2020	J7203	Factor ix recomb gly rebinyon	1 MG	\$	4.01	2020_J7203
2020	J7204	Inj recombin esperoct per iu	1 i.u.	\$	2.29	2020_J7204
2020	J7205	Factor viii fc fusion recomb	1 IU	\$	2.17	2020_J7205
2020	J7207	Factor viii pegylated recomb	1 IU	\$	1.87	2020_J7207
2020	J7208	Inj. jivi 1 iu	1 IU	\$	2.02	2020_J7208
2020	J7209	Factor viii nuwiq recomb 1iu	1 IU	\$	1.36	2020_J7209
2020	J7210	Inj. afstyla, 1 i.u.	1 IU	\$	1.34	2020_J7210
2020	J7211	Inj. kovaltry, 1 i.u.	1 IU	\$	1.22	2020_J7211
2020	J7308	Aminolevulinic acid hcl top	354 MG	\$	394.75	2020_J7308
2020	J7311	Inj., retisert, 0.01 mg	0.01 MG	\$	340.62	2020_J7311
2020	J7312	Dexamethasone intra implant	0.1 MG	\$	199.76	2020_J7312
2020	J7313	Inj., iluvien, 0.01 mg	0.01 MG	\$	490.87	2020_J7313
2020	J7314	Inj., yutiq, 0.01 mg	0.01 MG	\$	491.13	2020_J7314
2020	J7316	Inj, ocriplasmin, 0.125 mg	0.125 MG	\$	1,046.93	2020_J7316
2020	J7321	Hyalgan or supartz inj dose	per dose	\$	79.81	2020_J7321
2020	J7323	Euflexxa inj per dose	per dose	\$	140.31	2020_J7323
2020	J7324	Orthovisc inj per dose	PER DOSE	\$	128.41	2020_J7324
2020	J7325	Synvisc or synvisc-one	1 MG	\$	10.22	2020_J7325
2020	J7327	Monovisc inj per dose	PER DOSE	\$	694.58	2020_J7327
2020	J7331	Synjojoynt, inj., 1 mg	1 MG	\$	4.39	2020_J7331
2020	J7336	Capsaicin 8% patch	1 SQ CM	\$	3.25	2020_J7336
2020	J7340	Carbidopa levodopa ent 100ml	100 ML	\$	213.10	2020_J7340
2020	J7342	Ciprofloxacin otic susp 6 mg	6 MG	\$	29.97	2020_J7342
2020	J7345	Aminolevulinic acid, 10% gel	10 MG	\$	1.53	2020_J7345
2020	J7500	Azathioprine oral 50mg	50 MG	\$	1.16	2020_J7500
2020	J7502	Cyclosporine oral 100 mg	100 MG	\$	1.79	2020_J7502
2020	J7503	Tacrol envarsus ex rel oral	0.25 MG	\$	1.38	2020_J7503
2020	J7504	Lymphocyte immune globulin	250 MG	\$	2,257.67	2020_J7504
2020	J7507	Tacrolimus imme rel oral 1mg	1 MG	\$	0.75	2020_J7507
2020	J7508	Tacrol astagraf ex rel oral	0.1 MG	\$	0.48	2020_J7508

2020	J7509	Methylprednisolone oral	4 MG	\$	0.25	2020_J7509
2020	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.12	2020_J7510
2020	J7511	Antithymocyte globulin rabbit	25 MG	\$	817.12	2020_J7511
2020	J7512	Prednisone ir or dr oral 1mg	1 MG	\$	0.01	2020_J7512
2020	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.64	2020_J7515
2020	J7516	Cyclosporin parenteral 250mg	250 MG	\$	61.75	2020_J7516
2020	J7517	Mycophenolate mofetil oral	250 MG	\$	0.41	2020_J7517
2020	J7518	Mycophenolic acid	180 MG	\$	1.90	2020_J7518
2020	J7520	Sirolimus, oral	1 MG	\$	6.38	2020_J7520
2020	J7525	Tacrolimus injection	5 MG	\$	211.97	2020_J7525
2020	J7527	Oral everolimus	0.25 MG	\$	8.03	2020_J7527
2020	J7605	Arformoterol non-comp unit	15 mcg	\$	11.17	2020_J7605
2020	J7606	Formoterol fumarate, inh	20 MCG	\$	11.65	2020_J7606
2020	J7608	Acetylcysteine non-comp unit	1 GM	\$	5.92	2020_J7608
2020	J7611	Albuterol non-comp con	1 MG	\$	0.34	2020_J7611
2020	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.38	2020_J7612
2020	J7613	Albuterol non-comp unit	1 MG	\$	0.04	2020_J7613
2020	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.06	2020_J7614
2020	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.12	2020_J7620
2020	J7626	Budesonide non-comp unit	0.5 MG	\$	1.59	2020_J7626
2020	J7631	Cromolyn sodium noncomp unit	10 MG	\$	2.71	2020_J7631
2020	J7639	Dornase alfa non-comp unit	1 MG	\$	47.79	2020_J7639
2020	J7644	Ipratropium bromide non-comp	1 MG	\$	0.20	2020_J7644
2020	J7674	Methacholine chloride, neb	1 MG	\$	0.76	2020_J7674
2020	J7677	Revefenacin inh non-com 1mcg	1 MCG	\$	0.20	2020_J7677
2020	J7682	Tobramycin non-comp unit	300 MG	\$	32.46	2020_J7682
2020	J7686	Treprostinil, non-comp unit	1.74 MG	\$	642.99	2020_J7686
2020	J8501	Oral aprepitant	5 MG	\$	4.86	2020_J8501
2020	J8520	Capecitabine, oral, 150 mg	150 MG	\$	0.67	2020_J8520
2020	J8521	Capecitabine, oral, 500 mg	500 MG	\$	2.41	2020_J8521
2020	J8530	Cyclophosphamide oral 25 mg	25 MG	\$	2.02	2020_J8530
2020	J8540	Oral dexamethasone	0.25 MG	\$	0.10	2020_J8540
2020	J8560	Etoposide oral 50 mg	50 MG	\$	75.49	2020_J8560
2020	J8610	Methotrexate oral 2.5 mg	2.5 MG	\$	0.15	2020_J8610
2020	J8655	Oral netupitant, palonosetro	0.5 MG	\$	270.10	2020_J8655
2020	J8670	Rolapitant, oral, 1mg	1 MG	\$	2.27	2020_J8670
2020	J8700	Temozolomide	5 MG	\$	0.62	2020_J8700
2020	J8705	Topotecan oral	0.25 mg	\$	103.83	2020_J8705
2020	J9000	Doxorubicin hcl injection	10 MG	\$	2.70	2020_J9000
2020	J9017	Arsenic trioxide injection	1 MG	\$	22.06	2020_J9017
2020	J9019	Erwinaze injection	1,000 IU	\$	427.27	2020_J9019
2020	J9022	Inj, atezolizumab,10 mg	10 MG	\$	78.28	2020_J9022
2020	J9023	Injection, avelumab, 10 mg	10 MG	\$	84.70	2020_J9023
2020	J9025	Azacitidine injection	1 MG	\$	0.80	2020_J9025
2020	J9027	Clofarabine injection	1 MG	\$	52.64	2020_J9027
2020	J9030	Bcg live intravesical 1mg	1 MG	\$	2.79	2020_J9030
2020	J9032	Injection, belinostat, 10mg	10 MG	\$	42.79	2020_J9032
2020	J9033	Inj., treanda 1 mg	1 MG	\$	24.69	2020_J9033
2020	J9034	Inj., bendeka 1 mg	1 MG	\$	20.27	2020_J9034
2020	J9035	Bevacizumab injection	10 MG	\$	76.36	2020_J9035
2020	J9036	Inj. belrapzo/bendamustine	1 MG	\$	21.61	2020_J9036
2020	J9039	Injection, blinatumomab	1 MCG	\$	118.59	2020_J9039
2020	J9040	Bleomycin sulfate injection	15 UNITS	\$	26.92	2020_J9040
2020	J9041	Inj., velcade 0.1 mg	0.1 MG	\$	44.97	2020_J9041
2020	J9042	Brentuximab vedotin inj	1 MG	\$	175.28	2020_J9042
2020	J9043	Cabazitaxel injection	1 MG	\$	181.51	2020_J9043
2020	J9044	Inj, bortezomib, nos, 0.1 mg	0.1 MG	\$	22.04	2020_J9044
2020	J9045	Carboplatin injection	50 MG	\$	2.76	2020_J9045
2020	J9047	Injection, carfilzomib, 1 mg	1 MG	\$	39.20	2020_J9047

2020	J9050	Carmustine injection	100 MG	\$	2,016.27	2020_J9050
2020	J9055	Cetuximab injection	10 MG	\$	64.41	2020_J9055
2020	J9060	Cisplatin 10 mg injection	10 MG	\$	1.71	2020_J9060
2020	J9065	Inj cladribine per 1 mg	1 MG	\$	19.57	2020_J9065
2020	J9070	Cyclophosphamide 100 mg inj	100 MG	\$	29.67	2020_J9070
2020	J9100	Cytarabine hcl 100 mg inj	100 MG	\$	0.68	2020_J9100
2020	J9119	Inj, cemiplimab-rwlc, 1 mg	1 MG	\$	27.40	2020_J9119
2020	J9120	Dactinomycin injection	0.5 MG	\$	1,044.53	2020_J9120
2020	J9130	Dacarbazine 100 mg inj	100 MG	\$	4.46	2020_J9130
2020	J9145	Injection, daratumumab 10 mg	10 MG	\$	56.29	2020_J9145
2020	J9150	Daunorubicin injection	10 MG	\$	43.84	2020_J9150
2020	J9153	Inj daunorubicin, cytarabine	1 MG/2.27 MG	\$	197.79	2020_J9153
2020	J9155	Degarelix injection	1 MG	\$	3.84	2020_J9155
2020	J9171	Docetaxel injection	1 MG	\$	0.85	2020_J9171
2020	J9173	Inj, durvalumab, 10 mg	10 MG	\$	76.02	2020_J9173
2020	J9176	Injection, elotuzumab, 1mg	1 MG	\$	6.67	2020_J9176
2020	J9177	Inj enfort vedo-ejfv 0.25mg	0.25 MG	\$	27.96	2020_J9177
2020	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.53	2020_J9178
2020	J9179	Eribulin mesylate injection	0.1 MG	\$	117.66	2020_J9179
2020	J9181	Etoposide injection	10 MG	\$	0.77	2020_J9181
2020	J9185	Fludarabine phosphate inj	50 MG	\$	66.01	2020_J9185
2020	J9190	Fluorouracil injection	500 MG	\$	1.53	2020_J9190
2020	J9200	Floxuridine injection	500 MG	\$	46.44	2020_J9200
2020	J9201	In gemcitabine hcl nos 200mg	200 MG	\$	3.96	2020_J9201
2020	J9202	Goserelin acetate implant	3.6 MG	\$	503.59	2020_J9202
2020	J9203	Gemtuzumab ozogamicin 0.1 mg	0.1 MG	\$	205.38	2020_J9203
2020	J9204	Inj mogamulizumab-kpkc, 1 mg	1 MG	\$	203.88	2020_J9204
2020	J9205	Inj irinotecan liposome 1 mg	1 MG	\$	54.33	2020_J9205
2020	J9206	Irinotecan injection	20 MG	\$	2.54	2020_J9206
2020	J9207	Ixabepilone injection	1 MG	\$	101.19	2020_J9207
2020	J9208	Ifosfamide injection	1 GM	\$	26.31	2020_J9208
2020	J9209	Mesna injection	200 MG	\$	2.13	2020_J9209
2020	J9210	Inj, emapalumab-lzsg, 1 mg	1 MG	\$	441.59	2020_J9210
2020	J9211	Idarubicin hcl injection	5 MG	\$	37.66	2020_J9211
2020	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	34.35	2020_J9214
2020	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	224.45	2020_J9217
2020	J9218	Leuprolide acetate injecton	1 MG	\$	23.09	2020_J9218
2020	J9225	Vantas implant	50 MG	\$	4,558.13	2020_J9225
2020	J9226	Supprelin la implant	50 MG	\$	40,237.00	2020_J9226
2020	J9227	Inj. isatuximab-irfc 10 mg	10 MG	\$	66.67	2020_J9227
2020	J9228	Ipilimumab injection	1 MG	\$	157.38	2020_J9228
2020	J9229	Inj inotuzumab ozogam 0.1 mg	0.1 MG	\$	2,341.50	2020_J9229
2020	J9245	Inj melpha hydroch nos 50 mg	50 MG	\$	260.38	2020_J9245
2020	J9250	Methotrexate sodium inj	5 MG	\$	0.23	2020_J9250
2020	J9260	Methotrexate sodium inj	50 MG	\$	2.33	2020_J9260
2020	J9261	Nelarabine injection	50 MG	\$	152.15	2020_J9261
2020	J9262	Inj, omacetaxine mep, 0.01mg	0.01 MG	\$	2.98	2020_J9262
2020	J9263	Oxaliplatin	0.5 MG	\$	0.12	2020_J9263
2020	J9264	Paclitaxel protein bound	1 MG	\$	13.30	2020_J9264
2020	J9266	Pegaspargase injection	1 EA	\$	19,717.76	2020_J9266
2020	J9267	Paclitaxel injection	1 MG	\$	0.16	2020_J9267
2020	J9268	Pentostatin injection	10 MG	\$	2,060.28	2020_J9268
2020	J9269	Inj. tagraxofusp-erzs 10 mcg	10 MCG	\$	270.59	2020_J9269
2020	J9271	Inj pembrolizumab	1 MG	\$	50.85	2020_J9271
2020	J9280	Mitomycin injection	5 MG	\$	49.88	2020_J9280
2020	J9285	Inj. olaratumab, 10 mg	10 MG	\$	52.07	2020_J9285
2020	J9293	Mitoxantrone hydrochl / 5 mg	5 MG	\$	28.69	2020_J9293
2020	J9295	Injection, necitumumab, 1 mg	1 MG	\$	5.73	2020_J9295
2020	J9299	Injection, nivolumab	1 MG	\$	28.56	2020_J9299

2020	J9301	Obinutuzumab inj	10 MG	\$	63.74	2020_J9301
2020	J9302	Ofatumumab injection	10 MG	\$	61.94	2020_J9302
2020	J9303	Panitumumab injection	10 MG	\$	123.55	2020_J9303
2020	J9305	Inj. pemetrexed nos 10mg	10 MG	\$	71.95	2020_J9305
2020	J9306	Injection, pertuzumab, 1 mg	1 MG	\$	12.95	2020_J9306
2020	J9307	Pralatrexate injection	1 MG	\$	311.22	2020_J9307
2020	J9308	Injection, ramucirumab	5 MG	\$	60.71	2020_J9308
2020	J9309	Inj, polatuzumab vedotin 1mg	1 MG	\$	110.72	2020_J9309
2020	J9311	Inj rituximab, hyaluronidase	10 mg	\$	41.14	2020_J9311
2020	J9312	Inj., rituximab, 10 mg	10 MG	\$	92.56	2020_J9312
2020	J9313	Inj., lumoxiti, 0.01 mg	0.01 MG	\$	22.46	2020_J9313
2020	J9315	Romidepsin injection	1 MG	\$	336.54	2020_J9315
2020	J9320	Streptozocin injection	1 GM	\$	349.54	2020_J9320
2020	J9325	Inj talimogene laherparepvec	1 million PFU	\$	53.92	2020_J9325
2020	J9328	Temozolomide injection	1 MG	\$	10.38	2020_J9328
2020	J9330	Temsirolimus injection	1 MG	\$	44.99	2020_J9330
2020	J9340	Thiotepa injection	15 MG	\$	475.39	2020_J9340
2020	J9351	Topotecan injection	0.1 MG	\$	1.28	2020_J9351
2020	J9352	Injection trabectedin 0.1mg	0.1 MG	\$	318.93	2020_J9352
2020	J9354	Inj, ado-trastuzumab emt 1mg	1 MG	\$	32.79	2020_J9354
2020	J9355	Inj trastuzumab excl biosimi	10 MG	\$	99.68	2020_J9355
2020	J9356	Inj. herceptin hylecta, 10mg	10 MG	\$	75.08	2020_J9356
2020	J9357	Valrubicin injection	200 MG	\$	1,403.17	2020_J9357
2020	J9358	Inj fam-trastu deru-nxki 1mg	1 MG	\$	24.14	2020_J9358
2020	J9360	Vinblastine sulfate inj	1 MG	\$	3.98	2020_J9360
2020	J9370	Vincristine sulfate 1 mg inj	1 MG	\$	5.34	2020_J9370
2020	J9371	Inj, vincristine sul lip 1mg	1 MG	\$	3,320.17	2020_J9371
2020	J9390	Vinorelbine tartrate inj	10 MG	\$	9.46	2020_J9390
2020	J9395	Injection, fulvestrant	25 MG	\$	52.88	2020_J9395
2020	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.07	2020_J9400
2020	P9041	Albumin (human),5%, 50ml	50 ML	\$	10.49	2020_P9041
2020	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	52.45	2020_P9045
2020	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	20.98	2020_P9046
2020	P9047	Albumin (human), 25%, 50ml	50 ML	\$	52.45	2020_P9047
2020	Q0138	Ferumoxytol, non-esrd	1 MG	\$	0.98	2020_Q0138
2020	Q0139	Ferumoxytol, esrd use	1 MG	\$	0.98	2020_Q0139
2020	Q0162	Ondansetron oral	1 MG	\$	0.01	2020_Q0162
2020	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.26	2020_Q0164
2020	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	1.33	2020_Q0166
2020	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	0.68	2020_Q0167
2020	Q2043	Sipuleucel-t auto cd54+	Per infusion (minimum 50 million cells)	\$	49,671.77	2020_Q2043
2020	Q2050	Doxorubicin inj 10mg	10 MG	\$	315.73	2020_Q2050
2020	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	54.32	2020_Q3027
2020	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	140.40	2020_Q4074
2020	Q4081	Epoetin alfa, 100 units esrd	100 UNITS	\$	0.91	2020_Q4081
2020	Q4101	Apligraf	1 SQ CM	\$	30.46	2020_Q4101
2020	Q4102	Oasis wound matrix	1 SQ CM	\$	10.21	2020_Q4102
2020	Q4106	Dermagraft	1 SQ CM	\$	32.01	2020_Q4106
2020	Q4110	Primatrix	1 SQ CM	\$	46.41	2020_Q4110
2020	Q4111	Gammagraft	1 SQ CM	\$	6.94	2020_Q4111
2020	Q4121	Theraskin	1 SQ CM	\$	39.15	2020_Q4121
2020	Q4132	Grafix core, grafixpl core	1 SQ CM	\$	114.63	2020_Q4132
2020	Q4133	Grafix stravix prime pl sqcm	1 SQ CM	\$	131.42	2020_Q4133
2020	Q4137	Amnioexcel biodexcel 1sq cm	1 SQ CM	\$	85.36	2020_Q4137
2020	Q4145	Epifix, inj, 1mg	1 MG	\$	18.33	2020_Q4145
2020	Q4151	Amnioband, guardian 1 sq cm	1 SQ CM	\$	124.35	2020_Q4151
2020	Q4154	Biovance 1 square cm	1 SQ CM	\$	116.58	2020_Q4154
2020	Q4160	Nushield 1 square cm	1 SQ CM	\$	100.11	2020_Q4160
2020	Q4186	Epifix 1 sq cm	1 SQ CM	\$	155.99	2020_Q4186

2020	Q4195	Puraply 1 sq cm	1 SQ CM	\$	105.94	2020_Q4195
2020	Q4196	Puraply am 1 sq cm	1 SQ CM	\$	111.59	2020_Q4196
2020	Q5101	Injection, zarxio	1 MCG	\$	0.47	2020_Q5101
2020	Q5103	Injection, inflectra	10 MG	\$	43.72	2020_Q5103
2020	Q5104	Injection, renflexis	10 MG	\$	44.55	2020_Q5104
2020	Q5105	Inj retacrit esrd on dialysi	100 UNITS	\$	0.86	2020_Q5105
2020	Q5106	Inj retacrit non-esrd use	1000 UNITS	\$	8.61	2020_Q5106
2020	Q5107	Inj mvasi 10 mg	10 MG	\$	60.94	2020_Q5107
2020	Q5108	Injection, fulphila	0.5 MG	\$	269.04	2020_Q5108
2020	Q5110	Nivestym	1 MCG	\$	0.62	2020_Q5110
2020	Q5111	Injection, udenyca 0.5 mg	0.5 MG	\$	286.67	2020_Q5111
2020	Q5112	Inj ontruzant 10 mg	10 MG	\$	92.30	2020_Q5112
2020	Q5113	Inj herzuma 10 mg	10 MG	\$	91.52	2020_Q5113
2020	Q5114	Inj ogivri 10 mg	10 MG	\$	76.41	2020_Q5114
2020	Q5115	Inj truxima 10 mg	10 MG	\$	68.80	2020_Q5115
2020	Q5116	Inj., trazimera, 10 mg	10 MG	\$	83.10	2020_Q5116
2020	Q5117	Inj., kanjinti, 10 mg	10 MG	\$	78.72	2020_Q5117
2020	Q5118	Inj., zirabev, 10 mg	10 MG	\$	62.24	2020_Q5118
2020	Q5119	Inj ruxience, 10 mg	10 MG	\$	70.90	2020_Q5119
2020	Q5120	Inj pegfilgrastim-bmez 0.5mg	0.5 MG	\$	305.55	2020_Q5120
2020	Q5121	Inj. avsola, 10 mg	10 MG	\$	51.50	2020_Q5121
2020	Q9950	Inj sulf hexa lipid microsph	1 ML	\$	18.33	2020_Q9950
2020	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	31.75	2020_Q9956
2020	Q9957	Inj perflutren lip micros,ml	1 ML	\$	47.63	2020_Q9957
2020	Q9958	Hocm <= 149 mg/ml iodine, 1ml	1 ML	\$	0.07	2020_Q9958
2020	Q9960	Hocm 200-249mg/ml iodine,1ml	1 ML	\$	0.20	2020_Q9960
2020	Q9961	Hocm 250-299mg/ml iodine,1ml	1 ML	\$	0.25	2020_Q9961
2020	Q9963	Hocm 350-399mg/ml iodine,1ml	1 ML	\$	0.18	2020_Q9963
2020	Q9965	Locm 100-199mg/ml iodine,1ml	1 ML	\$	0.72	2020_Q9965
2020	Q9966	Locm 200-299mg/ml iodine,1ml	1 ML	\$	0.34	2020_Q9966
2020	Q9967	Locm 300-399mg/ml iodine,1ml	1 ML	\$	0.10	2020_Q9967
2020	Q9991	Buprenorph xr 100 mg or less	Less than or equal to 100 MG	\$	1,743.48	2020_Q9991
2020	Q9992	Buprenorphine xr over 100 mg	Greater than 100 MG	\$	1,743.48	2020_Q9992
2019	90371	Hep b ig im	1 ML	\$	110.67	2019_90371
2019	90375	Rabies ig im/sc	150 IU	\$	280.64	2019_90375
2019	90376	Rabies ig heat treated	150 IU	\$	271.37	2019_90376
2019	90585	Bcg vaccine percut	50 MG	\$	141.06	2019_90585
2019	90586	Bcg vaccine intravesical	1 EACH	\$	141.06	2019_90586
2019	90632	Hepa vaccine adult im	1 ML	\$	58.91	2019_90632
2019	90653	liv adjuvant vaccine im	0.5 ml	\$	59.53	2019_90653
2019	90662	liv no prsv increased ag im	0.5 ML	\$	56.01	2019_90662
2019	90670	Pcv13 vaccine im	0.5 ML	\$	215.33	2019_90670
2019	90672	Laiiv4 vaccine intranasal	0.2 ML	\$	26.88	2019_90672
2019	90674	Cciiv4 vac no prsv 0.5 ml im	0.5 ML	\$	28.13	2019_90674
2019	90675	Rabies vaccine im	1 ML	\$	297.59	2019_90675
2019	90682	Riv4 vacc recombinant dna im	0.5 ML	\$	56.01	2019_90682
2019	90685	liv4 vacc no prsv 0.25 ml im	0.25 mL	\$	20.34	2019_90685
2019	90686	liv4 vacc no prsv 0.5 ml im	0.5 ml	\$	19.03	2019_90686
2019	90687	liv4 vaccine splt 0.25 ml im	0.25 ML	\$	9.40	2019_90687
2019	90688	liv4 vaccine splt 0.5 ml im	0.5 ML	\$	17.84	2019_90688
2019	90691	Typhoid vaccine im	0.5 ML	\$	90.58	2019_90691
2019	90714	Td vacc no presv 7 yrs+ im	0.5 ML	\$	24.26	2019_90714
2019	90715	Tdap vaccine 7 yrs/> im	0.5 ML	\$	32.86	2019_90715
2019	90732	Ppsv23 vacc 2 yrs+ subq/im	0.5 ML	\$	114.21	2019_90732
2019	90739	Hepb vacc 2 dose adult im	1 dose	\$	131.10	2019_90739
2019	90740	Hepb vacc 3 dose immunsup im	40 MCG	\$	134.12	2019_90740
2019	90744	Hepb vacc 3 dose ped/adol im	1 DOSE	\$	26.90	2019_90744
2019	90746	Hepb vaccine 3 dose adult im	20 MCG	\$	67.06	2019_90746
2019	90747	Hepb vacc 4 dose immunsup im	40 MCG	\$	134.12	2019_90747

2019	90756	Cciiv4 vacc abx free im	0.5 ML	\$	26.66	2019_90756
2019	A9575	Inj gadoterate meglumi 0.1ml	0.1 ML	\$	0.19	2019_A9575
2019	A9576	Inj prohance multipack	1 ML	\$	1.42	2019_A9576
2019	A9577	Inj multihance	1 ML	\$	1.94	2019_A9577
2019	A9578	Inj multihance multipack	1 ML	\$	1.94	2019_A9578
2019	A9579	Gad-base mr contrast nos,1ml	1 ML	\$	1.59	2019_A9579
2019	A9581	Gadoxetate disodium inj	1 ML	\$	14.78	2019_A9581
2019	A9585	Gadobutrol injection	0.1 ML	\$	0.35	2019_A9585
2019	A9589	Insti hexaminolevulinate hcl	100 MG	\$	1,139.50	2019_A9589
2019	A9606	Radium ra223 dichloride ther	1 microCurie	N/A		2019_A9606
2019	J0129	Abatacept injection	10 MG	\$	54.32	2019_J0129
2019	J0130	Abciximab injection	10 MG	\$	1,429.07	2019_J0130
2019	J0132	Acetylcysteine injection	100 MG	\$	1.04	2019_J0132
2019	J0133	Acyclovir injection	5 MG	\$	0.04	2019_J0133
2019	J0153	Adenosine inj 1mg	1 MG	\$	0.70	2019_J0153
2019	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.83	2019_J0171
2019	J0178	Aflibercept injection	1 MG	\$	952.47	2019_J0178
2019	J0180	Agalsidase beta injection	1 MG	\$	183.43	2019_J0180
2019	J0185	Inj., aprepitant, 1 mg	1 MG	\$	2.21	2019_J0185
2019	J0202	Injection, alemtuzumab	1 MG	\$	1,917.04	2019_J0202
2019	J0207	Amifostine	500 MG	\$	1,003.59	2019_J0207
2019	J0221	Lumizyme injection	10 MG	\$	171.05	2019_J0221
2019	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.55	2019_J0256
2019	J0257	Glassia injection	10 MG	\$	4.82	2019_J0257
2019	J0278	Amikacin sulfate injection	100 MG	\$	1.11	2019_J0278
2019	J0280	Aminophyllin 250 mg inj	250 MG	\$	10.88	2019_J0280
2019	J0285	Amphotericin b	50 MG	\$	40.28	2019_J0285
2019	J0287	Amphotericin b lipid complex	10 MG	\$	6.18	2019_J0287
2019	J0289	Amphotericin b liposome inj	10 MG	\$	26.09	2019_J0289
2019	J0290	Ampicillin 500 mg inj	500 MG	\$	1.00	2019_J0290
2019	J0295	Ampicillin sulbactam 1.5 gm	1.5 GM	\$	2.06	2019_J0295
2019	J0348	Anidulafungin injection	1 MG	\$	0.55	2019_J0348
2019	J0360	Hydralazine hcl injection	20 MG	\$	4.21	2019_J0360
2019	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	5.70	2019_J0401
2019	J0456	Azithromycin	500 MG	\$	3.05	2019_J0456
2019	J0461	Atropine sulfate injection	0.01 MG	\$	0.07	2019_J0461
2019	J0470	Dimecaprol injection	100 MG	\$	55.29	2019_J0470
2019	J0475	Baclofen 10 mg injection	10 MG	\$	169.51	2019_J0475
2019	J0476	Baclofen intrathecal trial	50 MCG	\$	50.05	2019_J0476
2019	J0480	Basiliximab	20 MG	\$	3,799.93	2019_J0480
2019	J0485	Belatacept injection	1 MG	\$	3.78	2019_J0485
2019	J0490	Belimumab injection	10 MG	\$	44.82	2019_J0490
2019	J0500	Dicyclomine injection	20 MG	\$	57.58	2019_J0500
2019	J0515	Inj benztropine mesylate	1 MG	\$	17.74	2019_J0515
2019	J0517	Inj., benralizumab, 1 mg	1 MG	\$	168.50	2019_J0517
2019	J0558	Peng benzathine/procaine inj	100,000 UNITS	\$	10.89	2019_J0558
2019	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	13.82	2019_J0561
2019	J0565	Inj, bezlotoxumab, 10 mg	10 MG	\$	39.83	2019_J0565
2019	J0570	Buprenorphine implant 74.2mg	74.2 MG	\$	1,303.53	2019_J0570
2019	J0583	Bivalirudin	1 MG	\$	0.62	2019_J0583
2019	J0584	Injection, burosumab-twza 1m	1 MG	\$	353.21	2019_J0584
2019	J0585	Injection,onabotulinumtoxina	1 UNIT	\$	6.12	2019_J0585
2019	J0586	Abobotulinumtoxina	5 Unit	\$	8.43	2019_J0586
2019	J0587	Inj, rimabotulinumtoxinb	100 UNITS	\$	11.99	2019_J0587
2019	J0588	Incobotulinumtoxin a	1 UNIT	\$	5.05	2019_J0588
2019	J0592	Buprenorphine hydrochloride	0.1 MG	\$	4.56	2019_J0592
2019	J0594	Busulfan injection	1 MG	\$	4.58	2019_J0594
2019	J0595	Butorphanol tartrate 1 mg	1 MG	\$	2.71	2019_J0595
2019	J0596	Injection, ruconest	10 UNITS	\$	28.22	2019_J0596

2019	J0597	C-1 esterase, berinert	10 UNITS	\$	51.31	2019_J0597
2019	J0598	C-1 esterase, cinryze	10 UNITS	\$	57.03	2019_J0598
2019	J0600	Edetate calcium disodium inj	1000 MG	\$	5,594.42	2019_J0600
2019	J0610	Calcium gluconate injection	10 ML	\$	2.70	2019_J0610
2019	J0630	Calcitonin salmon injection	400 UNITS	\$	2,661.05	2019_J0630
2019	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.61	2019_J0636
2019	J0637	Caspofungin acetate	5 MG	\$	6.85	2019_J0637
2019	J0638	Canakinumab injection	1 MG	\$	111.01	2019_J0638
2019	J0640	Leucovorin calcium injection	50 MG	\$	3.02	2019_J0640
2019	J0641	Inj levoleucovorin nos 0.5mg	0.5 MG	\$	0.40	2019_J0641
2019	J0642	Injection, khapzory, 0.5 mg	0.5 MG	\$	2.04	2019_J0642
2019	J0670	Inj mepivacaine hcl/10 ml	10 ML	\$	2.45	2019_J0670
2019	J0690	Cefazolin sodium injection	500 MG	\$	0.77	2019_J0690
2019	J0692	Cefepime hcl for injection	500 MG	\$	1.91	2019_J0692
2019	J0694	Cefoxitin sodium injection	1 GM	\$	5.23	2019_J0694
2019	J0695	Inj ceftolozane tazobactam	75mg (50mg cft/25mg taz)	\$	5.60	2019_J0695
2019	J0696	Ceftriaxone sodium injection	250 MG	\$	0.54	2019_J0696
2019	J0697	Sterile cefuroxime injection	750 MG	\$	2.03	2019_J0697
2019	J0698	Cefotaxime sodium injection	1 GM	\$	2.33	2019_J0698
2019	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	6.96	2019_J0702
2019	J0712	Ceftaroline fosamil inj	10 MG	\$	3.19	2019_J0712
2019	J0713	Inj ceftazidime per 500 mg	500 MG	\$	2.00	2019_J0713
2019	J0714	Ceftazidime and avibactam	.625 GM	\$	92.05	2019_J0714
2019	J0717	Certolizumab pegol inj 1mg	1 MG	\$	8.02	2019_J0717
2019	J0720	Chloramphenicol sodium injec	1 GM	\$	38.54	2019_J0720
2019	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	22.62	2019_J0725
2019	J0735	Clonidine hydrochloride	1 MG	\$	13.71	2019_J0735
2019	J0740	Cidofovir injection	375 MG	\$	623.27	2019_J0740
2019	J0743	Cilastatin sodium injection	250 MG	\$	6.14	2019_J0743
2019	J0744	Ciprofloxacin iv	200 MG	\$	1.24	2019_J0744
2019	J0770	Colistimethate sodium inj	150 MG	\$	19.20	2019_J0770
2019	J0775	Collagenase, clost hist inj	0.01 MG	\$	48.76	2019_J0775
2019	J0780	Prochlorperazine injection	10 MG	\$	9.69	2019_J0780
2019	J0795	Corticotropin ovine triflural	1 MCG	\$	9.04	2019_J0795
2019	J0800	Corticotropin injection	40 UNITS	\$	3,946.50	2019_J0800
2019	J0834	Inj., cosyntropin, 0.25 mg	0.25 MG	\$	39.82	2019_J0834
2019	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	3,285.19	2019_J0840
2019	J0841	Inj crotalidae im f(ab')2 eq	120 MG	\$	1,264.42	2019_J0841
2019	J0850	Cytomegalovirus imm iv /vial	PER VIAL	\$	1,129.15	2019_J0850
2019	J0875	Injection, dalbavancin	5 MG	\$	14.95	2019_J0875
2019	J0878	Daptomycin injection	1 MG	\$	0.33	2019_J0878
2019	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.85	2019_J0881
2019	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.85	2019_J0882
2019	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	11.03	2019_J0885
2019	J0887	Epoetin beta esrd use	1 MCG	\$	1.80	2019_J0887
2019	J0888	Epoetin beta non esrd	1 MCG	\$	1.80	2019_J0888
2019	J0894	Decitabine injection	1 MG	\$	7.49	2019_J0894
2019	J0895	Deferoxamine mesylate inj	500 MG	\$	8.52	2019_J0895
2019	J0897	Denosumab injection	1 MG	\$	19.28	2019_J0897
2019	J1000	Depo-estradiol cypionate inj	5 MG	\$	21.89	2019_J1000
2019	J1020	Methylprednisolone 20 mg inj	20 MG	\$	3.70	2019_J1020
2019	J1030	Methylprednisolone 40 mg inj	40 MG	\$	6.25	2019_J1030
2019	J1040	Methylprednisolone 80 mg inj	80 MG	\$	11.93	2019_J1040
2019	J1050	Medroxyprogesterone acetate	1 MG	\$	0.56	2019_J1050
2019	J1071	Inj testosterone cypionate	1 MG	\$	0.02	2019_J1071
2019	J1100	Dexamethasone sodium phos	1 MG	\$	0.14	2019_J1100
2019	J1110	Inj dihydroergotamine mesylt	1 MG	\$	57.66	2019_J1110
2019	J1120	Acetazolamid sodium injectio	500 MG	\$	17.19	2019_J1120
2019	J1160	Digoxin injection	0.5 MG	\$	5.42	2019_J1160

2019	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	3,780.19	2019_J1162
2019	J1165	Phenytoin sodium injection	50 MG	\$	0.85	2019_J1165
2019	J1170	Hydromorphone injection	4 MG	\$	2.68	2019_J1170
2019	J1190	Dexrazoxane hcl injection	250 MG	\$	194.34	2019_J1190
2019	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.91	2019_J1200
2019	J1205	Chlorothiazide sodium inj	500 MG	\$	49.65	2019_J1205
2019	J1212	Dimethyl sulfoxide 50% 50 ml	50 ML	\$	586.51	2019_J1212
2019	J1230	Methadone injection	10 MG	\$	16.54	2019_J1230
2019	J1240	Dimenhydrinate injection	50 MG	\$	6.73	2019_J1240
2019	J1245	Dipyridamole injection	10 MG	\$	0.08	2019_J1245
2019	J1250	Inj dobutamine hcl/250 mg	250 MG	\$	6.99	2019_J1250
2019	J1265	Dopamine injection	40 MG	\$	0.76	2019_J1265
2019	J1270	Injection, doxercalciferol	1 MCG	\$	0.32	2019_J1270
2019	J1290	Ecallantide injection	1 MG	\$	493.74	2019_J1290
2019	J1300	Ecuzumab injection	10 MG	\$	230.48	2019_J1300
2019	J1301	Injection, edaravone, 1 mg	1 MG	\$	19.49	2019_J1301
2019	J1303	Inj., ravulizumab-cwvz 10 mg	10 MG	\$	226.28	2019_J1303
2019	J1322	Elosulfase alfa, injection	1 MG	\$	241.45	2019_J1322
2019	J1325	Epoprostenol injection	0.5 MG	\$	16.19	2019_J1325
2019	J1335	Ertapenem injection	500 MG	\$	43.47	2019_J1335
2019	J1364	Erythro lactobionate /500 mg	500 MG	\$	75.76	2019_J1364
2019	J1380	Estradiol valerate 10 mg inj	10 MG	\$	10.75	2019_J1380
2019	J1410	Inj estrogen conjugate 25 mg	25 MG	\$	308.93	2019_J1410
2019	J1430	Ethanolamine oleate 100 mg	100 MG	\$	444.10	2019_J1430
2019	J1439	Inj ferric carboxymaltos 1mg	1 MG	\$	1.10	2019_J1439
2019	J1442	Inj filgrastim excl biosimil	1 MCG	\$	0.96	2019_J1442
2019	J1447	Inj tbo filgrastim 1 microg	1 MCG	\$	0.57	2019_J1447
2019	J1450	Fluconazole	200 MG	\$	4.71	2019_J1450
2019	J1453	Fosaprepitant injection	1 MG	\$	1.97	2019_J1453
2019	J1454	Inj fosnetupitant, palonoset	0.25 MG	\$	416.87	2019_J1454
2019	J1458	Galsulfase injection	1 MG	\$	397.92	2019_J1458
2019	J1459	Inj ivig privigen 500 mg	500 MG	\$	40.12	2019_J1459
2019	J1460	Gamma globulin 1 cc inj	1 CC	\$	39.91	2019_J1460
2019	J1555	Inj cuvitru, 100 mg	100 MG	\$	13.79	2019_J1555
2019	J1556	Inj, imm glob bivigam, 500mg	500 MG	\$	70.52	2019_J1556
2019	J1557	Gammplex injection	500 MG	\$	45.82	2019_J1557
2019	J1559	Hizentra injection	100 MG	\$	10.44	2019_J1559
2019	J1560	Gamma globulin > 10 cc inj	10 CC	\$	399.09	2019_J1560
2019	J1561	Gamunex-c/gammaked	500 MG	\$	38.95	2019_J1561
2019	J1566	Immune globulin, powder	500 MG	\$	61.20	2019_J1566
2019	J1568	Octagam injection	500 MG	\$	35.68	2019_J1568
2019	J1569	Gammagard liquid injection	500 MG	\$	37.47	2019_J1569
2019	J1570	Ganciclovir sodium injection	500 MG	\$	48.41	2019_J1570
2019	J1571	Hepagam b im injection	0.5 ML	\$	60.06	2019_J1571
2019	J1572	Flebogamma injection	500 MG	\$	35.48	2019_J1572
2019	J1575	Hyqvia 100mg immunoglobulin	100 MG	\$	14.56	2019_J1575
2019	J1580	Garamycin gentamicin inj	80 MG	\$	1.91	2019_J1580
2019	J1602	Golimumab for iv use 1mg	1 MG	\$	21.58	2019_J1602
2019	J1610	Glucagon hydrochloride/1 mg	1 MG	\$	199.27	2019_J1610
2019	J1626	Granisetron hcl injection	100 MCG	\$	0.40	2019_J1626
2019	J1627	Inj, granisetron, xr, 0.1 mg	0.1 MG	\$	2.74	2019_J1627
2019	J1630	Haloperidol injection	5 MG	\$	0.97	2019_J1630
2019	J1631	Haloperidol decanoate inj	50 MG	\$	16.48	2019_J1631
2019	J1640	Hemin, 1 mg	1 MG	\$	23.72	2019_J1640
2019	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.02	2019_J1642
2019	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.21	2019_J1644
2019	J1645	Dalteparin sodium	2500 IU	\$	12.58	2019_J1645
2019	J1650	Inj enoxaparin sodium	10 MG	\$	0.83	2019_J1650
2019	J1652	Fondaparinux sodium	0.5 MG	\$	1.73	2019_J1652

2019	J1670	Tetanus immune globulin inj	250 UNITS	\$	432.66	2019_J1670
2019	J1720	Hydrocortisone sodium succ i	100 MG	\$	12.90	2019_J1720
2019	J1740	Ibandronate sodium injection	1 MG	\$	43.48	2019_J1740
2019	J1742	Ibutilide fumarate injection	1 MG	\$	278.77	2019_J1742
2019	J1743	Idursulfase injection	1 MG	\$	542.89	2019_J1743
2019	J1745	Infliximab not biosimil 10mg	10 MG	\$	63.29	2019_J1745
2019	J1746	Inj., ibalizumab-uiyk, 10 mg	10 MG	\$	60.16	2019_J1746
2019	J1750	Inj iron dextran	50 MG	\$	14.41	2019_J1750
2019	J1756	Iron sucrose injection	1 MG	\$	0.23	2019_J1756
2019	J1786	Imuglucerase injection	10 UNITS	\$	42.94	2019_J1786
2019	J1800	Propranolol injection	1 MG	\$	8.48	2019_J1800
2019	J1815	Insulin injection	5 UNITS	\$	0.88	2019_J1815
2019	J1817	Insulin for insulin pump use	50 UNITS	\$	10.78	2019_J1817
2019	J1885	Ketorolac tromethamine inj	15 MG	\$	0.50	2019_J1885
2019	J1930	Lanreotide injection	1 MG	\$	62.32	2019_J1930
2019	J1931	Laronidase injection	0.1 MG	\$	32.14	2019_J1931
2019	J1940	Furosemide injection	20 MG	\$	0.69	2019_J1940
2019	J1943	Inj., aristada initio, 1 mg	1 MG	\$	2.86	2019_J1943
2019	J1944	Aripiprazole lauroxil 1mg	1 MG	\$	2.78	2019_J1944
2019	J1950	Leuprolide acetate /3.75 mg	3.75 MG	\$	1,269.23	2019_J1950
2019	J1953	Levetiracetam injection	10 MG	\$	0.11	2019_J1953
2019	J1955	Inj levocarnitine per 1 gm	1 GM	\$	19.40	2019_J1955
2019	J1956	Levofloxacin injection	250 MG	\$	0.22	2019_J1956
2019	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	29.47	2019_J1980
2019	J2001	Lidocaine injection	10 MG	\$	0.03	2019_J2001
2019	J2010	Lincomycin injection	300 MG	\$	11.18	2019_J2010
2019	J2020	Linezolid injection	200 MG	\$	6.30	2019_J2020
2019	J2060	Lorazepam injection	2 MG	\$	0.66	2019_J2060
2019	J2150	Mannitol injection	50 ML	\$	2.62	2019_J2150
2019	J2175	Meperidine hydrochl /100 mg	100 MG	\$	6.07	2019_J2175
2019	J2182	Injection, mepolizumab, 1mg	1 MG	\$	29.72	2019_J2182
2019	J2185	Meropenem	100 MG	\$	0.90	2019_J2185
2019	J2210	Methylergonovin maleate inj	0.2 MG	\$	17.39	2019_J2210
2019	J2248	Micafungin sodium injection	1 MG	\$	1.04	2019_J2248
2019	J2250	Inj midazolam hydrochloride	1 MG	\$	0.12	2019_J2250
2019	J2260	Inj milrinone lactate / 5 mg	5 MG	\$	1.78	2019_J2260
2019	J2270	Morphine sulfate injection	10 MG	\$	4.40	2019_J2270
2019	J2274	Inj morphine pf epid ithc	10 MG	\$	14.99	2019_J2274
2019	J2278	Ziconotide injection	1 MCG	\$	7.91	2019_J2278
2019	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	8.79	2019_J2280
2019	J2300	Inj nalbuphine hydrochloride	10 MG	\$	3.17	2019_J2300
2019	J2310	Inj naloxone hydrochloride	1 MG	\$	15.28	2019_J2310
2019	J2315	Naltrexone, depot form	1 MG	\$	3.25	2019_J2315
2019	J2323	Natalizumab injection	1 MG	\$	20.24	2019_J2323
2019	J2350	Injection, ocrelizumab, 1 mg	1 MG	\$	57.42	2019_J2350
2019	J2353	Octreotide injection, depot	1 MG	\$	206.57	2019_J2353
2019	J2354	Octreotide inj, non-depot	25 MCG	\$	0.78	2019_J2354
2019	J2357	Omalizumab injection	5 MG	\$	36.78	2019_J2357
2019	J2358	Olanzapine long-acting inj	1 MG	\$	2.92	2019_J2358
2019	J2360	Orphenadrine injection	60 MG	\$	6.44	2019_J2360
2019	J2400	Chloroprocaine hcl injection	30 ML	\$	23.32	2019_J2400
2019	J2405	Ondansetron hcl injection	1 MG	\$	0.11	2019_J2405
2019	J2407	Injection, oritavancin	10 MG	\$	23.78	2019_J2407
2019	J2425	Palifermin injection	50 MCG	\$	21.28	2019_J2425
2019	J2426	Paliperidone palmitate inj	1 MG	\$	11.63	2019_J2426
2019	J2430	Pamidronate disodium /30 mg	30 MG	\$	12.06	2019_J2430
2019	J2469	Palonosetron hcl	25 MCG	\$	7.93	2019_J2469
2019	J2501	Paricalcitol	1 MCG	\$	0.79	2019_J2501
2019	J2503	Pegaptanib sodium injection	0.3 MG	\$	722.05	2019_J2503

2019	J2504	Pegademase bovine, 25 iu	25 IU	\$	367.96	2019_J2504
2019	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	4,429.63	2019_J2505
2019	J2507	Pegloticase injection	1 MG	\$	2,512.55	2019_J2507
2019	J2510	Penicillin g procaine inj	600000 UNITS	\$	29.97	2019_J2510
2019	J2515	Pentobarbital sodium inj	50 MG	\$	37.02	2019_J2515
2019	J2540	Penicillin g potassium inj	600000 UNITS	\$	1.02	2019_J2540
2019	J2543	Piperacillin/tazobactam	1.125 GM	\$	1.83	2019_J2543
2019	J2545	Pentamidine non-comp unit	300 MG	\$	105.27	2019_J2545
2019	J2550	Promethazine hcl injection	50 MG	\$	2.02	2019_J2550
2019	J2560	Phenobarbital sodium inj	120 MG	\$	42.04	2019_J2560
2019	J2562	Plerixafor injection	1 MG	\$	347.71	2019_J2562
2019	J2597	Inj desmopressin acetate	1 MCG	\$	12.14	2019_J2597
2019	J2675	Inj progesterone per 50 mg	50 MG	\$	2.21	2019_J2675
2019	J2680	Fluphenazine decanoate 25 mg	25 MG	\$	10.95	2019_J2680
2019	J2690	Procainamide hcl injection	1 GM	\$	77.49	2019_J2690
2019	J2700	Oxacillin sodium injection	250 MG	\$	1.37	2019_J2700
2019	J2704	Inj, propofol, 10 mg	10 MG	\$	0.11	2019_J2704
2019	J2720	Inj protamine sulfate/10 mg	10 MG	\$	1.09	2019_J2720
2019	J2724	Protein c concentrate	10 UNITS	\$	15.10	2019_J2724
2019	J2760	Phentolamine mesylate inj	5 MG	\$	377.57	2019_J2760
2019	J2765	Metoclopramide hcl injection	10 MG	\$	1.54	2019_J2765
2019	J2770	Quinupristin/dalfopristin	500 MG	\$	417.49	2019_J2770
2019	J2778	Ranibizumab injection	0.1 mg	\$	352.17	2019_J2778
2019	J2780	Ranitidine hydrochloride inj	25 MG	\$	4.10	2019_J2780
2019	J2783	Rasburicase	0.5 MG	\$	289.82	2019_J2783
2019	J2785	Regadenoson injection	0.1 MG	\$	59.22	2019_J2785
2019	J2786	Injection, reslizumab, 1mg	1 MG	\$	9.62	2019_J2786
2019	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	24.92	2019_J2788
2019	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	79.56	2019_J2790
2019	J2791	Rhophylac injection	100 IU	\$	4.76	2019_J2791
2019	J2792	Rho(d) immune globulin h, sd	100 IU	\$	29.78	2019_J2792
2019	J2794	Risperidone, long acting	0.5 MG	\$	10.04	2019_J2794
2019	J2795	Ropivacaine hcl injection	1 MG	\$	0.07	2019_J2795
2019	J2796	Romiplostim injection	10 MCG	\$	74.28	2019_J2796
2019	J2798	Inj., perseris, 0.5 mg	0.5 mg	\$	9.87	2019_J2798
2019	J2800	Methocarbamol injection	10 ML	\$	9.06	2019_J2800
2019	J2805	Sinacalide injection	5 MCG	\$	109.97	2019_J2805
2019	J2810	Inj theophylline per 40 mg	40 MG	\$	0.42	2019_J2810
2019	J2820	Sargramostim injection	50 MCG	\$	43.44	2019_J2820
2019	J2860	Injection, siltuximab	10 MG	\$	103.06	2019_J2860
2019	J2916	Na ferric gluconate complex	12.5 MG	\$	1.62	2019_J2916
2019	J2920	Methylprednisolone injection	40 MG	\$	4.49	2019_J2920
2019	J2930	Methylprednisolone injection	125 MG	\$	6.12	2019_J2930
2019	J2997	Alteplase recombinant	1 MG	\$	87.64	2019_J2997
2019	J3000	Streptomycin injection	1 GM	\$	31.53	2019_J3000
2019	J3010	Fentanyl citrate injection	0.1 MG	\$	0.89	2019_J3010
2019	J3060	Inj, taliglucerase alfa 10 u	10 UNITS	\$	40.08	2019_J3060
2019	J3070	Pentazocine injection	30 MG	\$	108.39	2019_J3070
2019	J3090	Inj tedizolid phosphate	1 MG	\$	1.49	2019_J3090
2019	J3095	Telavancin injection	10 MG	\$	5.74	2019_J3095
2019	J3101	Tenecteplase injection	1 MG	\$	121.83	2019_J3101
2019	J3105	Terbutaline sulfate inj	1 MG	\$	1.63	2019_J3105
2019	J3111	Inj. romosozumab-aqqg 1 mg	1 MG	\$	8.95	2019_J3111
2019	J3121	Inj testosterone enanthate 1mg	1 MG	\$	0.05	2019_J3121
2019	J3145	Testosterone undecanoate 1mg	1 MG	\$	1.47	2019_J3145
2019	J3230	Chlorpromazine hcl injection	50 MG	\$	31.61	2019_J3230
2019	J3240	Thyrotropin injection	0.9 MG	\$	1,695.12	2019_J3240
2019	J3243	Tigecycline injection	1 MG	\$	1.57	2019_J3243
2019	J3245	Inj., tildrakizumab, 1 mg	1 MG	\$	136.49	2019_J3245

2019	J3250	Trimethobenzamide hcl inj	200 MG	\$	36.79	2019_J3250
2019	J3260	Tobramycin sulfate injection	80 MG	\$	3.60	2019_J3260
2019	J3262	Tocilizumab injection	1 MG	\$	4.96	2019_J3262
2019	J3285	Treprostinil injection	1 MG	\$	63.85	2019_J3285
2019	J3300	Triamcinolone a inj prs-free	1 MG	\$	3.85	2019_J3300
2019	J3301	Triamcinolone acet inj nos	10 MG	\$	1.57	2019_J3301
2019	J3304	Inj triamcinolone ace xr 1mg	1 MG	\$	18.88	2019_J3304
2019	J3315	Triptorelin pamoate	3.75 MG	\$	258.74	2019_J3315
2019	J3357	Ustekinumab sub cu inj, 1 mg	1 MG	\$	191.39	2019_J3357
2019	J3358	Ustekinumab, iv inject, 1 mg	1 MG	\$	12.04	2019_J3358
2019	J3360	Diazepam injection	5 MG	\$	11.09	2019_J3360
2019	J3370	Vancomycin hcl injection	500 MG	\$	3.46	2019_J3370
2019	J3380	Injection, vedolizumab	1 MG	\$	19.86	2019_J3380
2019	J3385	Velaglucerase alfa	100 UNITS	\$	345.52	2019_J3385
2019	J3396	Verteporfin injection	0.1 MG	\$	11.08	2019_J3396
2019	J3410	Hydroxyzine hcl injection	25 MG	\$	6.59	2019_J3410
2019	J3411	Thiamine hcl 100 mg	100 MG	\$	1.91	2019_J3411
2019	J3415	Pyridoxine hcl 100 mg	100 MG	\$	9.45	2019_J3415
2019	J3420	Vitamin b12 injection	1000 MCG	\$	1.89	2019_J3420
2019	J3430	Vitamin k phytonadione inj	1 MG	\$	4.28	2019_J3430
2019	J3465	Injection, voriconazole	10 MG	\$	2.05	2019_J3465
2019	J3471	Ovine, up to 999 usp units	1 UNIT	\$	0.43	2019_J3471
2019	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.36	2019_J3473
2019	J3475	Inj magnesium sulfate	500 MG	\$	0.85	2019_J3475
2019	J3480	Inj potassium chloride	2 MEQ	\$	0.14	2019_J3480
2019	J3485	Zidovudine	10 MG	\$	1.51	2019_J3485
2019	J3486	Ziprasidone mesylate	10 MG	\$	17.71	2019_J3486
2019	J3489	Zoledronic acid 1mg	1 MG	\$	12.47	2019_J3489
2019	J7030	Normal saline solution infus	1000 ML	\$	2.42	2019_J7030
2019	J7040	Normal saline solution infus	500 ML	\$	1.21	2019_J7040
2019	J7042	5% dextrose/normal saline	500 ML	\$	0.91	2019_J7042
2019	J7050	Normal saline solution infus	250 ML	\$	0.60	2019_J7050
2019	J7060	5% dextrose/water	500 ML	\$	1.85	2019_J7060
2019	J7070	D5w infusion	1000 CC	\$	3.63	2019_J7070
2019	J7120	Ringers lactate infusion	1000 CC	\$	2.32	2019_J7120
2019	J7170	Inj., emicizumab-kxwh 0.5 mg	0.5 MG	\$	47.35	2019_J7170
2019	J7175	Inj, factor x, (human), 1iu	1 IU	\$	7.51	2019_J7175
2019	J7178	Inj human fibrinogen con nos	1 IU	\$	1.20	2019_J7178
2019	J7179	Vonvendi inj 1 iu vwfrco	1 IU	\$	1.83	2019_J7179
2019	J7180	Factor xiii anti-hem factor	1 IU	\$	8.47	2019_J7180
2019	J7181	Factor xiii recomb a-subunit	1 IU	\$	15.52	2019_J7181
2019	J7182	Factor viii recomb novoeight	1 IU	\$	1.31	2019_J7182
2019	J7183	Wilate injection	1 I.U. VWF:RCO	\$	0.97	2019_J7183
2019	J7185	Xyntha inj	1 IU	\$	1.27	2019_J7185
2019	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	1.06	2019_J7186
2019	J7187	Humate-p, inj	1 IU	\$	1.16	2019_J7187
2019	J7188	Factor viii recomb obizur	1 IU	\$	3.18	2019_J7188
2019	J7189	Factor viia	1 MCG	\$	2.15	2019_J7189
2019	J7190	Factor viii	1 IU	\$	1.07	2019_J7190
2019	J7192	Factor viii recombinant nos	1 IU	\$	1.25	2019_J7192
2019	J7193	Factor ix non-recombinant	1 IU	\$	1.15	2019_J7193
2019	J7194	Factor ix complex	1 IU	\$	1.47	2019_J7194
2019	J7195	Factor ix recombinant nos	1 IU	\$	1.50	2019_J7195
2019	J7197	Antithrombin iii injection	1 IU	\$	3.32	2019_J7197
2019	J7198	Anti-inhibitor	1 IU	\$	1.90	2019_J7198
2019	J7200	Factor ix recombinan rixubis	1 IU	\$	1.32	2019_J7200
2019	J7201	Factor ix alprolix recomb	1 IU	\$	3.11	2019_J7201
2019	J7202	Factor ix idelvion inj	1 IU	\$	4.29	2019_J7202
2019	J7205	Factor viii fc fusion recomb	1 IU	\$	2.08	2019_J7205

2019	J7207	Factor viii pegylated recomb	1 IU	\$	1.74	2019_J7207
2019	J7208	Inj. Jivi 1 iu	1 IU	\$	2.02	2019_J7208
2019	J7209	Factor viii nuwiq recomb 1iu	1 IU	\$	1.24	2019_J7209
2019	J7210	Inj. afstyla, 1 i.u.	1 IU	\$	1.36	2019_J7210
2019	J7211	Inj. kovaltry, 1 i.u.	1 IU	\$	1.26	2019_J7211
2019	J7308	Aminolevulinic acid hcl top	354 MG	\$	390.98	2019_J7308
2019	J7311	Fluocinolone acetoneide implt	0.01 MG	\$	341.62	2019_J7311
2019	J7312	Dexamethasone intra implant	0.1 MG	\$	200.03	2019_J7312
2019	J7313	Fluocinol acet intravit imp	0.01 MG	\$	490.87	2019_J7313
2019	J7316	Inj. ocriplasmin, 0.125 mg	0.125 MG	\$	1,046.93	2019_J7316
2019	J7321	Hyalgan supartz visco-3 dose	per dose	\$	81.57	2019_J7321
2019	J7323	Euflexxa inj per dose	per dose	\$	145.08	2019_J7323
2019	J7324	Orthovisc inj per dose	PER DOSE	\$	143.40	2019_J7324
2019	J7325	Synvisc or synvisc-one	1 MG	\$	11.41	2019_J7325
2019	J7327	Monovisc inj per dose	PER DOSE	\$	769.51	2019_J7327
2019	J7336	Capsaicin 8% patch	1 SQ CM	\$	3.15	2019_J7336
2019	J7340	Carbidopa levodopa ent 100ml	100 ML	\$	219.45	2019_J7340
2019	J7345	Aminolevulinic acid, 10% gel	10 MG	\$	1.45	2019_J7345
2019	J7500	Azathioprine oral 50mg	50 MG	\$	0.66	2019_J7500
2019	J7502	Cyclosporine oral 100 mg	100 MG	\$	2.34	2019_J7502
2019	J7503	Tacrol envarsus ex rel oral	0.25 MG	\$	1.33	2019_J7503
2019	J7504	Lymphocyte immune globulin	250 MG	\$	2,066.02	2019_J7504
2019	J7507	Tacrolimus imme rel oral 1mg	1 MG	\$	0.39	2019_J7507
2019	J7508	Tacrol astagraf ex rel oral	0.1 MG	\$	0.48	2019_J7508
2019	J7509	Methylprednisolone oral	4 MG	\$	0.36	2019_J7509
2019	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.09	2019_J7510
2019	J7511	Antithymocyte globuln rabbit	25 MG	\$	768.56	2019_J7511
2019	J7512	Prednisone ir or dr oral 1mg	1 MG	\$	0.01	2019_J7512
2019	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.70	2019_J7515
2019	J7516	Cyclosporin parenteral 250mg	250 MG	\$	49.25	2019_J7516
2019	J7517	Mycophenolate mofetil oral	250 MG	\$	0.54	2019_J7517
2019	J7518	Mycophenolic acid	180 MG	\$	3.34	2019_J7518
2019	J7520	Sirolimus, oral	1 MG	\$	5.95	2019_J7520
2019	J7525	Tacrolimus injection	5 MG	\$	211.84	2019_J7525
2019	J7527	Oral everolimus	0.25 MG	\$	8.97	2019_J7527
2019	J7605	Arformoterol non-comp unit	15 mcg	\$	10.38	2019_J7605
2019	J7606	Formoterol fumarate, inh	20 MCG	\$	12.17	2019_J7606
2019	J7608	Acetylcysteine non-comp unit	1 GM	\$	5.81	2019_J7608
2019	J7611	Albuterol non-comp con	1 MG	\$	0.19	2019_J7611
2019	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.27	2019_J7612
2019	J7613	Albuterol non-comp unit	1 MG	\$	0.04	2019_J7613
2019	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.06	2019_J7614
2019	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.13	2019_J7620
2019	J7626	Budesonide non-comp unit	0.5 MG	\$	2.16	2019_J7626
2019	J7631	Cromolyn sodium noncomp unit	10 MG	\$	4.75	2019_J7631
2019	J7639	Dornase alfa non-comp unit	1 MG	\$	47.79	2019_J7639
2019	J7644	Ipratropium bromide non-comp	1 MG	\$	0.20	2019_J7644
2019	J7674	Methacholine chloride, neb	1 MG	\$	0.67	2019_J7674
2019	J7682	Tobramycin non-comp unit	300 MG	\$	36.79	2019_J7682
2019	J7686	Treprostinil, non-comp unit	1.74 MG	\$	612.96	2019_J7686
2019	J8501	Oral aprepitant	5 MG	\$	4.31	2019_J8501
2019	J8510	Oral busulfan	2 MG	\$	24.18	2019_J8510
2019	J8520	Capecitabine, oral, 150 mg	150 MG	\$	1.36	2019_J8520
2019	J8521	Capecitabine, oral, 500 mg	500 MG	\$	3.48	2019_J8521
2019	J8530	Cyclophosphamide oral 25 mg	25 MG	\$	3.31	2019_J8530
2019	J8540	Oral dexamethasone	0.25 MG	\$	0.05	2019_J8540
2019	J8560	Etoposide oral 50 mg	50 MG	\$	75.36	2019_J8560
2019	J8600	Melphalan oral 2 mg	2 MG	\$	12.00	2019_J8600
2019	J8610	Methotrexate oral 2.5 mg	2.5 MG	\$	0.24	2019_J8610

2019	J8655	Oral netupitant, palonosetro	0.5 MG	\$	245.74	2019_J8655
2019	J8670	Rolapitant, oral, 1mg	1 MG	\$	2.12	2019_J8670
2019	J8700	Temozolomide	5 MG	\$	0.73	2019_J8700
2019	J8705	Topotecan oral	0.25 mg	\$	103.66	2019_J8705
2019	J9000	Doxorubicin hcl injection	10 MG	\$	3.73	2019_J9000
2019	J9017	Arsenic trioxide injection	1 MG	\$	44.31	2019_J9017
2019	J9019	Erwinaze injection	1,000 IU	\$	414.83	2019_J9019
2019	J9022	Inj, atezolizumab, 10 mg	10 MG	\$	77.01	2019_J9022
2019	J9023	Injection, avelumab, 10 mg	10 MG	\$	82.97	2019_J9023
2019	J9025	Azacitidine injection	1 MG	\$	1.16	2019_J9025
2019	J9027	Clofarabine injection	1 MG	\$	61.69	2019_J9027
2019	J9030	Bcg live intravesical 1mg	1 MG	\$	2.82	2019_J9030
2019	J9032	Injection, belinostat, 10mg	10 MG	\$	40.07	2019_J9032
2019	J9033	Inj., treanda 1 mg	1 MG	\$	27.84	2019_J9033
2019	J9034	Inj., bendeka 1 mg	1 MG	\$	22.85	2019_J9034
2019	J9035	Bevacizumab injection	10 MG	\$	81.18	2019_J9035
2019	J9036	Inj. belrapzo/bendamustine	1 MG	\$	24.36	2019_J9036
2019	J9039	Injection, blinatumomab	1 MCG	\$	113.40	2019_J9039
2019	J9040	Bleomycin sulfate injection	15 UNITS	\$	26.66	2019_J9040
2019	J9041	Inj., velcade 0.1 mg	0.1 MG	\$	44.69	2019_J9041
2019	J9042	Brentuximab vedotin inj	1 MG	\$	162.44	2019_J9042
2019	J9043	Cabazitaxel injection	1 MG	\$	173.67	2019_J9043
2019	J9044	Inj, bortezomib, nos, 0.1 mg	0.1 MG	\$	25.04	2019_J9044
2019	J9045	Carboplatin injection	50 MG	\$	2.89	2019_J9045
2019	J9047	Injection, carfilzomib, 1 mg	1 MG	\$	37.60	2019_J9047
2019	J9050	Carmustine injection	100 MG	\$	3,039.01	2019_J9050
2019	J9055	Cetuximab injection	10 MG	\$	62.05	2019_J9055
2019	J9060	Cisplatin 10 mg injection	10 MG	\$	1.88	2019_J9060
2019	J9065	Inj cladribine per 1 mg	1 MG	\$	19.00	2019_J9065
2019	J9070	Cyclophosphamide 100 mg inj	100 MG	\$	34.14	2019_J9070
2019	J9100	Cytarabine hcl 100 mg inj	100 MG	\$	0.56	2019_J9100
2019	J9119	Inj., cemiplimab-rwlc, 1 mg	1 MG	\$	27.45	2019_J9119
2019	J9120	Dactinomycin injection	0.5 MG	\$	1,098.20	2019_J9120
2019	J9130	Dacarbazine 100 mg inj	100 MG	\$	4.14	2019_J9130
2019	J9145	Injection, daratumumab 10 mg	10 MG	\$	53.95	2019_J9145
2019	J9150	Daunorubicin injection	10 MG	\$	46.74	2019_J9150
2019	J9153	Inj daunorubicin, cytarabine	1 MG/2.27 MG	\$	192.31	2019_J9153
2019	J9155	Degarelix injection	1 MG	\$	3.97	2019_J9155
2019	J9171	Docetaxel injection	1 MG	\$	0.87	2019_J9171
2019	J9173	Inj., durvalumab, 10 mg	10 MG	\$	74.64	2019_J9173
2019	J9176	Injection, elotuzumab, 1mg	1 MG	\$	6.50	2019_J9176
2019	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	0.95	2019_J9178
2019	J9179	Eribulin mesylate injection	0.1 MG	\$	114.27	2019_J9179
2019	J9181	Etoposide injection	10 MG	\$	0.56	2019_J9181
2019	J9185	Fludarabine phosphate inj	50 MG	\$	56.58	2019_J9185
2019	J9190	Fluorouracil injection	500 MG	\$	1.55	2019_J9190
2019	J9200	Floxuridine injection	500 MG	\$	82.68	2019_J9200
2019	J9201	Gemcitabine hcl injection	200 MG	\$	5.00	2019_J9201
2019	J9202	Goserelin acetate implant	3.6 MG	\$	497.72	2019_J9202
2019	J9203	Gemtuzumab ozogamicin 0.1 mg	0.1 MG	\$	199.23	2019_J9203
2019	J9204	Inj mogamulizumab-kpkc, 1 mg	1 MG	\$	200.87	2019_J9204
2019	J9205	Inj irinotecan liposome 1 mg	1 MG	\$	49.91	2019_J9205
2019	J9206	Irinotecan injection	20 MG	\$	2.47	2019_J9206
2019	J9207	Ixabepilone injection	1 MG	\$	91.07	2019_J9207
2019	J9208	Ifosfamide injection	1 GM	\$	26.44	2019_J9208
2019	J9209	Mesna injection	200 MG	\$	1.61	2019_J9209
2019	J9211	Idarubicin hcl injection	5 MG	\$	32.72	2019_J9211
2019	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	34.24	2019_J9214
2019	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	224.70	2019_J9217

2019	J9218	Leuprolide acetate injecton	1 MG	\$	16.60	2019_J9218
2019	J9225	Vantas implant	50 MG	\$	4,085.61	2019_J9225
2019	J9226	Supprelin la implant	50 MG	\$	36,647.60	2019_J9226
2019	J9228	Ipilimumab injection	1 MG	\$	153.13	2019_J9228
2019	J9229	Inj inotuzumab ozogam 0.1 mg	0.1 MG	\$	2,270.31	2019_J9229
2019	J9245	Inj melphalan hydrochl 50 mg	50 MG	\$	610.88	2019_J9245
2019	J9250	Methotrexate sodium inj	5 MG	\$	0.25	2019_J9250
2019	J9260	Methotrexate sodium inj	50 MG	\$	2.49	2019_J9260
2019	J9261	Nelarabine injection	50 MG	\$	152.48	2019_J9261
2019	J9262	Inj, omacetaxine mep, 0.01mg	0.01 MG	\$	3.11	2019_J9262
2019	J9263	Oxaliplatin	0.5 MG	\$	0.15	2019_J9263
2019	J9264	Paclitaxel protein bound	1 MG	\$	12.51	2019_J9264
2019	J9266	Pegaspargase injection	1 EA	\$	17,566.89	2019_J9266
2019	J9267	Paclitaxel injection	1 MG	\$	0.13	2019_J9267
2019	J9268	Pentostatin injection	10 MG	\$	1,968.61	2019_J9268
2019	J9271	Inj pembrolizumab	1 MG	\$	49.39	2019_J9271
2019	J9280	Mitomycin injection	5 MG	\$	87.75	2019_J9280
2019	J9285	Inj, olaratumab, 10 mg	10 MG	\$	52.13	2019_J9285
2019	J9293	Mitoxantrone hydrochl / 5 mg	5 MG	\$	27.39	2019_J9293
2019	J9295	Injection, necitumumab, 1 mg	1 MG	\$	5.74	2019_J9295
2019	J9299	Injection, nivolumab	1 MG	\$	27.81	2019_J9299
2019	J9301	Obinutuzumab inj	10 MG	\$	62.86	2019_J9301
2019	J9302	Ofatumumab injection	10 MG	\$	60.09	2019_J9302
2019	J9303	Panitumumab injection	10 MG	\$	119.07	2019_J9303
2019	J9305	Pemetrexed injection	10 MG	\$	69.47	2019_J9305
2019	J9306	Injection, pertuzumab, 1 mg	1 MG	\$	12.29	2019_J9306
2019	J9307	Pralatrexate injection	1 MG	\$	291.26	2019_J9307
2019	J9308	Injection, ramucirumab	5 MG	\$	58.42	2019_J9308
2019	J9311	Inj rituximab, hyaluronidase	10 mg	\$	43.53	2019_J9311
2019	J9312	Inj., rituximab, 10 mg	10 MG	\$	94.67	2019_J9312
2019	J9315	Romidepsin injection	1 MG	\$	297.59	2019_J9315
2019	J9320	Streptozocin injection	1 GM	\$	349.70	2019_J9320
2019	J9325	Inj talimogene laherparepvec	1 million PFU	\$	51.47	2019_J9325
2019	J9328	Temozolomide injection	1 MG	\$	10.39	2019_J9328
2019	J9330	Temsirolimus injection	1 MG	\$	53.14	2019_J9330
2019	J9340	Thiotepa injection	15 MG	\$	404.28	2019_J9340
2019	J9351	Topotecan injection	0.1 MG	\$	0.87	2019_J9351
2019	J9352	Injection trabectedin 0.1mg	0.1 MG	\$	312.91	2019_J9352
2019	J9354	Inj, ado-trastuzumab emt 1mg	1 MG	\$	31.36	2019_J9354
2019	J9355	Inj trastuzumab excl biosimi	10 MG	\$	106.62	2019_J9355
2019	J9356	Inj. herceptin hylecta, 10mg	10 MG	\$	80.26	2019_J9356
2019	J9357	Valrubicin injection	200 MG	\$	1,438.59	2019_J9357
2019	J9360	Vinblastine sulfate inj	1 MG	\$	3.80	2019_J9360
2019	J9370	Vincristine sulfate 1 mg inj	1 MG	\$	4.81	2019_J9370
2019	J9371	Inj, vincristine sul lip 1mg	1 MG	\$	3,080.04	2019_J9371
2019	J9390	Vinorelbine tartrate inj	10 MG	\$	11.66	2019_J9390
2019	J9395	Injection, fulvestrant	25 MG	\$	94.87	2019_J9395
2019	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.37	2019_J9400
2019	P9041	Albumin (human),5%, 50ml	50 ML	\$	10.49	2019_P9041
2019	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	52.45	2019_P9045
2019	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	20.98	2019_P9046
2019	P9047	Albumin (human), 25%, 50ml	50 ML	\$	52.45	2019_P9047
2019	Q0138	Ferumoxytol, non-esrd	1 MG	\$	1.00	2019_Q0138
2019	Q0139	Ferumoxytol, esrd use	1 MG	\$	1.00	2019_Q0139
2019	Q0162	Ondansetron oral	1 MG	\$	0.02	2019_Q0162
2019	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.22	2019_Q0164
2019	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	0.96	2019_Q0166
2019	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	0.62	2019_Q0167
2019	Q2043	Sipuleucel-t auto cd54+	Per infusion (minimum 50 million cells)	\$	46,374.20	2019_Q2043

2019	Q2050	Doxorubicin inj 10mg	10 MG	\$	355.07	2019_Q2050
2019	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	53.58	2019_Q3027
2019	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	141.83	2019_Q4074
2019	Q4081	Epoetin alfa, 100 units esrd	100 UNITS	\$	1.10	2019_Q4081
2019	Q4101	Apligraf	1 SQ CM	\$	30.71	2019_Q4101
2019	Q4102	Oasis wound matrix	1 SQ CM	\$	10.53	2019_Q4102
2019	Q4106	Dermagraft	1 SQ CM	\$	33.00	2019_Q4106
2019	Q4107	Graftjacket	1 SQ CM	\$	92.59	2019_Q4107
2019	Q4110	Primatrix	1 SQ CM	\$	47.65	2019_Q4110
2019	Q4111	Gammagraft	1 SQ CM	\$	6.97	2019_Q4111
2019	Q4113	Graftjacket xpress	1 CC	\$	919.55	2019_Q4113
2019	Q4115	Alloskin	1 SQ CM	\$	13.50	2019_Q4115
2019	Q4121	Theraskin	1 SQ CM	\$	41.07	2019_Q4121
2019	Q4132	Grafix core, grafixpl core	1 SQ CM	\$	117.92	2019_Q4132
2019	Q4133	Grafix stravax prime pl sqcm	1 SQ CM	\$	140.56	2019_Q4133
2019	Q4137	Amnioexcel biodexcel 1sq cm	1 SQ CM	\$	77.62	2019_Q4137
2019	Q4145	Epifix, inj, 1mg	1 MG	\$	21.08	2019_Q4145
2019	Q4151	Amnioband, guardian 1 sq cm	1 SQ CM	\$	158.28	2019_Q4151
2019	Q4154	Biovance 1 square cm	1 SQ CM	\$	113.98	2019_Q4154
2019	Q4159	Affinity1 square cm	1 SQ CM	\$	644.48	2019_Q4159
2019	Q4160	Nushield 1 square cm	1 SQ CM	\$	110.16	2019_Q4160
2019	Q4170	Cygnus, per sq cm	1 SQ CM	\$	132.78	2019_Q4170
2019	Q4186	Epifix 1 sq cm	1 SQ CM	\$	160.42	2019_Q4186
2019	Q4195	Puraply 1 sq cm	1 SQ CM	\$	89.70	2019_Q4195
2019	Q4196	Puraply am 1 sq cm	1 SQ CM	\$	104.83	2019_Q4196
2019	Q5101	Injection, zarxio	1 MCG	\$	0.57	2019_Q5101
2019	Q5103	Injection, inflectra	10 MG	\$	49.25	2019_Q5103
2019	Q5104	Injection, renflexis	10 MG	\$	53.40	2019_Q5104
2019	Q5105	Inj retacrit esrd on dialysi	100 UNITS	\$	0.96	2019_Q5105
2019	Q5106	Inj retacrit non-esrd use	1000 UNITS	\$	9.63	2019_Q5106
2019	Q5107	Inj mvasi 10 mg	10 MG	\$	69.77	2019_Q5107
2019	Q5108	Injection, fulphila	0.5 MG	\$	327.41	2019_Q5108
2019	Q5110	Nivestym	1 MCG	\$	0.64	2019_Q5110
2019	Q5111	Injection, udenyca 0.5 mg	0.5 MG	\$	347.06	2019_Q5111
2019	Q5117	Inj., kanjinti, 10 mg	10 MG	\$	90.67	2019_Q5117
2019	Q9950	Inj sulf hexa lipid microsph	1 ML	\$	19.54	2019_Q9950
2019	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	32.27	2019_Q9956
2019	Q9957	Inj perflutren lip micros,ml	1 ML	\$	48.41	2019_Q9957
2019	Q9958	Hocm <=149 mg/ml iodine, 1ml	1 ML	\$	0.07	2019_Q9958
2019	Q9960	Hocm 200-249mg/ml iodine,1ml	1 ML	\$	0.23	2019_Q9960
2019	Q9961	Hocm 250-299mg/ml iodine,1ml	1 ML	\$	0.26	2019_Q9961
2019	Q9963	Hocm 350-399mg/ml iodine,1ml	1 ML	\$	0.20	2019_Q9963
2019	Q9965	Locm 100-199mg/ml iodine,1ml	1 ML	\$	1.01	2019_Q9965
2019	Q9966	Locm 200-299mg/ml iodine,1ml	1 ML	\$	0.31	2019_Q9966
2019	Q9967	Locm 300-399mg/ml iodine,1ml	1 ML	\$	0.12	2019_Q9967
2019	Q9991	Buprenorph xr 100 mg or less	Less than or equal to 100 MG	\$	1,673.36	2019_Q9991
2019	Q9992	Buprenorphine xr over 100 mg	Greater than 100 MG	\$	1,673.36	2019_Q9992
2018	90371	Hep b ig im	1 ML	\$	112.33	2018_90371
2018	90375	Rabies ig im/sc	150 IU	\$	334.99	2018_90375
2018	90376	Rabies ig heat treated	150 IU	\$	324.95	2018_90376
2018	90585	Bcg vaccine percut	50 MG	\$	140.62	2018_90585
2018	90586	Bcg vaccine intravesical	1 EACH	\$	140.62	2018_90586
2018	90632	Hepa vaccine adult im	1 ML	\$	58.64	2018_90632
2018	90653	liv adjuvant vaccine im	0.5 ml	\$	54.67	2018_90653
2018	90656	liv3 vacc no prsv 0.5 ml im	0.5 ML	\$	19.77	2018_90656
2018	90662	liv no prsv increased ag im	0.5 ML	\$	53.37	2018_90662
2018	90670	Pcv13 vaccine im	0.5 ML	\$	205.11	2018_90670
2018	90674	Cciiv4 vac no prsv 0.5 ml im	0.5 ML	\$	24.05	2018_90674
2018	90675	Rabies vaccine im	1 ML	\$	291.44	2018_90675

2018	90682	Riv4 vacc recombinant dna im	0.5 ML	\$	53.37	2018_90682
2018	90685	liv4 vacc no prsv 0.25 ml im	0.25 mL	\$	21.81	2018_90685
2018	90686	liv4 vacc no prsv 0.5 ml im	0.5 ml	\$	19.03	2018_90686
2018	90687	liv4 vaccine splt 0.25 ml im	0.25 ML	\$	9.40	2018_90687
2018	90688	liv4 vaccine splt 0.5 ml im	0.5 ML	\$	17.84	2018_90688
2018	90691	Typhoid vaccine im	0.5 ML	\$	101.62	2018_90691
2018	90714	Td vacc no presv 7 yrs+ im	0.5 ML	\$	23.15	2018_90714
2018	90715	Tdap vaccine 7 yrs/> im	0.5 ML	\$	30.90	2018_90715
2018	90732	Ppsv23 vacc 2 yrs+ subq/im	0.5 ML	\$	107.75	2018_90732
2018	90739	Hepb vacc 2 dose adult im	1 dose	\$	131.10	2018_90739
2018	90740	Hepb vacc 3 dose immunsup im	40 MCG	\$	130.25	2018_90740
2018	90744	Hepb vacc 3 dose ped/adol im	1 DOSE	\$	26.14	2018_90744
2018	90746	Hepb vaccine 3 dose adult im	20 MCG	\$	65.12	2018_90746
2018	90747	Hepb vacc 4 dose immunsup im	40 MCG	\$	130.25	2018_90747
2018	90756	Cciiv4 vacc abx free im	0.5 ML	\$	22.79	2018_90756
2018	A9575	Inj gadoterate meglumi 0.1ml	0.1 ml	\$	0.21	2018_A9575
2018	A9576	Inj prohance multipack	1 ML	\$	1.57	2018_A9576
2018	A9577	Inj multihance	1 ML	\$	2.04	2018_A9577
2018	A9578	Inj multihance multipack	1 ML	\$	1.96	2018_A9578
2018	A9579	Gad-base mr contrast nos,1ml	1 ML	\$	1.72	2018_A9579
2018	A9581	Gadoxetate disodium inj	1 ML	\$	14.83	2018_A9581
2018	A9585	Gadobutrol injection	0.1 ML	\$	0.41	2018_A9585
2018	A9606	Radium ra223 dichloride ther	1 microCurie	N/A		2018_A9606
2018	J0129	Abatacept injection	10 MG	\$	52.93	2018_J0129
2018	J0130	Abciximab injection	10 MG	\$	1,299.26	2018_J0130
2018	J0132	Acetylcysteine injection	100 MG	\$	1.07	2018_J0132
2018	J0133	Acyclovir injection	5 MG	\$	0.03	2018_J0133
2018	J0153	Adenosine inj 1mg	1 MG	\$	0.83	2018_J0153
2018	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.74	2018_J0171
2018	J0178	Aflibercept injection	1 MG	\$	967.33	2018_J0178
2018	J0180	Agalsidase beta injection	1 MG	\$	175.62	2018_J0180
2018	J0202	Injection, alemtuzumab	1 MG	\$	1,842.13	2018_J0202
2018	J0207	Amifostine	500 MG	\$	973.41	2018_J0207
2018	J0221	Lumizyme injection	10 MG	\$	163.83	2018_J0221
2018	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.46	2018_J0256
2018	J0257	Glassia injection	10 MG	\$	4.65	2018_J0257
2018	J0278	Amikacin sulfate injection	100 MG	\$	1.12	2018_J0278
2018	J0280	Aminophyllin 250 mg inj	250 MG	\$	3.71	2018_J0280
2018	J0285	Amphotericin b	50 MG	\$	32.38	2018_J0285
2018	J0287	Amphotericin b lipid complex	10 MG	\$	17.72	2018_J0287
2018	J0289	Amphotericin b liposome inj	10 MG	\$	48.07	2018_J0289
2018	J0290	Ampicillin 500 mg inj	500 MG	\$	0.99	2018_J0290
2018	J0295	Ampicillin sodium per 1.5 gm	1.5 GM	\$	2.80	2018_J0295
2018	J0348	Anidulafungin injection	1 MG	\$	0.54	2018_J0348
2018	J0360	Hydralazine hcl injection	20 MG	\$	2.03	2018_J0360
2018	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	5.24	2018_J0401
2018	J0456	Azithromycin	500 MG	\$	2.85	2018_J0456
2018	J0461	Atropine sulfate injection	0.01 MG	\$	0.07	2018_J0461
2018	J0470	Dimecaprol injection	100 MG	\$	54.42	2018_J0470
2018	J0475	Baclofen 10 mg injection	10 MG	\$	176.02	2018_J0475
2018	J0476	Baclofen intrathecal trial	50 MCG	\$	54.66	2018_J0476
2018	J0480	Basiliximab	20 MG	\$	3,686.13	2018_J0480
2018	J0485	Belatacept injection	1 MG	\$	3.81	2018_J0485
2018	J0490	Belimumab injection	10 MG	\$	44.16	2018_J0490
2018	J0500	Dicyclomine injection	20 MG	\$	71.57	2018_J0500
2018	J0515	Inj benzotropine mesylate	1 MG	\$	18.47	2018_J0515
2018	J0558	Peng benzathine/procaine inj	100,000 UNITS	\$	11.10	2018_J0558
2018	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	13.90	2018_J0561
2018	J0570	Buprenorphine implant 74.2mg	74.2 MG	\$	1,260.23	2018_J0570

2018	J0583	Bivalirudin	1 MG	\$	0.97	2018_J0583
2018	J0585	Injection, onabotulinumtoxin a	1 UNIT	\$	6.14	2018_J0585
2018	J0586	Abobotulinumtoxin a	5 Unit	\$	8.42	2018_J0586
2018	J0587	Inj, rimabotulinumtoxin b	100 UNITS	\$	12.03	2018_J0587
2018	J0588	Incobotulinumtoxin a	1 UNIT	\$	5.08	2018_J0588
2018	J0592	Buprenorphine hydrochloride	0.1 MG	\$	4.35	2018_J0592
2018	J0594	Busulfan injection	1 MG	\$	10.37	2018_J0594
2018	J0595	Butorphanol tartrate 1 mg	1 MG	\$	2.69	2018_J0595
2018	J0596	Injection, ruconest	10 UNITS	\$	27.65	2018_J0596
2018	J0597	C-1 esterase, berinert	10 UNITS	\$	48.94	2018_J0597
2018	J0598	C-1 esterase, cinryze	10 UNITS	\$	54.26	2018_J0598
2018	J0600	Edetate calcium disodium inj	1000 MG	\$	5,594.42	2018_J0600
2018	J0610	Calcium gluconate injection	10 ML	\$	4.25	2018_J0610
2018	J0630	Calcitonin salmon injection	400 UNITS	\$	2,629.53	2018_J0630
2018	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.51	2018_J0636
2018	J0637	Caspofungin acetate	5 MG	\$	12.64	2018_J0637
2018	J0638	Canakinumab injection	1 MG	\$	111.00	2018_J0638
2018	J0640	Leucovorin calcium injection	50 MG	\$	3.41	2018_J0640
2018	J0641	Levoleucovorin injection	0.5 MG	\$	0.24	2018_J0641
2018	J0670	Inj mepivacaine hcl/10 ml	10 ML	\$	2.30	2018_J0670
2018	J0690	Cefazolin sodium injection	500 MG	\$	0.94	2018_J0690
2018	J0692	Cefepime hcl for injection	500 MG	\$	2.51	2018_J0692
2018	J0694	Cefoxitin sodium injection	1 GM	\$	4.87	2018_J0694
2018	J0696	Ceftriaxone sodium injection	250 MG	\$	0.59	2018_J0696
2018	J0697	Sterile cefuroxime injection	750 MG	\$	1.96	2018_J0697
2018	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	6.93	2018_J0702
2018	J0712	Ceftaroline fosamil inj	10 MG	\$	2.89	2018_J0712
2018	J0713	Inj ceftazidime per 500 mg	500 MG	\$	2.19	2018_J0713
2018	J0717	Certolizumab pegol inj 1mg	1 MG	\$	8.11	2018_J0717
2018	J0720	Chloramphenicol sodium injec	1 GM	\$	39.46	2018_J0720
2018	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	23.95	2018_J0725
2018	J0735	Clonidine hydrochloride	1 MG	\$	13.44	2018_J0735
2018	J0740	Cidofovir injection	375 MG	\$	478.07	2018_J0740
2018	J0743	Cilastatin sodium injection	250 MG	\$	5.98	2018_J0743
2018	J0744	Ciprofloxacin iv	200 MG	\$	1.65	2018_J0744
2018	J0770	Colistimethate sodium inj	150 MG	\$	17.66	2018_J0770
2018	J0775	Collagenase, clostr hist inj	0.01 MG	\$	45.05	2018_J0775
2018	J0780	Prochlorperazine injection	10 MG	\$	10.38	2018_J0780
2018	J0795	Corticotropin ovine triflural	1 MCG	\$	8.59	2018_J0795
2018	J0800	Corticotropin injection	40 UNITS	\$	3,984.76	2018_J0800
2018	J0834	Cosyntropin cortrosyn inj	0.25 MG	\$	36.00	2018_J0834
2018	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	3,250.52	2018_J0840
2018	J0850	Cytomegalovirus imm iv /vial	PER VIAL	\$	1,129.15	2018_J0850
2018	J0875	Injection, dalbavancin	5 MG	\$	14.35	2018_J0875
2018	J0878	Daptomycin injection	1 MG	\$	0.32	2018_J0878
2018	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.77	2018_J0881
2018	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.77	2018_J0882
2018	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	12.27	2018_J0885
2018	J0887	Epoetin beta esrd use	1 MCG	\$	1.74	2018_J0887
2018	J0888	Epoetin beta non esrd	1 MCG	\$	1.74	2018_J0888
2018	J0894	Decitabine injection	1 MG	\$	14.07	2018_J0894
2018	J0895	Deferoxamine mesylate inj	500 MG	\$	7.91	2018_J0895
2018	J0897	Denosumab injection	1 MG	\$	18.58	2018_J0897
2018	J1000	Depo-estradiol cypionate inj	5 MG	\$	21.98	2018_J1000
2018	J1020	Methylprednisolone 20 mg inj	20 MG	\$	4.31	2018_J1020
2018	J1030	Methylprednisolone 40 mg inj	40 MG	\$	6.77	2018_J1030
2018	J1040	Methylprednisolone 80 mg inj	80 MG	\$	13.32	2018_J1040
2018	J1050	Medroxyprogesterone acetate	1 MG	\$	0.56	2018_J1050
2018	J1071	Inj testosterone cypionate	1 MG	\$	0.02	2018_J1071

2018	J1100	Dexamethasone sodium phos	1 MG	\$	0.11	2018_J1100
2018	J1110	Inj dihydroergotamine mesylt	1 MG	\$	73.47	2018_J1110
2018	J1120	Acetazolamid sodium injectio	500 MG	\$	14.52	2018_J1120
2018	J1160	Digoxin injection	0.5 MG	\$	12.51	2018_J1160
2018	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	3,688.29	2018_J1162
2018	J1165	Phenytoin sodium injection	50 MG	\$	0.76	2018_J1165
2018	J1170	Hydromorphone injection	4 MG	\$	2.97	2018_J1170
2018	J1190	Dexrazoxane hcl injection	250 MG	\$	229.93	2018_J1190
2018	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.60	2018_J1200
2018	J1205	Chlorothiazide sodium inj	500 MG	\$	67.67	2018_J1205
2018	J1212	Dimethyl sulfoxide 50% 50 ml	50 ML	\$	535.99	2018_J1212
2018	J1230	Methadone injection	10 MG	\$	18.31	2018_J1230
2018	J1240	Dimenhydrinate injection	50 MG	\$	8.32	2018_J1240
2018	J1245	Dipyridamole injection	10 MG	\$	0.86	2018_J1245
2018	J1250	Inj dobutamine hcl/250 mg	250 MG	\$	5.52	2018_J1250
2018	J1265	Dopamine injection	40 MG	\$	0.56	2018_J1265
2018	J1267	Doripenem injection	10 MG	\$	0.88	2018_J1267
2018	J1270	Injection, doxercalciferol	1 MCG	\$	0.47	2018_J1270
2018	J1290	Ecallantide injection	1 MG	\$	477.96	2018_J1290
2018	J1300	Ecuzimab injection	10 MG	\$	230.48	2018_J1300
2018	J1325	Epoprostenol injection	0.5 MG	\$	16.14	2018_J1325
2018	J1335	Ertapenem injection	500 MG	\$	62.45	2018_J1335
2018	J1364	Erythro lactobionate /500 mg	500 MG	\$	78.87	2018_J1364
2018	J1380	Estradiol valerate 10 mg inj	10 MG	\$	18.09	2018_J1380
2018	J1410	Inj estrogen conjugate 25 mg	25 MG	\$	308.63	2018_J1410
2018	J1430	Ethanolamine oleate 100 mg	100 MG	\$	444.10	2018_J1430
2018	J1439	Inj ferric carboxymaltos 1mg	1 MG	\$	1.06	2018_J1439
2018	J1442	Inj filgrastim excl biosimil	1 MCG	\$	1.02	2018_J1442
2018	J1447	Inj tbo filgrastim 1 microg	1 MCG	\$	0.58	2018_J1447
2018	J1450	Fluconazole	200 MG	\$	4.68	2018_J1450
2018	J1453	Fosaprepitant injection	1 MG	\$	2.19	2018_J1453
2018	J1458	Galsulfase injection	1 MG	\$	389.95	2018_J1458
2018	J1459	Inj ivig privigen 500 mg	500 MG	\$	39.63	2018_J1459
2018	J1460	Gamma globulin 1 cc inj	1 CC	\$	38.05	2018_J1460
2018	J1555	Inj cuvitru, 100 mg	100 MG	\$	13.40	2018_J1555
2018	J1556	Inj, imm glob bivigam, 500mg	500 MG	\$	70.52	2018_J1556
2018	J1557	Gammplex injection	500 MG	\$	52.06	2018_J1557
2018	J1559	Hizentra injection	100 MG	\$	9.86	2018_J1559
2018	J1560	Gamma globulin > 10 cc inj	10 CC	\$	380.48	2018_J1560
2018	J1561	Gamunex-c/gammaked	500 MG	\$	39.49	2018_J1561
2018	J1566	Immune globulin, powder	500 MG	\$	37.95	2018_J1566
2018	J1568	Octagam injection	500 MG	\$	36.72	2018_J1568
2018	J1569	Gammagard liquid injection	500 MG	\$	43.14	2018_J1569
2018	J1570	Ganciclovir sodium injection	500 MG	\$	57.68	2018_J1570
2018	J1571	Hepagam b im injection	0.5 ML	\$	64.22	2018_J1571
2018	J1572	Flebogamma injection	500 MG	\$	35.07	2018_J1572
2018	J1575	Hyqvia 100mg immunoglobulin	100 MG	\$	14.13	2018_J1575
2018	J1580	Garamycin gentamicin inj	80 MG	\$	1.49	2018_J1580
2018	J1602	Golimumab for iv use 1mg	1 MG	\$	24.01	2018_J1602
2018	J1610	Glucagon hydrochloride/1 mg	1 MG	\$	214.39	2018_J1610
2018	J1626	Granisetron hcl injection	100 MCG	\$	0.35	2018_J1626
2018	J1627	Inj, granisetron, xr, 0.1 mg	0.1 MG	\$	3.58	2018_J1627
2018	J1630	Haloperidol injection	5 MG	\$	0.94	2018_J1630
2018	J1631	Haloperidol decanoate inj	50 MG	\$	17.45	2018_J1631
2018	J1640	Hemin, 1 mg	1 MG	\$	23.03	2018_J1640
2018	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.21	2018_J1642
2018	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.20	2018_J1644
2018	J1645	Dalteparin sodium	2500 IU	\$	14.29	2018_J1645
2018	J1650	Inj enoxaparin sodium	10 MG	\$	0.77	2018_J1650

2018	J1652	Fondaparinux sodium	0.5 MG	\$	2.23	2018_J1652
2018	J1670	Tetanus immune globulin inj	250 UNITS	\$	255.70	2018_J1670
2018	J1720	Hydrocortisone sodium succ i	100 MG	\$	13.05	2018_J1720
2018	J1740	Ibandronate sodium injection	1 MG	\$	56.24	2018_J1740
2018	J1742	Ibutilide fumarate injection	1 MG	\$	240.76	2018_J1742
2018	J1743	Idursulfase injection	1 MG	\$	536.56	2018_J1743
2018	J1745	Infliximab not biosimil 10mg	10 MG	\$	78.83	2018_J1745
2018	J1750	Inj iron dextran	50 MG	\$	14.06	2018_J1750
2018	J1756	Iron sucrose injection	1 MG	\$	0.23	2018_J1756
2018	J1786	Imuglucerase injection	10 UNITS	\$	41.45	2018_J1786
2018	J1800	Propranolol injection	1 MG	\$	4.26	2018_J1800
2018	J1815	Insulin injection	5 UNITS	\$	0.94	2018_J1815
2018	J1817	Insulin for insulin pump use	50 UNITS	\$	11.32	2018_J1817
2018	J1885	Ketorolac tromethamine inj	15 MG	\$	0.62	2018_J1885
2018	J1930	Lanreotide injection	1 MG	\$	58.84	2018_J1930
2018	J1931	Laronidase injection	0.1 MG	\$	30.78	2018_J1931
2018	J1940	Furosemide injection	20 MG	\$	0.90	2018_J1940
2018	J1942	Aripiprazole lauroxil 1mg	1 MG	\$	2.44	2018_J1942
2018	J1950	Leuprolide acetate /3.75 mg	3.75 MG	\$	1,193.67	2018_J1950
2018	J1953	Levetiracetam injection	10 MG	\$	0.15	2018_J1953
2018	J1955	Inj levocarnitine per 1 gm	1 GM	\$	29.52	2018_J1955
2018	J1956	Levofloxacin injection	250 MG	\$	1.40	2018_J1956
2018	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	30.46	2018_J1980
2018	J2001	Lidocaine injection	10 MG	\$	0.03	2018_J2001
2018	J2010	Lincomycin injection	300 MG	\$	11.87	2018_J2010
2018	J2020	Linezolid injection	200 MG	\$	9.86	2018_J2020
2018	J2060	Lorazepam injection	2 MG	\$	0.76	2018_J2060
2018	J2150	Mannitol injection	50 ML	\$	2.29	2018_J2150
2018	J2175	Meperidine hydrochl /100 mg	100 MG	\$	4.07	2018_J2175
2018	J2182	Injection, mepolizumab, 1mg	1 MG	\$	29.58	2018_J2182
2018	J2185	Meropenem	100 MG	\$	0.89	2018_J2185
2018	J2210	Methylergonovin maleate inj	0.2 MG	\$	15.83	2018_J2210
2018	J2248	Micafungin sodium injection	1 MG	\$	0.89	2018_J2248
2018	J2250	Inj midazolam hydrochloride	1 MG	\$	0.13	2018_J2250
2018	J2260	Inj milrinone lactate / 5 mg	5 MG	\$	1.50	2018_J2260
2018	J2270	Morphine sulfate injection	10 MG	\$	2.29	2018_J2270
2018	J2274	Inj morphine pf epid ithc	10 MG	\$	17.10	2018_J2274
2018	J2278	Ziconotide injection	1 MCG	\$	7.59	2018_J2278
2018	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	10.12	2018_J2280
2018	J2300	Inj nalbuphine hydrochloride	10 MG	\$	2.94	2018_J2300
2018	J2310	Inj naloxone hydrochloride	1 MG	\$	23.03	2018_J2310
2018	J2315	Naltrexone, depot form	1 MG	\$	3.26	2018_J2315
2018	J2323	Natalizumab injection	1 MG	\$	19.83	2018_J2323
2018	J2350	Injection, ocrelizumab, 1 mg	1 MG	\$	57.34	2018_J2350
2018	J2353	Octreotide injection, depot	1 MG	\$	198.51	2018_J2353
2018	J2354	Octreotide inj, non-depot	25 MCG	\$	0.84	2018_J2354
2018	J2357	Omalizumab injection	5 MG	\$	37.07	2018_J2357
2018	J2358	Olanzapine long-acting inj	1 MG	\$	2.92	2018_J2358
2018	J2360	Orphenadrine injection	60 MG	\$	6.94	2018_J2360
2018	J2400	Chloroprocaine hcl injection	30 ML	\$	30.11	2018_J2400
2018	J2405	Ondansetron hcl injection	1 MG	\$	0.13	2018_J2405
2018	J2407	Injection, oritavancin	10 MG	\$	23.08	2018_J2407
2018	J2425	Palifermin injection	50 MCG	\$	20.29	2018_J2425
2018	J2426	Paliperidone palmitate inj	1 MG	\$	10.94	2018_J2426
2018	J2430	Pamidronate disodium /30 mg	30 MG	\$	9.54	2018_J2430
2018	J2469	Palonosetron hcl	25 MCG	\$	17.14	2018_J2469
2018	J2501	Paricalcitol	1 MCG	\$	0.55	2018_J2501
2018	J2503	Pegaptanib sodium injection	0.3 MG	\$	713.86	2018_J2503
2018	J2504	Pegademase bovine, 25 iu	25 IU	\$	367.96	2018_J2504

2018	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	4,687.71	2018_J2505
2018	J2507	Pegloticase injection	1 MG	\$	2,334.59	2018_J2507
2018	J2510	Penicillin g procaine inj	600000 UNITS	\$	29.29	2018_J2510
2018	J2515	Pentobarbital sodium inj	50 MG	\$	47.08	2018_J2515
2018	J2540	Penicillin g potassium inj	600000 UNITS	\$	1.07	2018_J2540
2018	J2543	Piperacillin/tazobactam	1.125 GM	\$	2.09	2018_J2543
2018	J2545	Pentamidine non-comp unit	300 MG	\$	121.44	2018_J2545
2018	J2550	Promethazine hcl injection	50 MG	\$	1.62	2018_J2550
2018	J2560	Phenobarbital sodium inj	120 MG	\$	38.43	2018_J2560
2018	J2562	Plerixafor injection	1 MG	\$	330.41	2018_J2562
2018	J2597	Inj desmopressin acetate	1 MCG	\$	12.60	2018_J2597
2018	J2675	Inj progesterone per 50 mg	50 MG	\$	1.51	2018_J2675
2018	J2680	Fluphenazine decanoate 25 mg	25 MG	\$	14.31	2018_J2680
2018	J2690	Procainamide hcl injection	1 GM	\$	67.77	2018_J2690
2018	J2700	Oxacillin sodium injecton	250 MG	\$	1.82	2018_J2700
2018	J2704	Inj. propofol, 10 mg	10 MG	\$	0.11	2018_J2704
2018	J2720	Inj protamine sulfate/10 mg	10 MG	\$	1.04	2018_J2720
2018	J2724	Protein c concentrate	10 UNITS	\$	15.15	2018_J2724
2018	J2765	Metoclopramide hcl injection	10 MG	\$	1.16	2018_J2765
2018	J2770	Quinupristin/dalfopristin	500 MG	\$	418.37	2018_J2770
2018	J2778	Ranibizumab injection	0.1 mg	\$	373.36	2018_J2778
2018	J2780	Ranitidine hydrochloride inj	25 MG	\$	4.81	2018_J2780
2018	J2783	Rasburicase	0.5 MG	\$	278.15	2018_J2783
2018	J2785	Regadenoson injection	0.1 MG	\$	56.56	2018_J2785
2018	J2786	Injection, reslizumab, 1mg	1 MG	\$	9.30	2018_J2786
2018	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	28.14	2018_J2788
2018	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	86.78	2018_J2790
2018	J2791	Rhophylac injection	100 IU	\$	4.80	2018_J2791
2018	J2792	Rho(d) immune globulin h, sd	100 IU	\$	27.02	2018_J2792
2018	J2794	Risperidone, long acting	0.5 MG	\$	9.41	2018_J2794
2018	J2795	Ropivacaine hcl injection	1 MG	\$	0.10	2018_J2795
2018	J2796	Romiplostim injection	10 MCG	\$	71.40	2018_J2796
2018	J2800	Methocarbamol injection	10 ML	\$	22.19	2018_J2800
2018	J2805	Sinacalide injection	5 MCG	\$	104.86	2018_J2805
2018	J2810	Inj theophylline per 40 mg	40 MG	\$	0.32	2018_J2810
2018	J2820	Sargramostim injection	50 MCG	\$	37.61	2018_J2820
2018	J2916	Na ferric gluconate complex	12.5 MG	\$	2.28	2018_J2916
2018	J2920	Methylprednisolone injection	40 MG	\$	4.72	2018_J2920
2018	J2930	Methylprednisolone injection	125 MG	\$	6.94	2018_J2930
2018	J2997	Alteplase recombinant	1 MG	\$	87.78	2018_J2997
2018	J3000	Streptomycin injection	1 GM	\$	27.23	2018_J3000
2018	J3010	Fentanyl citrate injection	0.1 MG	\$	0.68	2018_J3010
2018	J3060	Inj, taliglucerase alfa 10 u	10 UNITS	\$	40.39	2018_J3060
2018	J3070	Pentazocine injection	30 MG	\$	108.39	2018_J3070
2018	J3090	Inj tedizolid phosphate	1 MG	\$	1.43	2018_J3090
2018	J3095	Telavancin injection	10 MG	\$	5.47	2018_J3095
2018	J3101	Tenecteplase injection	1 MG	\$	121.76	2018_J3101
2018	J3105	Terbutaline sulfate inj	1 MG	\$	1.98	2018_J3105
2018	J3121	Inj testosterone enanthate 1mg	1 MG	\$	0.04	2018_J3121
2018	J3145	Testosterone undecanoate 1mg	1 MG	\$	1.36	2018_J3145
2018	J3230	Chlorpromazine hcl injection	50 MG	\$	29.49	2018_J3230
2018	J3240	Thyrotropin injection	0.9 MG	\$	1,624.45	2018_J3240
2018	J3243	Tigecycline injection	1 MG	\$	2.06	2018_J3243
2018	J3250	Trimethobenzamide hcl inj	200 MG	\$	33.06	2018_J3250
2018	J3260	Tobramycin sulfate injection	80 MG	\$	3.30	2018_J3260
2018	J3262	Tocilizumab injection	1 MG	\$	4.73	2018_J3262
2018	J3285	Treprostinil injection	1 MG	\$	66.14	2018_J3285
2018	J3300	Triamcinolone a inj prs-free	1 MG	\$	3.86	2018_J3300
2018	J3301	Triamcinolone acet inj nos	10 MG	\$	1.74	2018_J3301

2018	J3315	Triptorelin pamoate	3.75 MG	\$	267.38	2018_J3315
2018	J3357	Ustekinumab sub cu inj, 1 mg	1 MG	\$	191.03	2018_J3357
2018	J3358	Ustekinumab, iv inject,1 mg	1 MG	\$	12.28	2018_J3358
2018	J3360	Diazepam injection	5 MG	\$	6.87	2018_J3360
2018	J3370	Vancomycin hcl injection	500 MG	\$	4.04	2018_J3370
2018	J3380	Injection, vedolizumab	1 MG	\$	19.58	2018_J3380
2018	J3385	Velaglucerase alfa	100 UNITS	\$	345.39	2018_J3385
2018	J3396	Verteporfin injection	0.1 MG	\$	10.95	2018_J3396
2018	J3410	Hydroxyzine hcl injection	25 MG	\$	4.79	2018_J3410
2018	J3411	Thiamine hcl 100 mg	100 MG	\$	3.01	2018_J3411
2018	J3415	Pyridoxine hcl 100 mg	100 MG	\$	8.53	2018_J3415
2018	J3420	Vitamin b12 injection	1000 MCG	\$	1.96	2018_J3420
2018	J3430	Vitamin k phytonadione inj	1 MG	\$	4.29	2018_J3430
2018	J3465	Injection, voriconazole	10 MG	\$	1.90	2018_J3465
2018	J3471	Ovine, up to 999 usp units	1 UNIT	\$	0.41	2018_J3471
2018	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.36	2018_J3473
2018	J3475	Inj magnesium sulfate	500 MG	\$	0.77	2018_J3475
2018	J3480	Inj potassium chloride	2 MEQ	\$	0.15	2018_J3480
2018	J3485	Zidovudine	10 MG	\$	1.51	2018_J3485
2018	J3486	Ziprasidone mesylate	10 MG	\$	18.86	2018_J3486
2018	J3489	Zoledronic acid 1mg	1 MG	\$	12.98	2018_J3489
2018	J7030	Normal saline solution infus	1000 ML	\$	2.63	2018_J7030
2018	J7040	Normal saline solution infus	500 ML	\$	1.32	2018_J7040
2018	J7042	5% dextrose/normal saline	500 ML	\$	1.08	2018_J7042
2018	J7050	Normal saline solution infus	250 ML	\$	0.68	2018_J7050
2018	J7060	5% dextrose/water	500 ML	\$	2.53	2018_J7060
2018	J7070	D5w infusion	1000 CC	\$	4.94	2018_J7070
2018	J7120	Ringers lactate infusion	1000 CC	\$	2.51	2018_J7120
2018	J7180	Factor xiii anti-hem factor	1 IU	\$	8.23	2018_J7180
2018	J7182	Factor viii recomb novoeight	1 IU	\$	1.34	2018_J7182
2018	J7183	Wilate injection	1 I.U. VWF:RCO	\$	1.01	2018_J7183
2018	J7185	Xyntha inj	1 IU	\$	1.22	2018_J7185
2018	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	0.99	2018_J7186
2018	J7187	Humate-p, inj	1 IU	\$	1.12	2018_J7187
2018	J7189	Factor viia	1 MCG	\$	2.06	2018_J7189
2018	J7190	Factor viii	1 IU	\$	1.07	2018_J7190
2018	J7192	Factor viii recombinant nos	1 IU	\$	1.33	2018_J7192
2018	J7193	Factor ix non-recombinant	1 IU	\$	1.12	2018_J7193
2018	J7194	Factor ix complex	1 IU	\$	1.42	2018_J7194
2018	J7195	Factor ix recombinant nos	1 IU	\$	1.51	2018_J7195
2018	J7197	Antithrombin iii injection	1 IU	\$	3.49	2018_J7197
2018	J7198	Anti-inhibitor	1 IU	\$	2.08	2018_J7198
2018	J7200	Factor ix recombinan rixubis	1 IU	\$	1.30	2018_J7200
2018	J7201	Factor ix alprolix recomb	1 IU	\$	2.99	2018_J7201
2018	J7202	Factor ix idelvion inj	1 IU	\$	4.28	2018_J7202
2018	J7205	Factor viii fc fusion recomb	1 IU	\$	2.01	2018_J7205
2018	J7207	Factor viii pegylated recomb	1 IU	\$	1.72	2018_J7207
2018	J7308	Aminolevulinic acid hcl top	354 MG	\$	404.59	2018_J7308
2018	J7311	Fluocinolone acetonide implt	0.59 MG	\$	20,130.50	2018_J7311
2018	J7312	Dexamethasone intra implant	0.1 MG	\$	200.17	2018_J7312
2018	J7313	Fluocinol acet intravit imp	0.01 MG	\$	490.33	2018_J7313
2018	J7316	Inj, ocriplasmin, 0.125 mg	0.125 MG	\$	1,040.50	2018_J7316
2018	J7321	Hyalgan supartz visco-3 dose	per dose	\$	85.30	2018_J7321
2018	J7323	Euflexxa inj per dose	per dose	\$	141.47	2018_J7323
2018	J7324	Orthovisc inj per dose	per dose	\$	147.79	2018_J7324
2018	J7325	Synvisc or synvisc-one	1 MG	\$	11.83	2018_J7325
2018	J7326	Gel-one	per dose	\$	537.36	2018_J7326
2018	J7327	Monovisc inj per dose	Per Dose	\$	779.35	2018_J7327
2018	J7336	Capsaicin 8% patch	1 SQ CM	\$	3.16	2018_J7336

2018	J7500	Azathioprine oral 50mg	50 MG	\$	0.67	2018_J7500
2018	J7502	Cyclosporine oral 100 mg	100 MG	\$	2.55	2018_J7502
2018	J7503	Tacrol envarsus ex rel oral	0.25 MG	\$	1.26	2018_J7503
2018	J7504	Lymphocyte immune globulin	250 MG	\$	2,081.22	2018_J7504
2018	J7507	Tacrolimus imme rel oral 1mg	1 MG	\$	0.63	2018_J7507
2018	J7508	Tacrol astagraf ex rel oral	0.1 MG	\$	0.47	2018_J7508
2018	J7509	Methylprednisolone oral	4 MG	\$	0.21	2018_J7509
2018	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.06	2018_J7510
2018	J7511	Antithymocyte globuln rabbit	25 MG	\$	751.25	2018_J7511
2018	J7512	Prednisone ir or dr oral 1mg	1 MG	\$	0.01	2018_J7512
2018	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.73	2018_J7515
2018	J7516	Cyclosporin parenteral 250mg	250 MG	\$	45.86	2018_J7516
2018	J7517	Mycophenolate mofetil oral	250 MG	\$	1.76	2018_J7517
2018	J7518	Mycophenolic acid	180 MG	\$	2.92	2018_J7518
2018	J7520	Sirolimus, oral	1 MG	\$	7.79	2018_J7520
2018	J7525	Tacrolimus injection	5 MG	\$	205.62	2018_J7525
2018	J7527	Oral everolimus	0.25 MG	\$	8.62	2018_J7527
2018	J7605	Arformoterol non-comp unit	15 mcg	\$	9.77	2018_J7605
2018	J7606	Formoterol fumarate, inh	20 MCG	\$	10.98	2018_J7606
2018	J7608	Acetylcysteine non-comp unit	1 GM	\$	6.73	2018_J7608
2018	J7611	Albuterol non-comp con	1 MG	\$	0.15	2018_J7611
2018	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.20	2018_J7612
2018	J7613	Albuterol non-comp unit	1 MG	\$	0.04	2018_J7613
2018	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.06	2018_J7614
2018	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.13	2018_J7620
2018	J7626	Budesonide non-comp unit	0.5 MG	\$	2.26	2018_J7626
2018	J7631	Cromolyn sodium noncomp unit	10 MG	\$	5.51	2018_J7631
2018	J7639	Dornase alfa non-comp unit	1 MG	\$	47.79	2018_J7639
2018	J7644	Ipratropium bromide non-comp	1 MG	\$	0.22	2018_J7644
2018	J7674	Methacholine chloride, neb	1 MG	\$	0.54	2018_J7674
2018	J7682	Tobramycin non-comp unit	300 MG	\$	38.79	2018_J7682
2018	J7686	Treprostinil, non-comp unit	1.74 MG	\$	584.33	2018_J7686
2018	J8501	Oral aprepitant	5 MG	\$	6.72	2018_J8501
2018	J8510	Oral busulfan	2 MG	\$	24.20	2018_J8510
2018	J8520	Capecitabine, oral, 150 mg	150 MG	\$	1.22	2018_J8520
2018	J8521	Capecitabine, oral, 500 mg	500 MG	\$	3.51	2018_J8521
2018	J8530	Cyclophosphamide oral 25 mg	25 MG	\$	4.86	2018_J8530
2018	J8540	Oral dexamethasone	0.25 MG	\$	0.07	2018_J8540
2018	J8560	Etoposide oral 50 mg	50 MG	\$	75.56	2018_J8560
2018	J8600	Melphalan oral 2 mg	2 MG	\$	12.00	2018_J8600
2018	J8610	Methotrexate oral 2.5 mg	2.5 MG	\$	0.71	2018_J8610
2018	J8655	Netupitant palonosetron oral	0.5 MG	\$	301.94	2018_J8655
2018	J8670	Rolapitant, oral, 1mg	1 MG	\$	2.21	2018_J8670
2018	J8700	Temozolomide	5 MG	\$	0.74	2018_J8700
2018	J8705	Topotecan oral	0.25 mg	\$	103.65	2018_J8705
2018	J9000	Doxorubicin hcl injection	10 MG	\$	2.93	2018_J9000
2018	J9017	Arsenic trioxide injection	1 MG	\$	77.03	2018_J9017
2018	J9019	Erwinaze injection	1,000 IU	\$	414.83	2018_J9019
2018	J9022	Inj, atezolizumab,10 mg	10 MG	\$	76.91	2018_J9022
2018	J9023	Injection, avelumab, 10 mg	10 MG	\$	81.82	2018_J9023
2018	J9025	Azacitidine injection	1 MG	\$	1.47	2018_J9025
2018	J9027	Clofarabine injection	1 MG	\$	111.29	2018_J9027
2018	J9031	Bcg live intravesical vac	1 EA	\$	140.62	2018_J9031
2018	J9032	Injection, belinostat, 10mg	10 MG	\$	37.74	2018_J9032
2018	J9033	Inj., treanda 1 mg	1 MG	\$	30.58	2018_J9033
2018	J9034	Inj., bendeka 1 mg	1 MG	\$	23.84	2018_J9034
2018	J9035	Bevacizumab injection	10 MG	\$	79.25	2018_J9035
2018	J9039	Injection, blinatumomab	1 MCG	\$	110.37	2018_J9039
2018	J9040	Bleomycin sulfate injection	15 UNITS	\$	29.41	2018_J9040

2018	J9041	Bortezomib injection	0.1 MG	\$	45.55	2018_J9041
2018	J9042	Brentuximab vedotin inj	1 MG	\$	150.48	2018_J9042
2018	J9043	Cabazitaxel injection	1 MG	\$	167.99	2018_J9043
2018	J9045	Carboplatin injection	50 MG	\$	3.18	2018_J9045
2018	J9047	Injection, carfilzomib, 1 mg	1 MG	\$	36.32	2018_J9047
2018	J9050	Carmustine injection	100 MG	\$	4,051.50	2018_J9050
2018	J9055	Cetuximab injection	10 MG	\$	60.63	2018_J9055
2018	J9060	Cisplatin 10 mg injection	10 MG	\$	1.76	2018_J9060
2018	J9065	Inj cladribine per 1 mg	1 MG	\$	22.64	2018_J9065
2018	J9070	Cyclophosphamide 100 mg inj	100 MG	\$	41.61	2018_J9070
2018	J9098	Cytarabine liposome inj	10 MG	\$	628.37	2018_J9098
2018	J9100	Cytarabine hcl 100 mg inj	100 MG	\$	0.63	2018_J9100
2018	J9120	Dactinomycin injection	0.5 MG	\$	1,427.67	2018_J9120
2018	J9130	Dacarbazine 100 mg inj	100 MG	\$	4.31	2018_J9130
2018	J9145	Injection, daratumumab 10 mg	10 MG	\$	52.41	2018_J9145
2018	J9150	Daunorubicin injection	10 MG	\$	50.66	2018_J9150
2018	J9155	Degarelix injection	1 MG	\$	3.72	2018_J9155
2018	J9171	Docetaxel injection	1 MG	\$	1.51	2018_J9171
2018	J9176	Injection, elotuzumab, 1mg	1 MG	\$	6.42	2018_J9176
2018	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.32	2018_J9178
2018	J9179	Eribulin mesylate injection	0.1 MG	\$	114.34	2018_J9179
2018	J9181	Etoposide injection	10 MG	\$	0.73	2018_J9181
2018	J9185	Fludarabine phosphate inj	50 MG	\$	59.94	2018_J9185
2018	J9190	Fluorouracil injection	500 MG	\$	1.80	2018_J9190
2018	J9200	Floxuridine injection	500 MG	\$	92.00	2018_J9200
2018	J9201	Gemcitabine hcl injection	200 MG	\$	7.43	2018_J9201
2018	J9202	Goserelin acetate implant	3.6 MG	\$	509.02	2018_J9202
2018	J9205	Inj irinotecan liposome 1 mg	1 MG	\$	45.53	2018_J9205
2018	J9206	Irinotecan injection	20 MG	\$	3.22	2018_J9206
2018	J9207	Ixabepilone injection	1 MG	\$	70.99	2018_J9207
2018	J9208	Ifosfamide injection	1 GM	\$	25.61	2018_J9208
2018	J9209	Mesna injection	200 MG	\$	2.38	2018_J9209
2018	J9211	Idarubicin hcl injection	5 MG	\$	34.26	2018_J9211
2018	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	34.15	2018_J9214
2018	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	228.41	2018_J9217
2018	J9218	Leuprolide acetate injecton	1 MG	\$	27.17	2018_J9218
2018	J9225	Vantas implant	50 MG	\$	3,610.32	2018_J9225
2018	J9226	Supprelin la implant	50 MG	\$	31,835.05	2018_J9226
2018	J9228	Ipilimumab injection	1 MG	\$	150.87	2018_J9228
2018	J9230	Mechlorethamine hcl inj	10 MG	\$	321.72	2018_J9230
2018	J9245	Inj melphalan hydrochl 50 mg	50 MG	\$	814.80	2018_J9245
2018	J9250	Methotrexate sodium inj	5 MG	\$	0.25	2018_J9250
2018	J9260	Methotrexate sodium inj	50 MG	\$	2.50	2018_J9260
2018	J9261	Nelarabine injection	50 MG	\$	152.21	2018_J9261
2018	J9263	Oxaliplatin	0.5 MG	\$	0.17	2018_J9263
2018	J9264	Paclitaxel protein bound	1 MG	\$	11.60	2018_J9264
2018	J9266	Pegaspargase injection	1 EA	\$	15,028.71	2018_J9266
2018	J9267	Paclitaxel injection	1 MG	\$	0.14	2018_J9267
2018	J9268	Pentostatin injection	10 MG	\$	2,096.29	2018_J9268
2018	J9271	Inj pembrolizumab	1 MG	\$	49.35	2018_J9271
2018	J9280	Mitomycin injection	5 MG	\$	134.25	2018_J9280
2018	J9285	Inj, olaratumab, 10 mg	10 MG	\$	51.04	2018_J9285
2018	J9293	Mitoxantrone hydrochl / 5 mg	5 MG	\$	27.36	2018_J9293
2018	J9295	Injection, necitumumab, 1 mg	1 MG	\$	5.57	2018_J9295
2018	J9299	Injection, nivolumab	1 MG	\$	27.54	2018_J9299
2018	J9301	Obinutuzumab inj	10 MG	\$	62.63	2018_J9301
2018	J9302	Ofatumumab injection	10 MG	\$	58.55	2018_J9302
2018	J9303	Panitumumab injection	10 MG	\$	114.38	2018_J9303
2018	J9305	Pemetrexed injection	10 MG	\$	68.22	2018_J9305

2018	J9306	Injection, pertuzumab, 1 mg	1 MG	\$	11.87	2018_J9306
2018	J9307	Pralatrexate injection	1 MG	\$	271.61	2018_J9307
2018	J9308	Injection, ramucirumab	5 MG	\$	57.68	2018_J9308
2018	J9310	Rituximab injection	100 MG	\$	919.85	2018_J9310
2018	J9315	Romidepsin injection	1 MG	\$	322.58	2018_J9315
2018	J9320	Streptozocin injection	1 GM	\$	348.71	2018_J9320
2018	J9325	Inj talimogene laherparepvec	1 million PFU	\$	49.99	2018_J9325
2018	J9328	Temozolomide injection	1 MG	\$	10.55	2018_J9328
2018	J9330	Temsirolimus injection	1 MG	\$	73.75	2018_J9330
2018	J9351	Topotecan injection	0.1 MG	\$	1.08	2018_J9351
2018	J9352	Injection trabectedin 0.1mg	0.1 MG	\$	300.67	2018_J9352
2018	J9354	Inj, ado-trastuzumab emt 1mg	1 MG	\$	30.78	2018_J9354
2018	J9355	Trastuzumab injection	10 MG	\$	104.12	2018_J9355
2018	J9357	Valrubicin injection	200 MG	\$	1,328.67	2018_J9357
2018	J9360	Vinblastine sulfate inj	1 MG	\$	3.79	2018_J9360
2018	J9370	Vincristine sulfate 1 mg inj	1 MG	\$	5.35	2018_J9370
2018	J9371	Inj, vincristine sul lip 1mg	1 MG	\$	2,916.62	2018_J9371
2018	J9390	Vinorelbine tartrate inj	10 MG	\$	17.65	2018_J9390
2018	J9395	Injection, fulvestrant	25 MG	\$	97.94	2018_J9395
2018	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.32	2018_J9400
2018	P9041	Albumin (human),5%, 50ml	50 ML	\$	10.49	2018_P9041
2018	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	52.45	2018_P9045
2018	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	20.98	2018_P9046
2018	P9047	Albumin (human), 25%, 50ml	50 ML	\$	52.45	2018_P9047
2018	Q0138	Ferumoxytol, non-esrd	1 MG	\$	0.98	2018_Q0138
2018	Q0139	Ferumoxytol, esrd use	1 MG	\$	0.98	2018_Q0139
2018	Q0162	Ondansetron oral	1 MG	\$	0.02	2018_Q0162
2018	Q0163	Diphenhydramine hcl 50mg	50 MG	\$	0.27	2018_Q0163
2018	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.03	2018_Q0164
2018	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	4.05	2018_Q0166
2018	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	1.92	2018_Q0167
2018	Q0169	Promethazine hcl 12.5mg oral	12.5 MG	\$	0.01	2018_Q0169
2018	Q2035	Afluria vacc, 3 yrs & >, im	0.5 ml	\$	18.24	2018_Q2035
2018	Q2043	Sipuleucel-t auto cd54+	Per infusion (minimum 50 million cells)	\$	43,419.43	2018_Q2043
2018	Q2050	Doxorubicin inj 10mg	10 MG	\$	383.57	2018_Q2050
2018	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	54.11	2018_Q3027
2018	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	141.85	2018_Q4074
2018	Q4081	Epoetin alfa, 100 units esrd	100 UNITS	\$	1.23	2018_Q4081
2018	Q4101	Apligraf	1 SQ CM	\$	30.80	2018_Q4101
2018	Q4102	Oasis wound matrix	1 SQ CM	\$	11.52	2018_Q4102
2018	Q4106	Dermagraft	1 SQ CM	\$	33.15	2018_Q4106
2018	Q4107	Graftjacket	1 SQ CM	\$	87.49	2018_Q4107
2018	Q4111	Gammagraft	1 SQ CM	\$	7.26	2018_Q4111
2018	Q4112	Cymetra injectable	1 CC	\$	754.72	2018_Q4112
2018	Q4113	Graftjacket xpress	1 CC	\$	754.72	2018_Q4113
2018	Q4115	Alloskin	1 SQ CM	\$	11.21	2018_Q4115
2018	Q4121	Theraskin	1 SQ CM	\$	45.83	2018_Q4121
2018	Q4123	Alloskin	1 SQ CM	\$	20.19	2018_Q4123
2018	Q4131	Epifix or epicord	1 SQ CM	\$	159.91	2018_Q4131
2018	Q4132	Grafix core, grafixpl core	1 SQ CM	\$	132.22	2018_Q4132
2018	Q4133	Grafix prime grafix pl prime	1 SQ CM	\$	131.79	2018_Q4133
2018	Q4172	Puraply or puraply am	1 SQ CM	\$	71.20	2018_Q4172
2018	Q5101	Inj filgrastim gcsf biosimil	1 MCG	\$	0.64	2018_Q5101
2018	Q5103	Injection, inflectra	10 MG	\$	61.36	2018_Q5103
2018	Q5104	Injection, renflexis	10 MG	\$	64.38	2018_Q5104
2018	Q5105	Inj Retacrit esrd on dialysi	100 UNITS	\$	1.17	2018_Q5105
2018	Q5106	Inj Retacrit non-esrd use	1000 UNITS	\$	11.69	2018_Q5106
2018	Q5108	Injection, fulphila	0.5 MG	\$	368.79	2018_Q5108
2018	Q9950	Inj sulf hexa lipid microsph	1 ML	\$	20.48	2018_Q9950

2018	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	32.47	2018_Q9956
2018	Q9957	Inj perflutren lip micros,ml	1 ML	\$	48.71	2018_Q9957
2018	Q9958	Hocm <=149 mg/ml iodine, 1ml	1 ML	\$	0.08	2018_Q9958
2018	Q9960	Hocm 200-249mg/ml iodine,1ml	1 ML	\$	0.24	2018_Q9960
2018	Q9961	Hocm 250-299mg/ml iodine,1ml	1 ML	\$	0.26	2018_Q9961
2018	Q9963	Hocm 350-399mg/ml iodine,1ml	1 ML	\$	0.20	2018_Q9963
2018	Q9965	Locm 100-199mg/ml iodine,1ml	1 ML	\$	1.04	2018_Q9965
2018	Q9966	Locm 200-299mg/ml iodine,1ml	1 ML	\$	0.34	2018_Q9966
2018	Q9967	Locm 300-399mg/ml iodine,1ml	1 ML	\$	0.12	2018_Q9967
2018	Q9991	Buprenorph xr 100 mg or less	Less than or equal to 100 MG	\$	1,674.80	2018_Q9991
2018	Q9992	Buprenorphine xr over 100 mg	Greater than 100 MG	\$	1,674.80	2018_Q9992
2018	Q9993	Inj., triamcinolone ext rel	1 MG	\$	18.88	2018_Q9993
2018	Q9995	Inj. emicizumab-kxwh, 0.5 mg	0.5 MG	\$	48.86	2018_Q9995
2017	90371	Hep b ig im	1 ML	\$	124.27	2017_90371
2017	90375	Rabies ig im/sc	150 IU	\$	314.27	2017_90375
2017	90376	Rabies ig heat treated	150 IU	\$	317.43	2017_90376
2017	90585	Bcg vaccine percut	50 MG	\$	131.25	2017_90585
2017	90586	Bcg vaccine intravesical	1 EACH	\$	131.25	2017_90586
2017	90630	Flu vacc iiv4 no preserv id	0.1 ml	\$	20.34	2017_90630
2017	90632	Hepa vaccine adult im	1 ML	\$	53.39	2017_90632
2017	90653	liv adjuvant vaccine im	0.5 ml	\$	50.22	2017_90653
2017	90656	liv3 vacc no prsv 0.5 ml im	0.5 ML	\$	19.25	2017_90656
2017	90662	liv no prsv increased ag im	0.5 ML	\$	49.03	2017_90662
2017	90670	Pcv13 vaccine im	0.5 ML	\$	192.64	2017_90670
2017	90673	Riv3 vaccine no preserv im	0.5 ML	\$	40.61	2017_90673
2017	90674	Cciiv4 vac no prsv 0.5 ml im	0.5 ML	\$	24.05	2017_90674
2017	90675	Rabies vaccine im	1 ML	\$	269.12	2017_90675
2017	90682	RIV4 VACC RECOMBINANT DNA IM	0.5 ML	\$	46.31	2017_90682
2017	90685	liv4 vacc no prsv 0.25 ml im	0.25 mL	\$	21.20	2017_90685
2017	90686	liv4 vacc no prsv 0.5 ml im	0.5 ml	\$	19.03	2017_90686
2017	90687	liv4 vaccine splt 0.25 ml im	0.25 ML	\$	9.40	2017_90687
2017	90688	liv4 vaccine splt 0.5 ml im	0.5 ML	\$	17.84	2017_90688
2017	90691	Typhoid vaccine im	0.5 ML	\$	82.16	2017_90691
2017	90714	Td vacc no presv 7 yrs+ im	0.5 ML	\$	22.07	2017_90714
2017	90715	Tdap vaccine 7 yrs/> im	0.5 ML	\$	31.67	2017_90715
2017	90732	Ppsv23 vacc 2 yrs+ subq/im	0.5 ML	\$	98.85	2017_90732
2017	90740	Hepb vacc 3 dose immunsup im	40 MCG	\$	126.60	2017_90740
2017	90743	Hepb vacc 2 doseadolesc im	1 DOSE	\$	26.13	2017_90743
2017	90744	Hepb vacc 3 dose ped/adol im	1 DOSE	\$	26.14	2017_90744
2017	90746	Hepb vaccine 3 dose adult im	20 MCG	\$	63.30	2017_90746
2017	90747	Hepb vacc 4 dose immunsup im	40 MCG	\$	126.60	2017_90747
2017	90756	CCIIV4 VACC ABX FREE IM	0.5 ML	\$	22.79	2017_90756
2017	A9575	Inj gadoterate meglumi 0.1ml	0.1 ml	\$	0.22	2017_A9575
2017	A9576	Inj prohance multipack	1 ML	\$	1.73	2017_A9576
2017	A9577	Inj multihance	1 ML	\$	2.08	2017_A9577
2017	A9578	Inj multihance multipack	1 ML	\$	1.99	2017_A9578
2017	A9579	Gad-base mr contrast nos,1ml	1 ML	\$	1.99	2017_A9579
2017	A9581	Gadoxetate disodium inj	1 ML	\$	13.94	2017_A9581
2017	A9585	Gadobutrol injection	0.1 ML	\$	0.38	2017_A9585
2017	A9606	Radium ra223 dichloride ther	1 microCurie	N/A		2017_A9606
2017	J0129	Abatacept injection	10 MG	\$	49.59	2017_J0129
2017	J0130	Abciximab injection	10 MG	\$	1,215.20	2017_J0130
2017	J0132	Acetylcysteine injection	100 MG	\$	1.23	2017_J0132
2017	J0133	Acyclovir injection	5 MG	\$	0.07	2017_J0133
2017	J0153	Adenosine inj 1mg	1 MG	\$	0.61	2017_J0153
2017	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.81	2017_J0171
2017	J0178	Aflibercept injection	1 MG	\$	974.59	2017_J0178
2017	J0180	Agalsidase beta injection	1 MG	\$	171.07	2017_J0180
2017	J0202	Injection, alemtuzumab	1 MG	\$	1,778.60	2017_J0202

2017	J0207	Amifostine	500 MG	\$	959.81	2017_J0207
2017	J0221	Lumizyme injection	10 MG	\$	159.73	2017_J0221
2017	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.94	2017_J0256
2017	J0257	Glassia injection	10 MG	\$	4.57	2017_J0257
2017	J0278	Amikacin sulfate injection	100 MG	\$	1.63	2017_J0278
2017	J0280	Aminophyllin 250 mg inj	250 MG	\$	9.22	2017_J0280
2017	J0285	Amphotericin b	50 MG	\$	32.78	2017_J0285
2017	J0287	Amphotericin b lipid complex	10 MG	\$	13.86	2017_J0287
2017	J0289	Amphotericin b liposome inj	10 MG	\$	21.52	2017_J0289
2017	J0290	Ampicillin 500 mg inj	500 MG	\$	1.11	2017_J0290
2017	J0295	Ampicillin sodium per 1.5 gm	1.5 GM	\$	2.97	2017_J0295
2017	J0348	Anidulafungin injection	1 MG	\$	0.54	2017_J0348
2017	J0360	Hydralazine hcl injection	20 MG	\$	3.26	2017_J0360
2017	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	4.89	2017_J0401
2017	J0456	Azithromycin	500 MG	\$	3.37	2017_J0456
2017	J0461	Atropine sulfate injection	0.01 MG	\$	0.05	2017_J0461
2017	J0470	Dimecaprol injection	100 MG	\$	52.69	2017_J0470
2017	J0475	Baclofen 10 mg injection	10 MG	\$	164.62	2017_J0475
2017	J0476	Baclofen intrathecal trial	50 MCG	\$	70.34	2017_J0476
2017	J0480	Basiliximab	20 MG	\$	3,440.37	2017_J0480
2017	J0485	Belatacept injection	1 MG	\$	3.94	2017_J0485
2017	J0490	Belimumab injection	10 MG	\$	42.81	2017_J0490
2017	J0500	Dicyclomine injection	20 MG	\$	74.94	2017_J0500
2017	J0515	Inj benzotropine mesylate	1 MG	\$	20.22	2017_J0515
2017	J0558	Peng benzathine/procaine inj	100,000 UNITS	\$	9.34	2017_J0558
2017	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	11.92	2017_J0561
2017	J0570	Buprenorphine implant 74.2mg	74.2 MG	\$	1,261.31	2017_J0570
2017	J0583	Bivalirudin	1 MG	\$	1.23	2017_J0583
2017	J0585	Injection,onabotulinumtoxina	1 UNIT	\$	6.03	2017_J0585
2017	J0586	Abobotulinumtoxina	5 Unit	\$	8.26	2017_J0586
2017	J0587	Inj, rimabotulinumtoxinb	100 UNITS	\$	11.98	2017_J0587
2017	J0588	Incobotulinumtoxin a	1 UNIT	\$	5.08	2017_J0588
2017	J0592	Buprenorphine hydrochloride	0.1 MG	\$	3.45	2017_J0592
2017	J0594	Busulfan injection	1 MG	\$	34.73	2017_J0594
2017	J0595	Butorphanol tartrate 1 mg	1 MG	\$	2.55	2017_J0595
2017	J0596	Injection, ruconest	10 UNITS	\$	27.99	2017_J0596
2017	J0597	C-1 esterase, berinert	10 UNITS	\$	48.97	2017_J0597
2017	J0598	C-1 esterase, cinryze	10 UNITS	\$	57.21	2017_J0598
2017	J0600	Edetate calcium disodium inj	1000 MG	\$	5,594.42	2017_J0600
2017	J0610	Calcium gluconate injection	10 ML	\$	2.98	2017_J0610
2017	J0630	Calcitonin salmon injection	400 UNITS	\$	2,287.94	2017_J0630
2017	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.66	2017_J0636
2017	J0637	Caspofungin acetate	5 MG	\$	12.46	2017_J0637
2017	J0638	Canakinumab injection	1 MG	\$	106.12	2017_J0638
2017	J0640	Leucovorin calcium injection	50 MG	\$	3.23	2017_J0640
2017	J0641	Levoleucovorin injection	0.5 MG	\$	0.53	2017_J0641
2017	J0670	Inj mepivacaine hcl/10 ml	10 ML	\$	2.66	2017_J0670
2017	J0690	Cefazolin sodium injection	500 MG	\$	0.86	2017_J0690
2017	J0692	Cefepime hcl for injection	500 MG	\$	2.89	2017_J0692
2017	J0694	Cefoxitin sodium injection	1 GM	\$	5.85	2017_J0694
2017	J0696	Ceftriaxone sodium injection	250 MG	\$	0.66	2017_J0696
2017	J0697	Sterile cefuroxime injection	750 MG	\$	2.70	2017_J0697
2017	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	8.18	2017_J0702
2017	J0712	Ceftaroline fosamil inj	10 MG	\$	2.63	2017_J0712
2017	J0713	Inj ceftazidime per 500 mg	500 MG	\$	2.39	2017_J0713
2017	J0717	Certolizumab pegol inj 1mg	1 MG	\$	7.47	2017_J0717
2017	J0720	Chloramphenicol sodium injec	1 GM	\$	39.43	2017_J0720
2017	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	20.53	2017_J0725
2017	J0735	Clonidine hydrochloride	1 MG	\$	12.15	2017_J0735

2017	J0740	Cidofovir injection	375 MG	\$	477.55	2017_J0740
2017	J0743	Cilastatin sodium injection	250 MG	\$	5.62	2017_J0743
2017	J0744	Ciprofloxacin iv	200 MG	\$	1.29	2017_J0744
2017	J0770	Colistimethate sodium inj	150 MG	\$	14.38	2017_J0770
2017	J0775	Collagenase, clost hist inj	0.01 MG	\$	41.83	2017_J0775
2017	J0780	Prochlorperazine injection	10 MG	\$	9.77	2017_J0780
2017	J0795	Corticotropin injection	1 MCG	\$	8.61	2017_J0795
2017	J0800	Cosyntropin cortrosyn inj	40 UNITS	\$	3,771.36	2017_J0800
2017	J0834	Crotalidae poly immune fab	0.25 MG	\$	43.06	2017_J0834
2017	J0840	Cytomegalovirus imm iv /vial	UP TO 1 GM	\$	2,870.72	2017_J0840
2017	J0850	Injection, dalbavancin	PER VIAL	\$	1,128.71	2017_J0850
2017	J0875	Daptomycin injection	5 MG	\$	14.40	2017_J0875
2017	J0878	Darbepoetin alfa, non-esrd	1 MG	\$	0.62	2017_J0878
2017	J0881	Darbepoetin alfa, esrd use	1 MCG	\$	3.95	2017_J0881
2017	J0882	Epoetin alfa, non-esrd	1 MCG	\$	3.95	2017_J0882
2017	J0885	Epoetin beta esrd use	1000 UNITS	\$	12.94	2017_J0885
2017	J0887	Epoetin beta non esrd	1 MCG	\$	1.63	2017_J0887
2017	J0888	Decitabine injection	1 MCG	\$	1.63	2017_J0888
2017	J0894	Deferoxamine mesylate inj	1 MG	\$	17.70	2017_J0894
2017	J0895	Denosumab injection	500 MG	\$	8.04	2017_J0895
2017	J0897	Depo-estradiol cypionate inj	1 MG	\$	17.33	2017_J0897
2017	J1000	Methylprednisolone 20 mg inj	5 MG	\$	19.54	2017_J1000
2017	J1020	Methylprednisolone 40 mg inj	20 MG	\$	5.59	2017_J1020
2017	J1030	Methylprednisolone 80 mg inj	40 MG	\$	6.36	2017_J1030
2017	J1040	Medroxyprogesterone acetate	80 MG	\$	12.26	2017_J1040
2017	J1050	Inj testosterone cypionate	1 MG	\$	0.50	2017_J1050
2017	J1071	Dexamethasone sodium phos	1 MG	\$	0.03	2017_J1071
2017	J1100	Inj dihydroergotamine mesylt	1 MG	\$	0.12	2017_J1100
2017	J1110	Acetazolamid sodium injectio	1 MG	\$	105.62	2017_J1110
2017	J1120	Digoxin injection	500 MG	\$	21.25	2017_J1120
2017	J1160	Digoxin immune fab (ovine)	0.5 MG	\$	8.40	2017_J1160
2017	J1162	Phenytoin sodium injection	PER VIAL	\$	3,267.03	2017_J1162
2017	J1165	Hydromorphone injection	50 MG	\$	0.60	2017_J1165
2017	J1170	Dextrazoxane hcl injection	4 MG	\$	2.05	2017_J1170
2017	J1190	Diphenhydramine hcl injectio	250 MG	\$	185.89	2017_J1190
2017	J1200	Chlorothiazide sodium inj	50 MG	\$	0.61	2017_J1200
2017	J1205	Dimethyl sulfoxide 50% 50 ml	500 MG	\$	60.94	2017_J1205
2017	J1212	Methadone injection	50 ML	\$	554.16	2017_J1212
2017	J1230	Dimenhydrinate injection	10 MG	\$	19.25	2017_J1230
2017	J1240	Dipyridamole injection	50 MG	\$	7.44	2017_J1240
2017	J1245	Inj dobutamine hcl/250 mg	10 MG	\$	0.80	2017_J1245
2017	J1250	Dopamine injection	250 MG	\$	5.60	2017_J1250
2017	J1265	Doripenem injection	40 MG	\$	0.64	2017_J1265
2017	J1267	Injection, doxercalciferol	10 MG	\$	0.71	2017_J1267
2017	J1270	Ecaltantide injection	1 MCG	\$	0.43	2017_J1270
2017	J1290	Ecuzumab injection	1 MG	\$	441.29	2017_J1290
2017	J1300	Epoprostenol injection	10 MG	\$	226.63	2017_J1300
2017	J1325	Ertapenem injection	0.5 MG	\$	15.57	2017_J1325
2017	J1335	Erythro lactobionate /500 mg	500 MG	\$	52.34	2017_J1335
2017	J1364	Estradiol valerate 10 mg inj	500 MG	\$	64.90	2017_J1364
2017	J1380	Inj estrogen conjugate 25 mg	10 MG	\$	10.00	2017_J1380
2017	J1410	Ethanolamine oleate 100 mg	25 MG	\$	304.61	2017_J1410
2017	J1430	Inj ferric carboxymaltos 1mg	100 MG	\$	443.68	2017_J1430
2017	J1439	Inj filgrastim excl biosimil	1 MG	\$	1.06	2017_J1439
2017	J1442	Inj tbo filgrastim 1 microg	1 MCG	\$	1.01	2017_J1442
2017	J1447	Fluconazole	1 MCG	\$	0.63	2017_J1447
2017	J1450	Fosaprepitant injection	200 MG	\$	4.85	2017_J1450
2017	J1453	Galsulfase injection	1 MG	\$	2.03	2017_J1453
2017	J1458		1 MG	\$	380.50	2017_J1458

2017	J1459	Inj ivig privigen 500 mg	500 MG	\$	38.51	2017_J1459
2017	J1460	Gamma globulin 1 cc inj	1 CC	\$	31.76	2017_J1460
2017	J1556	Inj, imm glob bivigam, 500mg	500 MG	\$	38.31	2017_J1556
2017	J1557	Gammplex injection	500 MG	\$	41.08	2017_J1557
2017	J1559	Hizentra injection	100 MG	\$	9.81	2017_J1559
2017	J1560	Gamma globulin > 10 cc inj	10 CC	\$	317.64	2017_J1560
2017	J1561	Gamunex-c/gammaked	500 MG	\$	38.94	2017_J1561
2017	J1566	Immune globulin, powder	500 MG	\$	34.28	2017_J1566
2017	J1568	Octagam injection	500 MG	\$	36.62	2017_J1568
2017	J1569	Gammagard liquid injection	500 MG	\$	39.78	2017_J1569
2017	J1570	Ganciclovir sodium injection	500 MG	\$	68.49	2017_J1570
2017	J1571	Hepagam b im injection	0.5 ML	\$	61.12	2017_J1571
2017	J1572	Flebogamma injection	500 MG	\$	29.84	2017_J1572
2017	J1575	Hyqvia 100mg immunoglobulin	100 MG	\$	13.14	2017_J1575
2017	J1580	Garamycin gentamicin inj	80 MG	\$	1.55	2017_J1580
2017	J1602	Golimumab for iv use 1mg	1 MG	\$	24.74	2017_J1602
2017	J1610	Glucagon hydrochloride/1 mg	1 MG	\$	205.55	2017_J1610
2017	J1626	Granisetron hcl injection	100 MCG	\$	0.36	2017_J1626
2017	J1630	Haloperidol injection	5 MG	\$	1.21	2017_J1630
2017	J1631	Haloperidol decanoate inj	50 MG	\$	18.14	2017_J1631
2017	J1640	Hemin, 1 mg	1 MG	\$	24.00	2017_J1640
2017	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.19	2017_J1642
2017	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.20	2017_J1644
2017	J1645	Dalteparin sodium	2500 IU	\$	15.27	2017_J1645
2017	J1650	Inj enoxaparin sodium	10 MG	\$	0.80	2017_J1650
2017	J1652	Fondaparinux sodium	0.5 MG	\$	2.09	2017_J1652
2017	J1670	Tetanus immune globulin inj	250 UNITS	\$	557.45	2017_J1670
2017	J1720	Hydrocortisone sodium succ i	100 MG	\$	11.28	2017_J1720
2017	J1740	Ibandronate sodium injection	1 MG	\$	82.87	2017_J1740
2017	J1742	Ibutilide fumarate injection	1 MG	\$	169.14	2017_J1742
2017	J1743	Idursulfase injection	1 MG	\$	542.86	2017_J1743
2017	J1745	Infliximab not biosimil 10mg	10 MG	\$	87.15	2017_J1745
2017	J1750	Inj iron dextran	50 MG	\$	13.04	2017_J1750
2017	J1756	Iron sucrose injection	1 MG	\$	0.26	2017_J1756
2017	J1786	Imuglucerase injection	10 UNITS	\$	41.69	2017_J1786
2017	J1800	Propranolol injection	1 MG	\$	1.62	2017_J1800
2017	J1815	Insulin injection	5 UNITS	\$	0.85	2017_J1815
2017	J1817	Insulin for insulin pump use	50 UNITS	\$	9.97	2017_J1817
2017	J1885	Ketorolac tromethamine inj	15 MG	\$	0.56	2017_J1885
2017	J1930	Lanreotide injection	1 MG	\$	55.98	2017_J1930
2017	J1931	Laronidase injection	0.1 MG	\$	30.61	2017_J1931
2017	J1940	Furosemide injection	20 MG	\$	1.05	2017_J1940
2017	J1942	Aripiprazole lauroxil 1mg	1 MG	\$	2.46	2017_J1942
2017	J1950	Leuprolide acetate /3.75 mg	3.75 MG	\$	1,087.91	2017_J1950
2017	J1953	Levetiracetam injection	10 MG	\$	0.12	2017_J1953
2017	J1955	Inj levocarnitine per 1 gm	1 GM	\$	22.08	2017_J1955
2017	J1956	Levofloxacin injection	250 MG	\$	1.18	2017_J1956
2017	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	27.62	2017_J1980
2017	J2001	Lidocaine injection	10 MG	\$	0.02	2017_J2001
2017	J2010	Lincomycin injection	300 MG	\$	12.58	2017_J2010
2017	J2020	Linezolid injection	200 MG	\$	13.91	2017_J2020
2017	J2060	Lorazepam injection	2 MG	\$	0.74	2017_J2060
2017	J2150	Mannitol injection	50 ML	\$	2.05	2017_J2150
2017	J2175	Meperidine hydrochl /100 mg	100 MG	\$	5.10	2017_J2175
2017	J2185	Meropenem	100 MG	\$	1.33	2017_J2185
2017	J2210	Methylergonovin maleate inj	0.2 MG	\$	16.11	2017_J2210
2017	J2248	Micafungin sodium injection	1 MG	\$	0.94	2017_J2248
2017	J2250	Inj midazolam hydrochloride	1 MG	\$	0.11	2017_J2250
2017	J2260	Inj milrinone lactate / 5 MG	5 MG	\$	1.94	2017_J2260

2017	J2270	Morphine sulfate injection	10 MG	\$	1.42	2017_J2270
2017	J2274	In morphine preservativ free	10 MG	\$	12.40	2017_J2274
2017	J2278	Ziconotide injection	1 MCG	\$	7.42	2017_J2278
2017	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	8.31	2017_J2280
2017	J2300	Inj nalbuphine hydrochloride	10 MG	\$	2.70	2017_J2300
2017	J2310	Inj naloxone hydrochloride	1 MG	\$	28.83	2017_J2310
2017	J2315	Naltrexone, depot form	1 MG	\$	3.26	2017_J2315
2017	J2323	Natalizumab injection	1 MG	\$	19.42	2017_J2323
2017	J2353	Octreotide injection, depot	1 MG	\$	183.64	2017_J2353
2017	J2354	Octreotide inj, non-depot	25 MCG	\$	0.96	2017_J2354
2017	J2355	Oprelvekin injection	5 MG	\$	467.22	2017_J2355
2017	J2357	Omalizumab injection	5 MG	\$	34.93	2017_J2357
2017	J2358	Olanzapine long-acting inj	1 MG	\$	2.92	2017_J2358
2017	J2360	Orphenadrine injection	60 MG	\$	6.91	2017_J2360
2017	J2400	Chloroprocaine hcl injection	30 ML	\$	23.21	2017_J2400
2017	J2405	Ondansetron hcl injection	1 MG	\$	0.09	2017_J2405
2017	J2407	Injection, oritavancin	10 MG	\$	23.36	2017_J2407
2017	J2410	Oxymorphone hcl injection	1 MG	\$	2.85	2017_J2410
2017	J2425	Palifermin injection	50 MCG	\$	19.20	2017_J2425
2017	J2426	Paliperidone palmitate inj	1 MG	\$	10.02	2017_J2426
2017	J2430	Pamidronate disodium /30 mg	30 MG	\$	8.42	2017_J2430
2017	J2469	Palonosetron hcl	25 MCG	\$	20.90	2017_J2469
2017	J2501	Paricalcitol	1 MCG	\$	1.10	2017_J2501
2017	J2503	Pegaptanib sodium injection	0.3 MG	\$	729.47	2017_J2503
2017	J2504	Pegademase bovine, 25 iu	25 IU	\$	352.27	2017_J2504
2017	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	4,320.73	2017_J2505
2017	J2507	Pegloticase injection	1 MG	\$	2,006.66	2017_J2507
2017	J2510	Penicillin g procaine inj	600000 UNITS	\$	29.30	2017_J2510
2017	J2515	Pentobarbital sodium inj	50 MG	\$	52.40	2017_J2515
2017	J2540	Penicillin g potassium inj	600000 UNITS	\$	1.05	2017_J2540
2017	J2543	Piperacillin/tazobactam	1.125 GM	\$	2.96	2017_J2543
2017	J2545	Pentamidine non-comp unit	300 MG	\$	115.20	2017_J2545
2017	J2550	Promethazine hcl injection	50 MG	\$	2.17	2017_J2550
2017	J2560	Phenobarbital sodium inj	120 MG	\$	35.86	2017_J2560
2017	J2562	Plerixafor injection	1 MG	\$	314.44	2017_J2562
2017	J2597	Inj desmopressin acetate	1 MCG	\$	12.75	2017_J2597
2017	J2675	Inj progesterone per 50 mg	50 MG	\$	1.46	2017_J2675
2017	J2680	Fluphenazine decanoate 25 mg	25 MG	\$	18.71	2017_J2680
2017	J2690	Procainamide hcl injection	1 GM	\$	72.65	2017_J2690
2017	J2700	Oxacillin sodium injecton	250 MG	\$	1.70	2017_J2700
2017	J2704	Inj, propofol, 10 mg	10 MG	\$	0.12	2017_J2704
2017	J2720	Inj protamine sulfate/10 mg	10 MG	\$	0.91	2017_J2720
2017	J2724	Protein c concentrate	10 UNITS	\$	15.13	2017_J2724
2017	J2765	Metoclopramide hcl injection	10 MG	\$	0.91	2017_J2765
2017	J2770	Quinupristin/dalfopristin	500 MG	\$	428.62	2017_J2770
2017	J2778	Ranibizumab injection	0.1 mg	\$	378.35	2017_J2778
2017	J2780	Ranitidine hydrochloride inj	25 MG	\$	6.77	2017_J2780
2017	J2783	Rasburicase	0.5 MG	\$	263.06	2017_J2783
2017	J2785	Regadenoson injection	0.1 MG	\$	55.41	2017_J2785
2017	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	24.71	2017_J2788
2017	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	79.07	2017_J2790
2017	J2791	Rhophylac injection	100 IU	\$	4.81	2017_J2791
2017	J2792	Rho(d) immune globulin h, sd	100 IU	\$	23.80	2017_J2792
2017	J2794	Risperidone, long acting	0.5 MG	\$	8.63	2017_J2794
2017	J2795	Ropivacaine hcl injection	1 MG	\$	0.07	2017_J2795
2017	J2796	Romiplostim injection	10 MCG	\$	66.86	2017_J2796
2017	J2800	Methocarbamol injection	10 ML	\$	37.24	2017_J2800
2017	J2805	Sinacalide injection	5 MCG	\$	105.54	2017_J2805
2017	J2810	Inj theophylline per 40 mg	40 MG	\$	0.30	2017_J2810

2017	J2820	Sargramostim injection	50 MCG	\$	37.70	2017_J2820
2017	J2850	Inj secretin synthetic human	1 MCG	\$	34.78	2017_J2850
2017	J2916	Na ferric gluconate complex	12.5 MG	\$	2.13	2017_J2916
2017	J2920	Methylprednisolone injection	40 MG	\$	4.34	2017_J2920
2017	J2930	Methylprednisolone injection	125 MG	\$	6.09	2017_J2930
2017	J2997	Alteplase recombinant	1 MG	\$	83.99	2017_J2997
2017	J3000	Streptomycin injection	1 GM	\$	15.37	2017_J3000
2017	J3010	Fentanyl citrate injecton	0.1 MG	\$	0.50	2017_J3010
2017	J3060	Inj, taliglucerase alfa 10 u	10 UNITS	\$	40.37	2017_J3060
2017	J3070	Pentazocine injection	30 MG	\$	71.47	2017_J3070
2017	J3090	Inj tedizolid phosphate	1 MG	\$	1.33	2017_J3090
2017	J3095	Telavancin injection	10 MG	\$	5.12	2017_J3095
2017	J3101	Tenecteplase injection	1 MG	\$	111.70	2017_J3101
2017	J3105	Terbutaline sulfate inj	1 MG	\$	3.42	2017_J3105
2017	J3121	Inj testostero enanthate 1mg	1 MG	\$	0.04	2017_J3121
2017	J3230	Chlorpromazine hcl injection	50 MG	\$	28.04	2017_J3230
2017	J3240	Thyrotropin injection	0.9 MG	\$	1,579.69	2017_J3240
2017	J3243	Tigecycline injection	1 MG	\$	2.99	2017_J3243
2017	J3250	Trimethobenzamide hcl inj	200 MG	\$	29.98	2017_J3250
2017	J3260	Tobramycin sulfate injection	80 MG	\$	2.54	2017_J3260
2017	J3262	Tocilizumab injection	1 MG	\$	4.37	2017_J3262
2017	J3285	Treprostinil injection	1 MG	\$	61.24	2017_J3285
2017	J3300	Triamcinolone a inj prs-free	1 MG	\$	3.88	2017_J3300
2017	J3301	Triamcinolone acet inj nos	10 MG	\$	1.88	2017_J3301
2017	J3315	Triptorelin pamoate	3.75 MG	\$	391.11	2017_J3315
2017	J3357	Ustekinumab sub cu inj, 1 mg	1 MG	\$	187.26	2017_J3357
2017	J3360	Diazepam injection	5 MG	\$	9.16	2017_J3360
2017	J3370	Vancomycin hcl injection	500 MG	\$	2.75	2017_J3370
2017	J3380	Injection, vedolizumab	1 MG	\$	18.59	2017_J3380
2017	J3385	Velaglucerase alfa	100 UNITS	\$	342.35	2017_J3385
2017	J3396	Verteporfin injection	0.1 MG	\$	10.76	2017_J3396
2017	J3410	Hydroxyzine hcl injection	25 MG	\$	8.51	2017_J3410
2017	J3411	Thiamine hcl 100 mg	100 MG	\$	3.03	2017_J3411
2017	J3415	Pyridoxine hcl 100 mg	100 MG	\$	10.32	2017_J3415
2017	J3420	Vitamin b12 injection	1000 MCG	\$	2.09	2017_J3420
2017	J3430	Vitamin k phytonadione inj	1 MG	\$	4.15	2017_J3430
2017	J3465	Injection, voriconazole	10 MG	\$	2.70	2017_J3465
2017	J3471	Ovine, up to 999 usp units	1 UNIT	\$	0.39	2017_J3471
2017	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.36	2017_J3473
2017	J3475	Inj magnesium sulfate	500 MG	\$	0.55	2017_J3475
2017	J3480	Inj potassium chloride	2 MEQ	\$	0.12	2017_J3480
2017	J3485	Zidovudine	10 MG	\$	1.52	2017_J3485
2017	J3486	Ziprasidone mesylate	10 MG	\$	22.18	2017_J3486
2017	J3489	Zoledronic acid 1mg	1 MG	\$	14.98	2017_J3489
2017	J7030	Normal saline solution infus	1000 ML	\$	2.21	2017_J7030
2017	J7040	Normal saline solution infus	500 ML	\$	1.10	2017_J7040
2017	J7042	5% dextrose/normal saline	500 ML	\$	0.89	2017_J7042
2017	J7050	Normal saline solution infus	250 ML	\$	0.55	2017_J7050
2017	J7060	5% dextrose/water	500 ML	\$	2.07	2017_J7060
2017	J7070	D5w infusion	1000 CC	\$	3.90	2017_J7070
2017	J7120	Ringers lactate infusion	1000 CC	\$	2.39	2017_J7120
2017	J7180	Factor xiii anti-hem factor	1 IU	\$	8.21	2017_J7180
2017	J7182	Factor viii recomb novoeight	1 IU	\$	1.29	2017_J7182
2017	J7183	Wilate injection	1 I.U. VWF:RCO	\$	1.04	2017_J7183
2017	J7185	Xyntha inj	1 IU	\$	1.25	2017_J7185
2017	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	0.98	2017_J7186
2017	J7187	Humate-p, inj	1 IU	\$	1.09	2017_J7187
2017	J7189	Factor viia	1 MCG	\$	2.00	2017_J7189
2017	J7190	Factor viii	1 IU	\$	1.02	2017_J7190

2017	J7192	Factor viii recombinant nos	1 IU	\$	1.24	2017_J7192
2017	J7193	Factor ix non-recombinant	1 IU	\$	1.14	2017_J7193
2017	J7194	Factor ix complex	1 IU	\$	1.39	2017_J7194
2017	J7195	Factor ix recombinant nos	1 IU	\$	1.50	2017_J7195
2017	J7197	Antithrombin iii injection	1 IU	\$	3.75	2017_J7197
2017	J7198	Anti-inhibitor	1 IU	\$	1.94	2017_J7198
2017	J7200	Factor ix recombinan rixubis	1 IU	\$	1.27	2017_J7200
2017	J7201	Factor ix alprolix recomb	1 IU	\$	2.99	2017_J7201
2017	J7205	Factor viii fc fusion recomb	1 IU	\$	2.02	2017_J7205
2017	J7308	Aminolevulinic acid hcl top	354 MG	\$	367.81	2017_J7308
2017	J7311	Fluocinolone acetonide implt	0.59 MG	\$	20,114.35	2017_J7311
2017	J7312	Dexamethasone intra implant	0.1 MG	\$	200.74	2017_J7312
2017	J7313	Fluocinol acet intravit imp	0.01 MG	\$	490.80	2017_J7313
2017	J7316	Inj, ocriplasmin, 0.125 mg	0.125 MG	\$	1,046.75	2017_J7316
2017	J7320	Genvisc 850, inj, 1mg	1 MG	\$	7.42	2017_J7320
2017	J7321	Hyalgan/supartz inj per dose	per dose	\$	87.64	2017_J7321
2017	J7323	Euflexxa inj per dose	per dose	\$	155.23	2017_J7323
2017	J7324	Orthovisc inj per dose	per dose	\$	149.48	2017_J7324
2017	J7325	Synvisc or synvisc-one	1 MG	\$	12.27	2017_J7325
2017	J7326	Gel-one	per dose	\$	510.57	2017_J7326
2017	J7327	Monovisc inj per dose	Per Dose	\$	856.79	2017_J7327
2017	J7336	Capsaicin 8% patch	1 SQ CM	\$	3.15	2017_J7336
2017	J7500	Azathioprine oral 50mg	50 MG	\$	0.27	2017_J7500
2017	J7502	Cyclosporine oral 100 mg	100 MG	\$	2.58	2017_J7502
2017	J7503	Tacrol envarsus ex rel oral	0.25 MG	\$	1.24	2017_J7503
2017	J7504	Lymphocyte immune globulin	250 MG	\$	1,817.04	2017_J7504
2017	J7507	Tacrolimus imme rel oral 1mg	1 MG	\$	0.61	2017_J7507
2017	J7508	Tacrol astagraf ex rel oral	0.1 MG	\$	0.43	2017_J7508
2017	J7509	Methylprednisolone oral	4 MG	\$	0.34	2017_J7509
2017	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.08	2017_J7510
2017	J7511	Antithymocyte globuln rabbit	25 MG	\$	710.35	2017_J7511
2017	J7512	Prednisone ir or dr oral 1mg	1 MG	\$	0.01	2017_J7512
2017	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.78	2017_J7515
2017	J7516	Cyclosporin parenteral 250mg	250 MG	\$	41.96	2017_J7516
2017	J7517	Mycophenolate mofetil oral	250 MG	\$	0.93	2017_J7517
2017	J7518	Mycophenolic acid	180 MG	\$	2.67	2017_J7518
2017	J7520	Sirolimus, oral	1 MG	\$	7.74	2017_J7520
2017	J7525	Tacrolimus injection	5 MG	\$	188.32	2017_J7525
2017	J7527	Oral everolimus	0.25 MG	\$	8.14	2017_J7527
2017	J7605	Arformoterol non-comp unit	15 mcg	\$	9.13	2017_J7605
2017	J7606	Formoterol fumarate, inh	20 MCG	\$	10.76	2017_J7606
2017	J7608	Acetylcysteine non-comp unit	1 GM	\$	5.08	2017_J7608
2017	J7611	Albuterol non-comp con	1 MG	\$	0.14	2017_J7611
2017	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.21	2017_J7612
2017	J7613	Albuterol non-comp unit	1 MG	\$	0.05	2017_J7613
2017	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.05	2017_J7614
2017	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.14	2017_J7620
2017	J7626	Budesonide non-comp unit	0.5 MG	\$	3.24	2017_J7626
2017	J7631	Cromolyn sodium noncomp unit	10 MG	\$	0.76	2017_J7631
2017	J7639	Dornase alfa non-comp unit	1 MG	\$	45.47	2017_J7639
2017	J7644	Ipratropium bromide non-comp	1 MG	\$	0.22	2017_J7644
2017	J7674	Methacholine chloride, neb	1 MG	\$	0.54	2017_J7674
2017	J7682	Tobramycin non-comp unit	300 MG	\$	38.38	2017_J7682
2017	J7686	Treprostinil, non-comp unit	1.74 MG	\$	557.08	2017_J7686
2017	J8501	Oral aprepitant	5 MG	\$	7.66	2017_J8501
2017	J8510	Oral busulfan	2 MG	\$	24.83	2017_J8510
2017	J8520	Capecitabine, oral, 150 mg	150 MG	\$	2.25	2017_J8520
2017	J8521	Capecitabine, oral, 500 mg	500 MG	\$	6.68	2017_J8521
2017	J8530	Cyclophosphamide oral 25 mg	25 MG	\$	3.28	2017_J8530

2017	J8540	Oral dexamethasone	0.25 MG	\$	0.08	2017_J8540
2017	J8560	Etoposide oral 50 mg	50 MG	\$	74.18	2017_J8560
2017	J8600	Melphalan oral 2 mg	2 MG	\$	11.72	2017_J8600
2017	J8610	Methotrexate oral 2.5 mg	2.5 MG	\$	0.47	2017_J8610
2017	J8655	Netupitant palonosetron oral	0.5 MG	\$	458.47	2017_J8655
2017	J8700	Temozolomide	5 MG	\$	1.46	2017_J8700
2017	J8705	Topotecan oral	0.25 mg	\$	103.63	2017_J8705
2017	J9000	Doxorubicin hcl injection	10 MG	\$	2.98	2017_J9000
2017	J9017	Arsenic trioxide injection	1 MG	\$	71.34	2017_J9017
2017	J9019	Erwinaze injection	1,000 IU	\$	402.74	2017_J9019
2017	J9025	Azacitidine injection	1 MG	\$	1.66	2017_J9025
2017	J9027	Clofarabine injection	1 MG	\$	149.96	2017_J9027
2017	J9031	Bcg live intravesical vac	1 EA	\$	131.25	2017_J9031
2017	J9032	Injection, belinostat, 10mg	10 MG	\$	35.21	2017_J9032
2017	J9033	Inj., treanda 1 mg	1 MG	\$	29.19	2017_J9033
2017	J9034	Inj., bendeka 1 mg	1 MG	\$	23.77	2017_J9034
2017	J9035	Bevacizumab injection	10 MG	\$	75.18	2017_J9035
2017	J9039	Injection, blinatumomab	1 MCG	\$	103.43	2017_J9039
2017	J9040	Bleomycin sulfate injection	15 UNITS	\$	37.18	2017_J9040
2017	J9041	Bortezomib injection	0.1 MG	\$	46.87	2017_J9041
2017	J9042	Brentuximab vedotin inj	1 MG	\$	139.39	2017_J9042
2017	J9043	Cabazitaxel injection	1 MG	\$	159.10	2017_J9043
2017	J9045	Carboplatin injection	50 MG	\$	3.48	2017_J9045
2017	J9047	Injection, carfilzomib, 1 mg	1 MG	\$	33.16	2017_J9047
2017	J9050	Carmustine injection	100 MG	\$	3,863.47	2017_J9050
2017	J9055	Cetuximab injection	10 MG	\$	57.62	2017_J9055
2017	J9060	Cisplatin 10 mg injection	10 MG	\$	2.08	2017_J9060
2017	J9065	Inj cladribine per 1 mg	1 MG	\$	20.66	2017_J9065
2017	J9070	Cyclophosphamide 100 mg inj	100 MG	\$	42.06	2017_J9070
2017	J9098	Cytarabine liposome inj	10 MG	\$	641.67	2017_J9098
2017	J9100	Cytarabine hcl 100 mg inj	100 MG	\$	0.82	2017_J9100
2017	J9120	Dactinomycin injection	0.5 MG	\$	1,404.01	2017_J9120
2017	J9130	Dacarbazine 100 mg inj	100 MG	\$	3.88	2017_J9130
2017	J9145	Injection, daratumumab 10 mg	10 MG	\$	49.15	2017_J9145
2017	J9150	Daunorubicin injection	10 MG	\$	37.86	2017_J9150
2017	J9155	Degarelix injection	1 MG	\$	3.64	2017_J9155
2017	J9171	Docetaxel injection	1 MG	\$	1.89	2017_J9171
2017	J9176	Injection, elotuzumab, 1mg	1 MG	\$	6.26	2017_J9176
2017	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.43	2017_J9178
2017	J9179	Eribulin mesylate injection	0.1 MG	\$	109.16	2017_J9179
2017	J9181	Etoposide injection	10 MG	\$	0.50	2017_J9181
2017	J9185	Fludarabine phosphate inj	50 MG	\$	104.89	2017_J9185
2017	J9190	Fluorouracil injection	500 MG	\$	1.62	2017_J9190
2017	J9200	Floxuridine injection	500 MG	\$	72.67	2017_J9200
2017	J9201	Gemcitabine hcl injection	200 MG	\$	5.82	2017_J9201
2017	J9202	Goserelin acetate implant	3.6 MG	\$	351.53	2017_J9202
2017	J9205	Inj irinotecan liposome 1 mg	1 MG	\$	41.13	2017_J9205
2017	J9206	Irinotecan injection	20 MG	\$	3.39	2017_J9206
2017	J9207	Ixabepilone injection	1 MG	\$	74.10	2017_J9207
2017	J9208	Ifosfamide injection	1 GM	\$	26.85	2017_J9208
2017	J9209	Mesna injection	200 MG	\$	2.15	2017_J9209
2017	J9211	Idarubicin hcl injection	5 MG	\$	39.47	2017_J9211
2017	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	31.71	2017_J9214
2017	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	209.71	2017_J9217
2017	J9218	Leuprolide acetate injecton	1 MG	\$	25.97	2017_J9218
2017	J9225	Vantas implant	50 MG	\$	3,284.12	2017_J9225
2017	J9226	Supprelin la implant	50 MG	\$	29,003.67	2017_J9226
2017	J9228	Ipilimumab injection	1 MG	\$	146.78	2017_J9228
2017	J9230	Mechlorethamine hcl inj	10 MG	\$	292.48	2017_J9230

2017	J9245	Inj melphalan hydrochl 50 mg	50 MG	\$	1,369.46	2017_J9245
2017	J9250	Methotrexate sodium inj	5 MG	\$	0.25	2017_J9250
2017	J9260	Methotrexate sodium inj	50 MG	\$	2.48	2017_J9260
2017	J9261	Nelarabine injection	50 MG	\$	151.66	2017_J9261
2017	J9263	Oxaliplatin	0.5 MG	\$	0.19	2017_J9263
2017	J9264	Paclitaxel protein bound	1 MG	\$	10.78	2017_J9264
2017	J9266	Pegaspargase injection	1 EA	\$	13,907.58	2017_J9266
2017	J9267	Paclitaxel injection	1 MG	\$	0.12	2017_J9267
2017	J9268	Pentostatin injection	10 MG	\$	2,001.26	2017_J9268
2017	J9271	Inj pembrolizumab	1 MG	\$	47.97	2017_J9271
2017	J9280	Mitomycin injection	5 MG	\$	133.65	2017_J9280
2017	J9293	Mitoxantrone hydrochl / 5 mg	5 MG	\$	38.98	2017_J9293
2017	J9295	Injection, necitumumab, 1 mg	1 MG	\$	5.29	2017_J9295
2017	J9299	Injection, nivolumab	1 MG	\$	26.80	2017_J9299
2017	J9301	Obinutuzumab inj	10 MG	\$	58.94	2017_J9301
2017	J9302	Ofatumumab injection	10 MG	\$	54.91	2017_J9302
2017	J9303	Panitumumab injection	10 MG	\$	110.28	2017_J9303
2017	J9305	Pemetrexed injection	10 MG	\$	64.98	2017_J9305
2017	J9306	Injection, pertuzumab, 1 mg	1 MG	\$	11.16	2017_J9306
2017	J9307	Pralatrexate injection	1 MG	\$	247.97	2017_J9307
2017	J9308	Injection, ramucirumab	5 MG	\$	56.53	2017_J9308
2017	J9310	Rituximab injection	100 MG	\$	848.41	2017_J9310
2017	J9315	Romidepsin injection	1 MG	\$	328.83	2017_J9315
2017	J9320	Streptozocin injection	1 GM	\$	322.73	2017_J9320
2017	J9325	Inj talimogene laherparepvec	1 million PFU	\$	47.21	2017_J9325
2017	J9328	Temozolomide injection	1 MG	\$	9.70	2017_J9328
2017	J9330	Temsirolimus injection	1 MG	\$	70.51	2017_J9330
2017	J9351	Topotecan injection	0.1 MG	\$	1.25	2017_J9351
2017	J9352	Injection trabectedin 0.1mg	0.1 MG	\$	289.17	2017_J9352
2017	J9354	Inj, ado-trastuzumab emt 1mg	1 MG	\$	29.81	2017_J9354
2017	J9355	Trastuzumab injection	10 MG	\$	97.80	2017_J9355
2017	J9357	Valrubicin injection	200 MG	\$	1,198.56	2017_J9357
2017	J9360	Vinblastine sulfate inj	1 MG	\$	3.48	2017_J9360
2017	J9370	Vincristine sulfate 1 mg inj	1 MG	\$	4.98	2017_J9370
2017	J9371	Inj, vincristine sul lip 1mg	1 MG	\$	2,701.78	2017_J9371
2017	J9390	Vinorelbine tartrate inj	10 MG	\$	9.29	2017_J9390
2017	J9395	Injection, fulvestrant	25 MG	\$	96.77	2017_J9395
2017	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.15	2017_J9400
2017	P9041	Albumin (human),5%, 50ml	50 ML	\$	11.80	2017_P9041
2017	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	54.72	2017_P9045
2017	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	22.49	2017_P9046
2017	P9047	Albumin (human), 25%, 50ml	50 ML	\$	53.44	2017_P9047
2017	Q0138	Ferumoxytol, non-esrd	1 MG	\$	0.91	2017_Q0138
2017	Q0139	Ferumoxytol, esrd use	1 MG	\$	0.91	2017_Q0139
2017	Q0162	Ondansetron oral	1 MG	\$	0.03	2017_Q0162
2017	Q0163	Diphenhydramine hcl 50mg	50 MG	\$	0.27	2017_Q0163
2017	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.04	2017_Q0164
2017	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	3.51	2017_Q0166
2017	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	4.26	2017_Q0167
2017	Q0169	Promethazine hcl 12.5mg oral	12.5 MG	\$	0.03	2017_Q0169
2017	Q2035	Afluria vacc, 3 yrs & >, im	0.5 ml	\$	17.69	2017_Q2035
2017	Q2037	Fluvirin vacc, 3 yrs & >, im	0.5 ML	\$	17.69	2017_Q2037
2017	Q2043	Sipuleucel-t auto cd54+	Per infusion (minimum 50 million cells)	\$	40,440.17	2017_Q2043
2017	Q2050	Doxorubicin inj 10mg	10 MG	\$	374.93	2017_Q2050
2017	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	50.11	2017_Q3027
2017	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	130.26	2017_Q4074
2017	Q4081	Epoetin alfa, 100 units esrd	100 UNITS	\$	1.29	2017_Q4081
2017	Q4101	Apilgraf	1 SQ CM	\$	30.90	2017_Q4101
2017	Q4102	Oasis wound matrix	1 SQ CM	\$	10.99	2017_Q4102

2017	Q4106	Dermagraft	1 SQ CM	\$	33.23	2017_Q4106
2017	Q4107	Graftjacket	1 SQ CM	\$	95.59	2017_Q4107
2017	Q4111	Gammagraft	1 SQ CM	\$	6.98	2017_Q4111
2017	Q4112	Cymetra injectable	1 CC	\$	203.34	2017_Q4112
2017	Q4113	Graftjacket xpress	1 CC	\$	203.34	2017_Q4113
2017	Q4115	Alloskin	1 SQ CM	\$	9.32	2017_Q4115
2017	Q4116	Alloderm	1 SQ CM	\$	31.70	2017_Q4116
2017	Q4121	Theraskin	1 SQ CM	\$	45.62	2017_Q4121
2017	Q4123	Alloskin	1 SQ CM	\$	26.92	2017_Q4123
2017	Q4131	Epifix or epicord	1 SQ CM	\$	165.18	2017_Q4131
2017	Q4132	Grafix core	1 SQ CM	\$	138.94	2017_Q4132
2017	Q4133	Grafix prime	1 SQ CM	\$	138.88	2017_Q4133
2017	Q5101	Inj filgrastim gcsf biosimil	1 MCG	\$	0.71	2017_Q5101
2017	Q5102	Inj., infliximab biosimilar	10 MG	\$	78.72	2017_Q5102
2017	Q9950	Inj sulf hexa lipid microsph	1 ML	\$	21.25	2017_Q9950
2017	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	33.99	2017_Q9956
2017	Q9957	Inj perflutren lip micros,ml	1 ML	\$	50.98	2017_Q9957
2017	Q9958	Hocm <= 149 mg/ml iodine, 1ml	1 ML	\$	0.08	2017_Q9958
2017	Q9960	Hocm 200-249mg/ml iodine,1ml	1 ML	\$	0.17	2017_Q9960
2017	Q9961	Hocm 250-299mg/ml iodine,1ml	1 ML	\$	0.26	2017_Q9961
2017	Q9963	Hocm 350-399mg/ml iodine,1ml	1 ML	\$	0.21	2017_Q9963
2017	Q9965	Locm 100-199mg/ml iodine,1ml	1 ML	\$	0.82	2017_Q9965
2017	Q9966	Locm 200-299mg/ml iodine,1ml	1 ML	\$	0.33	2017_Q9966
2017	Q9967	Locm 300-399mg/ml iodine,1ml	1 ML	\$	0.12	2017_Q9967
2017	Q9989	Ustekinumab IV Inj, 1 mg	1 MG	\$	12.88	2017_Q9989
2016	90371	Hep b ig im	1 ML	\$	111.33	2016_90371
2016	90375	Rabies ig im/sc	150 IU	\$	305.48	2016_90375
2016	90376	Rabies ig heat treated	150 IU	\$	294.59	2016_90376
2016	90585	Bcg vaccine percut	50 MG	\$	123.20	2016_90585
2016	90586	Bcg vaccine, intravesical	1 EACH	\$	123.20	2016_90586
2016	90630	Flu vacc iiv4 no preserv id	0.1 ml	\$	20.34	2016_90630
2016	90632	Hep a vaccine, adult im	1 ML	\$	50.85	2016_90632
2016	90653	liv adjuvant vaccine im	0.5 ml	\$	37.38	2016_90653
2016	90656	IIV3 VACC NO PRSV 0.5 ML IM	0.50 ML	\$	17.72	2016_90656
2016	90662	liv no prsv increased ag im	0.5 ML	\$	42.72	2016_90662
2016	90670	Pneumococcal vacc, 13 val im	0.5 ML	\$	181.06	2016_90670
2016	90672	Laiv4 vaccine intranasal	0.2 ml	\$	26.88	2016_90672
2016	90673	Riv3 vaccine no preserv im	0.5 ML	\$	40.61	2016_90673
2016	90674	CCIIV4 VAC NO PRSV 0.5 ML IM	0.5 ML	\$	22.94	2016_90674
2016	90675	Rabies vaccine im	1 ML	\$	272.49	2016_90675
2016	90685	IIV4 VACC NO PRSV 0.25 ML IM	0.25 mL	\$	26.27	2016_90685
2016	90686	IIV4 VACC NO PRSV 0.5 ML IM	0.5 ml	\$	19.03	2016_90686
2016	90687	IIV4 VACCINE SPLT 0.25 ML IM	0.25 ML	\$	9.40	2016_90687
2016	90688	IIV4 VACCINE SPLT 0.5 ML IM	0.5 ML	\$	17.84	2016_90688
2016	90691	Typhoid vaccine, im	0.5 ML	\$	84.04	2016_90691
2016	90714	Td vaccine no prsrv >/= 7 yo, im	0.5 ML	\$	24.19	2016_90714
2016	90715	Tdap => 7 yo, im	0.5 ML	\$	31.37	2016_90715
2016	90732	Pneumococcal vaccine	0.5 ML	\$	89.95	2016_90732
2016	90740	Hepb vacc, ill pat 3 dose im	40 MCG	\$	122.96	2016_90740
2016	90743	Hep b vacc, adol, 2 dose, im	1 DOSE	\$	25.39	2016_90743
2016	90744	Hepb vacc ped/adol 3 dose im	1 DOSE	\$	25.39	2016_90744
2016	90746	Hep b vaccine, adult, im	20 MCG	\$	61.47	2016_90746
2016	90747	Hepb vacc, ill pat 4 dose im	40 MCG	\$	122.96	2016_90747
2016	A9575	Inj gadoterate meglumi 0.1 ml	0.1 ml	\$	0.20	2016_A9575
2016	A9576	Inj prohance multipack	1 ML	\$	1.61	2016_A9576
2016	A9577	Inj multihance	1 ML	\$	2.08	2016_A9577
2016	A9578	Inj multihance multipack	1 ML	\$	2.01	2016_A9578
2016	A9579	Gad-base MR contrast NOS,1ml	1 ML	\$	1.84	2016_A9579
2016	A9581	Gadoxetate disodium inj	1 ML	\$	13.95	2016_A9581

2016	A9583	Gadofosveset trisodium inj	1 ML	\$	17.93	2016_A9583
2016	A9585	Gadobutrol injection	0.1 ML	\$	0.39	2016_A9585
2016	A9606	Radium ra223 dichloride ther	1 microCurie	N/A		2016_A9606
2016	J0129	Abatacept injection	10 MG	\$	44.75	2016_J0129
2016	J0130	Abciximab injection	10 MG	\$	1,136.51	2016_J0130
2016	J0132	Acetylcysteine injection	100 MG	\$	1.51	2016_J0132
2016	J0133	Acyclovir injection	5 MG	\$	0.07	2016_J0133
2016	J0135	Adalimumab injection	20 MG	\$	861.45	2016_J0135
2016	J0153	Adenosine inj 1mg	1 MG	\$	0.63	2016_J0153
2016	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.14	2016_J0171
2016	J0178	Aflibercept injection	1 MG	\$	980.46	2016_J0178
2016	J0180	Agalsidase beta injection	1 MG	\$	164.42	2016_J0180
2016	J0202	Injection, Alemtuzumab	1 MG	\$	1,738.36	2016_J0202
2016	J0207	Amifostine	500 MG	\$	416.53	2016_J0207
2016	J0221	Lumizyme injection	10 MG	\$	159.39	2016_J0221
2016	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.83	2016_J0256
2016	J0257	Glassia injection	10 MG	\$	4.37	2016_J0257
2016	J0278	Amikacin sulfate injection	100 MG	\$	1.48	2016_J0278
2016	J0280	Aminophyllin 250 MG inj	250 MG	\$	8.83	2016_J0280
2016	J0285	Amphotericin B	50 MG	\$	27.94	2016_J0285
2016	J0287	Amphotericin b lipid complex	10 MG	\$	13.41	2016_J0287
2016	J0289	Amphotericin b liposome inj	10 MG	\$	19.01	2016_J0289
2016	J0290	Ampicillin 500 MG inj	500 MG	\$	1.31	2016_J0290
2016	J0295	Ampicillin sodium per 1.5 gm	1.5 GM	\$	3.70	2016_J0295
2016	J0348	Anidulafungin injection	1 MG	\$	0.51	2016_J0348
2016	J0360	Hydralazine hcl injection	20 MG	\$	4.59	2016_J0360
2016	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	4.38	2016_J0401
2016	J0456	Azithromycin	500 MG	\$	3.31	2016_J0456
2016	J0461	Atropine sulfate injection	0.01 MG	\$	0.04	2016_J0461
2016	J0470	Dimecaprol injection	100 MG	\$	39.34	2016_J0470
2016	J0475	Baclofen 10 MG injection	10 MG	\$	173.43	2016_J0475
2016	J0476	Baclofen intrathecal trial	50 MCG	\$	76.96	2016_J0476
2016	J0480	Basiliximab	20 MG	\$	3,196.11	2016_J0480
2016	J0485	Belatacept injection	1 MG	\$	3.84	2016_J0485
2016	J0490	Belimumab injection	10 MG	\$	42.02	2016_J0490
2016	J0500	Dicyclomine injection	20 MG	\$	63.59	2016_J0500
2016	J0515	Inj benztropine mesylate	1 MG	\$	34.42	2016_J0515
2016	J0558	PenG benzathine/procaine inj	100,000 UNITS	\$	7.96	2016_J0558
2016	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	10.31	2016_J0561
2016	J0583	Bivalirudin	1 MG	\$	1.53	2016_J0583
2016	J0585	Injection,onabotulinumtoxinA	1 UNIT	\$	5.93	2016_J0585
2016	J0586	AbobotulinumtoxinA	5 Unit	\$	7.90	2016_J0586
2016	J0587	Inj. rimabotulinumtoxinB	100 UNITS	\$	11.71	2016_J0587
2016	J0588	Incobotulinumtoxin A	1 UNIT	\$	4.91	2016_J0588
2016	J0592	Buprenorphine hydrochloride	0.1 MG	\$	3.37	2016_J0592
2016	J0594	Busulfan injection	1 MG	\$	38.37	2016_J0594
2016	J0595	Butorphanol tartrate 1 mg	1 MG	\$	2.42	2016_J0595
2016	J0597	C-1 esterase, berinert	10 UNITS	\$	46.52	2016_J0597
2016	J0598	C-1 esterase, cinryze	10 UNITS	\$	55.55	2016_J0598
2016	J0600	Edetate calcium disodium inj	1000 MG	\$	5,594.42	2016_J0600
2016	J0610	Calcium gluconate injection	10 ML	\$	3.51	2016_J0610
2016	J0630	Calcitonin salmon injection	400 UNITS	\$	2,321.14	2016_J0630
2016	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.49	2016_J0636
2016	J0637	Caspofungin acetate	5 MG	\$	12.21	2016_J0637
2016	J0638	Canakinumab injection	1 MG	\$	92.49	2016_J0638
2016	J0640	Leucovorin calcium injection	50 MG	\$	3.09	2016_J0640
2016	J0641	Levoleucovorin injection	0.5 MG	\$	0.90	2016_J0641
2016	J0670	Inj mepivacaine HCL/10 ml	10 ML	\$	2.32	2016_J0670
2016	J0690	Cefazolin sodium injection	500 MG	\$	0.95	2016_J0690

2016	J0692	Cefepime HCl for injection	500 MG	\$	2.46	2016_J0692
2016	J0694	Cefoxitin sodium injection	1 GM	\$	4.62	2016_J0694
2016	J0696	Ceftriaxone sodium injection	250 MG	\$	0.50	2016_J0696
2016	J0697	Sterile cefuroxime injection	750 MG	\$	2.87	2016_J0697
2016	J0698	Cefotaxime sodium injection	1 GM	\$	0.46	2016_J0698
2016	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	6.03	2016_J0702
2016	J0712	Ceftaroline fosamil inj	10 MG	\$	2.48	2016_J0712
2016	J0713	Inj ceftazidime per 500 mg	500 MG	\$	2.26	2016_J0713
2016	J0717	Certolizumab Pegol Inj 1mg	1 MG	\$	7.11	2016_J0717
2016	J0720	Chloramphenicol sodium injec	1 GM	\$	40.36	2016_J0720
2016	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	24.62	2016_J0725
2016	J0735	Clonidine hydrochloride	1 MG	\$	14.31	2016_J0735
2016	J0740	Cidofovir injection	375 MG	\$	554.48	2016_J0740
2016	J0743	Cilastatin sodium injection	250 MG	\$	7.08	2016_J0743
2016	J0744	Ciprofloxacin iv	200 MG	\$	1.15	2016_J0744
2016	J0770	Colistimethate sodium inj	150 MG	\$	11.19	2016_J0770
2016	J0775	Collagenase, clost hist inj	0.01 MG	\$	41.42	2016_J0775
2016	J0780	Prochlorperazine injection	10 MG	\$	11.93	2016_J0780
2016	J0795	Corticotropin injection	40 UNITS	\$	3,555.35	2016_J0800
2016	J0800	Corticotropin injection	40 UNITS	\$	3,555.35	2016_J0800
2016	J0834	Cosyntropin cortrosyn inj	0.25 MG	\$	43.70	2016_J0834
2016	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	2,670.24	2016_J0840
2016	J0850	Cytomegalovirus imm IV /vial	PER VIAL	\$	1,126.55	2016_J0850
2016	J0875	Injection, dalbavancin	5 MG	\$	15.22	2016_J0875
2016	J0878	Daptomycin injection	1 MG	\$	0.90	2016_J0878
2016	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.93	2016_J0881
2016	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.93	2016_J0882
2016	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	12.59	2016_J0885
2016	J0887	Epoetin beta esrd use	1 MCG	\$	1.48	2016_J0887
2016	J0888	Epoetin beta non esrd	1 MCG	\$	1.48	2016_J0888
2016	J0894	Decitabine injection	1 MG	\$	20.83	2016_J0894
2016	J0895	Deferoxamine mesylate inj	500 MG	\$	8.85	2016_J0895
2016	J0897	Denosumab injection	1 MG	\$	16.23	2016_J0897
2016	J1000	Depo-estradiol cypionate inj	5 MG	\$	16.80	2016_J1000
2016	J1020	Methylprednisolone 20 MG inj	20 MG	\$	4.82	2016_J1020
2016	J1030	Methylprednisolone 40 MG inj	40 MG	\$	5.22	2016_J1030
2016	J1040	Methylprednisolone 80 MG inj	80 MG	\$	9.80	2016_J1040
2016	J1050	Medroxyprogesterone acetate	1 MG	\$	0.42	2016_J1050
2016	J1071	Inj testosterone cypionate	1 MG	\$	0.02	2016_J1071
2016	J1100	Dexamethasone sodium phos	1 MG	\$	0.12	2016_J1100
2016	J1110	Inj dihydroergotamine mesylt	1 MG	\$	75.49	2016_J1110
2016	J1120	Acetazolamid sodium injectio	500 MG	\$	21.18	2016_J1120
2016	J1160	Digoxin injection	0.5 MG	\$	4.82	2016_J1160
2016	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	3,039.53	2016_J1162
2016	J1165	Phenytoin sodium injection	50 MG	\$	1.41	2016_J1165
2016	J1170	Hydromorphone injection	4 MG	\$	2.14	2016_J1170
2016	J1190	Dexrazoxane HCl injection	250 MG	\$	184.05	2016_J1190
2016	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.63	2016_J1200
2016	J1205	Chlorothiazide sodium inj	500 MG	\$	86.68	2016_J1205
2016	J1212	Dimethyl sulfoxide 50% 50 ML	50 ML	\$	481.94	2016_J1212
2016	J1230	Methadone injection	10 MG	\$	17.14	2016_J1230
2016	J1240	Dimenhydrinate injection	50 MG	\$	6.32	2016_J1240
2016	J1245	Dipyridamole injection	10 MG	\$	0.78	2016_J1245
2016	J1250	Inj dobutamine HCL/250 mg	250 MG	\$	5.27	2016_J1250
2016	J1260	Dolasetron mesylate	10 MG	\$	6.17	2016_J1260
2016	J1265	Dopamine injection	40 MG	\$	0.65	2016_J1265
2016	J1267	Doripenem injection	10 MG	\$	0.78	2016_J1267
2016	J1270	Injection, doxercalciferol	1 MCG	\$	0.92	2016_J1270
2016	J1290	Ecallantide injection	1 MG	\$	399.56	2016_J1290

2016	J1300	Eculizumab injection	10 MG	\$	221.12	2016_J1300
2016	J1325	Epoprostenol injection	0.5 MG	\$	15.48	2016_J1325
2016	J1335	Ertapenem injection	500 MG	\$	45.17	2016_J1335
2016	J1364	Erythro lactobionate /500 MG	500 MG	\$	59.29	2016_J1364
2016	J1380	Estradiol valerate 10 MG inj	10 MG	\$	9.08	2016_J1380
2016	J1410	Inj estrogen conjugate 25 MG	25 MG	\$	261.40	2016_J1410
2016	J1430	Ethanolamine oleate 100 mg	100 MG	\$	404.09	2016_J1430
2016	J1439	Inj ferric carboxymaltos 1mg	1 MG	\$	1.05	2016_J1439
2016	J1442	Inj filgrastim excl biosimil	1 MCG	\$	1.00	2016_J1442
2016	J1447	Inj tbo filgrastim 1 microg	1 MCG	\$	0.74	2016_J1447
2016	J1450	Fluconazole	200 MG	\$	4.34	2016_J1450
2016	J1453	Fosaprepitant injection	1 MG	\$	1.89	2016_J1453
2016	J1458	Galsulfase injection	1 MG	\$	364.41	2016_J1458
2016	J1459	Inj IVIG privigen 500 mg	500 MG	\$	37.90	2016_J1459
2016	J1460	Gamma globulin 1 CC inj	1 CC	\$	36.41	2016_J1460
2016	J1556	Inj, Imm Glob Bivigam, 500mg	500 MG	\$	39.52	2016_J1556
2016	J1557	Gammplex injection	500 MG	\$	37.03	2016_J1557
2016	J1559	Hizentra injection	100 MG	\$	9.83	2016_J1559
2016	J1560	Gamma globulin > 10 CC inj	10 CC	\$	364.12	2016_J1560
2016	J1561	Gamunex-C/Gammaked	500 MG	\$	38.58	2016_J1561
2016	J1566	Immune globulin, powder	500 MG	\$	33.07	2016_J1566
2016	J1568	Octagam injection	500 MG	\$	35.98	2016_J1568
2016	J1569	Gammagard liquid injection	500 MG	\$	40.00	2016_J1569
2016	J1570	Ganciclovir sodium injection	500 MG	\$	58.65	2016_J1570
2016	J1571	Hepagam b im injection	0.5 ML	\$	56.06	2016_J1571
2016	J1572	Flebogamma injection	500 MG	\$	36.80	2016_J1572
2016	J1575	Hyqvia 100mg immunoglobulin	100 MG	\$	12.74	2016_J1575
2016	J1580	Garamycin gentamicin inj	80 MG	\$	1.41	2016_J1580
2016	J1602	Golimumab for iv use 1mg	1 MG	\$	24.79	2016_J1602
2016	J1610	Glucagon hydrochloride/1 MG	1 MG	\$	199.12	2016_J1610
2016	J1626	Granisetron hcl injection	100 MCG	\$	0.30	2016_J1626
2016	J1630	Haloperidol injection	5 MG	\$	1.52	2016_J1630
2016	J1631	Haloperidol decanoate inj	50 MG	\$	18.04	2016_J1631
2016	J1640	Hemin, 1 mg	1 MG	\$	22.86	2016_J1640
2016	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.18	2016_J1642
2016	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.21	2016_J1644
2016	J1645	Dalteparin sodium	2500 IU	\$	15.92	2016_J1645
2016	J1650	Inj enoxaparin sodium	10 MG	\$	0.87	2016_J1650
2016	J1652	Fondaparinux sodium	0.5 MG	\$	2.24	2016_J1652
2016	J1670	Tetanus immune globulin inj	250 UNITS	\$	433.06	2016_J1670
2016	J1720	Hydrocortisone sodium succ i	100 MG	\$	8.53	2016_J1720
2016	J1740	Ibandronate sodium injection	1 MG	\$	101.96	2016_J1740
2016	J1742	Ibutilide fumarate injection	1 MG	\$	186.19	2016_J1742
2016	J1743	Idursulfase injection	1 MG	\$	522.04	2016_J1743
2016	J1745	Infliximab injection	10 MG	\$	82.87	2016_J1745
2016	J1750	Inj iron dextran	50 MG	\$	12.41	2016_J1750
2016	J1756	Iron sucrose injection	1 MG	\$	0.26	2016_J1756
2016	J1786	Imuglucerase injection	10 UNITS	\$	41.93	2016_J1786
2016	J1800	Propranolol injection	1 MG	\$	1.15	2016_J1800
2016	J1815	Insulin injection	5 UNITS	\$	0.80	2016_J1815
2016	J1817	Insulin for insulin pump use	50 UNITS	\$	9.10	2016_J1817
2016	J1885	Ketorolac tromethamine inj	15 MG	\$	0.67	2016_J1885
2016	J1930	Lanreotide injection	1 MG	\$	51.31	2016_J1930
2016	J1931	Laronidase injection	0.1 MG	\$	30.59	2016_J1931
2016	J1940	Furosemide injection	20 MG	\$	2.05	2016_J1940
2016	J1950	Leuprolide acetate /3.75 MG	3.75 MG	\$	1,038.70	2016_J1950
2016	J1953	Levetiracetam injection	10 MG	\$	0.14	2016_J1953
2016	J1955	Inj levocarnitine per 1 gm	1 GM	\$	19.89	2016_J1955
2016	J1956	Levofloxacin injection	250 MG	\$	1.66	2016_J1956

2016	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	27.85	2016_J1980
2016	J2001	Lidocaine injection	10 MG	\$	0.02	2016_J2001
2016	J2010	Lincomycin injection	300 MG	\$	12.06	2016_J2010
2016	J2020	Linezolid injection	200 MG	\$	15.78	2016_J2020
2016	J2060	Lorazepam injection	2 MG	\$	0.80	2016_J2060
2016	J2150	Mannitol injection	50 ML	\$	1.85	2016_J2150
2016	J2175	Meperidine hydrochl /100 MG	100 MG	\$	5.09	2016_J2175
2016	J2185	Meropenem	100 MG	\$	1.31	2016_J2185
2016	J2210	Methylethylgonovin maleate inj	0.2 MG	\$	8.03	2016_J2210
2016	J2248	Micafungin sodium injection	1 MG	\$	0.97	2016_J2248
2016	J2250	Inj midazolam hydrochloride	1 MG	\$	0.14	2016_J2250
2016	J2270	Morphine sulfate injection	10 MG	\$	1.23	2016_J2270
2016	J2274	In morphine preservativ free	10MG	\$	9.05	2016_J2274
2016	J2278	Ziconotide injection	1 MCG	\$	7.31	2016_J2278
2016	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	8.49	2016_J2280
2016	J2300	Inj nalbuphine hydrochloride	10 MG	\$	2.52	2016_J2300
2016	J2310	Inj naloxone hydrochloride	1 MG	\$	32.41	2016_J2310
2016	J2315	Naltrexone, depot form	1 MG	\$	3.24	2016_J2315
2016	J2323	Natalizumab injection	1 MG	\$	17.89	2016_J2323
2016	J2353	Octreotide injection, depot	1 MG	\$	168.11	2016_J2353
2016	J2354	Octreotide inj, non-depot	25 MCG	\$	1.19	2016_J2354
2016	J2355	Oprelvekin injection	5 MG	\$	467.22	2016_J2355
2016	J2357	Omalizumab injection	5 MG	\$	32.31	2016_J2357
2016	J2358	Olanzapine long-acting inj	1 MG	\$	2.92	2016_J2358
2016	J2360	Orphenadrine injection	60 MG	\$	3.67	2016_J2360
2016	J2400	Chloroprocaine hcl injection	30 ML	\$	25.95	2016_J2400
2016	J2405	Ondansetron hcl injection	1 MG	\$	0.13	2016_J2405
2016	J2407	Injection, oritavancin	10 MG	\$	24.64	2016_J2407
2016	J2410	Oxymorphone hcl injection	1 MG	\$	2.89	2016_J2410
2016	J2425	Palifermin injection	50 MCG	\$	17.68	2016_J2425
2016	J2426	Paliperidone palmitate inj	1 MG	\$	9.12	2016_J2426
2016	J2430	Pamidronate disodium /30 MG	30 MG	\$	10.42	2016_J2430
2016	J2469	Palonosetron hcl	25 MCG	\$	22.88	2016_J2469
2016	J2501	Paricalcitol	1 MCG	\$	3.17	2016_J2501
2016	J2503	Pegaptanib sodium injection	0.3 MG	\$	1,054.70	2016_J2503
2016	J2504	Pegademase bovine, 25 iu	25 IU	\$	319.67	2016_J2504
2016	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	4,040.69	2016_J2505
2016	J2507	Pegloticase injection	1 MG	\$	1,642.46	2016_J2507
2016	J2510	Penicillin g procaine inj	600000 UNITS	\$	26.77	2016_J2510
2016	J2515	Pentobarbital sodium inj	50 MG	\$	47.18	2016_J2515
2016	J2540	Penicillin g potassium inj	600000 UNITS	\$	1.03	2016_J2540
2016	J2543	Piperacillin/tazobactam	1.125 GM	\$	2.90	2016_J2543
2016	J2545	Pentamidine non-comp unit	300 MG	\$	118.85	2016_J2545
2016	J2550	Promethazine hcl injection	50 MG	\$	1.64	2016_J2550
2016	J2560	Phenobarbital sodium inj	120 MG	\$	29.80	2016_J2560
2016	J2562	Plerixafor injection	1 MG	\$	312.11	2016_J2562
2016	J2597	Inj desmopressin acetate	1 MCG	\$	14.04	2016_J2597
2016	J2675	Inj progesterone per 50 MG	50 MG	\$	1.37	2016_J2675
2016	J2680	Fluphenazine decanoate 25 MG	25 MG	\$	22.78	2016_J2680
2016	J2690	Procainamide hcl injection	1 GM	\$	55.60	2016_J2690
2016	J2700	Oxacillin sodium injecton	250 MG	\$	1.61	2016_J2700
2016	J2704	Inj, propofol, 10 mg	10 MG	\$	0.12	2016_J2704
2016	J2720	Inj protamine sulfate/10 MG	10 MG	\$	1.12	2016_J2720
2016	J2724	Protein c concentrate	10 UNITS	\$	15.23	2016_J2724
2016	J2765	Metoclopramide hcl injection	10 MG	\$	0.89	2016_J2765
2016	J2770	Quinupristin/dalfopristin	500 MG	\$	413.52	2016_J2770
2016	J2778	Ranibizumab injection	0.1 mg	\$	383.23	2016_J2778
2016	J2780	Ranitidine hydrochloride inj	25 MG	\$	1.09	2016_J2780
2016	J2783	Rasburicase	0.5 MG	\$	254.11	2016_J2783

2016	J2785	Regadenoson injection	0.1 MG	\$	53.90	2016_J2785
2016	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	27.01	2016_J2788
2016	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	81.45	2016_J2790
2016	J2791	Rhophylac injection	100 IU	\$	4.74	2016_J2791
2016	J2792	Rho(D) immune globulin h, sd	100 IU	\$	21.33	2016_J2792
2016	J2794	Risperidone, long acting	0.5 MG	\$	7.82	2016_J2794
2016	J2795	Ropivacaine HCl injection	1 MG	\$	0.07	2016_J2795
2016	J2796	Romiplostim injection	10 MCG	\$	62.14	2016_J2796
2016	J2800	Methocarbamol injection	10 ML	\$	38.57	2016_J2800
2016	J2805	Sincalide injection	5 MCG	\$	97.45	2016_J2805
2016	J2810	Inj theophylline per 40 MG	40 MG	\$	0.30	2016_J2810
2016	J2820	Sargramostim injection	50 MCG	\$	36.23	2016_J2820
2016	J2850	Inj secretin synthetic human	1 MCG	\$	34.78	2016_J2850
2016	J2916	Na ferric gluconate complex	12.5 MG	\$	2.30	2016_J2916
2016	J2920	Methylprednisolone injection	40 MG	\$	3.73	2016_J2920
2016	J2930	Methylprednisolone injection	125 MG	\$	5.13	2016_J2930
2016	J2997	Alteplase recombinant	1 MG	\$	80.29	2016_J2997
2016	J3000	Streptomycin injection	1 GM	\$	13.34	2016_J3000
2016	J3010	Fentanyl citrate injecton	0.1 MG	\$	0.50	2016_J3010
2016	J3060	Inj, Taliglucerase Alfa 10 u	10 UNITS	\$	40.46	2016_J3060
2016	J3070	Pentazocine injection	30 MG	\$	140.39	2016_J3070
2016	J3090	Inj tedizolid phosphate	1 MG	\$	1.28	2016_J3090
2016	J3095	Telavancin injection	10 MG	\$	5.02	2016_J3095
2016	J3101	Tenecteplase injection	1 MG	\$	102.43	2016_J3101
2016	J3105	Terbutaline sulfate inj	1 MG	\$	3.13	2016_J3105
2016	J3121	Inj testostero enanthate 1mg	1 MG	\$	0.04	2016_J3121
2016	J3230	Chlorpromazine hcl injection	50 MG	\$	23.12	2016_J3230
2016	J3240	Thyrotropin injection	0.9 MG	\$	1,571.30	2016_J3240
2016	J3243	Tigecycline injection	1 MG	\$	3.13	2016_J3243
2016	J3250	Trimethobenzamide hcl inj	200 MG	\$	25.92	2016_J3250
2016	J3260	Tobramycin sulfate injection	80 MG	\$	1.39	2016_J3260
2016	J3262	Tocilizumab injection	1 MG	\$	4.10	2016_J3262
2016	J3285	Treprostinil injection	1 MG	\$	61.24	2016_J3285
2016	J3300	Triamcinolone A inj PRS-free	1 MG	\$	3.70	2016_J3300
2016	J3301	Triamcinolone acet inj NOS	10 MG	\$	1.77	2016_J3301
2016	J3303	Triamcinolone hexacetoni inj	5 MG	\$	3.61	2016_J3303
2016	J3315	Triptorelin pamoate	3.75 MG	\$	460.85	2016_J3315
2016	J3357	Ustekinumab injection	1 MG	\$	174.57	2016_J3357
2016	J3360	Diazepam injection	5 MG	\$	9.26	2016_J3360
2016	J3370	Vancomycin hcl injection	500 MG	\$	2.98	2016_J3370
2016	J3380	Injection, vedolizumab	1 MG	\$	17.43	2016_J3380
2016	J3385	Velaglucerase alfa	100 UNITS	\$	343.35	2016_J3385
2016	J3396	Verteporfin injection	0.1 MG	\$	10.88	2016_J3396
2016	J3410	Hydroxyzine hcl injection	25 MG	\$	2.39	2016_J3410
2016	J3411	Thiamine hcl 100 mg	100 MG	\$	3.24	2016_J3411
2016	J3415	Pyridoxine hcl 100 mg	100 MG	\$	9.52	2016_J3415
2016	J3420	Vitamin b12 injection	1000 MCG	\$	4.64	2016_J3420
2016	J3430	Vitamin k phytionadione inj	1 MG	\$	3.49	2016_J3430
2016	J3465	Injection, voriconazole	10 MG	\$	4.64	2016_J3465
2016	J3471	Ovine, up to 999 usp units	1 UNIT	\$	0.35	2016_J3471
2016	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.36	2016_J3473
2016	J3475	Inj magnesium sulfate	500 MG	\$	0.26	2016_J3475
2016	J3480	Inj potassium chloride	2 MEQ	\$	0.13	2016_J3480
2016	J3485	Zidovudine	10 MG	\$	1.51	2016_J3485
2016	J3486	Ziprasidone mesylate	10 MG	\$	18.88	2016_J3486
2016	J3489	Zoledronic Acid 1mg	1 MG	\$	15.67	2016_J3489
2016	J7030	Normal saline solution infus	1000 ML	\$	1.88	2016_J7030
2016	J7040	Normal saline solution infus	500 ML	\$	0.94	2016_J7040
2016	J7042	5% dextrose/normal saline	500 ML	\$	0.79	2016_J7042

2016	J7050	Normal saline solution infus	250 ML	\$	0.47	2016_J7050
2016	J7060	5% dextrose/water	500 ML	\$	1.85	2016_J7060
2016	J7070	D5w infusion	1000 CC	\$	3.62	2016_J7070
2016	J7120	Ringers lactate infusion	1000 CC	\$	2.15	2016_J7120
2016	J7180	Factor xiii anti-hem factor	1 IU	\$	8.18	2016_J7180
2016	J7182	Factor viii recomb novoeight	1 IU	\$	1.31	2016_J7182
2016	J7183	Wilate injection	1 I.U. VWF:RCO	\$	0.97	2016_J7183
2016	J7185	Xyntha inj	1 IU	\$	1.20	2016_J7185
2016	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	0.97	2016_J7186
2016	J7187	Humate-P, inj	1 IU	\$	1.04	2016_J7187
2016	J7189	Factor viia	1 MCG	\$	1.90	2016_J7189
2016	J7190	Factor viii	1 IU	\$	0.98	2016_J7190
2016	J7192	Factor viii recombinant NOS	1 IU	\$	1.20	2016_J7192
2016	J7193	Factor IX non-recombinant	1 IU	\$	1.11	2016_J7193
2016	J7194	Factor ix complex	1 IU	\$	1.29	2016_J7194
2016	J7195	Factor IX recombinant NOS	1 IU	\$	1.52	2016_J7195
2016	J7197	Antithrombin iii injection	1 IU	\$	3.43	2016_J7197
2016	J7198	Anti-inhibitor	1 IU	\$	1.92	2016_J7198
2016	J7200	Factor ix recombinan rixubis	1 IU	\$	1.25	2016_J7200
2016	J7201	Factor ix fc fusion recomb	1 IU	\$	2.82	2016_J7201
2016	J7205	Factor viii fc fusion recomb	1 IU	\$	1.89	2016_J7205
2016	J7308	Aminolevulinic acid hcl top	354 MG	\$	327.41	2016_J7308
2016	J7311	Fluocinolone acetone implt	0.59 MG	\$	20,126.60	2016_J7311
2016	J7312	Dexamethasone intra implant	0.1 MG	\$	200.90	2016_J7312
2016	J7313	Fluocinol acet intravit imp	0.01 MG	\$	490.95	2016_J7313
2016	J7316	Inj, Ocriplasmin, 0.125 mg	0.125 MG	\$	1,046.75	2016_J7316
2016	J7321	Hyalgan/supartz inj per dose	per dose	\$	87.73	2016_J7321
2016	J7323	Euflexxa inj per dose	per dose	\$	155.32	2016_J7323
2016	J7324	Orthovisc inj per dose	per dose	\$	159.28	2016_J7324
2016	J7325	Synvisc or Synvisc-One	1 MG	\$	12.77	2016_J7325
2016	J7326	Gel-One	per dose	\$	587.58	2016_J7326
2016	J7327	Monovisc inj per dose	Per Dose	\$	917.77	2016_J7327
2016	J7336	Capsaicin 8% patch	1 SQ CM	\$	2.98	2016_J7336
2016	J7500	Azathioprine oral 50mg	50 MG	\$	0.33	2016_J7500
2016	J7502	Cyclosporine oral 100 mg	100 MG	\$	3.37	2016_J7502
2016	J7503	Tacrol envarsus ex rel oral	0.25 MG	\$	1.23	2016_J7503
2016	J7504	Lymphocyte immune globulin	250 MG	\$	1,438.74	2016_J7504
2016	J7507	Tacrolimus Imme Rel oral 1mg	1 MG	\$	0.75	2016_J7507
2016	J7508	Tacrol astagraf ex rel oral	0.1 MG	\$	0.39	2016_J7508
2016	J7509	Methylprednisolone oral	4 MG	\$	0.34	2016_J7509
2016	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.10	2016_J7510
2016	J7511	Antithymocyte globuln rabbit	25 MG	\$	690.84	2016_J7511
2016	J7512	Prednisone ir or dr oral 1mg	1 MG	\$	0.01	2016_J7512
2016	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.90	2016_J7515
2016	J7516	Cyclosporin parenteral 250mg	250 MG	\$	41.56	2016_J7516
2016	J7517	Mycophenolate mofetil oral	250 MG	\$	0.95	2016_J7517
2016	J7518	Mycophenolic acid	180 MG	\$	2.88	2016_J7518
2016	J7520	Sirolimus, oral	1 MG	\$	7.57	2016_J7520
2016	J7525	Tacrolimus injection	5 MG	\$	163.77	2016_J7525
2016	J7527	Oral everolimus	0.25 MG	\$	7.69	2016_J7527
2016	J7605	Arformoterol non-comp unit	15 mcg	\$	8.97	2016_J7605
2016	J7606	Formoterol fumarate, inh	20 MCG	\$	10.67	2016_J7606
2016	J7608	Acetylcysteine non-comp unit	1 GM	\$	4.83	2016_J7608
2016	J7611	Albuterol non-comp con	1 MG	\$	0.12	2016_J7611
2016	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.20	2016_J7612
2016	J7613	Albuterol non-comp unit	1 MG	\$	0.05	2016_J7613
2016	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.07	2016_J7614
2016	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.17	2016_J7620
2016	J7626	Budesonide non-comp unit	0.5 MG	\$	3.98	2016_J7626

2016	J7631	Cromolyn sodium noncomp unit	10 MG	\$	0.88	2016_J7631
2016	J7639	Dornase alfa non-comp unit	1 MG	\$	42.50	2016_J7639
2016	J7644	Ipratropium bromide non-comp	1 MG	\$	0.23	2016_J7644
2016	J7674	Methacholine chloride, neb	1 MG	\$	0.52	2016_J7674
2016	J7682	Tobramycin non-comp unit	300 MG	\$	45.42	2016_J7682
2016	J7686	Treprostinil, non-comp unit	1.74 MG	\$	521.88	2016_J7686
2016	J8501	Oral aprepitant	5 MG	\$	11.11	2016_J8501
2016	J8510	Oral busulfan	2 MG	\$	23.69	2016_J8510
2016	J8520	Capecitabine, oral, 150 mg	150 MG	\$	4.12	2016_J8520
2016	J8521	Capecitabine, oral, 500 mg	500 MG	\$	13.78	2016_J8521
2016	J8530	Cyclophosphamide oral 25 MG	25 MG	\$	3.34	2016_J8530
2016	J8540	Oral dexamethasone	0.25 MG	\$	0.03	2016_J8540
2016	J8560	Etoposide oral 50 MG	50 MG	\$	71.61	2016_J8560
2016	J8600	Melphalan oral 2 MG	2 MG	\$	11.71	2016_J8600
2016	J8610	Methotrexate oral 2.5 MG	2.5 MG	\$	1.01	2016_J8610
2016	J8655	Netupitant palonosetron oral	0.5 MG	\$	461.97	2016_J8655
2016	J8700	Temozolomide	5 MG	\$	2.66	2016_J8700
2016	J8705	Topotecan oral	0.25 mg	\$	103.85	2016_J8705
2016	J9000	Doxorubicin hcl injection	10 MG	\$	2.53	2016_J9000
2016	J9017	Arsenic trioxide injection	1 MG	\$	64.62	2016_J9017
2016	J9019	Erwinaze injection	1,000 IU	\$	402.74	2016_J9019
2016	J9025	Azacitidine injection	1 MG	\$	2.84	2016_J9025
2016	J9027	Clofarabine injection	1 MG	\$	152.44	2016_J9027
2016	J9031	Bcg live intravesical vac	1 EA	\$	123.20	2016_J9031
2016	J9032	Injection, belinostat, 10mg	10 MG	\$	33.54	2016_J9032
2016	J9033	Bendamustine injection	1 MG	\$	27.01	2016_J9033
2016	J9035	Bevacizumab injection	10 MG	\$	72.31	2016_J9035
2016	J9040	Bleomycin sulfate injection	15 UNITS	\$	28.20	2016_J9040
2016	J9041	Bortezomib injection	0.1 MG	\$	46.52	2016_J9041
2016	J9042	Brentuximab vedotin inj	1 MG	\$	129.09	2016_J9042
2016	J9043	Cabazitaxel injection	1 MG	\$	154.57	2016_J9043
2016	J9045	Carboplatin injection	50 MG	\$	3.55	2016_J9045
2016	J9047	Injection, Carfilzomib, 1 mg	1 MG	\$	31.95	2016_J9047
2016	J9050	Carmustine injection	100 MG	\$	3,847.56	2016_J9050
2016	J9055	Cetuximab injection	10 MG	\$	55.63	2016_J9055
2016	J9060	Cisplatin 10 MG injection	10 MG	\$	2.07	2016_J9060
2016	J9065	Inj cladribine per 1 MG	1 MG	\$	21.75	2016_J9065
2016	J9070	Cyclophosphamide 100 MG inj	100 MG	\$	43.97	2016_J9070
2016	J9098	Cytarabine liposome inj	10 MG	\$	595.76	2016_J9098
2016	J9100	Cytarabine hcl 100 MG inj	100 MG	\$	0.90	2016_J9100
2016	J9120	Dactinomycin injection	0.5 MG	\$	1,276.38	2016_J9120
2016	J9130	Dacarbazine 100 mg inj	100 MG	\$	3.96	2016_J9130
2016	J9150	Daunorubicin injection	10 MG	\$	40.03	2016_J9150
2016	J9155	Degarelix injection	1 MG	\$	3.62	2016_J9155
2016	J9171	Docetaxel injection	1 MG	\$	2.72	2016_J9171
2016	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.17	2016_J9178
2016	J9179	Eribulin mesylate injection	0.1 MG	\$	106.08	2016_J9179
2016	J9181	Etoposide injection	10 MG	\$	0.69	2016_J9181
2016	J9185	Fludarabine phosphate inj	50 MG	\$	59.77	2016_J9185
2016	J9190	Fluorouracil injection	500 MG	\$	1.70	2016_J9190
2016	J9200	Floxuridine injection	500 MG	\$	52.80	2016_J9200
2016	J9201	Gemcitabine hcl injection	200 MG	\$	6.31	2016_J9201
2016	J9202	Goserelin acetate implant	3.6 MG	\$	327.12	2016_J9202
2016	J9206	Irinotecan injection	20 MG	\$	4.01	2016_J9206
2016	J9207	Ixabepilone injection	1 MG	\$	77.87	2016_J9207
2016	J9208	Ifosfamide injection	1 GM	\$	28.18	2016_J9208
2016	J9209	Mesna injection	200 MG	\$	2.39	2016_J9209
2016	J9211	Idarubicin hcl injection	5 MG	\$	29.76	2016_J9211
2016	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	26.86	2016_J9214

2016	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	225.01	2016_J9217
2016	J9218	Leuprolide acetate injecton	1 MG	\$	17.90	2016_J9218
2016	J9225	Vantas implant	50 MG	\$	3,138.04	2016_J9225
2016	J9226	Supprelin LA implant	50 MG	\$	26,205.50	2016_J9226
2016	J9228	Ipilimumab injection	1 MG	\$	142.65	2016_J9228
2016	J9230	Mechlorethamine hcl inj	10 MG	\$	265.89	2016_J9230
2016	J9245	Inj melphalan hydrochl 50 MG	50 MG	\$	1,871.63	2016_J9245
2016	J9250	Methotrexate sodium inj	5 MG	\$	0.24	2016_J9250
2016	J9260	Methotrexate sodium inj	50 MG	\$	2.38	2016_J9260
2016	J9261	Nelarabine injection	50 MG	\$	152.21	2016_J9261
2016	J9263	Oxaliplatin	0.5 MG	\$	0.39	2016_J9263
2016	J9264	Paclitaxel protein bound	1 MG	\$	10.32	2016_J9264
2016	J9266	Pegaspargase injection	1 EA	\$	13,911.23	2016_J9266
2016	J9267	Paclitaxel injection	1 MG	\$	0.18	2016_J9267
2016	J9268	Pentostatin injection	10 MG	\$	1,887.77	2016_J9268
2016	J9271	Inj pembrolizumab	1 MG	\$	46.50	2016_J9271
2016	J9280	Mitomycin injection	5 MG	\$	103.17	2016_J9280
2016	J9293	Mitoxantrone hydrochl / 5 MG	5 MG	\$	36.75	2016_J9293
2016	J9299	Injection, nivolumab	1 MG	\$	26.06	2016_J9299
2016	J9301	Obinutuzumab inj	10 MG	\$	56.20	2016_J9301
2016	J9302	Ofatumumab injection	10 MG	\$	51.87	2016_J9302
2016	J9303	Panitumumab injection	10 MG	\$	105.60	2016_J9303
2016	J9305	Pemetrexed injection	10 MG	\$	62.78	2016_J9305
2016	J9306	Injection, Pertuzumab, 1 mg	1 MG	\$	10.65	2016_J9306
2016	J9307	Pralatrexate injection	1 MG	\$	229.72	2016_J9307
2016	J9308	Injection, ramucirumab	5 MG	\$	55.93	2016_J9308
2016	J9310	Rituximab injection	100 MG	\$	792.92	2016_J9310
2016	J9315	Romidepsin injection	1 MG	\$	306.79	2016_J9315
2016	J9320	Streptozocin injection	1 GM	\$	323.60	2016_J9320
2016	J9328	Temozolomide injection	1 MG	\$	8.24	2016_J9328
2016	J9330	Temsirolimus injection	1 MG	\$	66.67	2016_J9330
2016	J9351	Topotecan injection	0.1 MG	\$	3.06	2016_J9351
2016	J9354	Inj, Ado-trastuzumab Emt 1mg	1 MG	\$	29.22	2016_J9354
2016	J9355	Trastuzumab injection	10 MG	\$	92.09	2016_J9355
2016	J9357	Valrubicin injection	200 MG	\$	1,148.73	2016_J9357
2016	J9360	Vinblastine sulfate inj	1 MG	\$	3.54	2016_J9360
2016	J9370	Vincristine sulfate 1 MG inj	1 MG	\$	4.25	2016_J9370
2016	J9371	Inj, vincristine sul lip 1 mg	1 MG	\$	2,506.49	2016_J9371
2016	J9390	Vinorelbine tartrate inj	10 MG	\$	10.35	2016_J9390
2016	J9395	Injection, Fulvestrant	25 MG	\$	95.77	2016_J9395
2016	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.45	2016_J9400
2016	P9041	Albumin (human),5%, 50ml	50 ML	\$	11.02	2016_P9041
2016	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	54.72	2016_P9045
2016	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	22.49	2016_P9046
2016	P9047	Albumin (human), 25%, 50ml	50 ML	\$	53.44	2016_P9047
2016	Q0138	Ferumoxitol, non-esrd	1 MG	\$	0.88	2016_Q0138
2016	Q0139	Ferumoxitol, esrd use	1 MG	\$	0.88	2016_Q0139
2016	Q0162	Ondansetron oral	1 MG	\$	1.01	2016_Q0162
2016	Q0163	Diphenhydramine HCl 50mg	50 MG	\$	0.27	2016_Q0163
2016	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.04	2016_Q0164
2016	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	0.41	2016_Q0166
2016	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	2.46	2016_Q0167
2016	Q0169	Promethazine HCl 12.5mg oral	12.5 MG	\$	0.02	2016_Q0169
2016	Q0180	Dolasetron mesylate oral	100 MG	\$	94.76	2016_Q0180
2016	Q2035	Afluria vacc, 3 yrs & >, im	0.5 ml	\$	16.28	2016_Q2035
2016	Q2037	Fluvirin vacc, 3 yrs & >, im	0.5 ML	\$	16.28	2016_Q2037
2016	Q2043	Sipuleucel-T auto CD54+	Per infusion (minimum 50 million cells)	\$	38,034.65	2016_Q2043
2016	Q2050	Doxorubicin inj 10mg	10 MG	\$	435.44	2016_Q2050
2016	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	45.37	2016_Q3027

2016	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	123.93	2016_Q4074
2016	Q4081	Epoetin alfa, 100 units ESRD	100 UNITS	\$	1.26	2016_Q4081
2016	Q4101	Apligraf skin sub	1 SQ CM	\$	31.02	2016_Q4101
2016	Q4102	Oasis wound matrix skin sub	1 SQ CM	\$	11.01	2016_Q4102
2016	Q4104	Integra BMWD skin sub	1 SQ CM	\$	34.26	2016_Q4104
2016	Q4105	Integra DRT skin sub	1 SQ CM	\$	16.57	2016_Q4105
2016	Q4106	Dermagraft skin sub	1 SQ CM	\$	33.44	2016_Q4106
2016	Q4107	Graftjacket skin sub	1 SQ CM	\$	88.33	2016_Q4107
2016	Q4108	Integra matrix skin sub	1 SQ CM	\$	37.63	2016_Q4108
2016	Q4110	Primatrix skin sub	1 SQ CM	\$	50.72	2016_Q4110
2016	Q4111	Gammagraft skin sub	1 SQ CM	\$	6.88	2016_Q4111
2016	Q4112	Cymetra allograft	1 CC	\$	223.47	2016_Q4112
2016	Q4113	Graftjacket express allograf	1 CC	\$	223.47	2016_Q4113
2016	Q4115	Alloskin	1 SQ CM	\$	9.98	2016_Q4115
2016	Q4116	Alloderm skin sub	1 SQ CM	\$	32.20	2016_Q4116
2016	Q4121	Theraskin	1 SQ CM	\$	42.71	2016_Q4121
2016	Q4123	Alloskin RT	1 SQ CM	\$	20.06	2016_Q4123
2016	Q4131	Epifix	1 SQ CM	\$	169.40	2016_Q4131
2016	Q5101	Inj filgrastim g-csf biosim	1 MCG	\$	0.83	2016_Q5101
2016	Q9950	Inj sulf hexa lipid microsph	1 ML	\$	22.33	2016_Q9950
2016	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	34.55	2016_Q9956
2016	Q9957	Inj perflutren lip micros,ml	1 ML	\$	51.82	2016_Q9957
2016	Q9958	HOCM <=149 mg/ml iodine, 1ml	1 ML	\$	0.08	2016_Q9958
2016	Q9960	HOCM 200-249mg/ml iodine,1ml	1 ML	\$	0.23	2016_Q9960
2016	Q9961	HOCM 250-299mg/ml iodine,1ml	1 ML	\$	0.20	2016_Q9961
2016	Q9963	HOCM 350-399mg/ml iodine,1ml	1 ML	\$	0.20	2016_Q9963
2016	Q9965	LOCM 100-199mg/ml iodine,1ml	1 ML	\$	0.85	2016_Q9965
2016	Q9966	LOCM 200-299mg/ml iodine,1ml	1 ML	\$	0.18	2016_Q9966
2016	Q9967	LOCM 300-399mg/ml iodine,1ml	1 ML	\$	0.12	2016_Q9967
2015	90371	Hep b ig, im	1 ML	\$	110.39	2015_90371
2015	90375	Rabies ig, im/sc	150 IU	\$	285.93	2015_90375
2015	90376	Rabies ig, heat treated	150 IU	\$	252.95	2015_90376
2015	90585	Bcg vaccine, percut	50 MG	\$	122.88	2015_90585
2015	90586	Bcg vaccine, intravesical	1 EACH	\$	122.88	2015_90586
2015	90630	IlV4 Vacc no prsv 3 yrs+ id	0.1 ml	\$	23.47	2015_90630
2015	90632	Hep a vaccine, adult im	1 ML	\$	49.40	2015_90632
2015	90656	Flu vaccine no preserv 3 yo & >, im	0.50 ML	\$	13.88	2015_90656
2015	90657	Flu vaccine, 6-35 mo, im	0.25 ML	\$	6.02	2015_90657
2015	90661	Flu vaccine, no preserv, 3 +, im, cell cultures	0.5 ML	\$	22.29	2015_90661
2015	90662	Flu vacc prsv free inc antig	0.5 ML	\$	36.31	2015_90662
2015	90670	Pneumococcal vacc, 13 val im	0.5 ML	\$	173.15	2015_90670
2015	90672	Flu vaccine 4 valent nasal	0.2 ml	\$	26.88	2015_90672
2015	90673	Flu vacc riv3 no preserv	0.5 ML	\$	37.19	2015_90673
2015	90675	Rabies vaccine, im	1 ML	\$	263.54	2015_90675
2015	90685	Flu vac no prsv 4 val 6-35 m	0.25 mL	\$	24.60	2015_90685
2015	90686	Flu vac no prsv 4 val 3 yrs+	0.5 ml	\$	18.15	2015_90686
2015	90687	Flu vaccine, 6-35 mon, IM, 4 val	0.25 ML	\$	9.13	2015_90687
2015	90688	Flu vaccine, 3 +, IM, 4 val	0.5 ML	\$	18.27	2015_90688
2015	90691	Typhoid vaccine, im	0.5 ML	\$	71.18	2015_90691
2015	90714	Td vaccine no prsv >/= 7 yo, im	0.5 ML	\$	21.06	2015_90714
2015	90715	Tdap => 7 yo, im	0.5 ML	\$	31.58	2015_90715
2015	90732	Pneumococcal vaccine	0.5 ML	\$	82.51	2015_90732
2015	90740	Hepb vacc, ill pat 3 dose im	40 MCG	\$	119.42	2015_90740
2015	90743	Hep b vacc, adol, 2 dose, im	1 DOSE	\$	24.22	2015_90743
2015	90744	Hepb vacc ped/adol 3 dose im	1 DOSE	\$	24.22	2015_90744
2015	90746	Hep b vaccine, adult, im	20 MCG	\$	59.71	2015_90746
2015	90747	Hepb vacc, ill pat 4 dose im	40 MCG	\$	119.42	2015_90747
2015	A9575	Inj gadoterate meglumi	0.1 ml	\$	0.22	2015_A9575
2015	A9576	Inj prohance multipack	1 ML	\$	1.61	2015_A9576

2015	A9577	Inj multihance	1 ML	\$	2.14	2015_A9577
2015	A9578	Inj multihance multipack	1 ML	\$	2.03	2015_A9578
2015	A9579	Gad-base MR contrast NOS,1ml	1 ML	\$	1.89	2015_A9579
2015	A9581	Gadoxetate disodium inj	1 ML	\$	14.00	2015_A9581
2015	A9583	Gadofosveset trisodium inj	1 ML	\$	14.92	2015_A9583
2015	A9585	Gadobutrol injection	0.1 ML	\$	0.39	2015_A9585
2015	A9606	Radium ra223 dichloride ther	1 microCurie	N/A		2015_A9606
2015	J0129	Abatacept injection	10 MG	\$	37.33	2015_J0129
2015	J0130	Abciximab injection	10 MG	\$	965.13	2015_J0130
2015	J0132	Acetylcysteine injection	100 MG	\$	2.00	2015_J0132
2015	J0133	Acyclovir injection	5 MG	\$	0.08	2015_J0133
2015	J0135	Adalimumab injection	20 MG	\$	742.96	2015_J0135
2015	J0153	Adenosine inj 1mg	1 MG	\$	0.98	2015_J0153
2015	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.14	2015_J0171
2015	J0178	Aflibercept injection (ophthalmic)	1 MG	\$	980.50	2015_J0178
2015	J0180	Agalsidase beta injection	1 MG	\$	158.04	2015_J0180
2015	J0207	Amifostine	500 MG	\$	363.93	2015_J0207
2015	J0210	Methyldopate hcl injection	250 MG	\$	42.40	2015_J0210
2015	J0220	Alglucosidase alfa injection	10 MG	\$	206.64	2015_J0220
2015	J0221	Lumizyme injection	10 MG	\$	153.60	2015_J0221
2015	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.45	2015_J0256
2015	J0257	Glassia injection	10 MG	\$	4.11	2015_J0257
2015	J0278	Amikacin sulfate injection	100 MG	\$	1.14	2015_J0278
2015	J0280	Aminophyllin 250 MG inj	250 MG	\$	9.38	2015_J0280
2015	J0285	Amphotericin B	50 MG	\$	18.18	2015_J0285
2015	J0287	Amphotericin b lipid complex	10 MG	\$	12.38	2015_J0287
2015	J0289	Amphotericin b liposome inj	10 MG	\$	18.23	2015_J0289
2015	J0290	Ampicillin 500 MG inj	500 MG	\$	1.17	2015_J0290
2015	J0295	Ampicillin sodium per 1.5 gm	1.5 GM	\$	2.48	2015_J0295
2015	J0348	Anidulafungin injection	1 MG	\$	0.60	2015_J0348
2015	J0360	Hydralazine hcl injection	20 MG	\$	17.03	2015_J0360
2015	J0400	Aripiprazole injection	0.25 MG	\$	0.74	2015_J0400
2015	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	4.10	2015_J0401
2015	J0456	Azithromycin	500 MG	\$	3.55	2015_J0456
2015	J0461	Atropine sulfate injection	0.01 MG	\$	0.05	2015_J0461
2015	J0470	Dimecaprol injection	100 MG	\$	39.73	2015_J0470
2015	J0475	Baclofen 10 MG injection	10 MG	\$	170.03	2015_J0475
2015	J0476	Baclofen intrathecal trial	50 MCG	\$	76.07	2015_J0476
2015	J0480	Basiliximab	20 MG	\$	2,851.52	2015_J0480
2015	J0485	Belatacept injection	1 MG	\$	3.80	2015_J0485
2015	J0490	Belimumab injection	10 MG	\$	40.54	2015_J0490
2015	J0500	Dicyclomine injection	20 MG	\$	57.03	2015_J0500
2015	J0515	Inj benztropine mesylate	1 MG	\$	19.21	2015_J0515
2015	J0558	PenG benzathine/procaine inj	100,000 UNITS	\$	6.18	2015_J0558
2015	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	7.84	2015_J0561
2015	J0583	Bivalirudin	1 MG	\$	3.71	2015_J0583
2015	J0585	Injection,onabotulinumtoxinA	1 UNIT	\$	5.72	2015_J0585
2015	J0586	AbobotulinumtoxinA	5 Unit	\$	8.00	2015_J0586
2015	J0587	Inj, rimabotulinumtoxinB	100 UNITS	\$	11.65	2015_J0587
2015	J0588	Incobotulinumtoxin A	1 UNIT	\$	4.67	2015_J0588
2015	J0592	Buprenorphine hydrochloride	0.1 MG	\$	3.08	2015_J0592
2015	J0594	Busulfan injection	1 MG	\$	33.20	2015_J0594
2015	J0595	Butorphanol tartrate 1 mg	1 MG	\$	2.20	2015_J0595
2015	J0597	C-1 esterase, berinert	10 UNITS	\$	40.52	2015_J0597
2015	J0598	C-1 esterase, cinryze	10 UNITS	\$	54.46	2015_J0598
2015	J0600	Edetate calcium disodium inj	1000 MG	\$	5,594.42	2015_J0600
2015	J0610	Calcium gluconate injection	10 ML	\$	3.48	2015_J0610
2015	J0630	Calcitonin salmon injection	400 UNITS	\$	2,006.85	2015_J0630
2015	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.35	2015_J0636

2015	J0637	Caspofungin acetate	5 MG	\$	12.75	2015_J0637
2015	J0638	Canakinumab injection	1 MG	\$	91.78	2015_J0638
2015	J0640	Leucovorin calcium injection	50 MG	\$	3.55	2015_J0640
2015	J0641	Levoleucovorin injection	0.5 MG	\$	1.92	2015_J0641
2015	J0670	Inj mepivacaine HCL/10 ml	10 ML	\$	2.09	2015_J0670
2015	J0690	Cefazolin sodium injection	500 MG	\$	0.85	2015_J0690
2015	J0692	Cefepime HCl for injection	500 MG	\$	2.44	2015_J0692
2015	J0694	Cefoxitin sodium injection	1 GM	\$	4.70	2015_J0694
2015	J0696	Ceftriaxone sodium injection	250 MG	\$	0.68	2015_J0696
2015	J0697	Sterile cefuroxime injection	750 MG	\$	2.63	2015_J0697
2015	J0698	Cefotaxime sodium injection	1 GM	\$	2.17	2015_J0698
2015	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	5.91	2015_J0702
2015	J0712	Ceftaroline fosamil inj	10 MG	\$	2.14	2015_J0712
2015	J0713	Inj ceftazidime per 500 mg	500 MG	\$	2.33	2015_J0713
2015	J0717	Certolizumab Pegol Inj 1mg	1 MG	\$	6.62	2015_J0717
2015	J0720	Chloramphenicol sodium injec	1 GM	\$	31.74	2015_J0720
2015	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	22.59	2015_J0725
2015	J0735	Clonidine hydrochloride	1 MG	\$	16.52	2015_J0735
2015	J0740	Cidofovir injection	375 MG	\$	650.18	2015_J0740
2015	J0743	Cilastatin sodium injection	250 MG	\$	4.19	2015_J0743
2015	J0744	Ciprofloxacin iv	200 MG	\$	1.03	2015_J0744
2015	J0770	Colistimethate sodium inj	150 MG	\$	11.62	2015_J0770
2015	J0775	Collagenase, clost hist inj	0.01 MG	\$	38.06	2015_J0775
2015	J0780	Prochlorperazine injection	10 MG	\$	13.23	2015_J0780
2015	J0795	Corticotropin ovine triflural	1 MCG	\$	7.74	2015_J0795
2015	J0800	Corticotropin injection	40 UNITS	\$	3,468.13	2015_J0800
2015	J0834	Cosyntropin cortrosyn inj	0.25 MG	\$	46.68	2015_J0834
2015	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	2,542.98	2015_J0840
2015	J0850	Cytomegalovirus imm IV /vial	PER VIAL	\$	1,064.77	2015_J0850
2015	J0878	Daptomycin injection	1 MG	\$	0.76	2015_J0878
2015	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	4.38	2015_J0881
2015	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	4.38	2015_J0882
2015	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	12.62	2015_J0885
2015	J0886	Epoetin alfa 1000 units ESRD	1000 UNITS	\$	12.62	2015_J0886
2015	J0894	Decitabine injection	1 MG	\$	22.13	2015_J0894
2015	J0895	Deferoxamine mesylate inj	500 MG	\$	9.62	2015_J0895
2015	J0897	Denosumab injection	1 MG	\$	15.24	2015_J0897
2015	J1000	Depo-estradiol cypionate inj	5 MG	\$	12.95	2015_J1000
2015	J1020	Methylprednisolone 20 MG inj	20 MG	\$	2.08	2015_J1020
2015	J1030	Methylprednisolone 40 MG inj	40 MG	\$	3.87	2015_J1030
2015	J1040	Methylprednisolone 80 MG inj	80 MG	\$	7.32	2015_J1040
2015	J1050	Medroxyprogesterone acetate	1 MG	\$	0.34	2015_J1050
2015	J1071	Inj testosterone cypionate	1 MG	\$	0.03	2015_J1071
2015	J1100	Dexamethasone sodium phos	1 MG	\$	0.15	2015_J1100
2015	J1110	Inj dihydroergotamine mesylt	1 MG	\$	78.95	2015_J1110
2015	J1120	Acetazolamid sodium injectio	500 MG	\$	20.69	2015_J1120
2015	J1160	Digoxin injection	0.5 MG	\$	114.94	2015_J1160
2015	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	2,639.26	2015_J1162
2015	J1165	Phenytoin sodium injection	50 MG	\$	0.61	2015_J1165
2015	J1170	Hydromorphone injection	4 MG	\$	1.92	2015_J1170
2015	J1190	Dextrazoxane HCl injection	250 MG	\$	146.38	2015_J1190
2015	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.65	2015_J1200
2015	J1205	Chlorothiazide sodium inj	500 MG	\$	119.93	2015_J1205
2015	J1212	Dimethyl sulfoxide 50% 50 ML	50 ML	\$	211.57	2015_J1212
2015	J1230	Methadone injection	10 MG	\$	10.18	2015_J1230
2015	J1240	Dimenhydrinate injection	50 MG	\$	6.17	2015_J1240
2015	J1245	Dipyridamole injection	10 MG	\$	0.81	2015_J1245
2015	J1250	Inj dobutamine HCL/250 mg	250 MG	\$	6.24	2015_J1250
2015	J1260	Dolasetron mesylate	10 MG	\$	8.86	2015_J1260

2015	J1265	Dopamine injection	40 MG	\$	0.63	2015_J1265
2015	J1267	Doripenem injection	10 MG	\$	0.74	2015_J1267
2015	J1270	Injection, doxercalciferol	1 MCG	\$	0.89	2015_J1270
2015	J1290	Ecallantide injection	1 MG	\$	402.44	2015_J1290
2015	J1300	Ecuzumab injection	10 MG	\$	215.92	2015_J1300
2015	J1325	Epoprostenol injection	0.5 MG	\$	15.49	2015_J1325
2015	J1335	Ertapenem injection	500 MG	\$	39.51	2015_J1335
2015	J1364	Erythro lactobionate /500 MG	500 MG	\$	50.75	2015_J1364
2015	J1380	Estradiol valerate 10 MG inj	10 MG	\$	10.92	2015_J1380
2015	J1410	Inj estrogen conjugate 25 MG	25 MG	\$	215.70	2015_J1410
2015	J1430	Ethanolamine oleate 100 mg	100 MG	\$	404.09	2015_J1430
2015	J1438	Etanercept injection	25 MG	\$	330.81	2015_J1438
2015	J1439	Inj ferric carboxymaltos 1mg	1 MG	\$	1.06	2015_J1439
2015	J1442	Inj, Filgrastim G-CSF 1mcg	1 MCG	\$	1.00	2015_J1442
2015	J1446	Inj., tbo-Filgrastim, 5 mcg	5 MCG	\$	3.86	2015_J1446
2015	J1450	Fluconazole	200 MG	\$	3.92	2015_J1450
2015	J1453	Fosaprepitant injection	1 MG	\$	1.73	2015_J1453
2015	J1458	Galsulfase injection	1 MG	\$	364.78	2015_J1458
2015	J1459	Inj IVIG privigen 500 mg	500 MG	\$	38.05	2015_J1459
2015	J1460	Gamma globulin 1 CC inj	1 CC	\$	32.32	2015_J1460
2015	J1556	Inj, Imm Glob Bivigam, 500mg	500 MG	\$	38.49	2015_J1556
2015	J1557	Gammplex injection	500 MG	\$	37.28	2015_J1557
2015	J1559	Hizentra injection	100 MG	\$	8.47	2015_J1559
2015	J1560	Gamma globulin > 10 CC inj	10 CC	\$	323.21	2015_J1560
2015	J1561	Gamunex-C/Gammaked	500 MG	\$	40.30	2015_J1561
2015	J1566	Immune globulin, powder	500 MG	\$	33.11	2015_J1566
2015	J1568	Octagam injection	500 MG	\$	42.80	2015_J1568
2015	J1569	Gammagard liquid injection	500 MG	\$	38.56	2015_J1569
2015	J1570	Ganciclovir sodium injection	500 MG	\$	72.17	2015_J1570
2015	J1571	Hepagam b im injection	0.5 ML	\$	54.43	2015_J1571
2015	J1572	Flebogamma injection	500 MG	\$	35.66	2015_J1572
2015	J1580	Garamycin gentamicin inj	80 MG	\$	1.42	2015_J1580
2015	J1602	Golimumab for iv use 1mg	1 MG	\$	24.33	2015_J1602
2015	J1610	Glucagon hydrochloride/1 MG	1 MG	\$	190.60	2015_J1610
2015	J1626	Granisetron hcl injection	100 MCG	\$	0.53	2015_J1626
2015	J1630	Haloperidol injection	5 MG	\$	1.73	2015_J1630
2015	J1631	Haloperidol decanoate inj	50 MG	\$	21.03	2015_J1631
2015	J1640	Hemin, 1 mg	1 MG	\$	21.77	2015_J1640
2015	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.17	2015_J1642
2015	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.22	2015_J1644
2015	J1645	Dalteparin sodium	2500 IU	\$	14.46	2015_J1645
2015	J1650	Inj enoxaparin sodium	10 MG	\$	1.34	2015_J1650
2015	J1652	Fondaparinux sodium	0.5 MG	\$	2.94	2015_J1652
2015	J1670	Tetanus immune globulin inj	250 UNITS	\$	255.21	2015_J1670
2015	J1720	Hydrocortisone sodium succ i	100 MG	\$	7.28	2015_J1720
2015	J1740	Ibandronate sodium injection	1 MG	\$	116.67	2015_J1740
2015	J1742	Ibutilide fumarate injection	1 MG	\$	63.10	2015_J1742
2015	J1743	Idursulfase injection	1 MG	\$	497.48	2015_J1743
2015	J1745	Infliximab injection	10 MG	\$	78.76	2015_J1745
2015	J1750	Inj iron dextran	50 MG	\$	12.08	2015_J1750
2015	J1756	Iron sucrose injection	1 MG	\$	0.27	2015_J1756
2015	J1786	Imuglucerase injection	10 UNITS	\$	42.00	2015_J1786
2015	J1790	Droperidol injection	5 MG	\$	2.14	2015_J1790
2015	J1800	Propranolol injection	1 MG	\$	3.97	2015_J1800
2015	J1815	Insulin injection	5 UNITS	\$	0.77	2015_J1815
2015	J1817	Insulin for insulin pump use	50 UNITS	\$	7.59	2015_J1817
2015	J1840	Kanamycin sulfate 500 MG inj	500 MG	\$	7.69	2015_J1840
2015	J1850	Kanamycin sulfate 75 MG inj	75 MG	\$	1.15	2015_J1850
2015	J1885	Ketorolac tromethamine inj	15 MG	\$	0.83	2015_J1885

2015	J1930	Lanreotide injection	1 MG	\$	47.18	2015_J1930
2015	J1931	Laronidase injection	0.1 MG	\$	29.45	2015_J1931
2015	J1940	Furosemide injection	20 MG	\$	1.59	2015_J1940
2015	J1950	Leuprolide acetate /3.75 MG	3.75 MG	\$	900.87	2015_J1950
2015	J1953	Levetiracetam injection	10 MG	\$	0.17	2015_J1953
2015	J1955	Inj levocarnitine per 1 gm	1 GM	\$	12.07	2015_J1955
2015	J1956	Levofloxacin injection	250 MG	\$	2.03	2015_J1956
2015	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	24.60	2015_J1980
2015	J2001	Lidocaine injection	10 MG	\$	0.02	2015_J2001
2015	J2010	Lincomycin injection	300 MG	\$	10.51	2015_J2010
2015	J2020	Linezolid injection	200 MG	\$	31.62	2015_J2020
2015	J2060	Lorazepam injection	2 MG	\$	0.69	2015_J2060
2015	J2150	Mannitol injection	50 ML	\$	1.52	2015_J2150
2015	J2175	Meperidine hydrochl /100 MG	100 MG	\$	4.68	2015_J2175
2015	J2185	Meropenem	100 MG	\$	1.21	2015_J2185
2015	J2210	Methylergonovin maleate inj	0.2 MG	\$	4.60	2015_J2210
2015	J2248	Micafungin sodium injection	1 MG	\$	0.95	2015_J2248
2015	J2250	Inj midazolam hydrochloride	1 MG	\$	0.12	2015_J2250
2015	J2260	Inj milrinone lactate / 5 MG	5 MG	\$	3.43	2015_J2260
2015	J2270	Morphine sulfate injection	10 MG	\$	1.42	2015_J2270
2015	J2274	In morphine preservativ free	10MG	\$	9.00	2015_J2274
2015	J2278	Ziconotide injection	1 MCG	\$	7.08	2015_J2278
2015	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	7.85	2015_J2280
2015	J2300	Inj nalbuphine hydrochloride	10 MG	\$	2.42	2015_J2300
2015	J2310	Inj naloxone hydrochloride	1 MG	\$	27.18	2015_J2310
2015	J2315	Naltrexone, depot form	1 MG	\$	3.18	2015_J2315
2015	J2323	Natalizumab injection	1 MG	\$	16.24	2015_J2323
2015	J2353	Octreotide injection, depot	1 MG	\$	156.94	2015_J2353
2015	J2354	Octreotide inj, non-depot	25 MCG	\$	1.11	2015_J2354
2015	J2355	Oprelvekin injection	5 MG	\$	417.79	2015_J2355
2015	J2357	Omalizumab injection	5 MG	\$	29.91	2015_J2357
2015	J2358	Olanzapine long-acting inj	1 MG	\$	2.92	2015_J2358
2015	J2360	Orphenadrine injection	60 MG	\$	3.44	2015_J2360
2015	J2400	Chloroprocaine hcl injection	30 ML	\$	25.76	2015_J2400
2015	J2405	Ondansetron hcl injection	1 MG	\$	0.10	2015_J2405
2015	J2410	Oxymorphone hcl injection	1 MG	\$	2.87	2015_J2410
2015	J2425	Palifermin injection	50 MCG	\$	15.59	2015_J2425
2015	J2426	Paliperidone palmitate inj	1 MG	\$	8.45	2015_J2426
2015	J2430	Pamidronate disodium /30 MG	30 MG	\$	12.32	2015_J2430
2015	J2469	Palonosetron hcl	25 MCG	\$	20.53	2015_J2469
2015	J2501	Paricalcitol	1 MCG	\$	1.09	2015_J2501
2015	J2503	Pegaptanib sodium injection	0.3 MG	\$	1,031.85	2015_J2503
2015	J2504	Pegademase bovine, 25 iu	25 IU	\$	281.12	2015_J2504
2015	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	3,772.79	2015_J2505
2015	J2507	Pegloticase injection	1 MG	\$	1,239.16	2015_J2507
2015	J2510	Penicillin g procaine inj	600000 UNITS	\$	21.59	2015_J2510
2015	J2515	Pentobarbital sodium inj	50 MG	\$	40.74	2015_J2515
2015	J2540	Penicillin g potassium inj	600000 UNITS	\$	0.85	2015_J2540
2015	J2543	Piperacillin/tazobactam	1.125 GM	\$	2.65	2015_J2543
2015	J2545	Pentamidine non-comp unit	300 MG	\$	119.49	2015_J2545
2015	J2550	Promethazine hcl injection	50 MG	\$	1.60	2015_J2550
2015	J2560	Phenobarbital sodium inj	120 MG	\$	26.86	2015_J2560
2015	J2562	Plerixafor injection	1 MG	\$	305.98	2015_J2562
2015	J2597	Inj desmopressin acetate	1 MCG	\$	8.97	2015_J2597
2015	J2675	Inj progesterone per 50 MG	50 MG	\$	0.77	2015_J2675
2015	J2680	Fluphenazine decanoate 25 MG	25 MG	\$	23.66	2015_J2680
2015	J2690	Procainamide hcl injection	1 GM	\$	47.36	2015_J2690
2015	J2700	Oxacillin sodium injecton	250 MG	\$	1.79	2015_J2700
2015	J2704	Inj, propofol, 10 mg	10 MG	\$	0.12	2015_J2704

2015	J2720	Inj protamine sulfate/10 MG	10 MG	\$	1.23	2015_J2720
2015	J2724	Protein c concentrate	10 UNITS	\$	15.12	2015_J2724
2015	J2730	Pralidoxime chloride inj	1 GM	\$	91.90	2015_J2730
2015	J2760	Phentolaine mesylate inj	5 MG	\$	159.00	2015_J2760
2015	J2765	Metoclopramide hcl injection	10 MG	\$	0.72	2015_J2765
2015	J2770	Quinupristin/dalfopristin	500 MG	\$	311.04	2015_J2770
2015	J2778	Ranibizumab injection	0.1 mg	\$	391.41	2015_J2778
2015	J2780	Ranitidine hydrochloride inj	25 MG	\$	1.04	2015_J2780
2015	J2783	Rasburicase	0.5 MG	\$	227.61	2015_J2783
2015	J2785	Regadenoson injection	0.1 MG	\$	53.77	2015_J2785
2015	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	24.19	2015_J2788
2015	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	83.17	2015_J2790
2015	J2791	Rhophylac injection	100 IU	\$	4.75	2015_J2791
2015	J2792	Rho(D) immune globulin h, sd	100 IU	\$	19.40	2015_J2792
2015	J2794	Risperidone, long acting	0.5 MG	\$	6.91	2015_J2794
2015	J2795	Ropivacaine HCl injection	1 MG	\$	0.08	2015_J2795
2015	J2796	Romiplostim injection	10 MCG	\$	57.47	2015_J2796
2015	J2800	Methocarbamol injection	10 ML	\$	46.19	2015_J2800
2015	J2805	Sincalide injection	5 MCG	\$	91.90	2015_J2805
2015	J2810	Inj theophylline per 40 MG	40 MG	\$	0.28	2015_J2810
2015	J2820	Sargramostim injection	50 MCG	\$	31.68	2015_J2820
2015	J2850	Inj secretin synthetic human	1 MCG	\$	34.78	2015_J2850
2015	J2916	Na ferric gluconate complex	12.5 MG	\$	2.52	2015_J2916
2015	J2920	Methylprednisolone injection	40 MG	\$	2.59	2015_J2920
2015	J2930	Methylprednisolone injection	125 MG	\$	3.73	2015_J2930
2015	J2993	Reteplase injection	18.1 MG	\$	2,301.91	2015_J2993
2015	J2997	Alteplase recombinant	1 MG	\$	73.74	2015_J2997
2015	J3000	Streptomycin injection	1 GM	\$	10.72	2015_J3000
2015	J3010	Fentanyl citrate injecton	0.1 MG	\$	0.49	2015_J3010
2015	J3060	Inj, Taliglucerase Alfa 10 u	10 UNITS	\$	36.48	2015_J3060
2015	J3070	Pentazocine injection	30 MG	\$	121.83	2015_J3070
2015	J3095	Telavancin injection	10 MG	\$	4.91	2015_J3095
2015	J3101	Tenecteplase injection	1 MG	\$	93.96	2015_J3101
2015	J3105	Terbutaline sulfate inj	1 MG	\$	1.82	2015_J3105
2015	J3121	Inj testostero enanthate 1mg	1 MG	\$	0.05	2015_J3121
2015	J3230	Chlorpromazine hcl injection	50 MG	\$	20.66	2015_J3230
2015	J3240	Thyrotropin injection	0.9 MG	\$	1,432.17	2015_J3240
2015	J3243	Tigecycline injection	1 MG	\$	2.35	2015_J3243
2015	J3250	Trimethobenzamide hcl inj	200 MG	\$	23.86	2015_J3250
2015	J3260	Tobramycin sulfate injection	80 MG	\$	2.64	2015_J3260
2015	J3262	Tocilizumab injection	1 MG	\$	3.85	2015_J3262
2015	J3285	Treprostinil injection	1 MG	\$	61.24	2015_J3285
2015	J3300	Triamcinolone A inj PRS-free	1 MG	\$	3.72	2015_J3300
2015	J3301	Triamcinolone acet inj NOS	10 MG	\$	1.75	2015_J3301
2015	J3303	Triamcinolone hexacetonl inj	5 MG	\$	1.81	2015_J3303
2015	J3315	Triptorelin pamoate	3.75 MG	\$	144.59	2015_J3315
2015	J3357	Ustekinumab injection	1 MG	\$	166.99	2015_J3357
2015	J3360	Diazepam injection	5 MG	\$	6.17	2015_J3360
2015	J3370	Vancomycin hcl injection	500 MG	\$	3.39	2015_J3370
2015	J3385	Velaglucerase alfa	100 UNITS	\$	346.08	2015_J3385
2015	J3396	Verteporfin injection	0.1 MG	\$	10.99	2015_J3396
2015	J3410	Hydroxyzine hcl injection	25 MG	\$	2.17	2015_J3410
2015	J3411	Thiamine hcl 100 mg	100 MG	\$	3.33	2015_J3411
2015	J3415	Pyridoxine hcl 100 mg	100 MG	\$	8.62	2015_J3415
2015	J3420	Vitamin b12 injection	1000 MCG	\$	2.63	2015_J3420
2015	J3430	Vitamin k phytonadione inj	1 MG	\$	2.83	2015_J3430
2015	J3465	Injection, voriconazole	10 MG	\$	4.19	2015_J3465
2015	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.35	2015_J3473
2015	J3475	Inj magnesium sulfate	500 MG	\$	0.25	2015_J3475

2015	J3480	Inj potassium chloride	2 MEQ	\$	0.13	2015_J3480
2015	J3485	Zidovudine	10 MG	\$	1.50	2015_J3485
2015	J3486	Ziprasidone mesylate	10 MG	\$	14.22	2015_J3486
2015	J3489	Zoledronic Acid 1mg	1 MG	\$	34.97	2015_J3489
2015	J7030	Normal saline solution infus	1000 ML	\$	1.84	2015_J7030
2015	J7040	Normal saline solution infus	500 ML	\$	0.92	2015_J7040
2015	J7042	5% dextrose/normal saline	500 ML	\$	0.61	2015_J7042
2015	J7050	Normal saline solution infus	250 ML	\$	0.46	2015_J7050
2015	J7060	5% dextrose/water	500 ML	\$	1.81	2015_J7060
2015	J7070	D5w infusion	1000 CC	\$	3.44	2015_J7070
2015	J7120	Ringers lactate infusion	1000 CC	\$	1.78	2015_J7120
2015	J7180	Factor xiii anti-hem factor	1 IU	\$	7.41	2015_J7180
2015	J7183	Wilate injection	1 I.U. VWF:RCO	\$	1.02	2015_J7183
2015	J7185	Xyntha inj	1 IU	\$	1.42	2015_J7185
2015	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	0.96	2015_J7186
2015	J7187	Humate-P, inj	1 IU	\$	0.99	2015_J7187
2015	J7189	Factor viia	1 MCG	\$	2.07	2015_J7189
2015	J7190	Factor viii	1 IU	\$	0.96	2015_J7190
2015	J7192	Factor viii recombinant NOS	1 IU	\$	1.16	2015_J7192
2015	J7193	Factor IX non-recombinant	1 IU	\$	1.07	2015_J7193
2015	J7194	Factor ix complex	1 IU	\$	1.19	2015_J7194
2015	J7195	Factor IX recombinant	1 IU	\$	1.46	2015_J7195
2015	J7197	Antithrombin iii injection	1 IU	\$	3.37	2015_J7197
2015	J7198	Anti-inhibitor	1 IU	\$	1.83	2015_J7198
2015	J7200	Factor ix recombinan rixubis	1 IU	\$	1.23	2015_J7200
2015	J7201	Factor ix fc fusion recomb	1 IU	\$	2.81	2015_J7201
2015	J7308	Aminolevulinic acid hcl top	354 MG	\$	292.79	2015_J7308
2015	J7310	Ganciclovir long act implant	4.5 MG	\$	16,960.00	2015_J7310
2015	J7311	Fluocinolone acetonide implt	0.59 MG	\$	20,138.08	2015_J7311
2015	J7312	Dexamethasone intra implant	0.1 MG	\$	201.03	2015_J7312
2015	J7316	Inj, Ocriplasmin, 0.125 mg	0.125 MG	\$	1,046.75	2015_J7316
2015	J7321	Hyalgan/supartz inj per dose	per dose	\$	88.61	2015_J7321
2015	J7323	Euflexxa inj per dose	per dose	\$	152.00	2015_J7323
2015	J7324	Orthovisc inj per dose	per dose	\$	172.63	2015_J7324
2015	J7325	Synvisc or Synvisc-One	1 MG	\$	12.87	2015_J7325
2015	J7326	Gel-One	per dose	\$	578.11	2015_J7326
2015	J7327	Monovisc inj per dose	Per Dose	\$	958.45	2015_J7327
2015	J7336	Capsaicin 8% patch	1 SQ CM	\$	2.81	2015_J7336
2015	J7500	Azathioprine oral 50mg	50 MG	\$	0.34	2015_J7500
2015	J7502	Cyclosporine oral 100 mg	100 MG	\$	2.85	2015_J7502
2015	J7504	Lymphocyte immune globulin	250 MG	\$	1,069.33	2015_J7504
2015	J7506	Prednisone oral	5 MG	\$	0.07	2015_J7506
2015	J7507	Tacrolimus Imme Rel oral 1mg	1 MG	\$	0.93	2015_J7507
2015	J7508	Tacrolimus Ex Rel oral 0.1mg	0.1 MG	\$	0.39	2015_J7508
2015	J7509	Methylprednisolone oral	4 MG	\$	0.36	2015_J7509
2015	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.12	2015_J7510
2015	J7511	Antithymocyte globuln rabbit	25 MG	\$	638.49	2015_J7511
2015	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.82	2015_J7515
2015	J7516	Cyclosporin parenteral 250mg	250 MG	\$	38.35	2015_J7516
2015	J7517	Mycophenolate mofetil oral	250 MG	\$	1.17	2015_J7517
2015	J7518	Mycophenolic acid	180 MG	\$	2.94	2015_J7518
2015	J7520	Sirolimus, oral	1 MG	\$	12.33	2015_J7520
2015	J7525	Tacrolimus injection	5 MG	\$	163.25	2015_J7525
2015	J7527	Oral everolimus	0.25 MG	\$	7.05	2015_J7527
2015	J7605	Arformoterol non-comp unit	15 mcg	\$	8.08	2015_J7605
2015	J7606	Formoterol fumarate, inh	20 MCG	\$	8.88	2015_J7606
2015	J7608	Acetylcysteine non-comp unit	1 GM	\$	4.82	2015_J7608
2015	J7611	Albuterol non-comp con	1 MG	\$	0.12	2015_J7611
2015	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.21	2015_J7612

2015	J7613	Albuterol non-comp unit	1 MG	\$	0.05	2015_J7613
2015	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.07	2015_J7614
2015	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.15	2015_J7620
2015	J7626	Budesonide non-comp unit	0.5 MG	\$	5.39	2015_J7626
2015	J7631	Cromolyn sodium noncomp unit	10 MG	\$	0.78	2015_J7631
2015	J7639	Dornase alfa non-comp unit	1 MG	\$	38.97	2015_J7639
2015	J7644	Ipratropium bromide non-comp	1 MG	\$	0.21	2015_J7644
2015	J7665	Mannitol for inhaler	5 MG	\$	0.67	2015_J7665
2015	J7674	Methacholine chloride, neb	1 MG	\$	0.51	2015_J7674
2015	J7682	Tobramycin non-comp unit	300 MG	\$	62.69	2015_J7682
2015	J7686	Treprostinil, non-comp unit	1.74 MG	\$	506.44	2015_J7686
2015	J8501	Oral aprepitant	5 MG	\$	9.54	2015_J8501
2015	J8510	Oral busulfan	2 MG	\$	12.62	2015_J8510
2015	J8520	Capecitabine, oral, 150 mg	150 MG	\$	5.53	2015_J8520
2015	J8521	Capecitabine, oral, 500 mg	500 MG	\$	19.50	2015_J8521
2015	J8530	Cyclophosphamide oral 25 MG	25 MG	\$	4.16	2015_J8530
2015	J8540	Oral dexamethasone	0.25 MG	\$	0.13	2015_J8540
2015	J8560	Etoposide oral 50 MG	50 MG	\$	68.74	2015_J8560
2015	J8600	Melphalan oral 2 MG	2 MG	\$	10.78	2015_J8600
2015	J8610	Methotrexate oral 2.5 MG	2.5 MG	\$	1.04	2015_J8610
2015	J8700	Temozolomide	5 MG	\$	2.66	2015_J8700
2015	J8705	Topotecan oral	0.25 mg	\$	101.36	2015_J8705
2015	J9000	Doxorubicin hcl injection	10 MG	\$	4.05	2015_J9000
2015	J9017	Arsenic trioxide injection	1 MG	\$	59.42	2015_J9017
2015	J9019	Erwinaze injection	1,000 IU	\$	376.49	2015_J9019
2015	J9020	Asparaginase, NOS	10000 UNITS	\$	64.56	2015_J9020
2015	J9025	Azacitidine injection	1 MG	\$	3.05	2015_J9025
2015	J9027	Clofarabine injection	1 MG	\$	138.38	2015_J9027
2015	J9031	Bcg live intravesical vac	1 EA	\$	122.88	2015_J9031
2015	J9033	Bendamustine injection	1 MG	\$	24.66	2015_J9033
2015	J9035	Bevacizumab injection	10 MG	\$	69.60	2015_J9035
2015	J9040	Bleomycin sulfate injection	15 UNITS	\$	22.97	2015_J9040
2015	J9041	Bortezomib injection	0.1 MG	\$	46.75	2015_J9041
2015	J9042	Brentuximab vedotin inj	1 MG	\$	119.62	2015_J9042
2015	J9043	Cabazitaxel injection	1 MG	\$	148.66	2015_J9043
2015	J9045	Carboplatin injection	50 MG	\$	3.82	2015_J9045
2015	J9047	Injection, Carfilzomib, 1 mg	1 MG	\$	31.06	2015_J9047
2015	J9050	Carmustine injection	100 MG	\$	2,973.34	2015_J9050
2015	J9055	Cetuximab injection	10 MG	\$	53.48	2015_J9055
2015	J9060	Cisplatin 10 MG injection	10 MG	\$	1.97	2015_J9060
2015	J9065	Inj cladribine per 1 MG	1 MG	\$	20.91	2015_J9065
2015	J9070	Cyclophosphamide 100 MG inj	100 MG	\$	48.95	2015_J9070
2015	J9098	Cytarabine liposome inj	10 MG	\$	576.48	2015_J9098
2015	J9100	Cytarabine hcl 100 MG inj	100 MG	\$	0.92	2015_J9100
2015	J9120	Dactinomycin injection	0.5 MG	\$	1,164.57	2015_J9120
2015	J9130	Dacarbazine 100 mg inj	100 MG	\$	3.91	2015_J9130
2015	J9150	Daunorubicin injection	10 MG	\$	26.45	2015_J9150
2015	J9155	Degarelix injection	1 MG	\$	3.59	2015_J9155
2015	J9171	Docetaxel injection	1 MG	\$	3.49	2015_J9171
2015	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.50	2015_J9178
2015	J9179	Eribulin mesylate injection	0.1 MG	\$	102.53	2015_J9179
2015	J9181	Etoposide injection	10 MG	\$	0.62	2015_J9181
2015	J9185	Fludarabine phosphate inj	50 MG	\$	72.85	2015_J9185
2015	J9190	Fluorouracil injection	500 MG	\$	1.95	2015_J9190
2015	J9200	Floxuridine injection	500 MG	\$	67.69	2015_J9200
2015	J9201	Gemcitabine hcl injection	200 MG	\$	9.22	2015_J9201
2015	J9202	Goserelin acetate implant	3.6 MG	\$	281.05	2015_J9202
2015	J9206	Irinotecan injection	20 MG	\$	4.00	2015_J9206
2015	J9207	Ixabepilone injection	1 MG	\$	72.08	2015_J9207

2015	J9208	Ifosfamide injection	1 GM	\$	32.20	2015_J9208
2015	J9209	Mesna injection	200 MG	\$	2.86	2015_J9209
2015	J9211	Idarubicin hcl injection	5 MG	\$	34.88	2015_J9211
2015	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	24.05	2015_J9214
2015	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	242.80	2015_J9217
2015	J9218	Leuprolide acetate injecton	1 MG	\$	7.15	2015_J9218
2015	J9225	Vantas implant	50 MG	\$	3,012.29	2015_J9225
2015	J9226	Supprelin LA implant	50 MG	\$	22,170.84	2015_J9226
2015	J9228	Ipilimumab injection	1 MG	\$	138.83	2015_J9228
2015	J9230	Mechlorethamine hcl inj	10 MG	\$	241.99	2015_J9230
2015	J9245	Inj melphalan hydrochl 50 MG	50 MG	\$	1,285.40	2015_J9245
2015	J9250	Methotrexate sodium inj	5 MG	\$	0.24	2015_J9250
2015	J9260	Methotrexate sodium inj	50 MG	\$	2.36	2015_J9260
2015	J9261	Nelarabine injection	50 MG	\$	148.57	2015_J9261
2015	J9263	Oxaliplatin	0.5 MG	\$	0.48	2015_J9263
2015	J9264	Paclitaxel protein bound	1 MG	\$	9.77	2015_J9264
2015	J9266	Pegaspargase injection	1 EA	\$	6,189.74	2015_J9266
2015	J9267	Paclitaxel injection	1 MG	\$	0.17	2015_J9267
2015	J9268	Pentostatin injection	10 MG	\$	1,471.48	2015_J9268
2015	J9280	Mitomycin injection	5 MG	\$	73.03	2015_J9280
2015	J9293	Mitoxantrone hydrochl / 5 MG	5 MG	\$	32.12	2015_J9293
2015	J9301	Obinutuzumab inj	10 MG	\$	54.21	2015_J9301
2015	J9302	Ofatumumab injection	10 MG	\$	49.47	2015_J9302
2015	J9303	Panitumumab injection	10 MG	\$	100.91	2015_J9303
2015	J9305	Pemetrexed injection	10 MG	\$	61.21	2015_J9305
2015	J9306	Injection, Pertuzumab, 1 mg	1 MG	\$	10.22	2015_J9306
2015	J9307	Pralatrexate injection	1 MG	\$	212.80	2015_J9307
2015	J9310	Rituximab injection	100 MG	\$	748.70	2015_J9310
2015	J9315	Romidepsin injection	1 MG	\$	290.84	2015_J9315
2015	J9320	Streptozocin injection	1 GM	\$	324.02	2015_J9320
2015	J9328	Temozolomide injection	1 MG	\$	6.84	2015_J9328
2015	J9330	Temsirolimus injection	1 MG	\$	62.50	2015_J9330
2015	J9351	Topotecan injection	0.1 MG	\$	2.05	2015_J9351
2015	J9354	Inj, Ado-trastuzumab Emt 1mg	1 MG	\$	29.21	2015_J9354
2015	J9355	Trastuzumab injection	10 MG	\$	87.36	2015_J9355
2015	J9357	Valrubicin injection	200 MG	\$	1,117.31	2015_J9357
2015	J9360	Vinblastine sulfate inj	1 MG	\$	2.94	2015_J9360
2015	J9370	Vincristine sulfate 1 MG inj	1 MG	\$	4.58	2015_J9370
2015	J9371	Inj, vincristine sul lip 1 mg	1 MG	\$	2,321.82	2015_J9371
2015	J9390	Vinorelbine tartrate inj	10 MG	\$	10.07	2015_J9390
2015	J9395	Injection, Fulvestrant	25 MG	\$	93.44	2015_J9395
2015	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.32	2015_J9400
2015	P9041	Albumin (human),5%, 50ml	50 ML	\$	10.91	2015_P9041
2015	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	54.54	2015_P9045
2015	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	22.49	2015_P9046
2015	P9047	Albumin (human), 25%, 50ml	50 ML	\$	53.44	2015_P9047
2015	Q0138	Ferumoxytol, non-esrd	1 MG	\$	0.81	2015_Q0138
2015	Q0139	Ferumoxytol, esrd use	1 MG	\$	0.81	2015_Q0139
2015	Q0162	Ondansetron oral	1 MG	\$	0.04	2015_Q0162
2015	Q0163	Diphenhydramine HCl 50mg	50 MG	\$	0.26	2015_Q0163
2015	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.04	2015_Q0164
2015	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	1.40	2015_Q0166
2015	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	1.03	2015_Q0167
2015	Q0169	Promethazine HCl 12.5mg oral	12.5 MG	\$	0.03	2015_Q0169
2015	Q0180	Dolasetron mesylate oral	100 MG	\$	103.18	2015_Q0180
2015	Q2035	Afluria vacc, 3 yrs & >, im	0.5 ml	\$	13.02	2015_Q2035
2015	Q2037	Fluvirin vacc, 3 yrs & >, im	0.5 ML	\$	15.83	2015_Q2037
2015	Q2038	Fluzone vacc, 3 yrs & >, im	0.5 ML	\$	12.04	2015_Q2038
2015	Q2043	Sipuleucel-T auto CD54+	Per infusion (minimum 50 million cells)	\$	36,704.05	2015_Q2043

2015	Q2049	Imported Lipodox inj	10 MG	\$	508.43	2015_Q2049
2015	Q2050	Doxorubicin inj 10mg	10 MG	\$	443.83	2015_Q2050
2015	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	40.52	2015_Q3027
2015	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	112.77	2015_Q4074
2015	Q4081	Epoetin alfa, 100 units ESRD	100 UNITS	\$	1.26	2015_Q4081
2015	Q4101	Apligraf skin sub	1 SQ CM	\$	31.23	2015_Q4101
2015	Q4102	Oasis wound matrix skin sub	1 SQ CM	\$	10.72	2015_Q4102
2015	Q4104	Integra BMWWD skin sub	1 SQ CM	\$	32.27	2015_Q4104
2015	Q4105	Integra DRT skin sub	1 SQ CM	\$	20.05	2015_Q4105
2015	Q4106	Dermagraft skin sub	1 SQ CM	\$	33.29	2015_Q4106
2015	Q4107	Graftjacket skin sub	1 SQ CM	\$	95.51	2015_Q4107
2015	Q4108	Integra matrix skin sub	1 SQ CM	\$	34.37	2015_Q4108
2015	Q4110	Primatrix skin sub	1 SQ CM	\$	37.09	2015_Q4110
2015	Q4111	Gammagraft skin sub	1 SQ CM	\$	6.90	2015_Q4111
2015	Q4112	Cymetra allograft	1 CC	\$	258.73	2015_Q4112
2015	Q4113	Graftjacket express allograf	1 CC	\$	258.73	2015_Q4113
2015	Q4114	Integra flowable wound matri	1 CC	\$	1,568.86	2015_Q4114
2015	Q4115	Alloskin	1 SQ CM	\$	6.98	2015_Q4115
2015	Q4116	Alloderm skin sub	1 SQ CM	\$	32.55	2015_Q4116
2015	Q4121	Theraskin	1 SQ CM	\$	36.00	2015_Q4121
2015	Q4123	Alloskin RT	1 SQ CM	\$	13.25	2015_Q4123
2015	Q4131	Epifix	1 SQ CM	\$	195.55	2015_Q4131
2015	Q5101	Inj filgrastim g-csf biosim	1 MCG	\$	0.97	2015_Q5101
2015	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	35.05	2015_Q9956
2015	Q9957	Inj perflutren lip micros,ml	1 ML	\$	52.57	2015_Q9957
2015	Q9958	HOCM <=149 mg/ml iodine, 1ml	1 ML	\$	0.09	2015_Q9958
2015	Q9960	HOCM 200-249mg/ml iodine,1ml	1 ML	\$	0.19	2015_Q9960
2015	Q9961	HOCM 250-299mg/ml iodine,1ml	1 ML	\$	0.20	2015_Q9961
2015	Q9963	HOCM 350-399mg/ml iodine,1ml	1 ML	\$	0.20	2015_Q9963
2015	Q9965	LOCM 100-199mg/ml iodine,1ml	1 ML	\$	0.93	2015_Q9965
2015	Q9966	LOCM 200-299mg/ml iodine,1ml	1 ML	\$	0.18	2015_Q9966
2015	Q9967	LOCM 300-399mg/ml iodine,1ml	1 ML	\$	0.14	2015_Q9967
2015	Q9975	Factor VIII FC Fusion Recomb	1 IU	\$	1.90	2015_Q9975
2015	Q9979	Injection, Alemtuzumab	1 MG	\$	1,743.19	2015_Q9979
2014	90371	Hep b ig, im	1 ML	\$	117.38	2014_90371
2014	90375	Rabies ig, im/sc	150 IU	\$	247.57	2014_90375
2014	90376	Rabies ig, heat treated	150 IU	\$	237.82	2014_90376
2014	90385	Rh ig, minidose, im	50 MCG	\$	34.66	2014_90385
2014	90585	Bcg vaccine, percut	50 MG	\$	121.96	2014_90585
2014	90586	Bcg vaccine, intravesical	1 EACH	\$	121.96	2014_90586
2014	90632	Hep a vaccine, adult im	1 ML	\$	49.54	2014_90632
2014	90654	Flu vaccine, intradermal, no preserv	0.1 ML	\$	18.92	2014_90654
2014	90656	Flu vaccine no preserv 3 yo & >, im	0.50 ML	\$	14.10	2014_90656
2014	90657	Flu vaccine, 6-35 mo, im	0.25 ML	\$	6.02	2014_90657
2014	90661	Flu vaccine, no preserv, 3 +, im, cell cultures	0.5 ML	\$	21.67	2014_90661
2014	90662	Flu vacc prsv free inc antig	0.5 ML	\$	33.37	2014_90662
2014	90670	Pneumococcal vacc, 13 val im	0.5 ML	\$	153.96	2014_90670
2014	90672	Flu vaccine 4 valent nasal	0.2 ml	\$	25.74	2014_90672
2014	90675	Rabies vaccine, im	1 ML	\$	223.78	2014_90675
2014	90685	Flu vac no prsv 4 val 6-35 m	0.25 mL	\$	23.90	2014_90685
2014	90686	Flu vac no prsv 4 val 3 yrs+	0.5 ml	\$	17.98	2014_90686
2014	90687	Flu vaccine, 6-35 mon, IM, 4 val	0.25 ML	\$	9.13	2014_90687
2014	90688	Flu vaccine, 3 +, IM, 4 val	0.5 ML	\$	16.84	2014_90688
2014	90691	Typhoid vaccine, im	0.5 ML	\$	68.55	2014_90691
2014	90703	Tetanus vaccine, im	0.5 ML	\$	41.27	2014_90703
2014	90714	Td vaccine no prsv >/= 7 yo, im	0.5 ML	\$	21.96	2014_90714
2014	90715	Tdap => 7 yo, im	0.5 ML	\$	33.32	2014_90715
2014	90732	Pneumococcal vaccine	0.5 ML	\$	77.85	2014_90732
2014	90733	Meningococcal vaccine, sc	0.5 ML	\$	106.49	2014_90733

2014	90740	Hepb vacc, ill pat 3 dose im	40 MCG	\$	119.42	2014_90740
2014	90743	Hep b vacc, adol, 2 dose, im	1 DOSE	\$	24.22	2014_90743
2014	90744	Hepb vacc ped/adol 3 dose im	1 DOSE	\$	24.22	2014_90744
2014	90746	Hep b vaccine, adult, im	20 MCG	\$	59.71	2014_90746
2014	90747	Hepb vacc, ill pat 4 dose im	40 MCG	\$	119.42	2014_90747
2014	A9575	Inj gadoterate meglumi	0.1 ml	\$	0.36	2014_A9575
2014	A9576	Inj prohance multipack	1 ML	\$	1.82	2014_A9576
2014	A9577	Inj multihance	1 ML	\$	2.22	2014_A9577
2014	A9578	Inj multihance multipack	1 ML	\$	1.75	2014_A9578
2014	A9579	Gad-base MR contrast NOS,1ml	1 ML	\$	2.01	2014_A9579
2014	A9581	Gadoxetate disodium inj	1 ML	\$	14.04	2014_A9581
2014	A9583	Gadofosveset trisodium inj	1 ML	\$	12.14	2014_A9583
2014	A9585	Gadobutrol injection	0.1 ML	\$	0.41	2014_A9585
2014	J0129	Abatacept injection	10 MG	\$	32.25	2014_J0129
2014	J0130	Abciximab injection	10 MG	\$	739.17	2014_J0130
2014	J0132	Acetylcysteine injection	100 MG	\$	2.19	2014_J0132
2014	J0133	Acyclovir injection	5 MG	\$	0.06	2014_J0133
2014	J0135	Adalimumab injection	20 MG	\$	570.94	2014_J0135
2014	J0150	Injection adenosine 6 MG	6 MG	\$	5.72	2014_J0150
2014	J0151	Inj Adenosine Diag 1mg	1 MG	\$	2.13	2014_J0151
2014	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.13	2014_J0171
2014	J0178	Aflibercept injection (ophthalmic)	1 MG	\$	980.50	2014_J0178
2014	J0180	Agalsidase beta injection	1 MG	\$	152.35	2014_J0180
2014	J0207	Amifostine	500 MG	\$	310.72	2014_J0207
2014	J0210	Methyldopate hcl injection	250 MG	\$	42.40	2014_J0210
2014	J0215	Alefacept	0.5 MG	\$	41.64	2014_J0215
2014	J0220	Alglucosidase alfa injection	10 MG	\$	206.63	2014_J0220
2014	J0221	Lumizyme injection	10 MG	\$	153.64	2014_J0221
2014	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.11	2014_J0256
2014	J0257	Glassia injection	10 MG	\$	3.98	2014_J0257
2014	J0278	Amikacin sulfate injection	100 MG	\$	1.27	2014_J0278
2014	J0280	Aminophyllin 250 MG inj	250 MG	\$	3.98	2014_J0280
2014	J0285	Amphotericin B	50 MG	\$	16.22	2014_J0285
2014	J0287	Amphotericin b lipid complex	10 MG	\$	10.41	2014_J0287
2014	J0289	Amphotericin b liposome inj	10 MG	\$	16.83	2014_J0289
2014	J0290	Ampicillin 500 MG inj	500 MG	\$	1.25	2014_J0290
2014	J0295	Ampicillin sodium per 1.5 gm	1.5 GM	\$	1.82	2014_J0295
2014	J0348	Anidulafungin injection	1 MG	\$	0.69	2014_J0348
2014	J0360	Hydralazine hcl injection	20 MG	\$	2.98	2014_J0360
2014	J0400	Aripiprazole injection	0.25 MG	\$	0.65	2014_J0400
2014	J0401	Inj aripiprazole ext rel 1mg	1 MG	\$	3.87	2014_J0401
2014	J0456	Azithromycin	500 MG	\$	2.34	2014_J0456
2014	J0461	Atropine sulfate injection	0.01 MG	\$	0.05	2014_J0461
2014	J0470	Dimecaprol injection	100 MG	\$	29.38	2014_J0470
2014	J0475	Baclofen 10 MG injection	10 MG	\$	162.80	2014_J0475
2014	J0476	Baclofen intrathecal trial	50 MCG	\$	76.29	2014_J0476
2014	J0480	Basiliximab	20 MG	\$	2,716.18	2014_J0480
2014	J0485	Belatacept injection	1 MG	\$	3.81	2014_J0485
2014	J0490	Belimumab injection	10 MG	\$	39.48	2014_J0490
2014	J0500	Dicyclomine injection	20 MG	\$	41.28	2014_J0500
2014	J0515	Inj benzotropine mesylate	1 MG	\$	20.38	2014_J0515
2014	J0558	PenG benzathine/procaine inj	100,000 UNITS	\$	4.92	2014_J0558
2014	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	6.29	2014_J0561
2014	J0583	Bivalirudin	1 MG	\$	3.42	2014_J0583
2014	J0585	Injection,onabotulinumtoxinA	1 UNIT	\$	5.56	2014_J0585
2014	J0586	AbobotulinumtoxinA	5 Unit	\$	7.43	2014_J0586
2014	J0587	Inj, rimabotulinumtoxinB	100 UNITS	\$	11.30	2014_J0587
2014	J0588	Incobotulinumtoxin A	1 UNIT	\$	4.48	2014_J0588
2014	J0592	Buprenorphine hydrochloride	0.1 MG	\$	3.06	2014_J0592

2014	J0594	Busulfan injection	1 MG	\$	28.94	2014_J0594
2014	J0595	Butorphanol tartrate 1 mg	1 MG	\$	1.76	2014_J0595
2014	J0597	C-1 esterase, berinert	10 UNITS	\$	37.64	2014_J0597
2014	J0598	C-1 esterase, cinryze	10 UNITS	\$	51.86	2014_J0598
2014	J0600	Edetate calcium disodium inj	1000 MG	\$	3,477.51	2014_J0600
2014	J0610	Calcium gluconate injection	10 ML	\$	1.27	2014_J0610
2014	J0630	Calcitonin salmon injection	400 UNITS	\$	69.29	2014_J0630
2014	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.39	2014_J0636
2014	J0637	Caspofungin acetate	5 MG	\$	11.84	2014_J0637
2014	J0638	Canakinumab injection	1 MG	\$	90.96	2014_J0638
2014	J0640	Leucovorin calcium injection	50 MG	\$	3.74	2014_J0640
2014	J0641	Levoleucovorin injection	0.5 MG	\$	1.77	2014_J0641
2014	J0670	Inj mepivacaine HCL/10 ml	10 ML	\$	2.20	2014_J0670
2014	J0690	Cefazolin sodium injection	500 MG	\$	1.19	2014_J0690
2014	J0692	Cefepime HCl for injection	500 MG	\$	2.40	2014_J0692
2014	J0694	Cefoxitin sodium injection	1 GM	\$	4.99	2014_J0694
2014	J0696	Ceftriaxone sodium injection	250 MG	\$	0.70	2014_J0696
2014	J0697	Sterile cefuroxime injection	750 MG	\$	2.79	2014_J0697
2014	J0698	Cefotaxime sodium injection	1 GM	\$	1.81	2014_J0698
2014	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	5.71	2014_J0702
2014	J0712	Ceftaroline fosamil inj	10 MG	\$	1.13	2014_J0712
2014	J0713	Inj ceftazidime per 500 mg	500 MG	\$	2.10	2014_J0713
2014	J0717	Certolizumab Pegol Inj 1mg	1 MG	\$	6.17	2014_J0717
2014	J0720	Chloramphenicol sodium injec	1 GM	\$	31.74	2014_J0720
2014	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	18.07	2014_J0725
2014	J0735	Clonidine hydrochloride	1 MG	\$	19.17	2014_J0735
2014	J0740	Cidofovir injection	375 MG	\$	588.10	2014_J0740
2014	J0743	Cilastatin sodium injection	250 MG	\$	4.83	2014_J0743
2014	J0744	Ciprofloxacin iv	200 MG	\$	1.10	2014_J0744
2014	J0770	Colistimethate sodium inj	150 MG	\$	11.50	2014_J0770
2014	J0775	Collagenase, clost hist inj	0.01 MG	\$	38.48	2014_J0775
2014	J0780	Prochlorperazine injection	10 MG	\$	9.36	2014_J0780
2014	J0795	Corticotropin ovine triflural	1 MCG	\$	7.72	2014_J0795
2014	J0800	Corticotropin injection	40 UNITS	\$	3,324.92	2014_J0800
2014	J0834	Cosyntropin cortrosyn inj	0.25 MG	\$	51.36	2014_J0834
2014	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	2,493.12	2014_J0840
2014	J0850	Cytomegalovirus imm IV /vial	PER VIAL	\$	1,013.87	2014_J0850
2014	J0878	Daptomycin injection	1 MG	\$	0.67	2014_J0878
2014	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.76	2014_J0881
2014	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.76	2014_J0882
2014	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	11.65	2014_J0885
2014	J0886	Epoetin alfa 1000 units ESRD	1000 UNITS	\$	11.65	2014_J0886
2014	J0894	Decitabine injection	1 MG	\$	28.25	2014_J0894
2014	J0895	Deferoxamine mesylate inj	500 MG	\$	8.66	2014_J0895
2014	J0897	Denosumab injection	1 MG	\$	14.45	2014_J0897
2014	J1000	Depo-estradiol cypionate inj	5 MG	\$	10.35	2014_J1000
2014	J1020	Methylprednisolone 20 MG inj	20 MG	\$	3.48	2014_J1020
2014	J1030	Methylprednisolone 40 MG inj	40 MG	\$	3.25	2014_J1030
2014	J1040	Methylprednisolone 80 MG inj	80 MG	\$	6.24	2014_J1040
2014	J1050	Medroxyprogesterone acetate	1 MG	\$	0.28	2014_J1050
2014	J1070	Testosterone cypionat 100 MG	100 MG	\$	4.94	2014_J1070
2014	J1080	Testosterone cypionat 200 MG	200 MG	\$	4.97	2014_J1080
2014	J1100	Dexamethasone sodium phos	1 MG	\$	0.14	2014_J1100
2014	J1110	Inj dihydroergotamine mesylt	1 MG	\$	65.27	2014_J1110
2014	J1120	Acetazolamid sodium injectio	500 MG	\$	22.39	2014_J1120
2014	J1160	Digoxin injection	0.5 MG	\$	5.54	2014_J1160
2014	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	2,051.63	2014_J1162
2014	J1165	Phenytoin sodium injection	50 MG	\$	0.53	2014_J1165
2014	J1170	Hydromorphone injection	4 MG	\$	1.83	2014_J1170

2014	J1190	Dexrazoxane HCl injection	250 MG	\$	144.86	2014_J1190
2014	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.53	2014_J1200
2014	J1205	Chlorothiazide sodium inj	500 MG	\$	122.65	2014_J1205
2014	J1212	Dimethyl sulfoxide 50% 50 ML	50 ML	\$	83.54	2014_J1212
2014	J1230	Methadone injection	10 MG	\$	8.50	2014_J1230
2014	J1240	Dimenhydrinate injection	50 MG	\$	5.32	2014_J1240
2014	J1245	Dipyridamole injection	10 MG	\$	0.82	2014_J1245
2014	J1250	Inj dobutamine HCL/250 mg	250 MG	\$	5.30	2014_J1250
2014	J1260	Dolasetron mesylate	10 MG	\$	6.19	2014_J1260
2014	J1265	Dopamine injection	40 MG	\$	0.57	2014_J1265
2014	J1267	Doripenem injection	10 MG	\$	0.63	2014_J1267
2014	J1270	Injection, doxercalciferol	1 MCG	\$	1.46	2014_J1270
2014	J1290	Ecaltantide injection	1 MG	\$	375.64	2014_J1290
2014	J1300	Ecuzimab injection	10 MG	\$	206.14	2014_J1300
2014	J1325	Epoprostenol injection	0.5 MG	\$	15.46	2014_J1325
2014	J1335	Ertapenem injection	500 MG	\$	35.28	2014_J1335
2014	J1364	Erythro lactobionate /500 MG	500 MG	\$	45.01	2014_J1364
2014	J1380	Estradiol valerate 10 MG inj	10 MG	\$	9.55	2014_J1380
2014	J1410	Inj estrogen conjugate 25 MG	25 MG	\$	180.14	2014_J1410
2014	J1430	Ethanolamine oleate 100 mg	100 MG	\$	311.06	2014_J1430
2014	J1438	Etanercept injection	25 MG	\$	285.27	2014_J1438
2014	J1442	Inj, Filgrastim G-CSF 1mcg	1 MCG	\$	0.99	2014_J1442
2014	J1446	Inj, tbo-Filgrastim, 5 mcg	5 MCG	\$	3.99	2014_J1446
2014	J1450	Fluconazole	200 MG	\$	4.22	2014_J1450
2014	J1453	Fosaprepitant injection	1 MG	\$	1.73	2014_J1453
2014	J1458	Galsulfase injection	1 MG	\$	359.12	2014_J1458
2014	J1459	Inj IVIG privigen 500 mg	500 MG	\$	37.03	2014_J1459
2014	J1460	Gamma globulin 1 CC inj	1 CC	\$	28.77	2014_J1460
2014	J1556	Inj, Imm Glob Bivigam, 500mg	500 MG	\$	36.21	2014_J1556
2014	J1557	Gammplex injection	500 MG	\$	35.84	2014_J1557
2014	J1559	Hizentra injection	100 MG	\$	7.94	2014_J1559
2014	J1560	Gamma globulin > 10 CC inj	10 CC	\$	287.67	2014_J1560
2014	J1561	Gamunex-C/Gammaked	500 MG	\$	40.02	2014_J1561
2014	J1566	Immune globulin, powder	500 MG	\$	26.75	2014_J1566
2014	J1568	Octagam injection	500 MG	\$	36.92	2014_J1568
2014	J1569	Gammagard liquid injection	500 MG	\$	39.36	2014_J1569
2014	J1570	Ganciclovir sodium injection	500 MG	\$	72.11	2014_J1570
2014	J1571	Hepagam b im injection	0.5 ML	\$	53.70	2014_J1571
2014	J1572	Flebogamma injection	500 MG	\$	37.76	2014_J1572
2014	J1580	Garamycin gentamicin inj	80 MG	\$	1.23	2014_J1580
2014	J1602	Golimumab for iv use 1mg	1 MG	\$	24.16	2014_J1602
2014	J1610	Glucagon hydrochloride/1 MG	1 MG	\$	146.07	2014_J1610
2014	J1626	Granisetron hcl injection	100 MCG	\$	0.25	2014_J1626
2014	J1630	Haloperidol injection	5 MG	\$	1.98	2014_J1630
2014	J1631	Haloperidol decanoate inj	50 MG	\$	18.98	2014_J1631
2014	J1640	Hemin, 1 mg	1 MG	\$	20.73	2014_J1640
2014	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.17	2014_J1642
2014	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.21	2014_J1644
2014	J1645	Dalteparin sodium	2500 IU	\$	14.22	2014_J1645
2014	J1650	Inj enoxaparin sodium	10 MG	\$	1.47	2014_J1650
2014	J1652	Fondaparinux sodium	0.5 MG	\$	3.93	2014_J1652
2014	J1670	Tetanus immune globulin inj	250 UNITS	\$	326.32	2014_J1670
2014	J1720	Hydrocortisone sodium succ i	100 MG	\$	6.08	2014_J1720
2014	J1740	Ibandronate sodium injection	1 MG	\$	151.80	2014_J1740
2014	J1742	Ibutilide fumarate injection	1 MG	\$	112.30	2014_J1742
2014	J1743	Idursulfase injection	1 MG	\$	483.05	2014_J1743
2014	J1745	Infliximab injection	10 MG	\$	74.34	2014_J1745
2014	J1750	Inj iron dextran	50 MG	\$	12.16	2014_J1750
2014	J1756	Iron sucrose injection	1 MG	\$	0.28	2014_J1756

2014	J1786	Imuglucerase injection	10 UNITS	\$	42.01	2014_J1786
2014	J1790	Droperidol injection	5 MG	\$	2.14	2014_J1790
2014	J1800	Propranolol injection	1 MG	\$	2.42	2014_J1800
2014	J1815	Insulin injection	5 UNITS	\$	0.43	2014_J1815
2014	J1817	Insulin for insulin pump use	50 UNITS	\$	5.31	2014_J1817
2014	J1840	Kanamycin sulfate 500 MG inj	500 MG	\$	7.69	2014_J1840
2014	J1850	Kanamycin sulfate 75 MG inj	75 MG	\$	1.15	2014_J1850
2014	J1885	Ketorolac tromethamine inj	15 MG	\$	0.29	2014_J1885
2014	J1930	Lanreotide injection	1 MG	\$	41.40	2014_J1930
2014	J1931	Laronidase injection	0.1 MG	\$	29.45	2014_J1931
2014	J1940	Furosemide injection	20 MG	\$	5.33	2014_J1940
2014	J1950	Leuprolide acetate /3.75 MG	3.75 MG	\$	829.72	2014_J1950
2014	J1953	Levetiracetam injection	10 MG	\$	0.12	2014_J1953
2014	J1955	Inj levocarnitine per 1 gm	1 GM	\$	8.00	2014_J1955
2014	J1956	Levofloxacin injection	250 MG	\$	2.34	2014_J1956
2014	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	18.53	2014_J1980
2014	J2001	Lidocaine injection	10 MG	\$	0.02	2014_J2001
2014	J2010	Lincomycin injection	300 MG	\$	9.05	2014_J2010
2014	J2020	Linezolid injection	200 MG	\$	45.66	2014_J2020
2014	J2060	Lorazepam injection	2 MG	\$	0.71	2014_J2060
2014	J2150	Mannitol injection	50 ML	\$	2.10	2014_J2150
2014	J2175	Meperidine hydrochl /100 MG	100 MG	\$	4.98	2014_J2175
2014	J2185	Meropenem	100 MG	\$	1.14	2014_J2185
2014	J2210	Methylegonovin maleate inj	0.2 MG	\$	5.03	2014_J2210
2014	J2248	Micafungin sodium injection	1 MG	\$	0.98	2014_J2248
2014	J2250	Inj midazolam hydrochloride	1 MG	\$	0.14	2014_J2250
2014	J2260	Inj milrinone lactate / 5 MG	5 MG	\$	3.78	2014_J2260
2014	J2270	Morphine sulfate injection	10 MG	\$	1.32	2014_J2270
2014	J2278	Ziconotide injection	1 MCG	\$	6.87	2014_J2278
2014	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	5.33	2014_J2280
2014	J2300	Inj nalbuphine hydrochloride	10 MG	\$	2.49	2014_J2300
2014	J2310	Inj naloxone hydrochloride	1 MG	\$	42.75	2014_J2310
2014	J2315	Naltrexone, depot form	1 MG	\$	2.88	2014_J2315
2014	J2323	Natalizumab injection	1 MG	\$	14.91	2014_J2323
2014	J2353	Octreotide injection, depot	1 MG	\$	141.87	2014_J2353
2014	J2354	Octreotide inj, non-depot	25 MCG	\$	1.14	2014_J2354
2014	J2355	Oprelvekin injection	5 MG	\$	321.88	2014_J2355
2014	J2357	Omalizumab injection	5 MG	\$	27.85	2014_J2357
2014	J2358	Olanzapine long-acting inj	1 MG	\$	2.75	2014_J2358
2014	J2360	Orphenadrine injection	60 MG	\$	6.49	2014_J2360
2014	J2370	Phenylephrine hcl injection	1 ML	\$	3.24	2014_J2370
2014	J2400	Chloroprocaine hcl injection	30 ML	\$	19.35	2014_J2400
2014	J2405	Ondansetron hcl injection	1 MG	\$	0.08	2014_J2405
2014	J2410	Oxymorphone hcl injection	1 MG	\$	2.90	2014_J2410
2014	J2425	Palifermin injection	50 MCG	\$	14.85	2014_J2425
2014	J2426	Paliperidone palmitate inj	1 MG	\$	7.91	2014_J2426
2014	J2430	Pamidronate disodium /30 MG	30 MG	\$	11.36	2014_J2430
2014	J2469	Palonosetron hcl	25 MCG	\$	20.01	2014_J2469
2014	J2501	Paricalcitol	1 MCG	\$	1.79	2014_J2501
2014	J2503	Pegaptanib sodium injection	0.3 MG	\$	1,034.02	2014_J2503
2014	J2504	Pegademase bovine, 25 iu	25 IU	\$	281.40	2014_J2504
2014	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	3,387.93	2014_J2505
2014	J2507	Pegloticase injection	1 MG	\$	856.64	2014_J2507
2014	J2510	Penicillin g procaine inj	600000 UNITS	\$	17.06	2014_J2510
2014	J2515	Pentobarbital sodium inj	50 MG	\$	35.82	2014_J2515
2014	J2540	Penicillin g potassium inj	600000 UNITS	\$	0.74	2014_J2540
2014	J2543	Piperacillin/tazobactam	1.125 GM	\$	1.48	2014_J2543
2014	J2545	Pentamidine non-comp unit	300 MG	\$	93.25	2014_J2545
2014	J2550	Promethazine hcl injection	50 MG	\$	1.57	2014_J2550

2014	J2560	Phenobarbital sodium inj	120 MG	\$	21.14	2014_J2560
2014	J2562	Plerixafor injection	1 MG	\$	301.20	2014_J2562
2014	J2597	Inj desmopressin acetate	1 MCG	\$	5.08	2014_J2597
2014	J2675	Inj progesterone per 50 MG	50 MG	\$	0.92	2014_J2675
2014	J2680	Fluphenazine decanoate 25 MG	25 MG	\$	24.00	2014_J2680
2014	J2690	Procainamide hcl injection	1 GM	\$	49.94	2014_J2690
2014	J2700	Oxacillin sodium injecton	250 MG	\$	1.76	2014_J2700
2014	J2720	Inj protamine sulfate/10 MG	10 MG	\$	1.04	2014_J2720
2014	J2724	Protein c concentrate	10 UNITS	\$	14.52	2014_J2724
2014	J2730	Pralidoxime chloride inj	1 GM	\$	89.16	2014_J2730
2014	J2760	Phentolaine mesylate inj	5 MG	\$	113.40	2014_J2760
2014	J2765	Metoclopramide hcl injection	10 MG	\$	0.70	2014_J2765
2014	J2770	Quinupristin/dalfopristin	500 MG	\$	245.22	2014_J2770
2014	J2778	Ranibizumab injection	0.1 mg	\$	396.43	2014_J2778
2014	J2780	Ranitidine hydrochloride inj	25 MG	\$	1.21	2014_J2780
2014	J2783	Rasburicase	0.5 MG	\$	218.75	2014_J2783
2014	J2785	Regadenoson injection	0.1 MG	\$	52.75	2014_J2785
2014	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	25.46	2014_J2788
2014	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	84.27	2014_J2790
2014	J2791	Rhophylac injection	100 IU	\$	4.80	2014_J2791
2014	J2792	Rho(D) immune globulin h, sd	100 IU	\$	18.85	2014_J2792
2014	J2794	Risperidone, long acting	0.5 MG	\$	6.16	2014_J2794
2014	J2795	Ropivacaine HCl injection	1 MG	\$	0.12	2014_J2795
2014	J2796	Romiplostim injection	10 MCG	\$	53.63	2014_J2796
2014	J2800	Methocarbamol injection	10 ML	\$	42.10	2014_J2800
2014	J2805	Sinacalide injection	5 MCG	\$	87.03	2014_J2805
2014	J2810	Inj theophylline per 40 MG	40 MG	\$	0.31	2014_J2810
2014	J2820	Sargramostim injection	50 MCG	\$	30.13	2014_J2820
2014	J2850	Inj secretin synthetic human	1 MCG	\$	34.78	2014_J2850
2014	J2916	Na ferric gluconate complex	12.5 MG	\$	2.56	2014_J2916
2014	J2920	Methylprednisolone injection	40 MG	\$	1.94	2014_J2920
2014	J2930	Methylprednisolone injection	125 MG	\$	2.87	2014_J2930
2014	J2993	Reteplase injection	18.1 MG	\$	2,301.91	2014_J2993
2014	J2997	Alteplase recombinant	1 MG	\$	64.30	2014_J2997
2014	J3000	Streptomycin injection	1 GM	\$	12.90	2014_J3000
2014	J3010	Fentanyl citrate injecton	0.1 MG	\$	0.52	2014_J3010
2014	J3060	Inj, Taliglucerase Alfa 10 u	10 UNITS	\$	31.94	2014_J3060
2014	J3070	Pentazocine injection	30 MG	\$	140.12	2014_J3070
2014	J3095	Telavancin injection	10 MG	\$	4.52	2014_J3095
2014	J3101	Tenecteplase injection	1 MG	\$	86.21	2014_J3101
2014	J3105	Terbutaline sulfate inj	1 MG	\$	4.09	2014_J3105
2014	J3120	Testosterone enanthate inj	100 MG	\$	7.20	2014_J3120
2014	J3130	Testosterone enanthate inj	200 MG	\$	8.91	2014_J3130
2014	J3230	Chlorpromazine hcl injection	50 MG	\$	23.02	2014_J3230
2014	J3240	Thyrotropin injection	0.9 MG	\$	1,430.43	2014_J3240
2014	J3243	Tigecycline injection	1 MG	\$	2.00	2014_J3243
2014	J3250	Trimethobenzamide hcl inj	200 MG	\$	19.70	2014_J3250
2014	J3260	Tobramycin sulfate injection	80 MG	\$	2.46	2014_J3260
2014	J3262	Tocilizumab injection	1 MG	\$	3.68	2014_J3262
2014	J3285	Treprostinil injection	1 MG	\$	61.24	2014_J3285
2014	J3300	Triamcinolone A inj PRS-free	1 MG	\$	3.73	2014_J3300
2014	J3301	Triamcinolone acet inj NOS	10 MG	\$	1.77	2014_J3301
2014	J3303	Triamcinolone hexacetonl inj	5 MG	\$	2.39	2014_J3303
2014	J3315	Triptorelin pamoate	3.75 MG	\$	170.77	2014_J3315
2014	J3357	Ustekinumab injection	1 MG	\$	162.29	2014_J3357
2014	J3360	Diazepam injection	5 MG	\$	4.79	2014_J3360
2014	J3370	Vancomycin hcl injection	500 MG	\$	2.18	2014_J3370
2014	J3385	Velaglucerase alfa	100 UNITS	\$	353.35	2014_J3385
2014	J3396	Verteporfin injection	0.1 MG	\$	10.79	2014_J3396

2014	J3410	Hydroxyzine hcl injection	25 MG	\$	0.45	2014_J3410
2014	J3411	Thiamine hcl 100 mg	100 MG	\$	3.45	2014_J3411
2014	J3415	Pyridoxine hcl 100 mg	100 MG	\$	6.99	2014_J3415
2014	J3420	Vitamin b12 injection	1000 MCG	\$	1.82	2014_J3420
2014	J3430	Vitamin k phytionadione inj	1 MG	\$	1.23	2014_J3430
2014	J3465	Injection, voriconazole	10 MG	\$	3.97	2014_J3465
2014	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.33	2014_J3473
2014	J3475	Inj magnesium sulfate	500 MG	\$	0.19	2014_J3475
2014	J3480	Inj potassium chloride	2 MEQ	\$	0.12	2014_J3480
2014	J3485	Zidovudine	10 MG	\$	1.50	2014_J3485
2014	J3486	Ziprasidone mesylate	10 MG	\$	11.73	2014_J3486
2014	J3489	Zoledronic Acid 1mg	1 MG	\$	47.48	2014_J3489
2014	J7030	Normal saline solution infus	1000 ML	\$	1.35	2014_J7030
2014	J7040	Normal saline solution infus	500 ML	\$	0.68	2014_J7040
2014	J7042	5% dextrose/normal saline	500 ML	\$	0.60	2014_J7042
2014	J7050	Normal saline solution infus	250 ML	\$	0.34	2014_J7050
2014	J7060	5% dextrose/water	500 ML	\$	1.18	2014_J7060
2014	J7070	D5w infusion	1000 CC	\$	2.32	2014_J7070
2014	J7100	Dextran 40 infusion	500 ML	\$	21.59	2014_J7100
2014	J7120	Ringers lactate infusion	1000 CC	\$	1.16	2014_J7120
2014	J7180	Factor xiii anti-hem factor	1 IU	\$	6.74	2014_J7180
2014	J7183	Wilate injection	1 I.U. VWF:RCO	\$	0.95	2014_J7183
2014	J7185	Xyntha inj	1 IU	\$	1.17	2014_J7185
2014	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	0.94	2014_J7186
2014	J7187	Humate-P, inj	1 IU	\$	0.95	2014_J7187
2014	J7189	Factor viia	1 MCG	\$	1.73	2014_J7189
2014	J7190	Factor viii	1 IU	\$	0.93	2014_J7190
2014	J7192	Factor viii recombinant NOS	1 IU	\$	1.14	2014_J7192
2014	J7193	Factor IX non-recombinant	1 IU	\$	1.01	2014_J7193
2014	J7194	Factor ix complex	1 IU	\$	1.12	2014_J7194
2014	J7195	Factor IX recombinant	1 IU	\$	1.35	2014_J7195
2014	J7197	Antithrombin iii injection	1 IU	\$	3.27	2014_J7197
2014	J7198	Anti-inhibitor	1 IU	\$	1.70	2014_J7198
2014	J7308	Aminolevulinic acid hcl top	354 MG	\$	242.30	2014_J7308
2014	J7310	Ganciclovir long act implant	4.5 MG	\$	16,960.00	2014_J7310
2014	J7311	Fluocinolone acetonide implt	0.59 MG	\$	19,641.05	2014_J7311
2014	J7312	Dexamethasone intra implant	0.1 MG	\$	201.31	2014_J7312
2014	J7316	Inj, Ocriplasmin, 0.125 mg	0.125 MG	\$	1,046.75	2014_J7316
2014	J7321	Hyalgan/supartz inj per dose	per dose	\$	90.81	2014_J7321
2014	J7323	Euflexxa inj per dose	per dose	\$	161.12	2014_J7323
2014	J7324	Orthovisc inj per dose	per dose	\$	186.89	2014_J7324
2014	J7325	Synvisc or Synvisc-One	1 MG	\$	12.50	2014_J7325
2014	J7326	Gel-One	per dose	\$	562.08	2014_J7326
2014	J7335	Capsaicin 8% patch	10 SQ CM	\$	26.50	2014_J7335
2014	J7500	Azathioprine oral 50mg	50 MG	\$	0.19	2014_J7500
2014	J7501	Azathioprine parenteral	100 MG	\$	217.30	2014_J7501
2014	J7502	Cyclosporine oral 100 mg	100 MG	\$	3.38	2014_J7502
2014	J7504	Lymphocyte immune globulin	250 MG	\$	852.69	2014_J7504
2014	J7506	Prednisone oral	5 MG	\$	0.08	2014_J7506
2014	J7507	Tacrolimus Imme Rel oral 1mg	1 MG	\$	1.20	2014_J7507
2014	J7508	Tacrolimus Ex Rel oral 0.1mg	0.1 MG	\$	0.40	2014_J7508
2014	J7509	Methylprednisolone oral	4 MG	\$	0.60	2014_J7509
2014	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.09	2014_J7510
2014	J7511	Antithymocyte globuln rabbit	25 MG	\$	594.74	2014_J7511
2014	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.88	2014_J7515
2014	J7516	Cyclosporin parenteral 250mg	250 MG	\$	33.84	2014_J7516
2014	J7517	Mycophenolate mofetil oral	250 MG	\$	1.53	2014_J7517
2014	J7518	Mycophenolic acid	180 MG	\$	3.41	2014_J7518
2014	J7520	Sirolimus, oral	1 MG	\$	16.23	2014_J7520

2014	J7525	Tacrolimus injection	5 MG	\$	141.10	2014_J7525
2014	J7527	Oral everolimus	0.25 MG	\$	6.85	2014_J7527
2014	J7605	Arformoterol non-comp unit	15 mcg	\$	6.70	2014_J7605
2014	J7606	Formoterol fumarate, inh	20 MCG	\$	7.46	2014_J7606
2014	J7608	Acetylcysteine non-comp unit	1 GM	\$	3.70	2014_J7608
2014	J7611	Albuterol non-comp con	1 MG	\$	0.11	2014_J7611
2014	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.19	2014_J7612
2014	J7613	Albuterol non-comp unit	1 MG	\$	0.06	2014_J7613
2014	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.10	2014_J7614
2014	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.17	2014_J7620
2014	J7626	Budesonide non-comp unit	0.5 MG	\$	5.38	2014_J7626
2014	J7631	Cromolyn sodium noncomp unit	10 MG	\$	0.46	2014_J7631
2014	J7639	Dornase alfa non-comp unit	1 MG	\$	35.75	2014_J7639
2014	J7644	Ipratropium bromide non-comp	1 MG	\$	0.24	2014_J7644
2014	J7665	Mannitol for inhaler	5 MG	\$	0.67	2014_J7665
2014	J7674	Methacholine chloride, neb	1 MG	\$	0.52	2014_J7674
2014	J7682	Tobramycin non-comp unit	300 MG	\$	95.96	2014_J7682
2014	J7686	Treprostinil, non-comp unit	1.74 MG	\$	483.00	2014_J7686
2014	J8501	Oral aprepitant	5 MG	\$	7.68	2014_J8501
2014	J8510	Oral busulfan	2 MG	\$	10.98	2014_J8510
2014	J8520	Capecitabine, oral, 150 mg	150 MG	\$	8.67	2014_J8520
2014	J8521	Capecitabine, oral, 500 mg	500 MG	\$	28.63	2014_J8521
2014	J8530	Cyclophosphamide oral 25 MG	25 MG	\$	1.07	2014_J8530
2014	J8540	Oral dexamethasone	0.25 MG	\$	0.20	2014_J8540
2014	J8560	Etoposide oral 50 MG	50 MG	\$	57.09	2014_J8560
2014	J8600	Melphalan oral 2 MG	2 MG	\$	9.42	2014_J8600
2014	J8610	Methotrexate oral 2.5 MG	2.5 MG	\$	1.08	2014_J8610
2014	J8700	Temozolomide	5 MG	\$	5.39	2014_J8700
2014	J8705	Topotecan oral	0.25 mg	\$	94.74	2014_J8705
2014	J9000	Doxorubicin hcl injection	10 MG	\$	3.00	2014_J9000
2014	J9015	Aldesleukin injection	1 EA	\$	2,110.63	2014_J9015
2014	J9017	Arsenic trioxide injection	1 MG	\$	53.58	2014_J9017
2014	J9019	Erwinaze injection	1,000 IU	\$	354.76	2014_J9019
2014	J9020	Asparaginase, NOS	10000 UNITS	\$	64.56	2014_J9020
2014	J9025	Azacitidine injection	1 MG	\$	3.92	2014_J9025
2014	J9027	Clofarabine injection	1 MG	\$	134.10	2014_J9027
2014	J9031	Bcg live intravesical vac	1 EA	\$	121.96	2014_J9031
2014	J9033	Bendamustine injection	1 MG	\$	22.21	2014_J9033
2014	J9035	Bevacizumab injection	10 MG	\$	66.65	2014_J9035
2014	J9040	Bleomycin sulfate injection	15 UNITS	\$	20.72	2014_J9040
2014	J9041	Bortezomib injection	0.1 MG	\$	46.08	2014_J9041
2014	J9042	Brentuximab vedotin inj	1 MG	\$	110.82	2014_J9042
2014	J9043	Cabazitaxel injection	1 MG	\$	142.42	2014_J9043
2014	J9045	Carboplatin injection	50 MG	\$	3.45	2014_J9045
2014	J9047	Injection, Carfilzomib, 1 mg	1 MG	\$	29.81	2014_J9047
2014	J9050	Carmustine injection	100 MG	\$	1,861.12	2014_J9050
2014	J9055	Cetuximab injection	10 MG	\$	53.29	2014_J9055
2014	J9060	Cisplatin 10 MG injection	10 MG	\$	2.04	2014_J9060
2014	J9065	Inj cladribine per 1 MG	1 MG	\$	21.21	2014_J9065
2014	J9070	Cyclophosphamide 100 MG inj	100 MG	\$	63.16	2014_J9070
2014	J9098	Cytarabine liposome inj	10 MG	\$	561.39	2014_J9098
2014	J9100	Cytarabine hcl 100 MG inj	100 MG	\$	0.94	2014_J9100
2014	J9120	Dactinomycin injection	0.5 MG	\$	807.19	2014_J9120
2014	J9130	Dacarbazine 100 mg inj	100 MG	\$	3.64	2014_J9130
2014	J9150	Daunorubicin injection	10 MG	\$	22.56	2014_J9150
2014	J9155	Degarelix injection	1 MG	\$	3.55	2014_J9155
2014	J9171	Docetaxel injection	1 MG	\$	4.59	2014_J9171
2014	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.35	2014_J9178
2014	J9179	Eribulin mesylate injection	0.1 MG	\$	99.01	2014_J9179

2014	J9181	Etoposide injection	10 MG	\$	0.68	2014_J9181
2014	J9185	Fludarabine phosphate inj	50 MG	\$	70.98	2014_J9185
2014	J9190	Fluorouracil injection	500 MG	\$	2.06	2014_J9190
2014	J9200	Floxuridine injection	500 MG	\$	55.65	2014_J9200
2014	J9201	Gemcitabine hcl injection	200 MG	\$	6.66	2014_J9201
2014	J9202	Goserelin acetate implant	3.6 MG	\$	225.02	2014_J9202
2014	J9206	Irinotecan injection	20 MG	\$	4.20	2014_J9206
2014	J9207	Ixabepilone injection	1 MG	\$	70.21	2014_J9207
2014	J9208	Ifosfamide injection	1 GM	\$	33.41	2014_J9208
2014	J9209	Mesna injection	200 MG	\$	2.84	2014_J9209
2014	J9211	Idarubicin hcl injection	5 MG	\$	49.11	2014_J9211
2014	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	21.17	2014_J9214
2014	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	229.26	2014_J9217
2014	J9218	Leuprolide acetate injecton	1 MG	\$	7.18	2014_J9218
2014	J9225	Vantas implant	50 MG	\$	3,001.59	2014_J9225
2014	J9226	Supprelin LA implant	50 MG	\$	18,317.24	2014_J9226
2014	J9228	Ipilimumab injection	1 MG	\$	133.61	2014_J9228
2014	J9230	Mechlorethamine hcl inj	10 MG	\$	189.63	2014_J9230
2014	J9245	Inj melphalan hydrochl 50 MG	50 MG	\$	1,226.63	2014_J9245
2014	J9250	Methotrexate sodium inj	5 MG	\$	0.21	2014_J9250
2014	J9260	Methotrexate sodium inj	50 MG	\$	2.11	2014_J9260
2014	J9261	Nelarabine injection	50 MG	\$	138.87	2014_J9261
2014	J9263	Oxaliplatin	0.5 MG	\$	0.58	2014_J9263
2014	J9264	Paclitaxel protein bound	1 MG	\$	9.70	2014_J9264
2014	J9265	Paclitaxel injection	30 MG	\$	3.82	2014_J9265
2014	J9266	Pegaspargase injection	1 EA	\$	6,220.80	2014_J9266
2014	J9268	Pentostatin injection	10 MG	\$	1,483.27	2014_J9268
2014	J9280	Mitomycin injection	5 MG	\$	20.88	2014_J9280
2014	J9293	Mitoxantrone hydrochl / 5 MG	5 MG	\$	32.34	2014_J9293
2014	J9302	Ofatumumab injection	10 MG	\$	47.76	2014_J9302
2014	J9303	Panitumumab injection	10 MG	\$	94.79	2014_J9303
2014	J9305	Pemetrexed injection	10 MG	\$	60.27	2014_J9305
2014	J9306	Injection, Pertuzumab, 1 mg	1 MG	\$	10.22	2014_J9306
2014	J9307	Pralatrexate injection	1 MG	\$	197.12	2014_J9307
2014	J9310	Rituximab injection	100 MG	\$	708.68	2014_J9310
2014	J9315	Romidepsin injection	1 MG	\$	270.64	2014_J9315
2014	J9320	Streptozocin injection	1 GM	\$	335.28	2014_J9320
2014	J9328	Temozolomide injection	1 MG	\$	5.68	2014_J9328
2014	J9330	Temsirolimus injection	1 MG	\$	58.83	2014_J9330
2014	J9351	Topotecan injection	0.1 MG	\$	1.83	2014_J9351
2014	J9354	Inj, Ado-trastuzumab Emt 1mg	1 MG	\$	29.14	2014_J9354
2014	J9355	Trastuzumab injection	10 MG	\$	82.49	2014_J9355
2014	J9357	Valrubicin injection	200 MG	\$	1,085.29	2014_J9357
2014	J9360	Vinblastine sulfate inj	1 MG	\$	2.71	2014_J9360
2014	J9370	Vincristine sulfate 1 MG inj	1 MG	\$	4.91	2014_J9370
2014	J9371	Inj, vincristine sul lip 1 mg	1 MG	\$	2,148.20	2014_J9371
2014	J9390	Vinorelbine tartrate inj	10 MG	\$	10.87	2014_J9390
2014	J9395	Injection, Fulvestrant	25 MG	\$	91.27	2014_J9395
2014	J9400	Inj, ziv-aflibercept, 1mg	1 MG	\$	8.12	2014_J9400
2014	P9041	Albumin (human),5%, 50ml	50 ML	\$	10.91	2014_P9041
2014	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	54.54	2014_P9045
2014	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	22.49	2014_P9046
2014	P9047	Albumin (human), 25%, 50ml	50 ML	\$	53.44	2014_P9047
2014	Q0138	Ferumoxitol, non-esrd	1 MG	\$	0.74	2014_Q0138
2014	Q0139	Ferumoxitol, esrd use	1 MG	\$	0.74	2014_Q0139
2014	Q0162	Ondansetron oral	1 MG	\$	0.07	2014_Q0162
2014	Q0163	Diphenhydramine HCl 50mg	50 MG	\$	0.21	2014_Q0163
2014	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.04	2014_Q0164
2014	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	1.84	2014_Q0166

2014	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	3.71	2014_Q0167
2014	Q0169	Promethazine HCl 12.5mg oral	12.5 MG	\$	0.08	2014_Q0169
2014	Q0180	Dolasetron mesylate oral	100 MG	\$	78.35	2014_Q0180
2014	Q2035	Afluria vacc, 3 yrs & >, im	0.5 ml	\$	11.89	2014_Q2035
2014	Q2036	Flulaval vacc, 3 yrs & >, im	0.5 ML	\$	8.58	2014_Q2036
2014	Q2037	Fluvirin vacc, 3 yrs & >, im	0.5 ML	\$	15.40	2014_Q2037
2014	Q2038	Fluzone vacc, 3 yrs & >, im	0.5 ML	\$	12.04	2014_Q2038
2014	Q2043	Sipuleucel-T auto CD54+	Per infusion (minimum 50 million cells)	\$	35,094.12	2014_Q2043
2014	Q2049	Imported Lipodox inj	10 MG	\$	508.43	2014_Q2049
2014	Q2050	Doxorubicin inj 10mg	10 MG	\$	490.49	2014_Q2050
2014	Q3027	Inj beta interferon im 1 mcg	1 MCG	\$	36.37	2014_Q3027
2014	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	95.01	2014_Q4074
2014	Q4081	Epoetin alfa, 100 units ESRD	100 UNITS	\$	1.17	2014_Q4081
2014	Q4101	Apligraf skin sub	1 SQ CM	\$	33.61	2014_Q4101
2014	Q4102	Oasis wound matrix skin sub	1 SQ CM	\$	8.87	2014_Q4102
2014	Q4104	Integra BMWd skin sub	1 SQ CM	\$	21.11	2014_Q4104
2014	Q4105	Integra DRT skin sub	1 SQ CM	\$	11.01	2014_Q4105
2014	Q4106	Dermagraft skin sub	1 SQ CM	\$	38.60	2014_Q4106
2014	Q4107	Graftjacket skin sub	1 SQ CM	\$	99.28	2014_Q4107
2014	Q4108	Integra matrix skin sub	1 SQ CM	\$	29.05	2014_Q4108
2014	Q4110	Primatrix skin sub	1 SQ CM	\$	37.22	2014_Q4110
2014	Q4111	Gammagraft skin sub	1 SQ CM	\$	6.90	2014_Q4111
2014	Q4112	Cymetra allograft	1 CC	\$	381.99	2014_Q4112
2014	Q4113	Graftjacket express allograf	1 CC	\$	381.99	2014_Q4113
2014	Q4114	Integra flowable wound matri	1 CC	\$	1,368.41	2014_Q4114
2014	Q4115	Alloskin	1 SQ CM	\$	7.70	2014_Q4115
2014	Q4116	Alloderm skin sub	1 SQ CM	\$	32.48	2014_Q4116
2014	Q4121	Theraskin	1 SQ CM	\$	32.42	2014_Q4121
2014	Q4123	Alloskin RT	1 SQ CM	\$	15.38	2014_Q4123
2014	Q4131	Epifix	1 SQ CM	\$	219.52	2014_Q4131
2014	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	37.24	2014_Q9956
2014	Q9957	Inj perflutren lip micros,ml	1 ML	\$	55.86	2014_Q9957
2014	Q9958	HOcm <=149 mg/ml iodine, 1ml	1 ML	\$	0.09	2014_Q9958
2014	Q9960	HOcm 200-249mg/ml iodine,1ml	1 ML	\$	0.17	2014_Q9960
2014	Q9961	HOcm 250-299mg/ml iodine,1ml	1 ML	\$	0.20	2014_Q9961
2014	Q9963	HOcm 350-399mg/ml iodine,1ml	1 ML	\$	0.20	2014_Q9963
2014	Q9965	LOCM 100-199mg/ml iodine,1ml	1 ML	\$	1.12	2014_Q9965
2014	Q9966	LOCM 200-299mg/ml iodine,1ml	1 ML	\$	0.21	2014_Q9966
2014	Q9967	LOCM 300-399mg/ml iodine,1ml	1 ML	\$	0.24	2014_Q9967
2014	Q9970	Inj Ferric Carboxymaltos 1mg	1 MG	\$	1.05	2014_Q9970
2014	Q9974	Morphine epidural/intratheca	10MG	\$	9.63	2014_Q9974
2013	90371	Hep b ig, im	1 ML	\$	112.03	2013_90371
2013	90375	Rabies ig, im/sc	150 IU	\$	219.82	2013_90375
2013	90376	Rabies ig, heat treated	150 IU	\$	216.54	2013_90376
2013	90385	Rh ig, minidose, im	50 MCG	\$	25.28	2013_90385
2013	90585	Bcg vaccine, percut	50 MG	\$	120.91	2013_90585
2013	90586	Bcg vaccine, intravesical	1 EACH	\$	120.91	2013_90586
2013	90632	Hep a vaccine, adult im	1 ML	\$	49.67	2013_90632
2013	90654	Flu vaccine, intradermal, no preserv	0.1 ML	\$	18.92	2013_90654
2013	90655	Flu vaccine no preserv 6-35m, im	0.25 ML	\$	17.24	2013_90655
2013	90656	Flu vaccine no preserv 3 yo & >, im	0.50 ML	\$	12.40	2013_90656
2013	90657	Flu vaccine, 6-35 mo, im	0.25 ML	\$	6.02	2013_90657
2013	90662	Flu vacc prsv free inc antig	0.5 ML	\$	31.82	2013_90662
2013	90669	Pneumococcal vacc, 7 val im	0.5 ML	\$	95.48	2013_90669
2013	90670	Pneumococcal vacc, 13 val im	0.5 ML	\$	145.11	2013_90670
2013	90672	Flu vaccine 4 valent nasal	0.2 ml	\$	24.60	2013_90672
2013	90675	Rabies vaccine, im	1 ML	\$	232.39	2013_90675
2013	90685	Flu vac no prsv 4 val 6-35 m	0.25 mL	\$	23.23	2013_90685
2013	90686	Flu vac no prsv 4 val 3 yrs+	0.5 ml	\$	19.41	2013_90686

2013	90691	Typhoid vaccine, im	0.5 ML	\$	62.55	2013_90691
2013	90703	Tetanus vaccine, im	0.5 ML	\$	39.29	2013_90703
2013	90714	Td vaccine no prsrv >/= 7 yo, im	0.5 ML	\$	19.47	2013_90714
2013	90715	Tdap => 7 yo, im	0.5 ML	\$	33.80	2013_90715
2013	90717	Yellow fever vaccine, sc	0.5 ML	\$	75.06	2013_90717
2013	90732	Pneumococcal vaccine	0.5 ML	\$	72.35	2013_90732
2013	90733	Meningococcal vaccine, sc	0.5 ML	\$	106.49	2013_90733
2013	90735	Encephalitis vaccine, sc	1 ML	\$	102.08	2013_90735
2013	90740	Hepb vacc, ill pat 3 dose im	40 MCG	\$	119.42	2013_90740
2013	90743	Hep b vacc, adol, 2 dose, im	1 DOSE	\$	24.22	2013_90743
2013	90744	Hepb vacc ped/adol 3 dose im	1 DOSE	\$	24.22	2013_90744
2013	90746	Hep b vaccine, adult, im	20 MCG	\$	59.71	2013_90746
2013	90747	Hepb vacc, ill pat 4 dose im	40 MCG	\$	119.42	2013_90747
2013	A9576	Inj prohance multipack	1 ML	\$	1.81	2013_A9576
2013	A9577	Inj multihance	1 ML	\$	2.22	2013_A9577
2013	A9578	Inj multihance multipack	1 ML	\$	2.11	2013_A9578
2013	A9579	Gad-base MR contrast NOS,1ml	1 ML	\$	1.95	2013_A9579
2013	A9581	Gadoxetate disodium inj	1 ML	\$	13.27	2013_A9581
2013	A9583	Gadofosveset trisodium inj	1 ML	\$	11.72	2013_A9583
2013	A9585	Gadobutrol injection	0.1 ML	\$	0.41	2013_A9585
2013	J0129	Abatacept injection	10 MG	\$	23.06	2013_J0129
2013	J0130	Abciximab injection	10 MG	\$	651.25	2013_J0130
2013	J0132	Acetylcysteine injection	100 MG	\$	2.65	2013_J0132
2013	J0133	Acyclovir injection	5 MG	\$	0.05	2013_J0133
2013	J0135	Adalimumab injection	20 MG	\$	515.89	2013_J0135
2013	J0150	Injection adenosine 6 MG	6 MG	\$	5.83	2013_J0150
2013	J0152	Adenosine injection	30 MG	\$	109.38	2013_J0152
2013	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.06	2013_J0171
2013	J0178	Aflibercept injection (ophthalmic)	1 MG	\$	980.50	2013_J0178
2013	J0180	Agalsidase beta injection	1 MG	\$	146.19	2013_J0180
2013	J0207	Amifostine	500 MG	\$	298.54	2013_J0207
2013	J0210	Methyldopate hcl injection	250 MG	\$	42.40	2013_J0210
2013	J0215	Alefacept	0.5 MG	\$	41.64	2013_J0215
2013	J0220	Alglucosidase alfa injection	10 MG	\$	206.64	2013_J0220
2013	J0221	Lumizyme injection	10 MG	\$	153.60	2013_J0221
2013	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	4.02	2013_J0256
2013	J0257	Glassia injection	10 MG	\$	3.99	2013_J0257
2013	J0278	Amikacin sulfate injection	100 MG	\$	1.08	2013_J0278
2013	J0280	Aminophyllin 250 MG inj	250 MG	\$	1.19	2013_J0280
2013	J0285	Amphotericin B	50 MG	\$	11.37	2013_J0285
2013	J0287	Amphotericin b lipid complex	10 MG	\$	11.42	2013_J0287
2013	J0288	Ampho b cholesteryl sulfate	10 MG	\$	14.00	2013_J0288
2013	J0289	Amphotericin b liposome inj	10 MG	\$	15.57	2013_J0289
2013	J0290	Ampicillin 500 MG inj	500 MG	\$	1.45	2013_J0290
2013	J0295	Ampicillin sodium per 1.5 gm	1.5 GM	\$	1.66	2013_J0295
2013	J0348	Anidulafungin injection	1 MG	\$	0.85	2013_J0348
2013	J0360	Hydralazine hcl injection	20 MG	\$	3.14	2013_J0360
2013	J0364	Apomorphine hydrochloride	1 MG	\$	33.06	2013_J0364
2013	J0365	Aprotonin, 10,000 kiu	10000 KIU	\$	2.65	2013_J0365
2013	J0400	Aripiprazole injection	0.25 MG	\$	0.55	2013_J0400
2013	J0456	Azithromycin	500 MG	\$	3.31	2013_J0456
2013	J0461	Atropine sulfate injection	0.01 MG	\$	0.04	2013_J0461
2013	J0470	Dimecaprol injection	100 MG	\$	29.55	2013_J0470
2013	J0475	Baclofen 10 MG injection	10 MG	\$	160.30	2013_J0475
2013	J0476	Baclofen intrathecal trial	50 MCG	\$	74.11	2013_J0476
2013	J0480	Basiliximab	20 MG	\$	2,442.92	2013_J0480
2013	J0485	Belatacept injection	1 MG	\$	3.80	2013_J0485
2013	J0490	Belimumab injection	10 MG	\$	38.25	2013_J0490
2013	J0500	Dicyclomine injection	20 MG	\$	38.61	2013_J0500

2013	J0515	Inj benzotropine mesylate	1 MG	\$	21.02	2013_J0515
2013	J0558	PenG benzathine/procaine inj	100,000 UNITS	\$	4.04	2013_J0558
2013	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	5.08	2013_J0561
2013	J0583	Bivalirudin	1 MG	\$	3.21	2013_J0583
2013	J0585	Injection,onabotulinumtoxinA	1 UNIT	\$	5.45	2013_J0585
2013	J0586	AbobotulinumtoxinA	5 Unit	\$	7.05	2013_J0586
2013	J0587	Inj, rimabotulinumtoxinB	100 UNITS	\$	10.89	2013_J0587
2013	J0588	Incobotulinumtoxin A	1 UNIT	\$	4.48	2013_J0588
2013	J0592	Buprenorphine hydrochloride	0.1 MG	\$	0.99	2013_J0592
2013	J0594	Busulfan injection	1 MG	\$	25.18	2013_J0594
2013	J0595	Butorphanol tartrate 1 mg	1 MG	\$	1.75	2013_J0595
2013	J0597	C-1 esterase, berinert	10 UNITS	\$	32.69	2013_J0597
2013	J0598	C-1 esterase, cinryze	10 UNITS	\$	49.34	2013_J0598
2013	J0600	Edetate calcium disodium inj	1000 MG	\$	201.40	2013_J0600
2013	J0610	Calcium gluconate injection	10 ML	\$	1.07	2013_J0610
2013	J0630	Calcitonin salmon injection	400 UNITS	\$	69.05	2013_J0630
2013	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.37	2013_J0636
2013	J0637	Caspofungin acetate	5 MG	\$	13.35	2013_J0637
2013	J0638	Canakinumab injection	1 MG	\$	91.02	2013_J0638
2013	J0640	Leucovorin calcium injection	50 MG	\$	4.50	2013_J0640
2013	J0641	Levoleucovorin injection	0.5 MG	\$	1.74	2013_J0641
2013	J0670	Inj mepivacaine HCL/10 ml	10 ML	\$	2.43	2013_J0670
2013	J0690	Cefazolin sodium injection	500 MG	\$	0.88	2013_J0690
2013	J0692	Cefepime HCl for injection	500 MG	\$	2.88	2013_J0692
2013	J0694	Cefoxitin sodium injection	1 GM	\$	5.19	2013_J0694
2013	J0696	Ceftriaxone sodium injection	250 MG	\$	0.74	2013_J0696
2013	J0697	Sterile cefuroxime injection	750 MG	\$	3.16	2013_J0697
2013	J0698	Cefotaxime sodium injection	1 GM	\$	1.75	2013_J0698
2013	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	5.70	2013_J0702
2013	J0706	Caffeine citrate injection	5 MG	\$	0.52	2013_J0706
2013	J0712	Ceftaroline fosamil inj	10 MG	\$	0.88	2013_J0712
2013	J0713	Inj ceftazidime per 500 mg	500 MG	\$	1.95	2013_J0713
2013	J0718	Certolizumab pegol inj	1 MG	\$	5.18	2013_J0718
2013	J0720	Chloramphenicol sodium injec	1 GM	\$	29.46	2013_J0720
2013	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	15.40	2013_J0725
2013	J0735	Clonidine hydrochloride	1 MG	\$	21.89	2013_J0735
2013	J0740	Cidofovir injection	375 MG	\$	648.43	2013_J0740
2013	J0743	Cilastatin sodium injection	250 MG	\$	5.69	2013_J0743
2013	J0744	Ciprofloxacin iv	200 MG	\$	1.16	2013_J0744
2013	J0770	Colistimethate sodium inj	150 MG	\$	12.36	2013_J0770
2013	J0775	Collagenase, clost hist inj	0.01 MG	\$	38.57	2013_J0775
2013	J0780	Prochlorperazine injection	10 MG	\$	4.07	2013_J0780
2013	J0795	Corticotropin ovine triflural	1 MCG	\$	7.78	2013_J0795
2013	J0800	Corticotropin injection	40 UNITS	\$	3,050.44	2013_J0800
2013	J0834	Cosyntropin cortrosyn inj	0.25 MG	\$	65.44	2013_J0834
2013	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	2,349.90	2013_J0840
2013	J0850	Cytomegalovirus imm IV /vial	PER VIAL	\$	1,013.87	2013_J0850
2013	J0878	Daptomycin injection	1 MG	\$	0.60	2013_J0878
2013	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.67	2013_J0881
2013	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.67	2013_J0882
2013	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	11.22	2013_J0885
2013	J0886	Epoetin alfa 1000 units ESRD	1000 UNITS	\$	11.22	2013_J0886
2013	J0894	Decitabine injection	1 MG	\$	34.78	2013_J0894
2013	J0895	Deferoxamine mesylate inj	500 MG	\$	7.89	2013_J0895
2013	J0897	Denosumab injection	1 MG	\$	14.15	2013_J0897
2013	J1000	Depo-estradiol cypionate inj	5 MG	\$	8.10	2013_J1000
2013	J1020	Methylprednisolone 20 MG inj	20 MG	\$	3.00	2013_J1020
2013	J1030	Methylprednisolone 40 MG inj	40 MG	\$	2.74	2013_J1030
2013	J1040	Methylprednisolone 80 MG inj	80 MG	\$	5.30	2013_J1040

2013	J1050	Medroxyprogesterone acetate	1 MG	\$	0.22	2013_J1050
2013	J1070	Testosterone cypionat 100 MG	100 MG	\$	4.48	2013_J1070
2013	J1080	Testosterone cypionat 200 MG	200 MG	\$	5.05	2013_J1080
2013	J1100	Dexamethasone sodium phos	1 MG	\$	0.12	2013_J1100
2013	J1110	Inj dihydroergotamine mesylt	1 MG	\$	33.47	2013_J1110
2013	J1120	Acetazolamid sodium injectio	500 MG	\$	26.54	2013_J1120
2013	J1160	Digoxin injection	0.5 MG	\$	2.04	2013_J1160
2013	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	1,241.37	2013_J1162
2013	J1165	Phenytoin sodium injection	50 MG	\$	0.54	2013_J1165
2013	J1170	Hydromorphone injection	4 MG	\$	2.21	2013_J1170
2013	J1190	Dexrazoxane HCl injection	250 MG	\$	139.65	2013_J1190
2013	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.64	2013_J1200
2013	J1205	Chlorothiazide sodium inj	500 MG	\$	163.98	2013_J1205
2013	J1212	Dimethyl sulfoxide 50% 50 ML	50 ML	\$	79.32	2013_J1212
2013	J1230	Methadone injection	10 MG	\$	7.46	2013_J1230
2013	J1240	Dimenhydrinate injection	50 MG	\$	5.19	2013_J1240
2013	J1245	Dipyridamole injection	10 MG	\$	0.82	2013_J1245
2013	J1250	Inj dobutamine HCL/250 mg	250 MG	\$	8.30	2013_J1250
2013	J1260	Dolasetron mesylate	10 MG	\$	5.46	2013_J1260
2013	J1265	Dopamine injection	40 MG	\$	0.51	2013_J1265
2013	J1267	Doripenem injection	10 MG	\$	0.56	2013_J1267
2013	J1270	Injection, doxercalciferol	1 MCG	\$	1.67	2013_J1270
2013	J1290	Ecaltantide injection	1 MG	\$	355.64	2013_J1290
2013	J1300	Ecuzumab injection	10 MG	\$	201.12	2013_J1300
2013	J1325	Epoprostenol injection	0.5 MG	\$	15.73	2013_J1325
2013	J1327	Eptifibatide injection	5 MG	\$	28.08	2013_J1327
2013	J1335	Ertapenem injection	500 MG	\$	33.70	2013_J1335
2013	J1364	Erythro lactobionate /500 MG	500 MG	\$	21.02	2013_J1364
2013	J1380	Estradiol valerate 10 MG inj	10 MG	\$	8.69	2013_J1380
2013	J1410	Inj estrogen conjugate 25 MG	25 MG	\$	149.57	2013_J1410
2013	J1430	Ethanolamine oleate 100 mg	100 MG	\$	299.94	2013_J1430
2013	J1438	Etanercept injection	25 MG	\$	255.10	2013_J1438
2013	J1440	Filgrastim 300 mcg injection	300 MCG	\$	288.26	2013_J1440
2013	J1441	Filgrastim 480 mcg injection	480 MCG	\$	458.00	2013_J1441
2013	J1450	Fluconazole	200 MG	\$	3.89	2013_J1450
2013	J1451	Fomepizole, 15 mg	15 MG	\$	7.17	2013_J1451
2013	J1453	Fosaprepitant injection	1 MG	\$	1.72	2013_J1453
2013	J1458	Galsulfase injection	1 MG	\$	359.70	2013_J1458
2013	J1459	Inj IVIG privigen 500 mg	500 MG	\$	36.52	2013_J1459
2013	J1460	Gamma globulin 1 CC inj	1 CC	\$	23.98	2013_J1460
2013	J1557	Gammaplex injection	500 MG	\$	36.78	2013_J1557
2013	J1559	Hizentra injection	100 MG	\$	7.65	2013_J1559
2013	J1560	Gamma globulin > 10 CC inj	10 CC	\$	239.77	2013_J1560
2013	J1561	Gamunex-C/Gammaked	500 MG	\$	40.47	2013_J1561
2013	J1566	Immune globulin, powder	500 MG	\$	35.75	2013_J1566
2013	J1568	Octagam injection	500 MG	\$	31.49	2013_J1568
2013	J1569	Gammagard liquid injection	500 MG	\$	39.27	2013_J1569
2013	J1570	Ganciclovir sodium injection	500 MG	\$	73.71	2013_J1570
2013	J1571	Hepagam b im injection	0.5 ML	\$	51.03	2013_J1571
2013	J1572	Flebogamma injection	500 MG	\$	36.08	2013_J1572
2013	J1573	Hepagam b intravenous, inj	0.5 ML	\$	51.03	2013_J1573
2013	J1580	Garamycin gentamicin inj	80 MG	\$	1.45	2013_J1580
2013	J1600	Gold sodium thiomaleate inj	50 MG	\$	30.15	2013_J1600
2013	J1610	Glucagon hydrochloride/1 MG	1 MG	\$	127.98	2013_J1610
2013	J1626	Granisetron hcl injection	100 MCG	\$	0.50	2013_J1626
2013	J1630	Haloperidol injection	5 MG	\$	1.32	2013_J1630
2013	J1631	Haloperidol decanoate inj	50 MG	\$	19.62	2013_J1631
2013	J1640	Hemin, 1 mg	1 MG	\$	16.59	2013_J1640
2013	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.15	2013_J1642

2013	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.18	2013_J1644
2013	J1645	Dalteparin sodium	2500 IU	\$	12.99	2013_J1645
2013	J1650	Inj enoxaparin sodium	10 MG	\$	1.58	2013_J1650
2013	J1652	Fondaparinux sodium	0.5 MG	\$	3.91	2013_J1652
2013	J1670	Tetanus immune globulin inj	250 UNITS	\$	272.52	2013_J1670
2013	J1720	Hydrocortisone sodium succ i	100 MG	\$	4.83	2013_J1720
2013	J1740	Ibandronate sodium injection	1 MG	\$	155.25	2013_J1740
2013	J1742	Ibutilide fumarate injection	1 MG	\$	78.93	2013_J1742
2013	J1743	Idursulfase injection	1 MG	\$	469.12	2013_J1743
2013	J1745	Infliximab injection	10 MG	\$	69.96	2013_J1745
2013	J1750	Inj iron dextran	50 MG	\$	12.13	2013_J1750
2013	J1756	Iron sucrose injection	1 MG	\$	0.27	2013_J1756
2013	J1786	Imuglucerase injection	10 UNITS	\$	42.01	2013_J1786
2013	J1790	Droperidol injection	5 MG	\$	2.14	2013_J1790
2013	J1800	Propranolol injection	1 MG	\$	2.04	2013_J1800
2013	J1815	Insulin injection	5 UNITS	\$	0.59	2013_J1815
2013	J1817	Insulin for insulin pump use	50 UNITS	\$	5.85	2013_J1817
2013	J1840	Kanamycin sulfate 500 MG inj	500 MG	\$	7.69	2013_J1840
2013	J1850	Kanamycin sulfate 75 MG inj	75 MG	\$	1.15	2013_J1850
2013	J1885	Ketorolac tromethamine inj	15 MG	\$	0.60	2013_J1885
2013	J1930	Lanreotide injection	1 MG	\$	37.16	2013_J1930
2013	J1931	Laronidase injection	0.1 MG	\$	28.31	2013_J1931
2013	J1940	Furosemide injection	20 MG	\$	3.61	2013_J1940
2013	J1945	Lepirudin	50 MG	\$	570.54	2013_J1945
2013	J1950	Leuprolide acetate /3.75 MG	3.75 MG	\$	747.92	2013_J1950
2013	J1953	Levetiracetam injection	10 MG	\$	0.15	2013_J1953
2013	J1955	Inj levocarnitine per 1 gm	1 GM	\$	8.73	2013_J1955
2013	J1956	Levofloxacin injection	250 MG	\$	2.56	2013_J1956
2013	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	17.28	2013_J1980
2013	J2001	Lidocaine injection	10 MG	\$	0.02	2013_J2001
2013	J2010	Lincomycin injection	300 MG	\$	7.77	2013_J2010
2013	J2020	Linezolid injection	200 MG	\$	39.71	2013_J2020
2013	J2060	Lorazepam injection	2 MG	\$	0.71	2013_J2060
2013	J2150	Mannitol injection	50 ML	\$	1.42	2013_J2150
2013	J2175	Meperidine hydrochl /100 MG	100 MG	\$	2.37	2013_J2175
2013	J2185	Meropenem	100 MG	\$	0.75	2013_J2185
2013	J2210	Methylergonovin maleate inj	0.2 MG	\$	3.94	2013_J2210
2013	J2248	Micafungin sodium injection	1 MG	\$	0.95	2013_J2248
2013	J2250	Inj midazolam hydrochloride	1 MG	\$	0.13	2013_J2250
2013	J2260	Inj milrinone lactate / 5 MG	5 MG	\$	2.58	2013_J2260
2013	J2270	Morphine sulfate injection	10 MG	\$	5.29	2013_J2270
2013	J2271	Morphine so4 injection 100mg	100 MG	\$	0.53	2013_J2271
2013	J2275	Morphine sulfate injection	10 MG	\$	3.78	2013_J2275
2013	J2278	Ziconotide injection	1 MCG	\$	6.60	2013_J2278
2013	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	3.39	2013_J2280
2013	J2300	Inj nalbuphine hydrochloride	10 MG	\$	1.27	2013_J2300
2013	J2310	Inj naloxone hydrochloride	1 MG	\$	13.66	2013_J2310
2013	J2315	Naltrexone, depot form	1 MG	\$	2.80	2013_J2315
2013	J2323	Natalizumab injection	1 MG	\$	12.99	2013_J2323
2013	J2325	Nesiritide injection	0.1 MG	\$	60.26	2013_J2325
2013	J2353	Octreotide injection, depot	1 MG	\$	136.14	2013_J2353
2013	J2354	Octreotide inj, non-depot	25 MCG	\$	1.42	2013_J2354
2013	J2355	Oprelvekin injection	5 MG	\$	276.60	2013_J2355
2013	J2357	Omalizumab injection	5 MG	\$	25.52	2013_J2357
2013	J2358	Olanzapine long-acting inj	1 MG	\$	2.75	2013_J2358
2013	J2360	Orphenadrine injection	60 MG	\$	5.23	2013_J2360
2013	J2370	Phenylephrine hcl injection	1 ML	\$	4.59	2013_J2370
2013	J2400	Chloroprocaine hcl injection	30 ML	\$	16.53	2013_J2400
2013	J2405	Ondansetron hcl injection	1 MG	\$	0.12	2013_J2405

2013	J2410	Oxymorphone hcl injection	1 MG	\$	2.35	2013_J2410
2013	J2425	Palifermin injection	50 MCG	\$	14.37	2013_J2425
2013	J2426	Paliperidone palmitate inj	1 MG	\$	7.43	2013_J2426
2013	J2430	Pamidronate disodium /30 MG	30 MG	\$	10.72	2013_J2430
2013	J2469	Palonosetron hcl	25 MCG	\$	19.38	2013_J2469
2013	J2501	Paricalcitol	1 MCG	\$	1.62	2013_J2501
2013	J2503	Pegaptanib sodium injection	0.3 MG	\$	1,026.70	2013_J2503
2013	J2504	Pegademase bovine, 25 iu	25 iu	\$	275.88	2013_J2504
2013	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	3,123.83	2013_J2505
2013	J2507	Pegloticase injection	1 MG	\$	508.89	2013_J2507
2013	J2510	Penicillin g procaine inj	600000 UNITS	\$	14.93	2013_J2510
2013	J2515	Pentobarbital sodium inj	50 MG	\$	32.16	2013_J2515
2013	J2540	Penicillin g potassium inj	600000 UNITS	\$	0.60	2013_J2540
2013	J2543	Piperacillin/tazobactam	1.125 GM	\$	1.70	2013_J2543
2013	J2545	Pentamidine non-comp unit	300 MG	\$	82.92	2013_J2545
2013	J2550	Promethazine hcl injection	50 MG	\$	1.57	2013_J2550
2013	J2560	Phenobarbital sodium inj	120 MG	\$	14.45	2013_J2560
2013	J2562	Plerixafor injection	1 MG	\$	297.65	2013_J2562
2013	J2590	Oxytocin injection	10 UNITS	\$	0.43	2013_J2590
2013	J2597	Inj desmopressin acetate	1 MCG	\$	5.63	2013_J2597
2013	J2675	Inj progesterone per 50 MG	50 MG	\$	1.49	2013_J2675
2013	J2680	Fluphenazine decanoate 25 MG	25 MG	\$	19.00	2013_J2680
2013	J2690	Procainamide hcl injection	1 GM	\$	18.86	2013_J2690
2013	J2700	Oxacillin sodium injeciton	250 MG	\$	1.72	2013_J2700
2013	J2720	Inj protamine sulfate/10 MG	10 MG	\$	0.86	2013_J2720
2013	J2724	Protein c concentrate	10 UNITS	\$	14.26	2013_J2724
2013	J2730	Pralidoxime chloride inj	1 GM	\$	88.93	2013_J2730
2013	J2760	Phentolaine mesylate inj	5 MG	\$	114.64	2013_J2760
2013	J2765	Metoclopramide hcl injection	10 MG	\$	0.53	2013_J2765
2013	J2770	Quinupristin/dalfopristin	500 MG	\$	194.32	2013_J2770
2013	J2778	Ranibizumab injection	0.1 mg	\$	397.26	2013_J2778
2013	J2780	Ranitidine hydrochloride inj	25 MG	\$	1.06	2013_J2780
2013	J2783	Rasburicase	0.5 MG	\$	211.35	2013_J2783
2013	J2785	Regadenoson injection	0.1 MG	\$	53.43	2013_J2785
2013	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	25.15	2013_J2788
2013	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	82.69	2013_J2790
2013	J2791	Rhophylac injection	100 IU	\$	4.78	2013_J2791
2013	J2792	Rho(D) immune globulin h, sd	100 IU	\$	18.67	2013_J2792
2013	J2794	Risperidone, long acting	0.5 MG	\$	5.78	2013_J2794
2013	J2795	Ropivacaine HCl injection	1 MG	\$	0.10	2013_J2795
2013	J2796	Romiplostim injection	10 MCG	\$	51.12	2013_J2796
2013	J2800	Methocarbamol injection	10 ML	\$	38.13	2013_J2800
2013	J2805	Sinacalide injection	5 MCG	\$	83.11	2013_J2805
2013	J2810	Inj theophylline per 40 MG	40 MG	\$	0.31	2013_J2810
2013	J2820	Sargramostim injection	50 MCG	\$	28.59	2013_J2820
2013	J2850	Inj secretin synthetic human	1 MCG	\$	27.49	2013_J2850
2013	J2916	Na ferric gluconate complex	12.5 MG	\$	2.90	2013_J2916
2013	J2920	Methylprednisolone injection	40 MG	\$	1.74	2013_J2920
2013	J2930	Methylprednisolone injection	125 MG	\$	2.58	2013_J2930
2013	J2993	Reteplase injection	18.1 MG	\$	2,301.91	2013_J2993
2013	J2997	Alteplase recombinant	1 MG	\$	56.01	2013_J2997
2013	J3000	Streptomycin injection	1 GM	\$	10.28	2013_J3000
2013	J3010	Fentanyl citrate injeciton	0.1 MG	\$	0.60	2013_J3010
2013	J3070	Pentazocine injection	30 MG	\$	31.75	2013_J3070
2013	J3095	Telavancin injection	10 MG	\$	2.65	2013_J3095
2013	J3101	Tenecteplase injection	1 MG	\$	78.99	2013_J3101
2013	J3105	Terbutaline sulfate inj	1 MG	\$	1.63	2013_J3105
2013	J3120	Testosterone enanthate inj	100 MG	\$	7.20	2013_J3120
2013	J3130	Testosterone enanthate inj	200 MG	\$	10.20	2013_J3130

2013	J3230	Chlorpromazine hcl injection	50 MG	\$	19.90	2013_J3230
2013	J3240	Thyrotropin injection	0.9 MG	\$	1,212.34	2013_J3240
2013	J3243	Tigecycline injection	1 MG	\$	1.77	2013_J3243
2013	J3246	Tirofiban HCl	0.25 MG	\$	8.95	2013_J3246
2013	J3250	Trimethobenzamide hcl inj	200 MG	\$	10.35	2013_J3250
2013	J3260	Tobramycin sulfate injection	80 MG	\$	2.29	2013_J3260
2013	J3262	Tocilizumab injection	1 MG	\$	3.70	2013_J3262
2013	J3285	Treprostinil injection	1 MG	\$	61.24	2013_J3285
2013	J3300	Triamcinolone A inj PRS-free	1 MG	\$	3.96	2013_J3300
2013	J3301	Triamcinolone acet inj NOS	10 MG	\$	1.74	2013_J3301
2013	J3302	Triamcinolone diacetate inj	5 MG	\$	0.28	2013_J3302
2013	J3303	Triamcinolone hexacetonl inj	5 MG	\$	2.56	2013_J3303
2013	J3315	Triptorelin pamoate	3.75 MG	\$	199.09	2013_J3315
2013	J3355	Urofollitropin, 75 iu	75 IU	\$	67.37	2013_J3355
2013	J3357	Ustekinumab injection	1 MG	\$	142.17	2013_J3357
2013	J3360	Diazepam injection	5 MG	\$	3.26	2013_J3360
2013	J3370	Vancomycin hcl injection	500 MG	\$	1.94	2013_J3370
2013	J3385	Velaglycerase alfa	100 UNITS	\$	348.35	2013_J3385
2013	J3396	Verteporfin injection	0.1 MG	\$	10.45	2013_J3396
2013	J3410	Hydroxyzine hcl injection	25 MG	\$	0.39	2013_J3410
2013	J3411	Thiamine hcl 100 mg	100 MG	\$	3.57	2013_J3411
2013	J3415	Pyridoxine hcl 100 mg	100 MG	\$	8.22	2013_J3415
2013	J3420	Vitamin b12 injection	1000 MCG	\$	0.81	2013_J3420
2013	J3430	Vitamin k phytionadione inj	1 MG	\$	0.77	2013_J3430
2013	J3465	Injection, voriconazole	10 MG	\$	4.49	2013_J3465
2013	J3470	Hyaluronidase injection	150 UNITS	\$	21.20	2013_J3470
2013	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.31	2013_J3473
2013	J3475	Inj magnesium sulfate	500 MG	\$	0.23	2013_J3475
2013	J3480	Inj potassium chloride	2 MEQ	\$	0.01	2013_J3480
2013	J3485	Zidovudine	10 MG	\$	1.50	2013_J3485
2013	J3486	Ziprasidone mesylate	10 MG	\$	9.54	2013_J3486
2013	J7030	Normal saline solution infus	1000 ML	\$	1.15	2013_J7030
2013	J7040	Normal saline solution infus	500 ML	\$	0.57	2013_J7040
2013	J7042	5% dextrose/normal saline	500 ML	\$	0.49	2013_J7042
2013	J7050	Normal saline solution infus	250 ML	\$	0.29	2013_J7050
2013	J7060	5% dextrose/water	500 ML	\$	1.02	2013_J7060
2013	J7070	D5w infusion	1000 CC	\$	2.02	2013_J7070
2013	J7100	Dextran 40 infusion	500 ML	\$	21.76	2013_J7100
2013	J7120	Ringers lactate infusion	1000 CC	\$	1.00	2013_J7120
2013	J7183	Wilate injection	1 I.U. VWF:RCO	\$	0.91	2013_J7183
2013	J7185	Xyntha inj	1 IU	\$	1.14	2013_J7185
2013	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	0.93	2013_J7186
2013	J7187	Humate-P, inj	1 IU	\$	0.90	2013_J7187
2013	J7189	Factor viia	1 MCG	\$	1.65	2013_J7189
2013	J7190	Factor viii	1 IU	\$	0.92	2013_J7190
2013	J7192	Factor viii recombinant NOS	1 IU	\$	1.13	2013_J7192
2013	J7193	Factor IX non-recombinant	1 IU	\$	0.95	2013_J7193
2013	J7194	Factor ix complex	1 IU	\$	1.10	2013_J7194
2013	J7195	Factor IX recombinant	1 IU	\$	1.38	2013_J7195
2013	J7197	Antithrombin iii injection	1 IU	\$	3.11	2013_J7197
2013	J7198	Anti-inhibitor	1 IU	\$	1.64	2013_J7198
2013	J7308	Aminolevulinic acid hcl top	354 MG	\$	172.60	2013_J7308
2013	J7309	Methyl aminolevulinate, top	1 GM	\$	83.69	2013_J7309
2013	J7310	Ganciclovir long act implant	4.5 MG	\$	16,960.00	2013_J7310
2013	J7311	Fluocinolone acetonide implt	0.59 MG	\$	19,345.00	2013_J7311
2013	J7312	Dexamethasone intra implant	0.1 MG	\$	195.91	2013_J7312
2013	J7321	Hyalgan/supartz inj per dose	per dose	\$	88.85	2013_J7321
2013	J7323	Euflexxa inj per dose	per dose	\$	153.41	2013_J7323
2013	J7324	Orthovisc inj per dose	per dose	\$	177.16	2013_J7324

2013	J7325	Synvisc or Synvisc-One	1 MG	\$	12.83	2013_J7325
2013	J7326	Gel-One	per dose	\$	613.28	2013_J7326
2013	J7330	Cultured chondrocytes implnt	1 EA	\$	30,549.35	2013_J7330
2013	J7335	Capsaicin 8% patch	10 SQ CM	\$	25.55	2013_J7335
2013	J7500	Azathioprine oral 50mg	50 MG	\$	0.12	2013_J7500
2013	J7501	Azathioprine parenteral	100 MG	\$	83.13	2013_J7501
2013	J7502	Cyclosporine oral 100 mg	100 MG	\$	3.18	2013_J7502
2013	J7504	Lymphocyte immune globulin	250 MG	\$	721.06	2013_J7504
2013	J7505	Monoclonal antibodies	5 MG	\$	1,156.08	2013_J7505
2013	J7506	Prednisone oral	5 MG	\$	0.04	2013_J7506
2013	J7507	Tacrolimus oral per 1 MG	1 MG	\$	1.72	2013_J7507
2013	J7509	Methylprednisolone oral	4 MG	\$	0.54	2013_J7509
2013	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.04	2013_J7510
2013	J7511	Antithymocyte globuln rabbit	25 MG	\$	569.53	2013_J7511
2013	J7513	Daclizumab, parenteral	25 MG	\$	526.34	2013_J7513
2013	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.89	2013_J7515
2013	J7516	Cyclosporin parenteral 250mg	250 MG	\$	31.54	2013_J7516
2013	J7517	Mycophenolate mofetil oral	250 MG	\$	1.03	2013_J7517
2013	J7518	Mycophenolic acid	180 MG	\$	3.81	2013_J7518
2013	J7520	Sirolimus, oral	1 MG	\$	13.28	2013_J7520
2013	J7525	Tacrolimus injection	5 MG	\$	136.89	2013_J7525
2013	J7527	Oral everolimus	0.25 MG	\$	6.48	2013_J7527
2013	J7605	Arformoterol non-comp unit	15 mcg	\$	5.55	2013_J7605
2013	J7606	Formoterol fumarate, inh	20 MCG	\$	6.30	2013_J7606
2013	J7608	Acetylcysteine non-comp unit	1 GM	\$	1.96	2013_J7608
2013	J7611	Albuterol non-comp con	1 MG	\$	0.10	2013_J7611
2013	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.23	2013_J7612
2013	J7613	Albuterol non-comp unit	1 MG	\$	0.05	2013_J7613
2013	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.12	2013_J7614
2013	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.18	2013_J7620
2013	J7626	Budesonide non-comp unit	0.5 MG	\$	5.95	2013_J7626
2013	J7631	Cromolyn sodium noncomp unit	10 MG	\$	0.50	2013_J7631
2013	J7639	Dornase alfa non-comp unit	1 MG	\$	32.78	2013_J7639
2013	J7644	Ipratropium bromide non-comp	1 MG	\$	0.24	2013_J7644
2013	J7665	Mannitol for inhaler	5 MG	\$	0.67	2013_J7665
2013	J7669	Metaproterenol non-comp unit	10 MG	\$	0.43	2013_J7669
2013	J7674	Methacholine chloride, neb	1 MG	\$	0.49	2013_J7674
2013	J7682	Tobramycin non-comp unit	300 MG	\$	120.00	2013_J7682
2013	J7686	Treprostinil, non-comp unit	1.74 MG	\$	460.45	2013_J7686
2013	J8501	Oral aprepitant	5 MG	\$	6.69	2013_J8501
2013	J8510	Oral busulfan	2 MG	\$	11.03	2013_J8510
2013	J8520	Capecitabine, oral, 150 mg	150 MG	\$	9.69	2013_J8520
2013	J8521	Capecitabine, oral, 500 mg	500 MG	\$	32.19	2013_J8521
2013	J8530	Cyclophosphamide oral 25 MG	25 MG	\$	0.98	2013_J8530
2013	J8540	Oral dexamethasone	0.25 MG	\$	0.18	2013_J8540
2013	J8560	Etoposide oral 50 MG	50 MG	\$	55.68	2013_J8560
2013	J8562	Oral fludarabine phosphate	10 MG	\$	81.77	2013_J8562
2013	J8600	Melphalan oral 2 MG	2 MG	\$	8.73	2013_J8600
2013	J8610	Methotrexate oral 2.5 MG	2.5 MG	\$	1.08	2013_J8610
2013	J8700	Temozolomide	5 MG	\$	11.56	2013_J8700
2013	J8705	Topotecan oral	0.25 mg	\$	89.13	2013_J8705
2013	J9000	Doxorubicin hcl injection	10 MG	\$	3.47	2013_J9000
2013	J9010	Alemtuzumab injection	10 MG	\$	623.63	2013_J9010
2013	J9017	Arsenic trioxide injection	1 MG	\$	49.40	2013_J9017
2013	J9019	Erwinaze injection	1,000 IU	\$	344.38	2013_J9019
2013	J9020	Asparaginase, NOS	10000 UNITS	\$	64.56	2013_J9020
2013	J9025	Azacitidine injection	1 MG	\$	5.74	2013_J9025
2013	J9027	Clofarabine injection	1 MG	\$	129.53	2013_J9027
2013	J9031	Bcg live intravesical vac	1 EA	\$	120.91	2013_J9031

2013	J9033	Bendamustine injection	1 MG	\$	21.06	2013_J9033
2013	J9035	Bevacizumab injection	10 MG	\$	64.62	2013_J9035
2013	J9040	Bleomycin sulfate injection	15 UNITS	\$	21.04	2013_J9040
2013	J9041	Bortezomib injection	0.1 MG	\$	44.89	2013_J9041
2013	J9042	Brentuximab vedotin inj	1 MG	\$	102.65	2013_J9042
2013	J9043	Cabazitaxel injection	1 MG	\$	139.11	2013_J9043
2013	J9045	Carboplatin injection	50 MG	\$	3.04	2013_J9045
2013	J9050	Carmustine injection	100 MG	\$	870.93	2013_J9050
2013	J9055	Cetuximab injection	10 MG	\$	52.56	2013_J9055
2013	J9060	Cisplatin 10 MG injection	10 MG	\$	2.11	2013_J9060
2013	J9065	Inj cladribine per 1 MG	1 MG	\$	23.99	2013_J9065
2013	J9070	Cyclophosphamide 100 MG inj	100 MG	\$	39.67	2013_J9070
2013	J9098	Cytarabine liposome inj	10 MG	\$	544.54	2013_J9098
2013	J9100	Cytarabine hcl 100 MG inj	100 MG	\$	0.97	2013_J9100
2013	J9120	Dactinomycin injection	0.5 MG	\$	645.75	2013_J9120
2013	J9130	Dacarbazine 100 mg inj	100 MG	\$	3.99	2013_J9130
2013	J9150	Daunorubicin injection	10 MG	\$	30.02	2013_J9150
2013	J9155	Degarelix injection	1 MG	\$	3.72	2013_J9155
2013	J9160	Denileukin diftotox inj	300 MCG	\$	1,646.18	2013_J9160
2013	J9171	Docetaxel injection	1 MG	\$	4.91	2013_J9171
2013	J9175	Elliotts b solution per ml	1 ML	\$	4.07	2013_J9175
2013	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.18	2013_J9178
2013	J9179	Eribulin mesylate injection	0.1 MG	\$	98.43	2013_J9179
2013	J9181	Etoposide injection	10 MG	\$	0.71	2013_J9181
2013	J9185	Fludarabine phosphate inj	50 MG	\$	84.17	2013_J9185
2013	J9190	Fluorouracil injection	500 MG	\$	2.00	2013_J9190
2013	J9200	Floxuridine injection	500 MG	\$	67.08	2013_J9200
2013	J9201	Gemcitabine hcl injection	200 MG	\$	7.96	2013_J9201
2013	J9202	Goserelin acetate implant	3.6 MG	\$	194.19	2013_J9202
2013	J9206	Irinotecan injection	20 MG	\$	5.20	2013_J9206
2013	J9207	Ixabepilone injection	1 MG	\$	68.65	2013_J9207
2013	J9208	Ifosfamide injection	1 GM	\$	31.04	2013_J9208
2013	J9209	Mesna injection	200 MG	\$	2.86	2013_J9209
2013	J9211	Idarubicin hcl injection	5 MG	\$	35.31	2013_J9211
2013	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	20.70	2013_J9214
2013	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	202.84	2013_J9217
2013	J9218	Leuprolide acetate injection	1 MG	\$	10.25	2013_J9218
2013	J9225	Vantas implant	50 MG	\$	2,966.80	2013_J9225
2013	J9226	Supprelin LA implant	50 MG	\$	16,660.71	2013_J9226
2013	J9228	Ipilimumab injection	1 MG	\$	128.96	2013_J9228
2013	J9230	Mechlorethamine hcl inj	10 MG	\$	154.70	2013_J9230
2013	J9245	Inj melphalan hydrochl 50 MG	50 MG	\$	1,293.55	2013_J9245
2013	J9250	Methotrexate sodium inj	5 MG	\$	0.26	2013_J9250
2013	J9260	Methotrexate sodium inj	50 MG	\$	2.50	2013_J9260
2013	J9261	Nelarabine injection	50 MG	\$	130.63	2013_J9261
2013	J9263	Oxaliplatin	0.5 MG	\$	0.54	2013_J9263
2013	J9264	Paclitaxel protein bound	1 MG	\$	9.55	2013_J9264
2013	J9265	Paclitaxel injection	30 MG	\$	4.35	2013_J9265
2013	J9266	Pegaspargase injection	1 EA	\$	6,007.38	2013_J9266
2013	J9268	Pentostatin injection	10 MG	\$	1,419.70	2013_J9268
2013	J9280	Mitomycin injection	5 MG	\$	24.54	2013_J9280
2013	J9293	Mitoxantrone hydrochl / 5 MG	5 MG	\$	34.62	2013_J9293
2013	J9300	Gemtuzumab ozogamicin inj	5 MG	\$	2,742.59	2013_J9300
2013	J9302	Ofatumumab injection	10 MG	\$	46.53	2013_J9302
2013	J9303	Panitumumab injection	10 MG	\$	91.38	2013_J9303
2013	J9305	Pemetrexed injection	10 MG	\$	59.49	2013_J9305
2013	J9307	Pralatrexate injection	1 MG	\$	182.61	2013_J9307
2013	J9310	Rituximab injection	100 MG	\$	678.70	2013_J9310
2013	J9315	Romidepsin injection	1 MG	\$	251.94	2013_J9315

2013	J9320	Streptozocin injection	1 GM	\$	274.35	2013_J9320
2013	J9328	Temozolomide injection	1 MG	\$	5.03	2013_J9328
2013	J9330	Temsirolimus injection	1 MG	\$	55.97	2013_J9330
2013	J9340	Thiotepa injection	15 MG	\$	630.70	2013_J9340
2013	J9351	Topotecan injection	0.1 MG	\$	2.20	2013_J9351
2013	J9355	Trastuzumab injection	10 MG	\$	78.72	2013_J9355
2013	J9357	Valrubicin injection	200 MG	\$	1,052.98	2013_J9357
2013	J9360	Vinblastine sulfate inj	1 MG	\$	1.66	2013_J9360
2013	J9370	Vincristine sulfate 1 MG inj	1 MG	\$	5.77	2013_J9370
2013	J9390	Vinorelbine tartrate inj	10 MG	\$	8.81	2013_J9390
2013	J9395	Injection, Fulvestrant	25 MG	\$	89.68	2013_J9395
2013	P9041	Albumin (human),5%, 50ml	50 ML	\$	9.55	2013_P9041
2013	P9043	Plasma protein fract,5%,50ml	50 ML	\$	8.82	2013_P9043
2013	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	47.73	2013_P9045
2013	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	19.68	2013_P9046
2013	P9047	Albumin (human), 25%, 50ml	50 ML	\$	49.20	2013_P9047
2013	P9048	Plasmaprotein fract,5%,250ml	250 ML	\$	44.08	2013_P9048
2013	Q0138	Ferumoxitol, non-esrd	1 MG	\$	0.68	2013_Q0138
2013	Q0139	Ferumoxitol, esrd use	1 MG	\$	0.68	2013_Q0139
2013	Q0162	Ondansetron oral	1 MG	\$	0.04	2013_Q0162
2013	Q0163	Diphenhydramine HCl 50mg	50 MG	\$	0.03	2013_Q0163
2013	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.03	2013_Q0164
2013	Q0165	Prochlorperazine maleate10mg	10 MG	\$	0.04	2013_Q0165
2013	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	2.54	2013_Q0166
2013	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	3.35	2013_Q0167
2013	Q0168	Dronabinol 5mg oral	5 MG	\$	6.82	2013_Q0168
2013	Q0169	Promethazine HCl 12.5mg oral	12.5 MG	\$	0.06	2013_Q0169
2013	Q0170	Promethazine HCl 25 mg oral	25 MG	\$	0.09	2013_Q0170
2013	Q0180	Dolasetron mesylate oral	100 MG	\$	69.47	2013_Q0180
2013	Q2009	Fosphenytoin inj PE	50 MG	\$	1.17	2013_Q2009
2013	Q2017	Teniposide, 50 mg	50 MG	\$	332.62	2013_Q2017
2013	Q2035	Afluria vacc, 3 yrs & >, im	0.5 ml	\$	11.54	2013_Q2035
2013	Q2036	Flulaval vacc, 3 yrs & >, im	0.5 ML	\$	8.58	2013_Q2036
2013	Q2037	Fluvirin vacc, 3 yrs & >, im	0.5 ML	\$	14.96	2013_Q2037
2013	Q2038	Fluzone vacc, 3 yrs & >, im	0.5 ML	\$	12.04	2013_Q2038
2013	Q2043	Sipuleucel-T auto CD54+	Per infusion (minimum 50 million cells)	\$	32,709.98	2013_Q2043
2013	Q2049	Imported Lipodox inj	10 MG	\$	498.26	2013_Q2049
2013	Q2050	Doxorubicin inj 10mg	10 MG	\$	545.48	2013_Q2050
2013	Q2051	Zoledronic acid 1mg	1 MG	\$	150.33	2013_Q2051
2013	Q3025	IM inj interferon beta 1-a	11 MCG	\$	307.14	2013_Q3025
2013	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	77.38	2013_Q4074
2013	Q4081	Epoetin alfa, 100 units ESRD	100 UNITS	\$	1.12	2013_Q4081
2013	Q4101	Apligraf skin sub	1 SQ CM	\$	41.06	2013_Q4101
2013	Q4102	Oasis wound matrix skin sub	1 SQ CM	\$	9.51	2013_Q4102
2013	Q4103	Oasis burn matrix skin sub	1 SQ CM	\$	9.51	2013_Q4103
2013	Q4104	Integra BMWD skin sub	1 SQ CM	\$	25.75	2013_Q4104
2013	Q4105	Integra DRT skin sub	1 SQ CM	\$	13.14	2013_Q4105
2013	Q4106	Dermagraft skin sub	1 SQ CM	\$	44.43	2013_Q4106
2013	Q4107	Graftjacket skin sub	1 SQ CM	\$	98.50	2013_Q4107
2013	Q4108	Integra matrix skin sub	1 SQ CM	\$	28.46	2013_Q4108
2013	Q4110	Primatrix skin sub	1 SQ CM	\$	38.59	2013_Q4110
2013	Q4111	Gammagraft skin sub	1 SQ CM	\$	6.91	2013_Q4111
2013	Q4112	Cymetra allograft	1 CC	\$	392.70	2013_Q4112
2013	Q4113	Graftjacket express allograf	1 CC	\$	392.70	2013_Q4113
2013	Q4114	Integra flowable wound matri	1 CC	\$	1,235.31	2013_Q4114
2013	Q4115	Alloskin	1 SQ CM	\$	12.68	2013_Q4115
2013	Q4116	Alloderm skin sub	1 SQ CM	\$	32.89	2013_Q4116
2013	Q4121	Theraskin	1 SQ CM	\$	23.21	2013_Q4121
2013	Q4123	Alloskin RT	1 SQ CM	\$	15.45	2013_Q4123

2013	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	36.65	2013_Q9956
2013	Q9957	Inj perflutren lip micros,ml	1 ML	\$	54.98	2013_Q9957
2013	Q9958	HOcm <=149 mg/ml iodine, 1ml	1 ML	\$	0.09	2013_Q9958
2013	Q9960	HOcm 200-249mg/ml iodine,1ml	1 ML	\$	0.17	2013_Q9960
2013	Q9961	HOcm 250-299mg/ml iodine,1ml	1 ML	\$	0.18	2013_Q9961
2013	Q9963	HOcm 350-399mg/ml iodine,1ml	1 ML	\$	0.18	2013_Q9963
2013	Q9965	LOcm 100-199mg/ml iodine,1ml	1 ML	\$	0.97	2013_Q9965
2013	Q9966	LOcm 200-299mg/ml iodine,1ml	1 ML	\$	0.25	2013_Q9966
2013	Q9967	LOcm 300-399mg/ml iodine,1ml	1 ML	\$	0.16	2013_Q9967
2012	90371	Hep b ig, im	1 ML	\$	97.15	2012_90371
2012	90375	Rabies ig, im/sc	150 IU	\$	207.35	2012_90375
2012	90376	Rabies ig, heat treated	150 IU	\$	194.67	2012_90376
2012	90385	Rh ig, minidose, im	50 MCG	\$	25.73	2012_90385
2012	90585	Bcg vaccine, percut	50 MG	\$	116.14	2012_90585
2012	90586	Bcg vaccine, intravesical	1 EACH	\$	116.81	2012_90586
2012	90632	Hep a vaccine, adult im	1 ML	\$	49.85	2012_90632
2012	90654	Flu vaccine, intradermal, no preserv	0.1 ML	\$	18.98	2012_90654
2012	90655	Flu vaccine no preserv 6-35m, im	0.25 ML	\$	16.46	2012_90655
2012	90656	Flu vaccine no preserv 3 yo & >, im	0.50 ML	\$	12.40	2012_90656
2012	90657	Flu vaccine, 6-35 mo, im	0.25 ML	\$	6.02	2012_90657
2012	90660	Flu vaccine, nasal	0.2 ML	\$	23.46	2012_90660
2012	90662	Flu vacc prsv free inc antig	0.5 ML	\$	30.92	2012_90662
2012	90669	Pneumococcal vacc, 7 val im	0.5 ML	\$	95.48	2012_90669
2012	90670	Pneumococcal vacc, 13 val im	0.5 ML	\$	137.03	2012_90670
2012	90675	Rabies vaccine, im	1 ML	\$	208.73	2012_90675
2012	90691	Typhoid vaccine, im	0.5 ML	\$	63.58	2012_90691
2012	90703	Tetanus vaccine, im	0.5 ML	\$	34.67	2012_90703
2012	90714	Td vaccine no prsv >/= 7 yo, im	0.5 ML	\$	19.31	2012_90714
2012	90715	Tdap => 7 yo, im	0.5 ML	\$	34.66	2012_90715
2012	90717	Yellow fever vaccine, sc	0.5 ML	\$	71.49	2012_90717
2012	90718	Td vaccine >/= 7 yo, im	0.5 ML	\$	20.35	2012_90718
2012	90732	Pneumococcal vaccine	0.5 ML	\$	65.77	2012_90732
2012	90733	Meningococcal vaccine, sc	0.5 ML	\$	106.49	2012_90733
2012	90735	Encephalitis vaccine, sc	1 ML	\$	102.08	2012_90735
2012	90740	Hepb vacc, ill pat 3 dose im	40 MCG	\$	119.42	2012_90740
2012	90743	Hep b vacc, adol, 2 dose, im	1 DOSE	\$	24.22	2012_90743
2012	90744	Hepb vacc ped/adol 3 dose im	1 DOSE	\$	24.22	2012_90744
2012	90746	Hep b vaccine, adult, im	20 MCG	\$	59.71	2012_90746
2012	90747	Hepb vacc, ill pat 4 dose im	40 MCG	\$	119.42	2012_90747
2012	A9576	Inj prohance multipack	1 ML	\$	1.95	2012_A9576
2012	A9577	Inj multihance	1 ML	\$	2.33	2012_A9577
2012	A9578	Inj multihance multipack	1 ML	\$	1.96	2012_A9578
2012	A9579	Gad-base MR contrast NOS,1ml	1 ML	\$	2.09	2012_A9579
2012	A9581	Gadoxetate disodium inj	1 ML	\$	13.45	2012_A9581
2012	A9583	Gadofosveset trisodium inj	1 ML	\$	11.90	2012_A9583
2012	A9585	Gadobutrol injection	0.1 ML	\$	0.51	2012_A9585
2012	J0129	Abatacept injection	10 MG	\$	22.19	2012_J0129
2012	J0130	Abciximab injection	10 MG	\$	575.03	2012_J0130
2012	J0132	Acetylcysteine injection	100 MG	\$	3.04	2012_J0132
2012	J0133	Acyclovir injection	5 MG	\$	0.05	2012_J0133
2012	J0135	Adalimumab injection	20 MG	\$	456.38	2012_J0135
2012	J0150	Injection adenosine 6 MG	6 MG	\$	5.95	2012_J0150
2012	J0152	Adenosine injection	30 MG	\$	109.40	2012_J0152
2012	J0171	Adrenalin epinephrine inject	0.1 MG	\$	0.05	2012_J0171
2012	J0180	Agalsidase beta injection	1 MG	\$	140.30	2012_J0180
2012	J0205	Alglucerase injection	10 UNITS	\$	41.99	2012_J0205
2012	J0207	Amifostine	500 MG	\$	310.18	2012_J0207
2012	J0210	Methyldopate hcl injection	250 MG	\$	42.40	2012_J0210
2012	J0215	Alefacept	0.5 MG	\$	41.64	2012_J0215

2012	J0220	Alglucosidase alfa injection	10 MG	\$	204.42	2012_J0220
2012	J0221	Lumizyme injection	10 MG	\$	153.61	2012_J0221
2012	J0256	Alpha 1 proteinase inhibitor	10 MG	\$	3.97	2012_J0256
2012	J0257	Glassia injection	10 MG	\$	3.92	2012_J0257
2012	J0278	Amikacin sulfate injection	100 MG	\$	0.80	2012_J0278
2012	J0280	Aminophyllin 250 MG inj	250 MG	\$	0.60	2012_J0280
2012	J0285	Amphotericin B	50 MG	\$	12.25	2012_J0285
2012	J0287	Amphotericin b lipid complex	10 MG	\$	10.99	2012_J0287
2012	J0288	Ampho b cholesteryl sulfate	10 MG	\$	14.00	2012_J0288
2012	J0289	Amphotericin b liposome inj	10 MG	\$	14.83	2012_J0289
2012	J0290	Ampicillin 500 MG inj	500 MG	\$	1.62	2012_J0290
2012	J0295	Ampicillin sodium per 1.5 gm	1.5 GM	\$	2.24	2012_J0295
2012	J0348	Anidulafungin injection	1 MG	\$	1.25	2012_J0348
2012	J0360	Hydralazine hcl injection	20 MG	\$	4.04	2012_J0360
2012	J0364	Apomorphine hydrochloride	1 MG	\$	32.76	2012_J0364
2012	J0365	Aprotonin, 10,000 kiu	10000 KIU	\$	2.65	2012_J0365
2012	J0400	Aripiprazole injection	0.25 MG	\$	0.47	2012_J0400
2012	J0456	Azithromycin	500 MG	\$	4.66	2012_J0456
2012	J0461	Atropine sulfate injection	0.01 MG	\$	0.03	2012_J0461
2012	J0470	Dimecaprol injection	100 MG	\$	28.34	2012_J0470
2012	J0475	Baclofen 10 MG injection	10 MG	\$	179.99	2012_J0475
2012	J0476	Baclofen intrathecal trial	50 MCG	\$	76.47	2012_J0476
2012	J0480	Basiliximab	20 MG	\$	2,324.18	2012_J0480
2012	J0490	Belimumab injection	10 MG	\$	38.32	2012_J0490
2012	J0500	Dicyclomine injection	20 MG	\$	32.00	2012_J0500
2012	J0515	Inj bantzropine mesylate	1 MG	\$	26.18	2012_J0515
2012	J0558	PenG benzathine/procaine inj	100,000 UNITS	\$	3.48	2012_J0558
2012	J0561	Penicillin g benzathine inj	100,000 UNITS	\$	4.39	2012_J0561
2012	J0583	Bivalirudin	1 MG	\$	2.98	2012_J0583
2012	J0585	Injection,onabotulinumtoxinA	1 UNIT	\$	5.47	2012_J0585
2012	J0586	AbobotulinumtoxinA	5 Unit	\$	6.95	2012_J0586
2012	J0587	Inj, rimabotulinumtoxinB	100 UNITS	\$	10.89	2012_J0587
2012	J0588	Incobotulinumtoxin A	1 UNIT	\$	4.46	2012_J0588
2012	J0592	Buprenorphine hydrochloride	0.1 MG	\$	0.99	2012_J0592
2012	J0594	Busulfan injection	1 MG	\$	21.90	2012_J0594
2012	J0595	Butorphanol tartrate 1 mg	1 MG	\$	0.95	2012_J0595
2012	J0597	C-1 esterase, berinert	10 UNITS	\$	30.23	2012_J0597
2012	J0598	C-1 esterase, cinryze	10 UNITS	\$	45.70	2012_J0598
2012	J0600	Edetate calcium disodium inj	1000 MG	\$	201.40	2012_J0600
2012	J0610	Calcium gluconate injection	10 ML	\$	0.64	2012_J0610
2012	J0630	Calcitonin salmon injection	400 UNITS	\$	62.74	2012_J0630
2012	J0636	Inj calcitriol per 0.1 mcg	0.1 MCG	\$	0.40	2012_J0636
2012	J0637	Caspofungin acetate	5 MG	\$	12.85	2012_J0637
2012	J0638	Canakinumab injection	1 MG	\$	89.41	2012_J0638
2012	J0640	Leucovorin calcium injection	50 MG	\$	2.74	2012_J0640
2012	J0641	Levoleucovorin injection	0.5 MG	\$	1.91	2012_J0641
2012	J0670	Inj mepivacaine HCL/10 ml	10 ML	\$	1.21	2012_J0670
2012	J0690	Cefazolin sodium injection	500 MG	\$	0.74	2012_J0690
2012	J0692	Cefepime HCl for injection	500 MG	\$	2.32	2012_J0692
2012	J0694	Cefoxitin sodium injection	1 GM	\$	5.65	2012_J0694
2012	J0696	Ceftriaxone sodium injection	250 MG	\$	0.72	2012_J0696
2012	J0697	Sterile cefuroxime injection	750 MG	\$	3.80	2012_J0697
2012	J0698	Cefotaxime sodium injection	1 GM	\$	2.06	2012_J0698
2012	J0702	Betamethasone acet&sod phosp	3 MG & 3 MG	\$	5.58	2012_J0702
2012	J0706	Caffeine citrate injection	5 MG	\$	0.48	2012_J0706
2012	J0712	Ceftaroline fosamil inj	10 MG	\$	0.78	2012_J0712
2012	J0713	Inj ceftazidime per 500 mg	500 MG	\$	2.62	2012_J0713
2012	J0718	Certolizumab pegol inj	1 MG	\$	4.91	2012_J0718
2012	J0720	Chloramphenicol sodium injec	1 GM	\$	20.61	2012_J0720

2012	J0725	Chorionic gonadotropin/1000u	1000 UNITS	\$	12.76	2012_J0725
2012	J0735	Clonidine hydrochloride	1 MG	\$	22.87	2012_J0735
2012	J0740	Cidofovir injection	375 MG	\$	757.02	2012_J0740
2012	J0743	Cilastatin sodium injection	250 MG	\$	8.11	2012_J0743
2012	J0744	Ciprofloxacin iv	200 MG	\$	1.00	2012_J0744
2012	J0745	Inj codeine phosphate /30 MG	30 MG	\$	1.35	2012_J0745
2012	J0760	Colchicine injection	1 MG	\$	6.57	2012_J0760
2012	J0770	Colistimethate sodium inj	150 MG	\$	11.58	2012_J0770
2012	J0775	Collagenase, clost hist inj	0.01 MG	\$	37.51	2012_J0775
2012	J0780	Prochlorperazine injection	10 MG	\$	3.64	2012_J0780
2012	J0795	Corticotropin ovine triflural	1 MCG	\$	5.82	2012_J0795
2012	J0800	Corticotropin injection	40 UNITS	\$	2,948.92	2012_J0800
2012	J0834	Cosyntropin cortrosyn inj	0.25 MG	\$	67.37	2012_J0834
2012	J0840	Crotalidae poly immune fab	UP TO 1 GM	\$	2,216.80	2012_J0840
2012	J0850	Cytomegalovirus imm IV /vial	PER VIAL	\$	1,013.87	2012_J0850
2012	J0878	Daptomycin injection	1 MG	\$	0.54	2012_J0878
2012	J0881	Darbepoetin alfa, non-esrd	1 MCG	\$	3.32	2012_J0881
2012	J0882	Darbepoetin alfa, esrd use	1 MCG	\$	3.32	2012_J0882
2012	J0885	Epoetin alfa, non-esrd	1000 UNITS	\$	9.87	2012_J0885
2012	J0886	Epoetin alfa 1000 units ESRD	1000 UNITS	\$	9.87	2012_J0886
2012	J0894	Decitabine injection	1 MG	\$	33.40	2012_J0894
2012	J0895	Deferoxamine mesylate inj	500 MG	\$	8.50	2012_J0895
2012	J0897	Denosumab injection	1 MG	\$	14.32	2012_J0897
2012	J1000	Depo-estradiol cypionate inj	5 MG	\$	6.83	2012_J1000
2012	J1020	Methylprednisolone 20 MG inj	20 MG	\$	3.06	2012_J1020
2012	J1030	Methylprednisolone 40 MG inj	40 MG	\$	4.03	2012_J1030
2012	J1040	Methylprednisolone 80 MG inj	80 MG	\$	7.04	2012_J1040
2012	J1051	Medroxyprogesterone inj	50 MG	\$	9.31	2012_J1051
2012	J1070	Testosterone cypionat 100 MG	100 MG	\$	5.29	2012_J1070
2012	J1080	Testosterone cypionat 200 MG	200 MG	\$	5.66	2012_J1080
2012	J1100	Dexamethasone sodium phos	1 MG	\$	0.11	2012_J1100
2012	J1110	Inj dihydroergotamine mesylt	1 MG	\$	33.41	2012_J1110
2012	J1120	Acetazolamid sodium injectio	500 MG	\$	28.82	2012_J1120
2012	J1160	Digoxin injection	0.5 MG	\$	4.63	2012_J1160
2012	J1162	Digoxin immune fab (ovine)	PER VIAL	\$	899.63	2012_J1162
2012	J1165	Phenytoin sodium injection	50 MG	\$	0.36	2012_J1165
2012	J1170	Hydromorphone injection	4 MG	\$	1.66	2012_J1170
2012	J1190	Dexrazoxane HCl injection	250 MG	\$	159.00	2012_J1190
2012	J1200	Diphenhydramine hcl injectio	50 MG	\$	0.90	2012_J1200
2012	J1205	Chlorothiazide sodium inj	500 MG	\$	259.14	2012_J1205
2012	J1212	Dimethyl sulfoxide 50% 50 ML	50 ML	\$	87.15	2012_J1212
2012	J1230	Methadone injection	10 MG	\$	7.02	2012_J1230
2012	J1240	Dimenhydrinate injection	50 MG	\$	4.33	2012_J1240
2012	J1245	Dipyridamole injection	10 MG	\$	0.81	2012_J1245
2012	J1250	Inj dobutamine HCL/250 mg	250 MG	\$	6.28	2012_J1250
2012	J1260	Dolasetron mesylate	10 MG	\$	4.06	2012_J1260
2012	J1265	Dopamine injection	40 MG	\$	0.40	2012_J1265
2012	J1267	Doripenem injection	10 MG	\$	0.45	2012_J1267
2012	J1270	Injection, doxercalciferol	1 MCG	\$	0.94	2012_J1270
2012	J1290	Ecallantide injection	1 MG	\$	318.22	2012_J1290
2012	J1300	Eculizumab injection	10 MCG	\$	195.46	2012_J1300
2012	J1325	Epoprostenol injection	0.5 MG	\$	14.23	2012_J1325
2012	J1327	Eptifibatide injection	5 MG	\$	24.64	2012_J1327
2012	J1335	Ertapenem injection	500 MG	\$	30.40	2012_J1335
2012	J1364	Erythro lactobionate /500 MG	500 MG	\$	11.59	2012_J1364
2012	J1380	Estradiol valerate 10 MG inj	10 MG	\$	9.42	2012_J1380
2012	J1410	Inj estrogen conjugate 25 MG	25 MG	\$	125.45	2012_J1410
2012	J1430	Ethanolamine oleate 100 mg	100 MG	\$	299.94	2012_J1430
2012	J1438	Etanercept injection	25 MG	\$	231.10	2012_J1438

2012	J1440	Filgrastim 300 mcg injection	300 MCG	\$	268.91	2012_J1440
2012	J1441	Filgrastim 480 mcg injection	480 MCG	\$	426.87	2012_J1441
2012	J1450	Fluconazole	200 MG	\$	5.07	2012_J1450
2012	J1451	Fomepizole, 15 mg	15 MG	\$	6.51	2012_J1451
2012	J1453	Fosaprepitant injection	1 MG	\$	1.72	2012_J1453
2012	J1455	Foscarnet sodium injection	1000 MG	\$	3.50	2012_J1455
2012	J1457	Gallium nitrate injection	1 MG	\$	2.08	2012_J1457
2012	J1458	Galsulfase injection	1 MG	\$	354.35	2012_J1458
2012	J1459	Inj IVIG privigen 500 mg	500 MG	\$	35.14	2012_J1459
2012	J1460	Gamma globulin 1 CC inj	1 CC	\$	23.34	2012_J1460
2012	J1557	Gammaplex injection	500 MG	\$	37.25	2012_J1557
2012	J1559	Hizentra injection	100 MG	\$	7.29	2012_J1559
2012	J1560	Gamma globulin > 10 CC inj	10 CC	\$	233.37	2012_J1560
2012	J1561	Gamunex, Gamunex-C, Gammaked	500 MG	\$	38.28	2012_J1561
2012	J1566	Immune globulin, powder	500 MG	\$	32.21	2012_J1566
2012	J1568	Octagam injection	500 MG	\$	33.21	2012_J1568
2012	J1569	Gammagard liquid injection	500 MG	\$	37.62	2012_J1569
2012	J1570	Ganciclovir sodium injection	500 MG	\$	73.04	2012_J1570
2012	J1571	Hepagam b im injection	0.5 ML	\$	52.14	2012_J1571
2012	J1572	Flebogamma injection	500 MG	\$	34.43	2012_J1572
2012	J1573	Hepagam b intravenous, inj	0.5 ML	\$	52.14	2012_J1573
2012	J1580	Garamycin gentamicin inj	80 MG	\$	1.29	2012_J1580
2012	J1600	Gold sodium thiomaleate inj	50 MG	\$	25.04	2012_J1600
2012	J1610	Glucagon hydrochloride/1 MG	1 MG	\$	111.23	2012_J1610
2012	J1626	Granisetron hcl injection	100 MCG	\$	0.44	2012_J1626
2012	J1630	Haloperidol injection	5 MG	\$	2.22	2012_J1630
2012	J1631	Haloperidol decanoate inj	50 MG	\$	19.51	2012_J1631
2012	J1640	Hemin, 1 mg	1 MG	\$	13.26	2012_J1640
2012	J1642	Inj heparin sodium per 10 u	10 UNITS	\$	0.17	2012_J1642
2012	J1644	Inj heparin sodium per 1000u	1000 UNITS	\$	0.21	2012_J1644
2012	J1645	Dalteparin sodium	2500 IU	\$	11.04	2012_J1645
2012	J1650	Inj enoxaparin sodium	10 MG	\$	4.20	2012_J1650
2012	J1652	Fondaparinux sodium	0.5 MG	\$	4.67	2012_J1652
2012	J1670	Tetanus immune globulin inj	250 UNITS	\$	276.27	2012_J1670
2012	J1720	Hydrocortisone sodium succ i	100 MG	\$	4.28	2012_J1720
2012	J1740	Ibandronate sodium injection	1 MG	\$	151.64	2012_J1740
2012	J1742	Ibutilide fumarate injection	1 MG	\$	139.24	2012_J1742
2012	J1743	Idursulfase injection	1 MG	\$	455.03	2012_J1743
2012	J1745	Infliximab injection	10 MG	\$	65.18	2012_J1745
2012	J1750	Inj iron dextran	50 MG	\$	12.00	2012_J1750
2012	J1756	Iron sucrose injection	1 MG	\$	0.29	2012_J1756
2012	J1786	Imuglucerase injection	10 UNITS	\$	41.74	2012_J1786
2012	J1790	Droperidol injection	5 MG	\$	3.32	2012_J1790
2012	J1800	Propranolol injection	1 MG	\$	3.43	2012_J1800
2012	J1815	Insulin injection	5 UNITS	\$	0.51	2012_J1815
2012	J1817	Insulin for insulin pump use	50 UNITS	\$	3.09	2012_J1817
2012	J1840	Kanamycin sulfate 500 MG inj	500 MG	\$	7.69	2012_J1840
2012	J1850	Kanamycin sulfate 75 MG inj	75 MG	\$	1.15	2012_J1850
2012	J1885	Ketorolac tromethamine inj	15 MG	\$	0.23	2012_J1885
2012	J1930	Lanreotide injection	1 MG	\$	33.82	2012_J1930
2012	J1931	Laronidase injection	0.1 MG	\$	26.67	2012_J1931
2012	J1940	Furosemide injection	20 MG	\$	0.67	2012_J1940
2012	J1945	Lepirudin	50 MG	\$	551.76	2012_J1945
2012	J1950	Leuprolide acetate /3.75 MG	3.75 MG	\$	663.95	2012_J1950
2012	J1953	Levetiracetam injection	10 MG	\$	0.25	2012_J1953
2012	J1955	Inj levocarnitine per 1 gm	1 GM	\$	6.24	2012_J1955
2012	J1956	Levofloxacin injection	250 MG	\$	3.79	2012_J1956
2012	J1980	Hyoscyamine sulfate inj	0.25 MG	\$	14.74	2012_J1980
2012	J2001	Lidocaine injection	10 MG	\$	0.02	2012_J2001

2012	J2010	Lincomycin injection	300 MG	\$	7.05	2012_J2010
2012	J2020	Linezolid injection	200 MG	\$	39.32	2012_J2020
2012	J2060	Lorazepam injection	2 MG	\$	1.34	2012_J2060
2012	J2150	Mannitol injection	50 ML	\$	1.47	2012_J2150
2012	J2175	Meperidine hydrochl /100 MG	100 MG	\$	2.16	2012_J2175
2012	J2185	Meropenem	100 MG	\$	1.42	2012_J2185
2012	J2210	Methylergonovin maleate inj	0.2 MG	\$	3.80	2012_J2210
2012	J2248	Micafungin sodium injection	1 MG	\$	0.94	2012_J2248
2012	J2250	Inj midazolam hydrochloride	1 MG	\$	0.16	2012_J2250
2012	J2260	Inj milrinone lactate / 5 MG	5 MG	\$	3.94	2012_J2260
2012	J2270	Morphine sulfate injection	10 MG	\$	3.39	2012_J2270
2012	J2271	Morphine so4 injection 100mg	100 MG	\$	1.20	2012_J2271
2012	J2275	Morphine sulfate injection	10 MG	\$	2.71	2012_J2275
2012	J2278	Ziconotide injection	1 MCG	\$	6.61	2012_J2278
2012	J2280	Inj, moxifloxacin 100 mg	100 MG	\$	4.08	2012_J2280
2012	J2300	Inj nalbuphine hydrochloride	10 MG	\$	0.89	2012_J2300
2012	J2310	Inj naloxone hydrochloride	1 MG	\$	10.18	2012_J2310
2012	J2315	Naltrexone, depot form	1 MG	\$	2.85	2012_J2315
2012	J2323	Natalizumab injection	1 MG	\$	11.59	2012_J2323
2012	J2325	Nesiritide injection	0.1 MG	\$	51.81	2012_J2325
2012	J2353	Octreotide injection, depot	1 MG	\$	127.00	2012_J2353
2012	J2354	Octreotide inj, non-depot	25 MCG	\$	1.51	2012_J2354
2012	J2355	Oprelvekin injection	5 MG	\$	244.00	2012_J2355
2012	J2357	Omalizumab injection	5 MG	\$	23.53	2012_J2357
2012	J2358	Olanzapine long-acting inj	1 MG	\$	2.75	2012_J2358
2012	J2360	Orphenadrine injection	60 MG	\$	6.93	2012_J2360
2012	J2370	Phenylephrine hcl injection	1 ML	\$	0.42	2012_J2370
2012	J2400	Chloroprocaine hcl injection	30 ML	\$	24.33	2012_J2400
2012	J2405	Ondansetron hcl injection	1 MG	\$	0.22	2012_J2405
2012	J2410	Oxymorphone hcl injection	1 MG	\$	2.28	2012_J2410
2012	J2425	Palifermin injection	50 MCG	\$	12.12	2012_J2425
2012	J2426	Paliperidone palmitate inj	1 MG	\$	7.02	2012_J2426
2012	J2430	Pamidronate disodium /30 MG	30 MG	\$	10.50	2012_J2430
2012	J2440	Papaverin hcl injection	60 MG	\$	1.08	2012_J2440
2012	J2469	Palonosetron hcl	25 MCG	\$	19.02	2012_J2469
2012	J2501	Paricalcitol	1 MCG	\$	1.74	2012_J2501
2012	J2503	Pegaptanib sodium injection	0.3 MG	\$	1,029.95	2012_J2503
2012	J2504	Pegademase bovine, 25 iu	25 IU	\$	265.48	2012_J2504
2012	J2505	Injection, pegfilgrastim 6mg	6 MG	\$	2,838.89	2012_J2505
2012	J2507	Pegloticase injection	1 MG	\$	320.77	2012_J2507
2012	J2510	Penicillin g procaine inj	600000 UNITS	\$	12.62	2012_J2510
2012	J2515	Pentobarbital sodium inj	50 MG	\$	26.36	2012_J2515
2012	J2540	Penicillin g potassium inj	600000 UNITS	\$	0.60	2012_J2540
2012	J2543	Piperacillin/tazobactam	1.125 GM	\$	2.54	2012_J2543
2012	J2545	Pentamidine non-comp unit	300 MG	\$	60.78	2012_J2545
2012	J2550	Promethazine hcl injection	50 MG	\$	1.90	2012_J2550
2012	J2560	Phenobarbital sodium inj	120 MG	\$	16.13	2012_J2560
2012	J2562	Plerixafor injection	1 MG	\$	287.45	2012_J2562
2012	J2590	Oxytocin injection	10 UNITS	\$	0.69	2012_J2590
2012	J2597	Inj desmopressin acetate	1 MCG	\$	6.12	2012_J2597
2012	J2675	Inj progesterone per 50 MG	50 MG	\$	1.58	2012_J2675
2012	J2680	Fluphenazine decanoate 25 MG	25 MG	\$	15.51	2012_J2680
2012	J2690	Procainamide hcl injection	1 GM	\$	12.61	2012_J2690
2012	J2700	Oxacillin sodium injeciton	250 MG	\$	2.38	2012_J2700
2012	J2720	Inj protamine sulfate/10 MG	10 MG	\$	0.59	2012_J2720
2012	J2724	Protein c concentrate	10 UNITS	\$	13.59	2012_J2724
2012	J2730	Pralidoxime chloride inj	1 GM	\$	88.60	2012_J2730
2012	J2760	Phentolaine mesylate inj	5 MG	\$	111.04	2012_J2760
2012	J2765	Metoclopramide hcl injection	10 MG	\$	0.36	2012_J2765

2012	J2770	Quinupristin/dalfopristin	500 MG	\$	175.05	2012_J2770
2012	J2778	Ranibizumab injection	0.1 mg	\$	398.31	2012_J2778
2012	J2780	Ranitidine hydrochloride inj	25 MG	\$	1.34	2012_J2780
2012	J2783	Rasburicase	0.5 MG	\$	204.73	2012_J2783
2012	J2785	Regadenoson injection	0.1 MG	\$	53.67	2012_J2785
2012	J2788	Rho d immune globulin 50 mcg	50 MCG (250 IU)	\$	25.86	2012_J2788
2012	J2790	Rho d immune globulin inj	300 MCG (1500 IU)	\$	83.77	2012_J2790
2012	J2791	Rhophylac injection	100 IU	\$	5.19	2012_J2791
2012	J2792	Rho(D) immune globulin h, sd	100 IU	\$	18.43	2012_J2792
2012	J2794	Risperidone, long acting	0.5 MG	\$	5.45	2012_J2794
2012	J2795	Ropivacaine HCl injection	1 MG	\$	0.08	2012_J2795
2012	J2796	Romiplostim injection	10 MCG	\$	48.18	2012_J2796
2012	J2800	Methocarbamol injection	10 ML	\$	37.10	2012_J2800
2012	J2805	Sinacalide injection	5 MCG	\$	67.01	2012_J2805
2012	J2810	Inj theophylline per 40 MG	40 MG	\$	0.26	2012_J2810
2012	J2820	Sargramostim injection	50 MCG	\$	31.59	2012_J2820
2012	J2850	Inj secretin synthetic human	1 MCG	\$	27.49	2012_J2850
2012	J2916	Na ferric gluconate complex	12.5 MG	\$	3.32	2012_J2916
2012	J2920	Methylprednisolone injection	40 MG	\$	2.07	2012_J2920
2012	J2930	Methylprednisolone injection	125 MG	\$	2.86	2012_J2930
2012	J2993	Reteplase injection	18.1 MG	\$	2,301.90	2012_J2993
2012	J2997	Alteplase recombinant	1 MG	\$	49.22	2012_J2997
2012	J3000	Streptomycin injection	1 GM	\$	11.35	2012_J3000
2012	J3010	Fentanyl citrate injecton	0.1 MG	\$	0.80	2012_J3010
2012	J3030	Sumatriptan succinate / 6 MG	6 MG	\$	51.89	2012_J3030
2012	J3070	Pentazocine injection	30 MG	\$	19.61	2012_J3070
2012	J3095	Telavancin injection	10 MG	\$	2.65	2012_J3095
2012	J3101	Tenecteplase injection	1 MG	\$	66.50	2012_J3101
2012	J3105	Terbutaline sulfate inj	1 MG	\$	5.52	2012_J3105
2012	J3120	Testosterone enanthate inj	100 MG	\$	4.64	2012_J3120
2012	J3130	Testosterone enanthate inj	200 MG	\$	9.28	2012_J3130
2012	J3230	Chlorpromazine hcl injection	50 MG	\$	25.08	2012_J3230
2012	J3240	Thyrotropin injection	0.9 MG	\$	1,053.79	2012_J3240
2012	J3243	Tigecycline injection	1 MG	\$	1.46	2012_J3243
2012	J3246	Tirofiban HCl	0.25 MG	\$	8.69	2012_J3246
2012	J3250	Trimethobenzamide hcl inj	200 MG	\$	10.44	2012_J3250
2012	J3260	Tobramycin sulfate injection	80 MG	\$	2.75	2012_J3260
2012	J3262	Tocilizumab injection	1 MG	\$	3.57	2012_J3262
2012	J3285	Treprostinil injection	1 MG	\$	61.24	2012_J3285
2012	J3300	Triamcinolone A inj PRS-free	1 MG	\$	3.57	2012_J3300
2012	J3301	Triamcinolone acet inj NOS	10 MG	\$	1.67	2012_J3301
2012	J3302	Triamcinolone diacetate inj	5 MG	\$	0.28	2012_J3302
2012	J3303	Triamcinolone hexacetonl inj	5 MG	\$	1.51	2012_J3303
2012	J3315	Triptorelin pamoate	3.75 MG	\$	160.30	2012_J3315
2012	J3355	Urofollitropin, 75 iu	75 IU	\$	66.69	2012_J3355
2012	J3357	Ustekinumab injection	1 MG	\$	130.53	2012_J3357
2012	J3360	Diazepam injection	5 MG	\$	1.42	2012_J3360
2012	J3365	Urokinase 250,000 IU inj	250000 IU	\$	457.73	2012_J3365
2012	J3370	Vancomycin hcl injection	500 MG	\$	2.40	2012_J3370
2012	J3385	Velaglugerase alfa	100 UNITS	\$	349.31	2012_J3385
2012	J3396	Verteporfin injection	0.1 MG	\$	10.16	2012_J3396
2012	J3410	Hydroxyzine hcl injection	25 MG	\$	1.44	2012_J3410
2012	J3411	Thiamine hcl 100 mg	100 MG	\$	3.51	2012_J3411
2012	J3415	Pyridoxine hcl 100 mg	100 MG	\$	6.94	2012_J3415
2012	J3420	Vitamin b12 injection	1000 MCG	\$	0.54	2012_J3420
2012	J3430	Vitamin k phytonadione inj	1 MG	\$	1.43	2012_J3430
2012	J3465	Injection, voriconazole	10 MG	\$	6.63	2012_J3465
2012	J3470	Hyaluronidase injection	150 UNITS	\$	21.20	2012_J3470
2012	J3471	Ovine, up to 999 USP units	1 USP UNIT	\$	0.24	2012_J3471

2012	J3473	Hyaluronidase recombinant	1 USP UNIT	\$	0.34	2012_J3473
2012	J3475	Inj magnesium sulfate	500 MG	\$	0.12	2012_J3475
2012	J3480	Inj potassium chloride	2 MEQ	\$	0.01	2012_J3480
2012	J3485	Zidovudine	10 MG	\$	1.51	2012_J3485
2012	J3486	Ziprasidone mesylate	10 MG	\$	8.76	2012_J3486
2012	J3487	Zoledronic acid	1 MG	\$	224.10	2012_J3487
2012	J3488	Reclast injection	1 MG	\$	224.75	2012_J3488
2012	J7030	Normal saline solution infus	1000 ML	\$	1.10	2012_J7030
2012	J7040	Normal saline solution infus	500 ML	\$	0.55	2012_J7040
2012	J7042	5% dextrose/normal saline	500 ML	\$	0.36	2012_J7042
2012	J7050	Normal saline solution infus	250 ML	\$	0.27	2012_J7050
2012	J7060	5% dextrose/water	500 ML	\$	1.05	2012_J7060
2012	J7070	D5w infusion	1000 CC	\$	2.10	2012_J7070
2012	J7100	Dextran 40 infusion	500 ML	\$	21.02	2012_J7100
2012	J7110	Dextran 75 infusion	500 ML	\$	14.52	2012_J7110
2012	J7120	Ringers lactate infusion	1000 CC	\$	1.02	2012_J7120
2012	J7183	Wilate injection	1 I.U. VWF:RCO	\$	0.88	2012_J7183
2012	J7185	Xyntha inj	1 IU	\$	1.10	2012_J7185
2012	J7186	Antihemophilic viii/vwf comp	PER FACTOR VIII IU	\$	0.93	2012_J7186
2012	J7187	Humate-P, inj	1 IU	\$	0.90	2012_J7187
2012	J7189	Factor viia	1 MCG	\$	1.61	2012_J7189
2012	J7190	Factor viii	1 IU	\$	0.90	2012_J7190
2012	J7192	Factor viii recombinant NOS	1 IU	\$	1.11	2012_J7192
2012	J7193	Factor IX non-recombinant	1 IU	\$	0.94	2012_J7193
2012	J7194	Factor ix complex	1 IU	\$	1.03	2012_J7194
2012	J7195	Factor IX recombinant	1 IU	\$	1.24	2012_J7195
2012	J7197	Antithrombin iii injection	1 IU	\$	3.04	2012_J7197
2012	J7198	Anti-inhibitor	1 IU	\$	1.63	2012_J7198
2012	J7308	Aminolevulinic acid hcl top	354 MG	\$	161.18	2012_J7308
2012	J7309	Methyl aminolevulinate, top	1 GM	\$	75.95	2012_J7309
2012	J7310	Ganciclovir long act implant	4.5 MG	\$	16,960.00	2012_J7310
2012	J7311	Fluocinolone acetonide implt	0.59 MG	\$	19,345.00	2012_J7311
2012	J7312	Dexamethasone intra implant	0.1 MG	\$	195.76	2012_J7312
2012	J7321	Hyalgan/supartz inj per dose	per dose	\$	92.25	2012_J7321
2012	J7323	Euflexxa inj per dose	per dose	\$	151.09	2012_J7323
2012	J7324	Orthovisc inj per dose	per dose	\$	169.91	2012_J7324
2012	J7325	Synvisc or Synvisc-One	1 MG	\$	12.22	2012_J7325
2012	J7326	Gel-One	per dose	\$	614.91	2012_J7326
2012	J7330	Cultured chondrocytes implnt	1 EA	\$	29,193.23	2012_J7330
2012	J7335	Capsaicin 8% patch	10 SQ CM	\$	25.55	2012_J7335
2012	J7500	Azathioprine oral 50mg	50 MG	\$	0.06	2012_J7500
2012	J7501	Azathioprine parenteral	100 MG	\$	144.62	2012_J7501
2012	J7502	Cyclosporine oral 100 mg	100 MG	\$	3.22	2012_J7502
2012	J7504	Lymphocyte immune globulin	250 MG	\$	646.10	2012_J7504
2012	J7505	Monoclonal antibodies	5 MG	\$	1,156.08	2012_J7505
2012	J7506	Prednisone oral	5 MG	\$	0.05	2012_J7506
2012	J7507	Tacrolimus oral per 1 MG	1 MG	\$	2.09	2012_J7507
2012	J7509	Methylprednisolone oral	4 MG	\$	0.68	2012_J7509
2012	J7510	Prednisolone oral per 5 mg	5 MG	\$	0.03	2012_J7510
2012	J7511	Antithymocyte globuln rabbit	25 MG	\$	465.73	2012_J7511
2012	J7513	Daclizumab, parenteral	25 MG	\$	526.34	2012_J7513
2012	J7515	Cyclosporine oral 25 mg	25 MG	\$	0.88	2012_J7515
2012	J7516	Cyclosporin parenteral 250mg	250 MG	\$	30.61	2012_J7516
2012	J7517	Mycophenolate mofetil oral	250 MG	\$	1.28	2012_J7517
2012	J7518	Mycophenolic acid	180 MG	\$	3.60	2012_J7518
2012	J7520	Sirolimus, oral	1 MG	\$	11.55	2012_J7520
2012	J7525	Tacrolimus injection	5 MG	\$	139.36	2012_J7525
2012	J7605	Arformoterol non-comp unit	15 mcg	\$	5.22	2012_J7605
2012	J7606	Formoterol fumarate, inh	20 MCG	\$	5.21	2012_J7606

2012	J7608	Acetylcysteine non-comp unit	1 GM	\$	2.17	2012_J7608
2012	J7611	Albuterol non-comp con	1 MG	\$	0.11	2012_J7611
2012	J7612	Levalbuterol non-comp con	0.5 MG	\$	0.28	2012_J7612
2012	J7613	Albuterol non-comp unit	1 MG	\$	0.05	2012_J7613
2012	J7614	Levalbuterol non-comp unit	0.5 MG	\$	0.26	2012_J7614
2012	J7620	Albuterol ipratrop non-comp	2.5 MG/0.5 MG	\$	0.21	2012_J7620
2012	J7626	Budesonide non-comp unit	0.5 MG	\$	4.87	2012_J7626
2012	J7631	Cromolyn sodium noncomp unit	10 MG	\$	0.53	2012_J7631
2012	J7639	Dornase alfa non-comp unit	1 MG	\$	30.64	2012_J7639
2012	J7644	Ipratropium bromide non-comp	1 MG	\$	0.25	2012_J7644
2012	J7665	Mannitol for inhaler	5 MG	\$	0.63	2012_J7665
2012	J7669	Metaproterenol non-comp unit	10 MG	\$	0.25	2012_J7669
2012	J7674	Methacholine chloride, neb	1 MG	\$	0.50	2012_J7674
2012	J7682	Tobramycin non-comp unit	300 MG	\$	92.45	2012_J7682
2012	J7686	Treprostinil, non-comp unit	1.74 MG	\$	438.93	2012_J7686
2012	J8501	Oral aprepitant	5 MG	\$	6.29	2012_J8501
2012	J8510	Oral busulfan	2 MG	\$	5.31	2012_J8510
2012	J8520	Capecitabine, oral, 150 mg	150 MG	\$	8.28	2012_J8520
2012	J8521	Capecitabine, oral, 500 mg	500 MG	\$	27.55	2012_J8521
2012	J8530	Cyclophosphamide oral 25 MG	25 MG	\$	0.95	2012_J8530
2012	J8540	Oral dexamethasone	0.25 MG	\$	0.35	2012_J8540
2012	J8560	Etoposide oral 50 MG	50 MG	\$	52.17	2012_J8560
2012	J8561	Oral everolimus	0.25 MG	\$	6.18	2012_J8561
2012	J8562	Oral fludarabine phosphate	10 MG	\$	81.77	2012_J8562
2012	J8600	Melphalan oral 2 MG	2 MG	\$	8.22	2012_J8600
2012	J8610	Methotrexate oral 2.5 MG	2.5 MG	\$	0.12	2012_J8610
2012	J8700	Temozolomide	5 MG	\$	10.67	2012_J8700
2012	J8705	Topotecan oral	0.25 mg	\$	83.93	2012_J8705
2012	J9000	Doxorubicin hcl injection	10 MG	\$	3.74	2012_J9000
2012	J9010	Alemtuzumab injection	10 MG	\$	587.78	2012_J9010
2012	J9015	Aldesleukin injection	1 EA	\$	1,246.98	2012_J9015
2012	J9017	Arsenic trioxide injection	1 MG	\$	44.99	2012_J9017
2012	J9020	Asparaginase injection	10000 UNITS	\$	63.21	2012_J9020
2012	J9025	Azacididine injection	1 MG	\$	5.52	2012_J9025
2012	J9027	Clofarabine injection	1 MG	\$	125.76	2012_J9027
2012	J9031	Bcg live intravesical vac	1 EA	\$	116.81	2012_J9031
2012	J9033	Bendamustine injection	1 MG	\$	20.61	2012_J9033
2012	J9035	Bevacizumab injection	10 MG	\$	62.32	2012_J9035
2012	J9040	Bleomycin sulfate injection	15 UNITS	\$	24.16	2012_J9040
2012	J9041	Bortezomib injection	0.1 MG	\$	43.47	2012_J9041
2012	J9043	Cabazitaxel injection	1 MG	\$	136.07	2012_J9043
2012	J9045	Carboplatin injection	50 MG	\$	3.28	2012_J9045
2012	J9050	Carmustine injection	100 MG	\$	175.76	2012_J9050
2012	J9055	Cetuximab injection	10 MG	\$	51.09	2012_J9055
2012	J9060	Cisplatin 10 MG injection	10 MG	\$	1.90	2012_J9060
2012	J9065	Inj cladribine per 1 MG	1 MG	\$	28.24	2012_J9065
2012	J9070	Cyclophosphamide 100 MG inj	100 MG	\$	23.48	2012_J9070
2012	J9098	Cytarabine liposome inj	10 MG	\$	523.87	2012_J9098
2012	J9100	Cytarabine hcl 100 MG inj	100 MG	\$	0.95	2012_J9100
2012	J9120	Dactinomycin injection	0.5 MG	\$	578.93	2012_J9120
2012	J9130	Dacarbazine 100 mg inj	100 MG	\$	3.40	2012_J9130
2012	J9150	Daunorubicin injection	10 MG	\$	19.19	2012_J9150
2012	J9155	Degarelix injection	1 MG	\$	2.99	2012_J9155
2012	J9160	Denileukin diftitox inj	300 MCG	\$	1,646.18	2012_J9160
2012	J9171	Docetaxel injection	1 MG	\$	6.69	2012_J9171
2012	J9175	Elliotts b solution per ml	1 ML	\$	4.07	2012_J9175
2012	J9178	Inj, epirubicin hcl, 2 mg	2 MG	\$	1.61	2012_J9178
2012	J9179	Eribulin mesylate injection	0.1 MG	\$	92.81	2012_J9179
2012	J9181	Etoposide injection	10 MG	\$	0.78	2012_J9181

2012	J9185	Fludarabine phosphate inj	50 MG	\$	84.88	2012_J9185
2012	J9190	Fluorouracil injection	500 MG	\$	2.34	2012_J9190
2012	J9200	Floxuridine injection	500 MG	\$	52.39	2012_J9200
2012	J9201	Gemcitabine hcl injection	200 MG	\$	12.25	2012_J9201
2012	J9202	Goserelin acetate implant	3.6 MG	\$	166.01	2012_J9202
2012	J9206	Irinotecan injection	20 MG	\$	4.38	2012_J9206
2012	J9207	Ixabepilone injection	1 MG	\$	66.49	2012_J9207
2012	J9208	Ifosfamide injection	1 GM	\$	30.49	2012_J9208
2012	J9209	Mesna injection	200 MG	\$	3.79	2012_J9209
2012	J9211	Idarubicin hcl injection	5 MG	\$	100.00	2012_J9211
2012	J9214	Interferon alfa-2b inj	1 MIL UNITS	\$	19.06	2012_J9214
2012	J9217	Leuprolide acetate suspnsion	7.5 MG	\$	217.02	2012_J9217
2012	J9218	Leuprolide acetate injeciton	1 MG	\$	5.98	2012_J9218
2012	J9219	Leuprolide acetate implant	65 MG	\$	4,819.82	2012_J9219
2012	J9225	Vantas implant	50 MG	\$	3,016.50	2012_J9225
2012	J9226	Supprelin LA implant	50 MG	\$	16,172.58	2012_J9226
2012	J9228	Ipilimumab injection	1 MG	\$	125.16	2012_J9228
2012	J9230	Mechlorethamine hcl inj	10 MG	\$	157.86	2012_J9230
2012	J9245	Inj melphalan hydrochl 50 MG	50 MG	\$	1,312.54	2012_J9245
2012	J9250	Methotrexate sodium inj	5 MG	\$	0.19	2012_J9250
2012	J9260	Methotrexate sodium inj	50 MG	\$	1.96	2012_J9260
2012	J9261	Nelarabine injection	50 MG	\$	122.65	2012_J9261
2012	J9263	Oxaliplatin	0.5 MG	\$	9.25	2012_J9263
2012	J9264	Paclitaxel protein bound	1 MG	\$	9.59	2012_J9264
2012	J9265	Paclitaxel injection	30 MG	\$	6.69	2012_J9265
2012	J9266	Pegaspargase injection	1 EA	\$	5,890.00	2012_J9266
2012	J9268	Pentostatin injection	10 MG	\$	946.92	2012_J9268
2012	J9280	Mitomycin 5 MG inj	5 MG	\$	22.90	2012_J9280
2012	J9293	Mitoxantrone hydrochl / 5 MG	5 MG	\$	36.22	2012_J9293
2012	J9300	Gemtuzumab ozogamicin inj	5 MG	\$	2,742.59	2012_J9300
2012	J9302	Ofatumumab injection	10 MG	\$	45.44	2012_J9302
2012	J9303	Panitumumab injection	10 MG	\$	89.02	2012_J9303
2012	J9305	Pemetrexed injection	10 MG	\$	56.51	2012_J9305
2012	J9307	Pralatrexate injection	1 MG	\$	173.94	2012_J9307
2012	J9310	Rituximab injection	100 MG	\$	659.72	2012_J9310
2012	J9315	Romidepsin injection	1 MG	\$	233.16	2012_J9315
2012	J9320	Streptozocin injection	1 GM	\$	274.16	2012_J9320
2012	J9328	Temozolomide injection	1 MG	\$	4.82	2012_J9328
2012	J9330	Temsirolimus injection	1 MG	\$	53.51	2012_J9330
2012	J9340	Thiotepa injection	15 MG	\$	175.30	2012_J9340
2012	J9351	Topotecan injection	0.1 MG	\$	3.13	2012_J9351
2012	J9355	Trastuzumab injection	10 MG	\$	76.40	2012_J9355
2012	J9357	Valrubicin injection	200 MG	\$	1,006.27	2012_J9357
2012	J9360	Vinblastine sulfate inj	1 MG	\$	1.07	2012_J9360
2012	J9370	Vincristine sulfate 1 MG inj	1 MG	\$	3.60	2012_J9370
2012	J9390	Vinorelbine tartrate inj	10 MG	\$	9.16	2012_J9390
2012	J9395	Injection, Fulvestrant	25 MG	\$	87.04	2012_J9395
2012	P9041	Albumin (human),5%, 50ml	50 ML	\$	9.55	2012_P9041
2012	P9043	Plasma protein fract,5%,50ml	50 ML	\$	8.33	2012_P9043
2012	P9045	Albumin (human), 5%, 250 ml	250 ML	\$	47.73	2012_P9045
2012	P9046	Albumin (human), 25%, 20 ml	20 ML	\$	19.68	2012_P9046
2012	P9047	Albumin (human), 25%, 50ml	50 ML	\$	49.20	2012_P9047
2012	P9048	Plasmaprotein fract,5%,250ml	250 ML	\$	41.67	2012_P9048
2012	Q0138	Ferumoxitol, non-esrd	1 MG	\$	0.64	2012_Q0138
2012	Q0139	Ferumoxitol, esrd use	1 MG	\$	0.64	2012_Q0139
2012	Q0162	Ondansetron oral	1 MG	\$	0.06	2012_Q0162
2012	Q0163	Diphenhydramine HCl 50mg	50 MG	\$	0.02	2012_Q0163
2012	Q0164	Prochlorperazine maleate 5mg	5 MG	\$	0.05	2012_Q0164
2012	Q0165	Prochlorperazine maleate10mg	10 MG	\$	0.05	2012_Q0165

2012	Q0166	Granisetron hcl 1 mg oral	1 MG	\$	1.64	2012_Q0166
2012	Q0167	Dronabinol 2.5mg oral	2.5 MG	\$	3.58	2012_Q0167
2012	Q0168	Dronabinol 5mg oral	5 MG	\$	7.29	2012_Q0168
2012	Q0169	Promethazine HCl 12.5mg oral	12.5 MG	\$	0.08	2012_Q0169
2012	Q0170	Promethazine HCl 25 mg oral	25 MG	\$	0.03	2012_Q0170
2012	Q0180	Dolasetron mesylate oral	100 MG	\$	69.50	2012_Q0180
2012	Q0515	Sermorelin acetate injection	1 MCG	\$	1.80	2012_Q0515
2012	Q2009	Fosphenytoin inj PE	50 MG	\$	0.92	2012_Q2009
2012	Q2017	Teniposide, 50 mg	50 MG	\$	321.83	2012_Q2017
2012	Q2035	Afluria vacc, 3 yrs & >, im	0.5 ml	\$	11.54	2012_Q2035
2012	Q2036	Flulaval vacc, 3 yrs & >, im	0.5 ML	\$	9.83	2012_Q2036
2012	Q2037	Fluvirin vacc, 3 yrs & >, im	0.5 ML	\$	14.05	2012_Q2037
2012	Q2038	Fluzone vacc, 3 yrs & >, im	0.5 ML	\$	12.05	2012_Q2038
2012	Q2043	Sipuleucel-T auto CD54+	Per infusion (minimum 50 million cells)	\$	32,696.25	2012_Q2043
2012	Q2046	Aflibercept injection	1 MG	\$	980.50	2012_Q2046
2012	Q2047	Peginesatide injection	0.1 MG	\$	11.46	2012_Q2047
2012	Q2048	Doxil injection	10 MG	\$	532.03	2012_Q2048
2012	Q2049	Imported Lipodox inj	10 MG	\$	498.27	2012_Q2049
2012	Q3025	IM inj interferon beta 1-a	11 MCG	\$	287.09	2012_Q3025
2012	Q4074	Iloprost non-comp unit dose	UP TO 20 MCG	\$	73.67	2012_Q4074
2012	Q4081	Epoetin alfa, 100 units ESRD	100 UNITS	\$	0.99	2012_Q4081
2012	Q4101	Apligraf skin sub	1 SQ CM	\$	38.06	2012_Q4101
2012	Q4102	Oasis wound matrix skin sub	1 SQ CM	\$	7.78	2012_Q4102
2012	Q4103	Oasis burn matrix skin sub	1 SQ CM	\$	7.78	2012_Q4103
2012	Q4104	Integra BMWD skin sub	1 SQ CM	\$	20.97	2012_Q4104
2012	Q4105	Integra DRT skin sub	1 SQ CM	\$	11.40	2012_Q4105
2012	Q4106	Dermagraft skin sub	1 SQ CM	\$	42.57	2012_Q4106
2012	Q4107	Graftjacket skin sub	1 SQ CM	\$	98.39	2012_Q4107
2012	Q4108	Integra matrix skin sub	1 SQ CM	\$	25.17	2012_Q4108
2012	Q4110	Primatrix skin sub	1 SQ CM	\$	37.76	2012_Q4110
2012	Q4111	Gammagraft skin sub	1 SQ CM	\$	6.87	2012_Q4111
2012	Q4112	Cymetra allograft	1 CC	\$	442.20	2012_Q4112
2012	Q4113	Graftjacket express allograf	1 CC	\$	442.20	2012_Q4113
2012	Q4114	Integra flowable wound matri	1 CC	\$	1,176.14	2012_Q4114
2012	Q4115	Alloskin	1 SQ CM	\$	10.19	2012_Q4115
2012	Q4116	Alloderm skin sub	1 SQ CM	\$	32.21	2012_Q4116
2012	Q4121	Theraskin	1 SQ CM	\$	22.29	2012_Q4121
2012	Q4123	Alloskin RT	1 SQ CM	\$	13.37	2012_Q4123
2012	Q9954	Oral MR contrast, 100 ml	100 ML	\$	9.34	2012_Q9954
2012	Q9956	Inj octafluoropropane mic,ml	1 ML	\$	38.61	2012_Q9956
2012	Q9957	Inj perflutren lip micros,ml	1 ML	\$	57.91	2012_Q9957
2012	Q9958	HOcm <=149 mg/ml iodine, 1ml	1 ML	\$	0.09	2012_Q9958
2012	Q9960	HOcm 200-249mg/ml iodine,1ml	1 ML	\$	0.16	2012_Q9960
2012	Q9961	HOcm 250-299mg/ml iodine,1ml	1 ML	\$	0.19	2012_Q9961
2012	Q9963	HOcm 350-399mg/ml iodine,1ml	1 ML	\$	0.18	2012_Q9963
2012	Q9965	LOCM 100-199mg/ml iodine,1ml	1 ML	\$	0.90	2012_Q9965
2012	Q9966	LOCM 200-299mg/ml iodine,1ml	1 ML	\$	0.27	2012_Q9966
2012	Q9967	LOCM 300-399mg/ml iodine,1ml	1 ML	\$	0.17	2012_Q9967

Notes and sources:

Data is aggregated using the October ASP pricing file available annually at the following webpages:

- Ex. 2242 (Centers for Medicare & Medicaid Services, October 2021 ASP Pricing File, <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2021-asp-drug-pricing-files>).
- Ex. 2241 (Centers for Medicare & Medicaid Services, October 2020 ASP Pricing File, <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files>).
- Ex. 2239 (Centers for Medicare & Medicaid Services, October 2019 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles>).
- Ex. 2238 (Centers for Medicare & Medicaid Services, October 2018 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles>).
- Ex. 2237 (Centers for Medicare & Medicaid Services, October 2017 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles>).
- Ex. 2236 (Centers for Medicare & Medicaid Services, October 2016 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles>).
- Ex. 2235 (Centers for Medicare & Medicaid Services, October 2015 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2015ASPFiles>).
- Ex. 2240 (Centers for Medicare & Medicaid Services, October 2014 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2014ASPFiles>).
- Ex. 2234 (Centers for Medicare & Medicaid Services, October 2013 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2013ASPFiles>).
- Ex. 2233 (Centers for Medicare & Medicaid Services, October 2012 ASP Pricing File, <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2012ASPFiles>).